
<html lang="en"     class="pb-page"  data-request-id="e29a6881-6358-4722-b873-96a1c01b4a11"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm400887j;issue:issue:10.1021/jmcmar.2014.57.issue-2;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?" /></meta><meta name="dc.Creator" content="Fabrizio  Giordanetto" /></meta><meta name="dc.Creator" content="Jan  Kihlberg" /></meta><meta name="dc.Description" content="Macrocycles are ideal in efforts to tackle “difficult” targets, but our understanding of what makes them cell permeable and orally bioavailable is limited. Analysis of approximately 100 macrocyclic..." /></meta><meta name="Description" content="Macrocycles are ideal in efforts to tackle “difficult” targets, but our understanding of what makes them cell permeable and orally bioavailable is limited. Analysis of approximately 100 macrocyclic..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 17, 2013" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400887j" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400887j" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400887j" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400887j" /></link>
        
    
    

<title>Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties? | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400887j" /></meta><meta property="og:title" content="Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0016.jpeg" /></meta><meta property="og:description" content="Macrocycles are ideal in efforts to tackle “difficult” targets, but our understanding of what makes them cell permeable and orally bioavailable is limited. Analysis of approximately 100 macrocyclic drugs and clinical candidates revealed that macrocycles are predominantly used for infectious disease and in oncology and that most belong to the macrolide or cyclic peptide class. A significant number (N = 34) of these macrocycles are administered orally, revealing that oral bioavailability can be obtained at molecular weights up to and above 1 kDa and polar surface areas ranging toward 250 Å2. Moreover, insight from a group of “de novo designed” oral macrocycles in clinical studies and understanding of how cyclosporin A and model cyclic hexapeptides cross cell membranes may unlock wider opportunities in drug discovery. However, the number of oral macrocycles is still low and it remains to be seen if they are outliers or if macrocycles will open up novel oral druggable space." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400887j"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400887j">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400887j&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400887j&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400887j&amp;href=/doi/10.1021/jm400887j" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 278-295</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400378w" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm4019405" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fabrizio++Giordanetto">Fabrizio Giordanetto</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jan++Kihlberg">Jan Kihlberg</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Cardiovascular and Metabolic Disorders Research Area, AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden</span></div><div class="corresp-info"><strong>*</strong>For F.G.: phone, +49 (0)231 9742-7211; fax, +49 (0)231 9742-7219; e-mail, <a href="/cdn-cgi/l/email-protection#99fffef0f6ebfdf8f7fcededf6d9edf8ebf6eab7fdfc"><span class="__cf_email__" data-cfemail="107677797f6274717e7564647f506471627f633e7475">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For J.K.: phone, +46 (0)18 4713801; e-mail, <a href="/cdn-cgi/l/email-protection#3953585717525051555b5c4b5e79525c5450174c4c174a5c"><span class="__cf_email__" data-cfemail="4b212a256520222327292e392c0b202e2622653e3e65382e">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400887j&amp;href=/doi/10.1021%2Fjm400887j" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 278–295</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 28, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 June 2013</li><li><span class="item_label"><b>Published</b> online</span>17 September 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 January 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400887j" title="DOI URL">https://doi.org/10.1021/jm400887j</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D278%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DFabrizio%2BGiordanetto%252C%2BJan%2BKihlberg%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D2%26contentID%3Djm400887j%26title%3DMacrocyclic%2BDrugs%2Band%2BClinical%2BCandidates%253A%2BWhat%2BCan%2BMedicinal%2BChemists%2BLearn%2Bfrom%2BTheir%2BProperties%253F%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D295%26publicationDate%3DJanuary%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400887j"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">13293</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">340</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400887j" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Fabrizio&quot;,&quot;last_name&quot;:&quot;Giordanetto&quot;},{&quot;first_name&quot;:&quot;Jan&quot;,&quot;last_name&quot;:&quot;Kihlberg&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;278-295&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400887j&quot;},&quot;abstract&quot;:&quot;Macrocycles are ideal in efforts to tackle “difficult” targets, but our understanding of what makes them cell permeable and orally bioavailable is limited. Analysis of approximately 100 macrocyclic drugs and clinical candidates revealed that macrocycles are predominantly used for infectious disease and in oncology and that most belong to the macrolide or cyclic peptide class. A significant number (N = 34) of these macrocycles are administered orally, revealing that oral bioavailability can be obtained at molecular weights up to and above 1 kDa and polar surface areas ranging toward 250 Å2. Moreover, insight from a group of “de novo designed” oral macrocycles in clinical studies and understanding of how cyclosporin A and model cyclic hexapeptides cross cell membranes may unlock wider opportunities in drug discovery. However, the number of oral macrocycles is still low and it remains to be seen if they are outliers or if macrocycles will open up novel oral druggable space.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400887j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400887j" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400887j&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400887j" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400887j&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400887j" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400887j&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400887j&amp;href=/doi/10.1021/jm400887j" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400887j" /></input><a href="/doi/pdf/10.1021/jm400887j" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400887j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400887j%26sid%3Dliteratum%253Aachs%26pmid%3D24044773%26genre%3Darticle%26aulast%3DGiordanetto%26date%3D2014%26atitle%3DMacrocyclic%2BDrugs%2Band%2BClinical%2BCandidates%253A%2BWhat%2BCan%2BMedicinal%2BChemists%2BLearn%2Bfrom%2BTheir%2BProperties%253F%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D2%26spage%3D278%26epage%3D295%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292357" title="Macrocyclic compounds">Macrocyclic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291298" title="Lactones">Lactones</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=291163" title="Macrocycles">Macrocycles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jmcmar.2014.57.issue-2/production/jmcmar.2014.57.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0016.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Macrocycles are ideal in efforts to tackle “difficult” targets, but our understanding of what makes them cell permeable and orally bioavailable is limited. Analysis of approximately 100 macrocyclic drugs and clinical candidates revealed that macrocycles are predominantly used for infectious disease and in oncology and that most belong to the macrolide or cyclic peptide class. A significant number (<i>N</i> = 34) of these macrocycles are administered orally, revealing that oral bioavailability can be obtained at molecular weights up to and above 1 kDa and polar surface areas ranging toward 250 Å<sup>2</sup>. Moreover, insight from a group of “de novo designed” oral macrocycles in clinical studies and understanding of how cyclosporin A and model cyclic hexapeptides cross cell membranes may unlock wider opportunities in drug discovery. However, the number of oral macrocycles is still low and it remains to be seen if they are outliers or if macrocycles will open up novel oral druggable space.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It has proven to be extremely difficult to develop small molecule probes and drugs against targets with extended binding sites, i.e., class B G-protein-coupled receptors (GPCRs), protein–protein interactions, and some enzymes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Currently “biologics” constitute the most common approach for modulation of these targets, with limitations such as high cost, reduced patient compliance, lack of cellular penetration, and low oral bioavailability. One reason for these difficulties could be that small molecule hits and leads that are compliant with Lipinski’s rule-of-five have been sought to increase the likelihood of obtaining favorable physicochemical and pharmacokinetic properties<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and in order to reduce risks of compound related toxicity.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> However, by stepping slightly outside the rule-of-five chemical space, compound diversity and opportunities to develop probes and drugs against “difficult” targets can be enhanced.</div><div class="NLM_p">Macrocycles have several features that make them interesting in efforts to tackle “difficult” targets with extended binding sites.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Because of their size and complexity, they can engage targets through numerous and spatially distributed binding interactions, thereby increasing both binding affinity and selectivity. Furthermore, cyclization provides a degree of structural preorganization that may reduce the entropy cost of receptor binding compared to linear analogues.<a onclick="showRef(event, 'ref5 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref7">(5, 7)</a> It should, however, be pointed out that macrocycles are not completely rigid. Instead they may offer a suitable compromise between preorganization and sufficient flexibility that could facilitate interactions with dynamic protein targets. In addition some reports suggest that cyclization has a favorable impact on other essential properties required for drugs, such as membrane permeability,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> metabolic stability, and overall pharmacokinetics.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a></div><div class="NLM_p">A significant number of macrocyclic drugs are currently on the market, predominantly of natural product origin with complex structures. Concerns that synthetic tractability will limit opportunities for lead optimization and increase costs for scale up are reasons why the pharmaceutical industry has been cautious about development of macrocyclic drugs. These concerns have resulted in macrocycles being excluded from most academic and industry screening collections; for example, the AstraZeneca high throughput screening (HTS) collection contains <1000 macrocycles. However, significant progress has recently been made that has increased the synthetic tractability of macrocycles.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9-12)</a> Another and potentially more serious concern is that our understanding of macrocycle absorption, distribution, metabolism, excretion, and toxicity (ADMET) is extremely poor and limiting for drug discovery efforts. A recent summit highlighted the need to generate a far better insight of what features confer cell permeability, including passive permeability, as well as transporter mediated uptake and uptake through endocytosis to macrocycles.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Improved understanding of oral bioavailability, tissue and organelle distribution, and factors governing metabolic stability, excretion, and toxicity is also required. Finally, a more detailed knowledge of how macrocycles engage their targets should also be searched for.</div><div class="NLM_p last">Pharmaceutical research has struggled with a declining efficiency for several decades,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and it has been argued that improving the selection of biological targets that influence disease is the single most important factor in order to deliver innovative medicines.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> A consequence of this reasoning is an increasing interest for the opportunities to modulate high priority targets with compound classes other than traditional organic small molecule drugs, such as macrocycles.<a onclick="showRef(event, 'ref5 ref6 ref13'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref13">(5, 6, 13)</a> Learning from the properties of macrocyclic drugs that are already launched, or in clinical development, constitutes an important step in efforts to capitalize on the macrocycle opportunity in the future. We have therefore reviewed which macrocyclic drugs are marketed for human use, what indications they are registered for, and which chemical class they come from. We have also investigated macrocycles in clinical development in a similar manner. Particular emphasis has been put on the route of administration of macrocyclic drugs and clinical candidates and on analyzing which properties allow oral administration in the major chemical classes.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2 Generation of Macrocyclic Drug Data Sets</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Various sources of structured information on marketed drugs are available today that provide an ideal platform for data analysis, e.g., DrugBank,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Thomson Reuters Integrity,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and the GVK BIO online structure–activity relationship database (GOSTAR).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In this study we mined GOSTAR, which provides assembled and curated data from the literature on marketed drugs and research compounds. Macrocyclic drugs (size of macrocycle, ≥12 atoms) that are marketed today for human use and their associated data consisting of chemical information, pharmacokinetics, pharmacology, and results from clinical development were extracted. Biologics and proteins, defined as polypeptides with >30 amino acids, as well as contrast agents and veterinary drugs were removed from further analysis. This curation resulted in a data set consisting of 68 macrocyclic drugs, which were further annotated with in silico molecular descriptors<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and information obtained from the literature on their route of administration,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> bioavailability, and dose in humans (cf. Table S1 in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for structures, indication, physical chemical properties, etc.). A data set of 35 macrocycles currently in clinical development was obtained in an analogous manner by mining of Adis R&D Insight<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and the literature, followed by curation and annotation just as for the set of marketed drugs (cf. Table S2 in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for structures, indication, physical chemical properties, etc.). In addition, compounds for which structures were not available were excluded from the latter data set. Through these efforts we have striven to make the two data sets of macrocycles as complete and accurate as possible. As information on launched drugs is readily available, we assume that the data set of marketed macrocyclic drugs is essentially complete. In contrast, the data set of macrocycles in clinical development is most likely less complete because some companies do not disclose structures, in particular for compounds in phase I but also in phase II studies.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3 Classification and Properties of Marketed Macrocyclic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">3.1 General Characteristics of Macrocyclic Drugs</h3><div class="NLM_p">Inspection of the 68 macrocyclic drugs on the market revealed that half of them are used to treat infections (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a). Most of these are used for infections of bacterial origin, and a few are for parasites or fungi. Oncology is the second largest therapeutic area, with one out of seven macrocycles being applied for treatment of various types of cancer. A few macrocyclic drugs are employed for managing cardiovascular disease (heart failure, thrombosis, acute coronary syndrome, and hypertension), as well as in gynecology (fertility, induction or inhibition of labor) and immunology (immunosuppression to prevent transplant rejection). The remainder of the macrocyclic drugs have found use in indications ranging from anesthesiology to pain.</div><div class="NLM_p">Most of the macrocyclic drugs were distributed almost equally between only two chemical classes: cyclic peptides and macrolides (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b). The cyclic peptides are delivered parenterally, with the exception of cyclosporin A. The macrolide class, however, contains 15 macrocyclic drugs that allow oral administration as well as an additional nine macrolides that are administered parenterally. Of the remaining macrocycles, a few belong to the ansamycin and porphyrin classes, while the alkaloid, bicyclam, cyclodextrin, and epothilone classes each have one macrocyclic drug member. Three out of the four registered ansamycins are administered orally to patients, while the macrocycles from the remaining five minor classes all are parenterals. Thus, oral macrocycles predominantly originate from the macrolide class, with a few being ansamycins and one a cyclic peptide. In contrast, parenteral macrocycles span a much broader chemical space. Interestingly oral macrocyclic drugs serve just two indications, infection and immunology, while parenteral macrocycles find application in a wider range of therapeutic areas. A complete overview of the distribution of marketed macrocyclic drugs across indication and chemical classes is given in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information (Table S1)">Supporting Information (Table S1)</a>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Distribution of oral (green bars, <i>N</i> = 19) and parenteral (red bars, <i>N</i> = 49) macrocyclic drugs across different therapeutic indications (a) and chemical classes (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As mentioned above, only 19 of the 68 macrocyclic drugs are administered orally, and 15 of these belong to the macrolide class (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b, green bars). As could be expected, a comparison of the calculated physical chemical properties of parenteral and oral macrocycles with oral small molecule drugs provides an explanation for the route of administration (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Parenteral macrocycles as a class are significantly more polar than either the oral macrocycles or small molecule drugs. Thus, the parenterals have more hydrogen bond donors, and consequently larger polar surface areas, than the two classes of orals. The calculated lipophilicity (cLogP) is also significantly lower for the parenteral macrocycles than for either class of oral drugs. In addition, the mean molecular weight of the parenteral macrocycles is higher than for the oral macrocycles. Comparing the oral macrocycles with the oral small molecule drugs reveals that molecular weight, cLogP, polar surface area, and number of hydrogen bond donors are on average ≥2 times higher for the oral macrocycles. A small number (<i>N</i> = 89, 5.6%) of the oral small molecule drugs have a molecular weight of >500 and are not macrocyclic. A comparison of this subset with the oral macrocyclic drugs reveals that the polarity is lower (fewer hydrogen bond donors and smaller polar surface area) for the nonmacrocyclic drug subset with molecular weight of >500, that the lipophilicity is similar, and that the macrocyclic drugs have a higher molecular weight. In conclusion, parenteral administration of macrocycles appears to be driven by the higher number of hydrogen bond donors displayed by this class than for macrocycles and small molecule drugs that are administered orally. Interestingly, even though relatively few oral macrocyclic drugs exist, their molecular weight is indeed significantly higher than for oral small molecules, as well as the subset of nonmacrocyclic drugs with molecular weight of >500 (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Most likely, oral availability among macrocyclic drugs and nonmacrocyclic drugs with molecular weight of >500 is facilitated by their relatively high lipophilicity compared to the “average” oral small molecule drug.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Calculated Physical Chemical Properties<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> for Oral Small Molecule Drugs, Different Classes of Registered Macrocycle Drugs, and Macrocycles in Clinical Development</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">class</th><th class="colsep0 rowsep0" align="center">route of administration</th><th class="colsep0 rowsep0" align="center"><i>N</i></th><th class="colsep0 rowsep0" align="center">HBD<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">PSA<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">cLogP <a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">MW<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="8" align="left">registered</td><td class="colsep0 rowsep0" align="left">small molecule</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left">1589</td><td class="colsep0 rowsep0" align="left">2 (2–2)</td><td class="colsep0 rowsep0" align="left">74 (71–76)</td><td class="colsep0 rowsep0" align="left">2.2 (2.1–2.4)</td><td class="colsep0 rowsep0" align="left">322 (317–328)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oral, MW > 500</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left">2 (2–3)</td><td class="colsep0 rowsep0" align="left">139 (127–152)</td><td class="colsep0 rowsep0" align="left">4.2 (3.7–4.9)</td><td class="colsep0 rowsep0" align="left">602 (582–624)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">macrocycle</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">4 (3–5)</td><td class="colsep0 rowsep0" align="left">212 (200–225)</td><td class="colsep0 rowsep0" align="left">4.4 (3.0–5.8)</td><td class="colsep0 rowsep0" align="left">852 (805–901)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">parenteral</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">14 (11–17)</td><td class="colsep0 rowsep0" align="left">417 (347–488)</td><td class="colsep0 rowsep0" align="left">0.6 (−1.2–2.3)</td><td class="colsep0 rowsep0" align="left">1126 (996–1257)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cyclic peptide</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">290</td><td class="colsep0 rowsep0" align="left">14.4</td><td class="colsep0 rowsep0" align="left">1203</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">parenteral</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">19 (15–22)</td><td class="colsep0 rowsep0" align="left">529 (444–614)</td><td class="colsep0 rowsep0" align="left">–0.8 (−3.0–1.4)</td><td class="colsep0 rowsep0" align="left">1294 (1128–1461)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">macrolide</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">4 (3–4)</td><td class="colsep0 rowsep0" align="left">205 (194–215)</td><td class="colsep0 rowsep0" align="left">3.7 (2.7–4.6)</td><td class="colsep0 rowsep0" align="left">831 (798–864)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">parenteral</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">6 (3–9)</td><td class="colsep0 rowsep0" align="left">240 (194–286)</td><td class="colsep0 rowsep0" align="left">2.1 (−1.2–5.5)</td><td class="colsep0 rowsep0" align="left">867 (771–963)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="8" align="left">clinical development</td><td class="colsep0 rowsep0" align="left">macrocycle</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">3 (2–4)</td><td class="colsep0 rowsep0" align="left">171 (130–214)</td><td class="colsep0 rowsep0" align="left">6.9 (5.3–8.5)</td><td class="colsep0 rowsep0" align="left">775 (634–916)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">parenteral</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">8 (5–11)</td><td class="colsep0 rowsep0" align="left">270 (189–351)</td><td class="colsep0 rowsep0" align="left">2.4 (0.5–4.2)</td><td class="colsep0 rowsep0" align="left">908 (751–1065)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cyclic peptide</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">5 (4–6)</td><td class="colsep0 rowsep0" align="left">277 (227–327)</td><td class="colsep0 rowsep0" align="left">11.3 (6.3–16.2)</td><td class="colsep0 rowsep0" align="left">1162 (946–1379)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">parenteral</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">15 (10–20)</td><td class="colsep0 rowsep0" align="left">450 (339–561)</td><td class="colsep0 rowsep0" align="left">–0.1 (−2.7–2.7)</td><td class="colsep0 rowsep0" align="left">1176 (936–1416)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">macrolide</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">3 (2–3)</td><td class="colsep0 rowsep0" align="left">203 (190–215)</td><td class="colsep0 rowsep0" align="left">5.2 (1.2–9.1)</td><td class="colsep0 rowsep0" align="left">911 (755–1067)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">parenteral</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">3 (2–4)</td><td class="colsep0 rowsep0" align="left">173 (87–260)</td><td class="colsep0 rowsep0" align="left">4.8 (0.9–8.8)</td><td class="colsep0 rowsep0" align="left">733 (402–1064)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">“de novo designed”</td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">2 (1–2)</td><td class="colsep0 rowsep0" align="left">121 (78–165)</td><td class="colsep0 rowsep0" align="left">5.7 (4.9–6.4)</td><td class="colsep0 rowsep0" align="left">598 (494–701)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">parenteral</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">173</td><td class="colsep0 rowsep0" align="left">6.1</td><td class="colsep0 rowsep0" align="left">937</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Mean value (lower and upper margins of 95% confidence interval).</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Hydrogen bond donors.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Polar surface area.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Calculated log <i>P</i>.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Molecular weight.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.2 Properties of Macrocyclic Drugs in the Cyclic Peptide Class</h3><div class="NLM_p">Exactly 30 of the macrocyclic drugs are cyclic peptides, which can be divided further into several subclasses (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, <a class="ref internalNav" href="#notes-1" aria-label="Table S1">Table S1</a>). The disulfide-bridged cyclic peptide subclass is the largest of these, with members such as argipressin and lanreotide. The glycopeptide subclass (e.g., vancomycin hydrochloride), the lipopeptide class of echinocandins (e.g., anidulafungin), and cyclic peptides with chemical modifications on amino acid side chains (e.g., pasireotide) each have three members, whereas the few remaining cyclic peptide drugs belong to six different subclasses. All macrocyclic peptide drugs except cyclosporin A, an N-methylated undecapeptide, are administered through various parenteral routes, in line with the general observation that insufficient oral bioavailability is a key limitation for peptide therapeutics. Inspection of the physical chemical properties of this set of parenteral cyclic peptide drugs shows that they are highly polar with a large number of hydrogen bond donors, a resulting large polar surface area, and low cLogP (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The mean molecular weight is also high. Taken together, the physical chemical properties of nonoral cyclic peptide drugs provide a clear rationale for why parenteral administration is required.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Distribution of oral (green bar) and parenteral (red bars, <i>N</i> = 29) macrocyclic peptide drugs across different subclasses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As mentioned above, cyclosporin A is the only one of the marketed macrocyclic peptide drugs that is administered orally. However, absorption in the gastrointestinal tract is highly variable, resulting in bioavailabilities ranging from <5% to 60% in bone marrow and kidney recipients, with a mean of 30%.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> At least in part, this variability has been shown to be a result of competing processes for uptake through passive diffusion and active secretion by p-glycoprotein.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> However, bioavailability can be improved and variability reduced by use of lipid based formulations.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Cyclosporin A is less polar than the parenteral cyclic peptide drugs (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), but having five hydrogen bond donors (four amide bonds and one hydroxyl group) still puts it at the limits of Lipinski’s rules. Studies performed by nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography as well in silico modeling have shown that cyclosporin A is conformationally flexible. In nonpolar media, such as phospholipid membranes, the hydrogen bond donors and acceptors form intramolecular hydrogen bonds that internalize polarity, thereby contributing to the high permeability and bioavailability of cyclosporin A.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a></div><div class="NLM_p last">Even though our general understanding of what structural and conformational features confer oral availability to peptides is still in its infancy, a few comprehensive studies of well-defined model systems provide valuable general insight. A study of linear tetra- and pentapeptides showed that single amino acid replacements that increased the propensity to form more compact β-turns resulted in increased lipophilicity and membrane permeability in Caco-2 cells.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In other studies, cyclization of linear hexapeptides were found to provide modest to dramatic increases in membrane permeability.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> In these studies, the increased lipophilicity and membrane permeability were proposed to be a result of intramolecular hydrogen bonding of amide bonds in the β-turn or cyclic peptide. In addition, transformation of an extended conformation into a compact one is also known to lead to increased diffusion across membranes.<a onclick="showRef(event, 'ref8 ref31'); return false;" href="javascript:void(0);" class="ref ref8 ref31">(8, 31)</a> Studies of stereoisomers and N-methylated derivatives of cyclo[Leu<sub>4</sub>-Pro-Tyr] provided another example that druglike passive membrane permeability can be obtained for cyclic peptides in which amide bonds may form intramolecular hydrogen bonds, providing further support for the hypothesis that shielding of amide bonds from the surrounding environment facilitates transport across cell membranes.<a onclick="showRef(event, 'ref30 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref32">(30, 32)</a> In contrast, a study of a library of cyclo[<span class="smallcaps smallerCapital">d</span>-Ala-Ala<sub>5</sub>] peptides with different N-methylation patterns revealed no such relationship.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Instead it was concluded that membrane permeability, which was observed for some members of the library, was due to transporter mediated permeation. In summary, these studies of model peptides highlight the fact that a more compact molecule will have a greater membrane permeability than an extended one with the same molecular weight.<a onclick="showRef(event, 'ref8 ref31'); return false;" href="javascript:void(0);" class="ref ref8 ref31">(8, 31)</a> In addition, intramolecular hydrogen bonding of amide bonds in cyclic peptides may increase membrane permeability, just as observed for cyclosporin A.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.3 Properties of Macrocyclic Drugs in the Macrolide and Ansamycin Classes</h3><div class="NLM_p">Several different subclasses are featured among the orally administered macrolides (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). These include all the erythronolides, ranging from the prototypical erythromycin to first generation derivatives aimed at improving its acid instability (e.g., erythromycin ethylsuccinate) and to second generation drugs with improved pharmacokinetics and antibacterial spectrum (e.g., azithromycin and clarithromycin).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Leucomycins, such as rokitamycin, and rapamycins, such as everolimus, are also delivered orally, just as tacrolimus of the ascomycin subclass. Parenterally delivered macrolide drugs show additional structural variation, including polyene macrolides, e.g., amphotericin B and natamycin. All four ansamycin antibiotics belong to the naphtoquinone chemical subclass, and three of them are administered orally.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Distribution of oral (green bars) and parenteral (red bars) ansamycin and macrolide drugs across different subclasses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Calculation of the physical chemical properties of oral and parenteral macrolides, respectively, did not reveal any significant difference with regard to the number of hydrogen bond donors, polar surface area, lipophilicity, or molecular weight that could explain why some were dosed orally and others were not (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). However, the number of drugs in each group is small and there is a nonsignificant trend for the parenterals to be more polar, less lipophilic, and have a higher molecular weight. The 18 oral macrolides and ansamycins had molecular weights ranging from 700 to just under 1000 Da, and a correlation was found between increasing molecular weight and lipophilicity (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>a). This suggests that an increased lipophilicity is required to obtain sufficient oral uptake as molecular weight increases, in line with an earlier study for oral small molecule drug projects.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Interestingly, all but one oral macrocyclic drug have a polar surface area between 180 and 240 Å<sup>2</sup> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b), which is higher than the preferred range of ≤140 Å<sup>2</sup> for small molecule drugs.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> The maximum number of hydrogen bond donors decreases from six to three with increasing molecular weight (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>c). It is possible that this decrease in hydrogen bond donors is driven by the need to keep polar surface area within the allowed range for oral bioavailability as molecular weight, and thereby the number of heteroatoms, increases. The human bioavailability of the oral macrolides and ansamycins range from 10% to 75%, with a mean of 50%. However, no trends were found when the bioavailabilities were analyzed as a function of molecular weight, lipophilicity, polar surface area, and the number of hydrogen bond donors (Figure S1 in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Altogether, this suggests that Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> may begin to define the limits of chemical space within which macrocycles are confined in order to have sufficient cell permeability to allow oral administration. As illustrated by cyclosporin A, rule-breaking outliers exist far outside this chemical space (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Calculated lipophilicity (a, cLogP), polar surface area (b, PSA), and number of hydrogen bond donors (c, HBD) as a function of molecular weight (MW) for oral macrocyclic drugs from the macrolide (cyan) and ansamycin (magenta) classes. Cyclosporin A (black) has been included for comparison.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Three subclasses feature examples of both oral and parenteral macrocycles: the ascomycin and rapamycin macrolides and the naphthoquinone-based ansamycins. In the following, we compare and contrast drugs belonging to these subclasses to highlight structural differences and their impact on the route of administration. In contrast to the other three approved ansamycins antibiotics (rifampicin, rifabutin and rifapentine, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), rifaximin is poorly absorbed in the intestine,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> which makes it an effective treatment of choice for traveler’s diarrhea. The low gastrointestinal absorption is due to its pyridoimidazo nucleus existing in a mesomeric betaine form.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> This zwitterionic feature, which is absent in the other three ansamycins, coupled with the presence of anionic phenolic hydroxyl groups ensures that rifaximin is ionized throughout the intestine, thus minimizing its systemic absorption.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Macrocyclic Drugs of the Ansamycin Class</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0009.gif" alt="" id="fx1" /></img><div></div></div><div class="NLM_p">The ascomycin macrolide subclass of approved drugs includes tacrolimus (FK-506),<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> an oral immunosuppressant used after allogeneic organ transplant, and pimecrolimus, a topical treatment for atopic eczema (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). The structural differences between the two drugs are small. Pimecrolimus shows an ethyl substituent in position 8 of the macrolactam instead of a propenyl group. Furthermore, pimecrolimus has a chlorine atom substituting position 4 of the pendent cyclohexyl ring in lieu of a hydroxyl group in tacrolimus. Reflecting the similar physicochemical profiles of the two ascomycins, pimecrolimus was found to be rapidly absorbed after oral dosing in phase I and phase II clinical trials,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> just as tacrolimus. When both drugs were compared in their topical forms, tacrolimus as an ointment proved to be more efficacious than pimecrolimus cream in treating atopic dermatitis.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> This difference in efficacy could be attributed to the fact that topical pimecrolimus displays lower permeation through the skin<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> because of a higher affinity to skin proteins.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The two ascomycins thereby illustrate that drugs may be administered through different routes of administration in spite of having very similar physicochemical and pharmacokinetic properties. This is a caveat that must be kept in mind in analysis and discussions assuming that the route of administration reflects the properties of the drug.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Macrocyclic Drugs of the Ascomycin Macrolide Subclass</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0010.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">Sirolimus was the first marketed drug in the rapamycin macrolide class (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). It is administered orally to prevent rejection of organ transplants, particularly kidney transplants.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Temsirolimus, a dihydroxypivalate ester prodrug of sirolimus, offers enhanced solubility and reduced half-life over sirolimus and can thus be administered intravenously to effectively treat renal cell carcinoma.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> In line with its prodrug nature, temsirolimus demonstrated minimal oral bioavailability (1.5–2.5%) in cancer patients.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The hydroxyl group at position 43 (C-43) of sirolimus was replaced by a 1<i>H</i>-tetrazol-1-yl substituent in zotarolimus, an immunosuppressant drug loaded on stents to reduce coronary artery restenosis. The increased lipophilicity and reduced solubility of zotarolimus allow a slow, extended release of the drug and an effective penetration of the coronary tissue, rendering it ideal for drug-eluting stents.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Everolimus, the 40-<i>O</i>-2-hydroxyethyl ether of sirolimus, was designed to improve the pharmacokinetic profile of sirolimus. It is extensively metabolized in vivo, and as a result, its half-life is shorter than that of sirolimus (28 and 62 h, respectively).<a onclick="showRef(event, 'ref47 ref51'); return false;" href="javascript:void(0);" class="ref ref47 ref51">(47, 51)</a> Everolimus is used to prevent rejection of organ transplants and for treatment of renal cancer and other tumors. Just as the other rapamycin derivatives, everolimus is a substrate for p-glycoprotein, which affects its oral bioavailability. Nevertheless, the oral bioavailability of everolimus in humans is somewhat higher than sirolimus (20 vs 14%, respectively), less variable, and more proportional to the administered dose.<a onclick="showRef(event, 'ref47 ref51'); return false;" href="javascript:void(0);" class="ref ref47 ref51">(47, 51)</a> The rapamycin macrolides have high molecular weights, ranging from just over 900 to a bit over 1000. They are also highly lipophilic, and the two oral agents, sirolimus and everolimus, illustrate the correlation toward increasing lipophilicity with increased molecular weight found for oral macrocyclic drugs (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). With the compounds being close to the limits of oral macrocycle chemical space, it is not unexpected that further addition of hydrophobicity, as contributed by the tetrazole moiety of zotarolimus, results in reduced solubility and low oral bioavailability.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Macrocyclic Drugs of the Rapamycin Macrolide Subclass</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0011.gif" alt="" id="fx3" /></img><div></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.4 Human Doses and Bioavailabilities of Macrocyclic Drugs</h3><div class="NLM_p">Compilation of the daily dose administered to humans highlighted a clear difference between the oral (macrolides, ansamycins, and cyclosporin A) and parenteral macrocyclic drugs across chemical classes. The daily dose for orally administered macrocyclic drugs was significantly higher than for macrocyclic drugs that are generally administered via the parentaral route (mean/median: 633/500 mg versus 199/20 mg, respectively, <i>p</i> < 0.05). As the vast majority of the orally administered macrocyclic drugs are used to treat bacterial infections, this difference might simply be due to the therapeutic requirements, where a high dose is preferred to maximize bacteriostatic and/or bactericidal action rather than to circumvent absorption and/or metabolic stability liabilities of the drugs. Intriguingly and supporting this hypothesis, all seven outliers among the parenteral macrocyclic drugs that have daily doses of ≥500 mg are antiinfective drugs, ranging from the depsipeptide ramoplanin (500 mg) to the streptogramin dalfopristin (∼1300 mg) and the glycopeptides vancomycin (2000 mg).</div><div class="NLM_p">It might be envisioned that high doses would be used to compensate for low bioavailabilities among oral macrocyclic drugs. However, an analysis of human daily doses and oral bioavailabilities for the oral macrocyclic drugs did not reveal such a dependency (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). An interesting example of the role of formulation is provided by ivermectin, an exceptionally potent oral antiparasitic agent belonging to the avermectin macrolide class. Because of its unusual potency, ivermectin is normally dosed in the 3–15 mg/day range and displays a dose-independent systemic bioavailability (60%).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, the pharmaceutical form plays a critical role, with an ethanolic solution of ivermectin offering twice as high bioavailability as tablets and capsules.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Daily dose (mg) versus oral bioavailabities (%) for macrocyclic drugs administered orally. Colors indicate the corresponding chemical class (black, cyclic peptide = cyclosporin A; cyan, macrolide; magenta, ansamycin).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">4 Classification and Properties of Macrocycles in Clinical Studies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">4.1 General Characteristics of Macrocycles in Clinical Studies</h3><div class="NLM_p">The current clinical development landscape contains at least 35 macrocycles in various phases, with actual numbers assumed to be higher, as compounds for which structures were unavailable, e.g., POL6326 and POL7080<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> developed by Polyphor, have been excluded from this analysis. Compounds that have been discontinued, e.g., TZP101 and TZP102 developed by Tranzyme until recently,<a onclick="showRef(event, 'ref9 ref54'); return false;" href="javascript:void(0);" class="ref ref9 ref54">(9, 54)</a> have also been excluded. The current data set reveals that macrocycles are still predominantly developed for use in oncology and infection (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a), just as registered macrocyclic drugs (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a). Other indications ranging from dermatology to urinary are also being addressed via macrocycles. When the chemical nature of the macrocycles in clinical studies is considered, cyclic peptides constitute the largest group (<i>N</i> = 11), while porphyrins, macrolides, epothilones, and ansamycins are smaller (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b). Overall this resembles the situation for marketed macrocyclic drugs (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b). Interestingly, a relatively large number of clinical candidates (<i>N</i> = 10) do not belong to any of the established structural groups of marketed macrocyclic drugs. Instead their structural features are novel and they can be characterized as de novo designed macrocycles. A complete list of macrocycles in clinical trials, across indications and chemical class, is given in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information (Table S2)">Supporting Information (Table S2)</a>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Distribution of oral (green bars, <i>N</i> = 15) and parenteral (red bars, <i>N</i> = 20) macrocyclic compounds in clinical development across different therapeutic areas (a) and chemical classes (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A relatively large proportion of the macrocyclic compounds currently in clinical trials are administered orally (43%, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). This represents an increase over the registered drugs described above, 28% of which are oral agents. Oral macrocycles currently in development are predominantly directed against the two major indications, infectious diseases and cancer. Interestingly, three of the cyclic peptides and all but one of the “de novo designed” macrocycles are being evaluated as oral drugs (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b). Thus, even though numbers are small and may be affected by future clinical attrition, there is clearly a trend toward increased development of macrocycles for oral administration.</div><div class="NLM_p">Oral macrocycles in clinical development have fewer hydrogen bond donors and higher lipophilicity than nonoral macrocycles in development (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). They also have lower mean values for polar surface area and molecular weight compared to their parenteral counterparts, even though these differences are not statistically significant. This pattern reflects the situation for the registered macrocyclic drugs. However, when macrocyclic drugs and clinical candidates are pooled, all four descriptors are significantly different between orally and parenterally administered macrocycles. Just as for the marketed macrocycles, the molecular weight of the orals in clinical studies ranges up to 1000 Da or over 1200 Da when the two cyclic peptides, which are analogues of cyclosporin A, are included (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). One difference, when compared to macrocyclic drugs, is the presence of a group of four macrocycles in clinical studies that have a molecular weight of approximately 400, i.e., in the range of small molecule drugs. The trend that lipophilicity increases with molecular weight and the presence of an upper limit for the polar surface area at approximately 250 Å<sup>2</sup>, found for the marketed macrocycles, are also observed for those in clinical studies (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>a and Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>b). However, in contrast to the marketed macrocyclic drugs, there is no decrease in the number of hydrogen bond donors as molecular weight increases (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>c).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Lipophilicity (a, cLogP), polar surface area (b, PSA), and the number of hydrogen bond donors (c, HBD) as a function of molecular weight (MW) for oral macrocycles in clinical studies. Clinical candidates come from the macrolide (cyan), ansamycin (magenta), “de novo designed” (green), and cyclic peptide (black) classes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">4.2 Properties of Orally Administered Ansamycins and Macrolides in Clinical Studies</h3><div class="NLM_p">The limited number of compounds from the macrolide and ansamycin classes (<i>N</i> = 5 and <i>N</i> = 2, respectively, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) prevents a general discussion of physical chemical properties with regard to oral absorption. Nevertheless, the three oral agents rifalazil, ridaforolimus, and solithromycin provide interesting medicinal chemistry information on how structural features affect pharmacokinetics. Rifalazil is a novel ansamycin antibiotic being developed for treatment of chlamydia and tubercolosis. Compared to the other orally administered ansamycin drugs, it contains a disubstituted benzoxazine ring (cf. Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), which makes rifalazil a very lipophilic compound with unique properties in the ansamycin class. Thus, treatment with rifalazil provides adequate oral bioavailability allowing for high intracellular levels and high tissue penetration in both preclinical species<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and humans.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Interestingly, the large volume of distribution in humans and rifalazil’s metabolic stability result in a half-life of approximately 100 h,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> enabling once weekly dosing. Ridaforolimus is a member of the rapamycin subclass of macrolide antibiotics. It is a nonprodrug analogue of sirolimus, where the hydroxyl group at position C-43 of sirolimus has been derivatized to a dimethylphosphinate (cf. Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). This afforded a more soluble sirolimus analogue, with less variable and more predictable pharmacokinetics suitable for both oral and intravenous administration.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58, 59)</a> Solithromycin belongs to the ketolide subclass of macrolides, a group of erythromycin derivatives that, unlike erythromycin, are stable to gastric pH and can thus be administered orally. Similar to other ketolides, solithromycin is rapidly and efficiently absorbed in humans.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The fluoro atom at the macrolide 2 position and the 4-(3-aminophenyl)-1,2,3-triazol-1-yl side chain make solithromycin a much safer alternative than telithromycin, the first approved ketolide that displays dose limiting adverse effects (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Orally Administered Ansamycin and Macrolides in Clinical Development<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup>Table a</sup><p class="last">The approved ketolide telithromycin is included for comparison to solithromycin.</p></div></div><div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">4.3 Properties of Orally Administered Cyclic Peptides in Clinical Studies</h3><div class="NLM_p">Cyclic peptides represent the largest group of macrocycles in clinical trials (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). They show structural variation with subclassification based on the nature of the side chain to side chain cyclization, i.e., via a lactam (<i>N</i> = 3) or a disulfide (<i>N</i> = 2) bridge, or by belonging to the depsipeptide (<i>N</i> = 3) or backbone-N-methylated subgroups (<i>N</i> = 3). As expected, the three oral cyclic peptides in the clinic had fewer hydrogen bond donors and lower polar surface areas and were consequently more lipophilic than the ones investigated for parenteral administration (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The molecular weight was high in both groups (1100–1200 Da), providing yet another example that molecular weight can be stretched up to and above 1000 Da with acceptable oral uptake.</div><div class="NLM_p">Two of the three oral cyclic peptides in clinical development are close analogues of cyclosporin A [SCY365 (<b>1</b>) and voclosporin, Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>]. Cyclic peptide <b>1</b> differs from cyclosporin A at positions 3 and 4; a dimethylaminoethylthio substituent is installed on the α-carbon of the <i>N</i>-methylglycine at position 3, and a hydroxyl group is added to the γ-carbon of the <i>N</i>-methylvaline at position 4 (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). These structural modifications make <b>1</b> a potent inhibitor of HCV replication,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and a recent clinical trial established its antiviral activity in patients with chronic genotype 1 HCV infection.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Cyclic peptide <b>1</b> is a poor substrate and a weak inhibitor of p-glycoprotein mediated transport, which should contribute to its ready permeation through cellular membranes, affording significant oral bioavailability (15–22%) in preclinical species.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Elongation of the original (4<i>R</i>)-4-[(<i>E</i>)-2-butenyl]-4,<i>N</i>-dimethyl-<span class="smallcaps smallerCapital">l</span>-threonine (MeBMT) residue at position 1 of cyclosporin A by one carbon to yield the terminal diene in voclosporin resulted in a significantly more potent immunosuppressive agent.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Interestingly, in spite of the minor difference in structure compared to cyclosporin A, voclosporin was well absorbed after oral administration in both preclinical species and humans, offering less variability in plasma concentrations and a more predictable pharmacokinetics/pharmacodynamics (PK/PD) relationship compared to cyclosporin A.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64, 65)</a> As a result, voclosporin will now be evaluated for its efficacy in reducing kidney transplant acute rejection. As close analogues of cyclosporine A, it can be assumed that <b>1</b> and voclosporin undergo conformational changes and form intramolecular hydrogen bonds in nonpolar media and that this results in high cell permeability and oral bioavailability for both of them.</div><div class="NLM_p">NXL-103 consists of two streptogramin antibiotics in a 30/70 combination: linopristin, a morpholino-containing derivative of pristinamycin IA, and flopristin, a fluorinated analogue of pristinamycin IIB (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). This synergistic combination yields a broad spectrum Gram positive antibiotic with activity against a wide range of bacteria, not affected by either beta-lactam or macrolide resistance mechanisms.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Unlike current antibiotic therapies with similar activity profiles, this linopristin/flopristin combination is orally bioavailable with rapid absorption, especially as a solution and after food consumption. The physical chemical properties of linopristin, the cyclic peptide component of the combination, are druglike; i.e., the number of hydrogen bond donors is low, and lipophilicity is relatively high; most likely this contributes to making linopristin orally available. In addition, linopristin resembles cyclosporin A by having few hydrogen bond donors in the cyclic peptide backbone. Conformational studies of linopristin in different media have not been reported, but it cannot be ruled out that linopristin, just as cyclosporin A, adopts an intramolecularily hydrogen bonded conformation in nonpolar media that contributes to oral bioavailability.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Orally Administered Cyclic Peptides in Clinical Development</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0013.gif" alt="" id="fx5" /></img><div></div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">4.4 Properties of Oral “de Novo Designed” Macrocycles in Clinical Studies</h3><div class="NLM_p">Interestingly, a new group of macrocycles, which are mainly orally administered, is featured in our analysis (<i>N</i> = 10). The members of this group have been developed through structure based approaches and include peptide-inspired hepatitis C virus (HCV) protease and polymerase inhibitors (<i>N</i> = 5) and macrocyclic kinase inhibitors (<i>N</i> = 4) (Tables <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a> and <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). The physical chemical properties of the five HCV protease and polymerase inhibitors are essentially identical to those of the marketed macrocyclic drugs; e.g., molecular weights are close to 750 Da, and polar surface areas are just under 200 Å<sup>2</sup> (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). In contrast, the macrocyclic kinase inhibitors are more related to oral small molecule drugs with molecular weights in the range 375–475 and polar surface areas close to 50 Å<sup>2</sup> (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>).</div><div class="NLM_p">First generation HCV inhibitors boceprevir<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> and telaprevir<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> bind covalently to the catalytic serine of viral NS3/4A protease and are used to treat chronic genotype 1 HCV infections. Currently, a second generation of reversible macrocyclic-based NS3/4a inhibitors, inspired by the early NS3 macrocyclic inhibitor BILN2061<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> (<b>2</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>), is being evaluated in clinical studies. NS3 inhibitor <b>2</b> provided the first clinical proof-of-concept for NS3 inhibition but was not developed further due to cardiac toxicity.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Interestingly, the initial rational for the design of <b>2</b> was structure-based and pharmacokinetic to employ macrocyclization to reduce entropic loss upon binding to NS3 while simultaneously improving the metabolic stability by reducing the peptidic nature of the compound.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The most advanced of these second generation inhibitors is simeprevir, now in preregistration, where an olefin tether connects the so-called P1 and P3 moieties. Simeprevir has good passive permeability properties (Caco-2 <i>P</i><sub>app</sub> = 8 × 10<sup>–6</sup> cm/s) and low to moderate oral bioavailability in rats (11–44%).<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71, 72)</a> Initial phase III clinical trials results indicate that simeprevir improves response rates for difficult-to-treat chronic genotype 1 hepatitis C infections. Danoprevir is another P1–P3-cyclized, HCV NS3/4a inhibitor in clinical development. While the macrocylic element is similar to simeprevir, it is interesting to note the presence of a pyrrolidine ring as a central moiety replacing the trisubstituted cyclopentane of simeprevir. Following oral administration to healthy subjects, danoprevir is well absorbed and its bioavailability can be enhanced by coadministration with food.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Danoprevir is metabolized by CYP3A4, but its pharmacokinetics profile is greatly improved when co-dosed with the CYP3A4 inhibitor ritonavir.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> It is therefore now developed as a combination with ritonavir, allowing for lower efficacious doses.</div><div class="NLM_p">Vaniprevir is another potent and selective NS3/4a inhibitor now being tested in phase III in combination with pegylated interferon and ribavirin. On the basis of molecular modeling, a different macrocyclization strategy was engineered,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> this time connecting the P2 and P4 units of typical HCV NS3/4a inhibitors (cf. Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Plasma exposure following oral dosing varied significantly across preclinical species ranging from poor (rat, dog, and rhesus, 5 mg/kg dose as a PEG400 solution) to excellent (chimpanzees, 10 mg/kg as a chocolate milk solution).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Aiming at extending the activity profile of vaniprevir to include additional HCV genotypes, Merck started a back-up program based on the assumption that its structural constraints would limit vaniprevir’s ability to be broadly effective.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Different P2–P4 cyclization attempts borrowing structural elements from both vaniprevir and danoprevir and subsequent structure–activity relationship (SAR) optimization resulted in the identification of MK-5172 (<b>3</b>),<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> which exhibited potent activity against several HCV genotypes and resistant variants. Although it displayed modest oral bioavailability in rats and dogs (1% and 13%, respectively), its excellent liver exposure resulted in improved efficacy in a chimpanzee model of HCV infection<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> and it is now being tested in the clinic. TMC647055 (<b>4</b>)<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> is another HCV inhibitor that targets the NS5b RNA-dependent RNA-polymerase, currently being evaluated in phase II clinical trials as a combination with simeprevir. Similar to <b>2</b>, its design aimed at (i) increasing potency by “freezing” the ligand’s bound conformation and (ii) reducing metabolism by preventing molecular recognition at cytochromes via a rigidified structure.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> As a result, <b>4</b> displayed potent HCV NS5b inhibition, reduced clearance, and optimal bioavailability in rats and dogs (66% and 87%, respectively).<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79, 80)</a></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. De Novo Designed Macrocyclic HCV Protease NS3/4a and Polymerase NS5b Inhibitors in Clinical Development and Progenitor Compound <b>2</b> with Annotated Structural Elements P1–P4</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0014.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_p">A class consisting of four macrocyclic kinase inhibitors, with physical chemical properties similar to oral small molecule drugs, is also in clinical development. The most advanced is pacritinib (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>), identified through a structure-based approach.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Here, ring closing methathesis using <i>O</i>-allyl precursors served to connect the two terminal phenyl rings of the original hits. Preclinical studies revealed moderate and variable bioavailability in mice (39%), rat (24%), and dog (10%).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Pacritinib showed fast and extensive oral absorption in humans<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> and is currently being evaluated in phase III clinical trials in patients with primary myelofibrosis. Isosteric replacement of one of the phenyl rings of pacritinib by a furane yielded SB1578 (<b>5</b>), a novel Jak2, FLT3, and c-Fms kinase inhibitor with low-to-moderate bioavailability in rats and mice, currently tested in the clinics for the treatment of rheumatoid arthritis.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> SAR studies on the cyclization element in pacritinib’s chemotype indicated that incorporation of a basic group gave macrocycles with a broad kinase selectivity profile.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Optimization of the macrocycle size and substitution pattern identified SB1317 (<b>6</b>),<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> which displayed variable oral bioavailability in preclinical species (4–37%) despite its relatively high passive diffusion in Caco-2 monolayer (<i>P</i><sub>app</sub> = 28 × 10–6 cm/s).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Kinase inhibitor <b>6</b> is currently undergoing phase I clinical trials for advanced/refractory hematological malignancies. JNJ-26483327 (<b>7</b>)<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> is a potent, multitargeted macrocyclic tyrosine kinase inhibitor in phase I studies. When administered orally and twice daily to mice, its bioavailability was approximately 80%.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> A study in patients with advanced solid tumors indicated rapid and significant oral absorption. Here, the overall plasma exposure of <b>7</b> was not dose-proportional at the highest doses, suggesting limitations in the absorption process.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. De Novo Designed Kinase Inhibitors in Clinical Development</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0015.gif" alt="" id="fx7" /></img><div></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">5 Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">5.1 Overview of Macrocyclic Drugs and Clinical Candidates</h3><div class="NLM_p last">By mining of GOSTAR and Adis R&D Insight, respectively, 68 approved macrocyclic drugs and 35 macrocycles in various phases of clinical development were identified. Most likely the actual number of clinical candidates is higher, as only macrocycles for which structures have been disclosed were included in the data set. Half of the approved drugs are used to treat various kinds of infections, and another 15% have applications in oncology. Infection and oncology account for approximately 70% among the macrocyclic clinical candidates, but a shift has taken place so that oncology has become the major indication. The remainder of the drugs and clinical candidates is distributed between approximately 10 other indications. Cyclic peptides and macrolides were found to be dominating chemical classes for both the marketed drugs and the clinical candidates, reflecting their natural product origin. In fact three out of four approved macrocycles belonged to either of these two classes, with roughly equal numbers of drugs in each class. Among the clinical candidates half were cyclic peptides or macrolides, with cyclic peptides being the larger class. Interestingly, a novel class of “de novo designed” macrocycles, making up just below 30% of the total and acting on enzyme targets, has emerged in the group in clinical studies. This reveals a shift away from the traditional natural product dominance toward macrocyclic drugs that also originate from structure based design. Most registered macrocyclic drugs are delivered by various parenteral routes, but 28% were found to be delivered orally for systemic activity. Encouragingly, the proportion intended for oral administration and systemic action has increased to 43% among the clinical candidates, with most of these belonging to the class of “de novo designed” macrocycles. The increased proportion of orals thus illustrates that the move into novel chemical space also has been accompanied by improved physical chemical properties that permit oral adminstration. However, orally administered macrocyclic drugs or clinical candidates are still rare with only 19 and 15 macrocycles in each category.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">5.2 Implications for the Design of Orally Available Macrocycles</h3><div class="NLM_p">The vast majority of orally administered macrocycles, i.e., 30 out of 34 drugs and clinical candidates, belong to the macrolide, ansamycin, and “de novo designed” classes. Their molecular weights reach up to just under 1000 Da, while polar surface areas range up to approximately 250 Å<sup>2</sup> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Encouragingly, this illustrates that macrocycles with oral bioavailability can be found far outside the boundaries generally preferred for oral small molecule drugs, i.e., molecular weight of <500–600 Da and polar surface area of <140–150 Å<sup>2</sup>.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> However, the current number of oral macrocycles is low and members come from only a few chemical classes. It therefore remains to be seen if the current oral macrocycles are outliers or if macrocycles will open up novel oral druggable space. It is emphasized that an increased lipophilicity appears to be required to obtain sufficient oral uptake as molecular weight increases for macrocycles, just as reported for oral small molecules from different drug discovery projects.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> For oral small molecule drugs an increased lipophilicity is known to be correlated to higher levels of target promiscuity,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> as well as increased risks of in vivo animal toxicity.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> It may be speculated that structurally more complex macrocycles might be more selective, and therefore, the risks of increased lipophilicity could be lower than for oral small molecule drugs.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lipophilicity (a, cLogP), polar surface area (b, PSA), and hydrogen bond donor count (c, HBD) as a function of molecular weight (MW) for macrocycles in clinical development and registered macrocyclic drugs. Macrocycles administered orally are in green, and those given parenterally are in red. Solid black boxes indicate preferred molecular property space for oral small molecules (MW < 500, cLogP < 5, PSA < 140, HBD < 5). Dashed black boxes indicate preferred molecular property space for oral macrocycles (MW < 1000, cLogP < 10, PSA < 250, HBD < 5). Cyclosporin A and two analogues in clinical development are the only oral macrocycles outside the dashed space.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Even though the current analysis may begin to define the limits of physical chemical space within which orally available macrocycles may be found, a significant number of parenterals are also found within this space (cf. Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The finding that orally administered macrocyclic drugs had significantly higher daily doses than parenterals first suggested that high doses might have been used to compensate for low bioavailabilities, thereby influencing the route of administration. However, further analysis instead revealed that high daily doses reflected the fact that these drugs were used to treat bacterial infections, where a high dose is preferred to maximize efficacy. Inspection of the registered drugs belonging to the ansamycin and rapamycin macrolide classes provided some examples that minor structural variations can have a major impact on the route of administration (cf. rifaximin vs rifabutin in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and zotarolimus vs sirolimus in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). The medicinal chemistry variations on display in the macrolide class of macrocyclic drugs thus highlight the challenge of predicting the absorption profile from the molecular structure in that even minor modifications can have substantial effects. The class of “de novo designed” macrocycles in clinical development, with 9 out of 10 members being oral, suggests that medicinal chemists may be able to engineer macrocycles having both desired pharmacodynamics and pharmacokinetics properties, including oral bioavailability. It is worth pointing out that these oral “de novo designed” macrocycles target proteases, kinases, and polymerases and that structure-based approaches were instrumental in their development.</div><div class="NLM_p last">The cyclic peptide cyclosporin A<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> and its two analogues <b>1</b><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and voclosporin,<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> which are in clinical development, reveal that rule-breaking outliers may exist outside the physical chemical space defined by the majority of the oral macrocycles (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). These three orals differ from the vast majority of parenteral macrocyclic peptide drugs and clinical candidates by having significantly fewer hydrogen bond donors and higher lipophilicities (cf. Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In addition, cyclosporin A has been found to be conformationally flexible allowing internalization of polarity through intramolecular hydrogen bonding which facilitates transport across phospholipid membranes, thereby contributing to the unexpectedly high bioavailability.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> Most likely, intramolecular hydrogen bonding also explains why <b>1</b> and voclosporin can be administered orally. Interestingly, recent studies reveal that it is possible to design cyclic hexapeptides with druglike membrane permeability and potential oral bioavailability.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> This may result in wider applications of macrocyclic peptides in drug discovery, provided that it is also possible to engineer desired pharmacology in such peptides.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">5.3 Future of Macrocycles in Drug Discovery</h3><div class="NLM_p">As summarized in the current review and other reviews,<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> macrocycles, mainly of natural product origin, have already proven their value as pharmaceutical agents. In particular macrolides and cyclic peptides have been developed for treatment of infectious disease and for use in oncology. The presence of a significant clinical pipeline of macrocycles and an increasing number of publications and reviews also reveal a durable and increasing interest in the field. Recent advances in synthetic methodology have contributed to a steady improvement in synthetic access to macrocycles, ranging from collections of large cyclic peptides to smaller tethered oligopeptides and diverse natural product like macrocycle collections.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9-12)</a> As a result, a number of drug discovery enterprises have emerged that base their research efforts exclusively on macrocycles, for instance, Tranzyme (now Ocera Therapeutics), Ensemble, Polyphor, Aileron, Peptidream, Bicycle Therapeutics, and Ra Pharmaceuticals.</div><div class="NLM_p last">At present 34 macrocycles, marketed as drugs or in clinical development, are administered orally. This may appear as few but should be viewed in the context that only approximately 90 out of 1600 nonmacrocyclic oral small molecule drugs have molecular weights in the same range as macrocycles (>500 Da). Parenteral administration may be an option, but the true future opportunity of macrocycles in drug discovery relies on our ability to design cell permeable and orally bioavailable compounds, thereby providing differentiation versus “biologics”. Thus, there is a clear need to generate a far better understanding of the features that confer cell permeability, oral bioavailability, and tissue and organelle distribution to macrocycles.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Encouragingly, as revealed in the current overview, macrocycles with physical chemical properties, i.e., molecular weight and polar surface area, far beyond oral small molecule drug space can indeed be discovered and employed for oral administration. In this context the emergence of a group of oral “de novo designed” macrocycle clinical candidates, developed through structure based approaches, is particularly interesting. In addition, information from oral cyclic peptides, i.e. cyclosporin A and analogues,<a onclick="showRef(event, 'ref26 ref27 ref62 ref64'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref62 ref64">(26, 27, 62, 64)</a> as well as recent understandings from cell permeable cyclic hexapeptides<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> may also result in wider applications of macrocyclic peptides in drug discovery. The current macrocyclic drugs and clinical agents also reveal how minor chemical modifications significantly affect key compound properties such as pharmacokinetics and toxicology. Consequently, in order to reap the fruits of macrocyclic chemical space, the need for rigorous medicinal chemistry to deliver multiparameter optimization remains.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26"><a href="/doi/suppl/10.1021/jm400887j">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82756" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82756" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">A description of the methods used for assembly of the data sets of marketed macrocyclic drugs and macrocycles in clinical development; tables listing the name, structure, chemical class and subclass, therapeutic area, route of administration (oral or parenteral), average human daily dose, human bioavailability and physical chemical properties (HBD, PSA, MW and cLogP) for the members of the two data sets; a figure describing the relationship between human oral bioavailability and MW, cLogP, PSA, and the number of HBDs, respectively, for macrolide, ansamycin, and cyclic peptide macrocyclic drugs. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400887j/suppl_file/jm400887j_si_001.pdf">jm400887j_si_001.pdf (1.08 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm400887j" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabrizio Giordanetto</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular and Metabolic
Disorders Research Area, AstraZeneca R&D
Mölndal, SE-431 83 Mölndal, Sweden</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#680e0f01071a0c09060d1c1c07281c091a071b460c0d"><span class="__cf_email__" data-cfemail="1573727c7a6771747b7061617a556174677a663b7170">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jan Kihlberg</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular and Metabolic
Disorders Research Area, AstraZeneca R&D
Mölndal, SE-431 83 Mölndal, Sweden</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c9a3a8a7e7a2a0a1a5abacbbae89a2aca4a0e7bcbce7baac"><span class="__cf_email__" data-cfemail="b7ddd6d999dcdedfdbd5d2c5d0f7dcd2dade99c2c299c4d2">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Fabrizio Giordanetto</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=BIO-d314e1439-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Fabrizio Giordanetto</b> graduated with first class honors in Medicinal Chemistry in 2000 from University of Genoa, Italy). He completed his Ph.D. in Computational Medicinal Chemistry in 2003 at University of London, U.K. while working for the chemistry unit of Pharmacia (Pfizer) in Nerviano, Italy. In 2004 he joined the Medicinal Chemistry Department of AstraZeneca in Mölndal (Sweden) where he grew professionally to the position of Principal Scientist and Preclinical Project Leader. Since 2013, he has been Director of Medicinal Chemistry for Taros Gmbh, a research-based SME in Dortmund, Germany, where he leads proprietary and third party medicinal chemistry activities. During his career, he worked on several drug discovery projects resulting in multiple clinical candidates spanning oncology and cardiovascular indications and >80 peer–reviewed publications, book chapters, and international patents.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Jan Kihlberg</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=BIO-d314e1444-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jan Kihlberg</b> obtained his Ph.D. in Organic chemistry in 1988 from Lund Institute of Technology, Sweden. After postdoctoral research at the National Research Council Canada, he established his research group at Lund institute of Technology in 1991 and then became Professor of Organic chemistry at Umeå University, Sweden, in 1996. In 2003 he joined AstraZeneca R&D Mölndal as Director of Medicinal Chemistry, then moved to a role as Director of Competitive Intelligence and Business Foresight Analysis in 2009. In parallel he maintained academic research first at Umeå University and then at Uppsala University, Sweden. In 2013 he became Professor of Organic Chemistry at Uppsala University. His research interests focus on the chemical biology of macrocycles, peptides, glycopeptides, and their mimetics. He has published 150 peer–reviewed publications, book chapters, and patents.</p></figure></div><div class="ack" id="ACK-d314e1449-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was funded by AstraZeneca R&D Mölndal. We thank Dr. Nicola Detta for mining of Adis R&D Insight as a starting point for generation of the data set of macrocycles in clinical studies. We also thank Drs. Adrian Gill and David Rees at AstraZeneca R&D and Astex Pharmaceuticals, respectively, for critical reading of this manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i33" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i33"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i34" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i34"> Abbreviations Used</h2><tr><td class="NLM_term">GOSTAR</td><td class="NLM_def"><p class="first last">the GVK BIO online structure–activity relationship database</p></td></tr><tr><td class="NLM_term">MeBMT</td><td class="NLM_def"><p class="first last">(4<i>R</i>)-4-[(<i>E</i>)-2-butenyl]-4,<i>N</i>-dimethyl-<span class="smallcaps smallerCapital">l</span>-threonine</p></td></tr><tr><td class="NLM_term">PK/PD</td><td class="NLM_def"><p class="first last">pharmacokinetics/pharmacodynamics</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08716" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08716" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 87 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Surade, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blundell, T. L.</span><span> </span><span class="NLM_article-title">Structural biology and drug discovery of difficult targets: the limits of ligandability</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.chembiol.2011.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22284353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=42-50&author=S.+Suradeauthor=T.+L.+Blundell&title=Structural+biology+and+drug+discovery+of+difficult+targets%3A+the+limits+of+ligandability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability</span></div><div class="casAuthors">Surade, Sachin; Blundell, Tom L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the past decade, researchers in the pharmaceutical industry and academia have made retrospective analyses of successful drug campaigns in order to establish "rules" to guide the selection of new target proteins.  They have identified features that are considered undesirable and some that make targets "unligandable.".  This review focuses on the factors that make targets difficult: featureless binding sites, the lack of hydrogen-bond donors and acceptors, the presence of metal ions, the need for adaptive changes in conformation, and the lipophilicity of residues at the protein-ligand interface.  Protein-protein interfaces of multiprotein assemblies share many of these undesirable features, although those that involve concerted binding and folding in their assembly have better defined pockets or grooves, and these can provide opportunities for identifying hits and for lead optimization.  In some protein-protein interfaces conformational changes-often involving rearrangement of large side chains such as those of tyrosine, tryptophan, or arginine-are required to configure an appropriate binding site, and this may require tethering of the ligands until higher affinity is achieved.  In many enzymes, larger conformational rearrangements are required to form the binding site, and these can make fragment-based approaches particularly difficult.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqCA_OH6VRoLVg90H21EOLACvtfcHk0lg5XILtaghQvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crsbc%253D&md5=646b6cad327b44785848375383ca90ea</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DSurade%26aufirst%3DS.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26atitle%3DStructural%2520biology%2520and%2520drug%2520discovery%2520of%2520difficult%2520targets%253A%2520the%2520limits%2520of%2520ligandability%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D42%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lieRl4hKgpkGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=191-200&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D11%26spage%3D191%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hann, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span> </span><span class="NLM_article-title">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnrd3701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22543468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=355-365&author=M.+M.+Hannauthor=G.+M.+Keseru&title=Finding+the+sweet+spot%3A+the+role+of+nature+and+nurture+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span></div><div class="casAuthors">Hann, Michael M.; Keserue, Gyoergy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Given its position at the heart of small-mol. drug discovery, medicinal chem. has an important role in tackling the well-known productivity challenges in pharmaceutical research and development.  In recent years, extensive analyses of successful and failed discovery compds. and drug candidates have improved our understanding of the role of physicochem. properties in drug attrition.  Based on the clarified challenges in finding the 'sweet spot' in medicinal chem. programs, we suggest that this goal can be achieved through a combination of first identifying chem. starting points with appropriate 'nature' and then rigorously 'nurturing' them during lead optimization.  Here, we discuss scientific, strategic, organizational and cultural considerations for medicinal chem. practices, with the aim of promoting more effective use of what is already known, as well as a wider appreciation of the risks of pursuing suboptimal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrURciGjB2A3LVg90H21EOLACvtfcHk0lieRl4hKgpkGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D&md5=90170e3f4e69e52bfa38667df380516a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd3701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3701%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DFinding%2520the%2520sweet%2520spot%253A%2520the%2520role%2520of%2520nature%2520and%2520nurture%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D355%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Mallinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Macrocycles in new drug discovery</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.4155%2Ffmc.12.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22857532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCht7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1409-1438&author=J.+Mallinsonauthor=I.+Collins&title=Macrocycles+in+new+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles in new drug discovery</span></div><div class="casAuthors">Mallinson, Jamie; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1409-1438</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of drug-like macrocycles is emerging as an exciting area of medicinal chem., with several recent examples highlighting the favorable changes in biol. and physicochem. properties that macrocyclization can afford.  Natural product macrocycles and their synthetic derivs. have long been clin. useful and attention is now being focused on the wider use of macrocyclic scaffolds in medicinal chem. in the search for new drugs for increasingly challenging targets.  With the increasing awareness of concepts of drug-likeness and the dangers of mol. obesity', functionalized macrocyclic scaffolds could provide a way to generate ligand-efficient mols. with enhanced properties.  In this review we will sep. discuss the effects of macrocyclization upon potency, selectivity and physicochem. properties, concg. on recent case histories in oncol. drug discovery.  Addnl., we will highlight selected advances in the synthesis of macrocycles and provide an outlook on the future use of macrocyclic scaffolds in medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSrzcbKW7Tc7Vg90H21EOLACvtfcHk0lieRl4hKgpkGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCht7rO&md5=63ad275af92ac89ae6b36c5071b578f8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.93%26sid%3Dliteratum%253Aachs%26aulast%3DMallinson%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMacrocycles%2520in%2520new%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1409%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Driggers, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrett, N. F.</span><span> </span><span class="NLM_article-title">The exploration of macrocycles for drug discovery—an underexploited structural class</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+F.+Terrett&title=The+exploration+of+macrocycles+for+drug+discovery%E2%80%94an+underexploited+structural+class"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BF.%26atitle%3DThe%2520exploration%2520of%2520macrocycles%2520for%2520drug%2520discovery%25E2%2580%2594an%2520underexploited%2520structural%2520class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">DeLorbe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clements, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiddon, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. F.</span><span> </span><span class="NLM_article-title">Thermodynamic and structural effects of macrocyclic constraints in protein-ligand interactions</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">448</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml100142y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A280%3ADC%252BC2srmt1OisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=448-452&author=J.+E.+DeLorbeauthor=J.+H.+Clementsauthor=B.+B.+Whiddonauthor=S.+F.+Martin&title=Thermodynamic+and+structural+effects+of+macrocyclic+constraints+in+protein-ligand+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Thermodynamic and Structural Effects of Macrocyclization as a Constraining Method in Protein-Ligand Interactions</span></div><div class="casAuthors">Delorbe John E; Clements John H; Whiddon Benjamin B; Martin Stephen F</div><div class="citationInfo"><span class="NLM_cas:title">ACS medicinal chemistry letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">448-452</span>
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    </div><div class="casAbstract">The thermodynamic and structural effects of macrocyclization as a tactic for stabilizing the biologically-active conformation of Grb2 SH2 binding peptides were investigated using isothermal titration calorimetry and x-ray crystallography. 23-Membered macrocycles containing the sequence pYVN were slightly more potent than their linear controls; however, preorganization did not necessarily eventuate in a more favorable binding entropy.  Structures of complexes of macrocycle 7 and its acyclic control 8 are similar except for differences in relative orientations of corresponding atoms in the linking moieties of 7 and 8.  There are no differences in the number of direct or water-mediated protein-ligand contacts that might account for the less favorable binding enthalpy of 7; however, an intramolecular hydrogen bond between the pY and pY+3 residues in 8 that is absent in 7 may be a factor.  These studies highlight the difficulties associated with correlating energetics and structure in protein-ligand interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdL3gvK7FnJAwxfk_AGB-EfW6udTcc2ea3VQBaLoKUJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srmt1OisA%253D%253D&md5=bec2aeb7e9127f0f6310dbccf2663c76</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fml100142y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100142y%26sid%3Dliteratum%253Aachs%26aulast%3DDeLorbe%26aufirst%3DJ.%2BE.%26aulast%3DClements%26aufirst%3DJ.%2BH.%26aulast%3DWhiddon%26aufirst%3DB.%2BB.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DThermodynamic%2520and%2520structural%2520effects%2520of%2520macrocyclic%2520constraints%2520in%2520protein-ligand%2520interactions%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D448%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Bogdan, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span> </span><span class="NLM_article-title">Comparison of diffusion coefficients for matched pairs of macrocyclic and linear molecules over a drug-like molecular weight range</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">7727</span><span class="NLM_x">–</span> <span class="NLM_lpage">7733</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=7727-7733&author=A.+R.+Bogdanauthor=N.+L.+Daviesauthor=K.+James&title=Comparison+of+diffusion+coefficients+for+matched+pairs+of+macrocyclic+and+linear+molecules+over+a+drug-like+molecular+weight+range"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBogdan%26aufirst%3DA.%2BR.%26aulast%3DDavies%26aufirst%3DN.%2BL.%26aulast%3DJames%26aufirst%3DK.%26atitle%3DComparison%2520of%2520diffusion%2520coefficients%2520for%2520matched%2520pairs%2520of%2520macrocyclic%2520and%2520linear%2520molecules%2520over%2520a%2520drug-like%2520molecular%2520weight%2520range%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D7727%26epage%3D7733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Marsault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. L.</span><span> </span><span class="NLM_article-title">Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macocycles in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1961</span><span class="NLM_x">–</span> <span class="NLM_lpage">2004</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1012374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1961-2004&author=E.+Marsaultauthor=M.+L.+Peterson&title=Macrocycles+are+great+cycles%3A+applications%2C+opportunities%2C+and+challenges+of+synthetic+macocycles+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm1012374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012374%26sid%3Dliteratum%253Aachs%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26atitle%3DMacrocycles%2520are%2520great%2520cycles%253A%2520applications%252C%2520opportunities%252C%2520and%2520challenges%2520of%2520synthetic%2520macocycles%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1961%26epage%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Schreiber, S. L.</span><span> </span><span class="NLM_article-title">Molecular diversity by design</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">457</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2F457153a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=19129834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=457&publication_year=2009&pages=153-154&author=S.+L.+Schreiber&title=Molecular+diversity+by+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular diversity by design</span></div><div class="casAuthors">Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">457</span>
        (<span class="NLM_cas:issue">7226</span>),
    <span class="NLM_cas:pages">153-154</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many org. syntheses are target-oriented - each multi-step route is designed to make just one compd.  But now a diversity-oriented synthesis can make 80 different mol. skeletons in just a few steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNnW8LJ03ahbVg90H21EOLACvtfcHk0lgAQfYzy6Z1eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlSgug%253D%253D&md5=2ddc5e57f47d2e83598e644fb0259245</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F457153a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F457153a%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DMolecular%2520diversity%2520by%2520design%26jtitle%3DNature%26date%3D2009%26volume%3D457%26spage%3D153%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Terrett, N. F.</span><span> </span><span class="NLM_article-title">Methods for the synthesis of macrocycle libraries for drug discovery</span> <span class="citation_source-journal">Drug Discovery Today: Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e97</span><span class="NLM_x">–</span> <span class="NLM_lpage">e104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.ddtec.2010.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVegsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=e97-e104&author=N.+F.+Terrett&title=Methods+for+the+synthesis+of+macrocycle+libraries+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for the synthesis of macrocycle libraries for drug discovery</span></div><div class="casAuthors">Terrett, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">E97-E104</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Macrocyclic compds. are found widely in nature where they fulfill numerous specific functions.  However, they have been generally under-exploited as drug mols., as they are larger than more conventional rule-of-five (Lepinski's rule of five) compliant mols. and their synthesis and screening has been considered a challenge.  Consequently most pharmaceutical companies have very few macrocyclic compds. in their screening files and, yet, these compds. can have potent and selective pharmacol. activity, and exhibit drug-like properties such as cell membrane permeability and oral bioavailability.  To permit the further investigation of macrocyclic drugs, several groups have developed diverse methods for the rapid synthesis and screening of macrocyclic libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMnUro57zsW7Vg90H21EOLACvtfcHk0likTjY7lcU0Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVegsLY%253D&md5=e7968c6c505322bcf07f9d2a3558be1f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2010.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2010.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DTerrett%26aufirst%3DN.%2BF.%26atitle%3DMethods%2520for%2520the%2520synthesis%2520of%2520macrocycle%2520libraries%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2010%26volume%3D7%26spage%3De97%26epage%3De104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Obrecht, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevalier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moehle, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, J. A.</span><span> </span><span class="NLM_article-title">β-Hairpin protein epitope mimetic technology in drug discovery</span> <span class="citation_source-journal">Drug Discovery Today: Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e63</span><span class="NLM_x">–</span> <span class="NLM_lpage">e69</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=e63-e69&author=D.+Obrechtauthor=E.+Chevalierauthor=K.+Moehleauthor=J.+A.+Robinson&title=%CE%B2-Hairpin+protein+epitope+mimetic+technology+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObrecht%26aufirst%3DD.%26aulast%3DChevalier%26aufirst%3DE.%26aulast%3DMoehle%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DJ.%2BA.%26atitle%3D%25CE%25B2-Hairpin%2520protein%2520epitope%2520mimetic%2520technology%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2011%26volume%3D9%26spage%3De63%26epage%3De69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kotz, J.</span><span> </span><span class="NLM_article-title">Bringing macrocycles full circle</span>.  <span class="citation_source-journal">SciBX</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span>, DOI: <span class="refDoi"> DOI: 10.1038/scibx.2012.1176</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fscibx.2012.1176" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&author=J.+Kotz&title=Bringing+macrocycles+full+circle&doi=10.1038%2Fscibx.2012.1176"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fscibx.2012.1176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fscibx.2012.1176%26sid%3Dliteratum%253Aachs%26aulast%3DKotz%26aufirst%3DJ.%26atitle%3DBringing%2520macrocycles%2520full%2520circle%26jtitle%3DSciBX%26date%3D2012%26volume%3D5%26doi%3D10.1038%2Fscibx.2012.1176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Scannell, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanckley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, B.</span><span> </span><span class="NLM_article-title">Diagnosing the decline in pharmaceutical R&D efficiency</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&author=J.+W.+Scannellauthor=A.+Blanckleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+decline+in+pharmaceutical+R%26D+efficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0likTjY7lcU0Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%2BW.%26aulast%3DBlanckley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520decline%2520in%2520pharmaceutical%2520R%2526D%2520efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D191%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Bunnage, M. E.</span><span> </span><span class="NLM_article-title">Getting pharmaceutical R&D back on track</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnchembio.581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=21587251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtF2lur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=335-339&author=M.+E.+Bunnage&title=Getting+pharmaceutical+R%26D+back+on+track"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Getting pharmaceutical R&D back on target</span></div><div class="casAuthors">Bunnage, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">335-339</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry is in a period of crisis due to the low no. of new drug approvals relative to the high levels of R&D investment.  It is argued here that improving the quality of target selection is the single most important factor to transform industry productivity and bring innovative new medicines to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyfBkdRkjR8LVg90H21EOLACvtfcHk0likTjY7lcU0Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtF2lur4%253D&md5=458abeefd10325afc74b5ced717d3b40</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.581%26sid%3Dliteratum%253Aachs%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26atitle%3DGetting%2520pharmaceutical%2520R%2526D%2520back%2520on%2520track%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D335%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Knox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frolkis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banco, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neveu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djoumbou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, D. S.</span><span> </span><span class="NLM_article-title">DrugBank 3.0: a comprehensive resource for “omics” research on drugs</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">D1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">D1041</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=D1035-D1041&author=C.+Knoxauthor=V.+Lawauthor=T.+Jewisonauthor=P.+Liuauthor=S.+Lyauthor=A.+Frolkisauthor=A.+Ponauthor=K.+Bancoauthor=C.+Makauthor=V.+Neveuauthor=Y.+Djoumbouauthor=R.+Eisnerauthor=A.+C.+Guoauthor=D.+S.+Wishart&title=DrugBank+3.0%3A+a+comprehensive+resource+for+%E2%80%9Comics%E2%80%9D+research+on+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DC.%26aulast%3DLaw%26aufirst%3DV.%26aulast%3DJewison%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLy%26aufirst%3DS.%26aulast%3DFrolkis%26aufirst%3DA.%26aulast%3DPon%26aufirst%3DA.%26aulast%3DBanco%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DC.%26aulast%3DNeveu%26aufirst%3DV.%26aulast%3DDjoumbou%26aufirst%3DY.%26aulast%3DEisner%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DA.%2BC.%26aulast%3DWishart%26aufirst%3DD.%2BS.%26atitle%3DDrugBank%25203.0%253A%2520a%2520comprehensive%2520resource%2520for%2520%25E2%2580%259Comics%25E2%2580%259D%2520research%2520on%2520drugs%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2011%26volume%3D39%26spage%3DD1035%26epage%3DD1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span>Thomson Reuters Integrity. <a href="http://integrity.prous.com" class="extLink">http://integrity.prous.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Thomson+Reuters+Integrity.+http%3A%2F%2Fintegrity.prous.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span>About GOSTAR. <a href="http://gostardb.com/gostar/doc/HyperlinkDownloadPDF.pdf" class="extLink">http://gostardb.com/gostar/doc/HyperlinkDownloadPDF.pdf</a> (accessed in April,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=About+GOSTAR.+http%3A%2F%2Fgostardb.com%2Fgostar%2Fdoc%2FHyperlinkDownloadPDF.pdf+%28accessed+in+April%2C+2013%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirrette, A.</span><span> </span><span class="NLM_article-title">Better compounds faster: the development and exploitation of a desktop predictive chemistry toolkit</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span><span class="NLM_x">–</span> <span class="NLM_lpage">927</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=923-927&author=J.+G.+Cummingauthor=J.+Winterauthor=A.+Poirrette&title=Better+compounds+faster%3A+the+development+and+exploitation+of+a+desktop+predictive+chemistry+toolkit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DWinter%26aufirst%3DJ.%26aulast%3DPoirrette%26aufirst%3DA.%26atitle%3DBetter%2520compounds%2520faster%253A%2520the%2520development%2520and%2520exploitation%2520of%2520a%2520desktop%2520predictive%2520chemistry%2520toolkit%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D923%26epage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="note"><p class="first last">In this analysis drugs were annotated as oral if they were administered orally and required systemic exposure to exert their effect. Drugs delivered by all other routes were classified as parenteral. Drugs delivered orally that exert their pharmacological action in the gastrointestinal tract, without the need for systemic absorption, were included in the parenteral class.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span>Adis. <a href="http://www.springer.com/adis/databases?SGWID=0-1749113-0-0-0" class="extLink">http://www.springer.com/adis/databases?SGWID=0-1749113-0-0-0</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Adis.+http%3A%2F%2Fwww.springer.com%2Fadis%2Fdatabases%3FSGWID%3D0-1749113-0-0-0."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ptachcinski, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burckart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataramanan, R.</span><span> </span><span class="NLM_article-title">Cyclosporine</span> <span class="citation_source-journal">Drug Intell. Clin. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=3882378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADyaL2MXht1CqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1985&pages=90-100&author=R.+J.+Ptachcinskiauthor=G.+J.+Burckartauthor=R.+Venkataramanan&title=Cyclosporine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporine</span></div><div class="casAuthors">Ptachcinski, Richard J.; Burckart, Gilbert J.; Venkataramanan, Raman</div><div class="citationInfo"><span class="NLM_cas:title">Drug Intelligence & Clinical Pharmacy</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">90-100</span>CODEN:
                <span class="NLM_cas:coden">DICPBB</span>;
        ISSN:<span class="NLM_cas:issn">0012-6578</span>.
    </div><div class="casAbstract">A review with 114 refs. of the pharmacol., pharmacokinetics, clin. use, toxicity, and drug interaction of the immunosuppressant, cyclosporin  [79217-60-0].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDc8LUB5zyULVg90H21EOLACvtfcHk0lic_-gT9lDKQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXht1CqsLg%253D&md5=3344619d849b258dc951e3ea35b6e5c1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPtachcinski%26aufirst%3DR.%2BJ.%26aulast%3DBurckart%26aufirst%3DG.%2BJ.%26aulast%3DVenkataramanan%26aufirst%3DR.%26atitle%3DCyclosporine%26jtitle%3DDrug%2520Intell.%2520Clin.%2520Pharm.%26date%3D1985%26volume%3D19%26spage%3D90%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Fahr, A.</span><span> </span><span class="NLM_article-title">Cyclosporin clinical pharmacokinetics</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">495</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1993&pages=472-495&author=A.+Fahr&title=Cyclosporin+clinical+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahr%26aufirst%3DA.%26atitle%3DCyclosporin%2520clinical%2520pharmacokinetics%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1993%26volume%3D24%26spage%3D472%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Fricker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huwyler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beglinger, C.</span><span> </span><span class="NLM_article-title">Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro–in vivo correlation</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">1841</span><span class="NLM_x">–</span> <span class="NLM_lpage">1847</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1111%2Fj.1476-5381.1996.tb15612.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=8842452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADyaK28XkvVartrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=1841-1847&author=G.+Frickerauthor=J.+Dreweauthor=J.+Huwylerauthor=H.+Gutmannauthor=C.+Beglinger&title=Relevance+of+p-glycoprotein+for+the+enteral+absorption+of+cyclosporin+A%3A+in+vitro%E2%80%93in+vivo+correlation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation</span></div><div class="casAuthors">Fricker, G.; Drewe, J.; Huwyler, J.; Gutmann, H.; Beglinger, C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1841-1847</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The interaction of cyclosporin A (CyA) with p-glycoprotein during intestinal uptake was investigated by a combination of in vitro expts. with human Caco-2 cells and an intubation study in healthy volunteers.  CyA uptake into the cells was not saturable and exhibited only a low, temp. sensitivity, suggesting passive diffusion.  When the permeation of CyA across Caco-2 monolayers from the apical to the basolateral side was detd., overall transport had an apparently saturable component up to a concn. of 1 μM.  At higher concns. permeation increased over-proportionally.  Calcn. of the kinetic parameters of apical to basolateral permeation suggested a diffusional process with a KD of 0.5 μl min-1 per filter, which was overlayed by an active system in basolateral to apical direction with a KM of 3.8 μM and a Jmax of 6.5 picomol min-1 per filter.  CyA permeation was significantly higher when the drug was given from the basolateral side as compared to the permeation from the apical side.  Apical to basolateral transport of CyA was increased in the presence of vinblastine, daunomycin and a non-immunosuppressive CyA-deriv.  All compds. inhibit p-glycoprotein-mediated transport processes.  Basolateral to apical permeation of CyA showed a dose-dependent decrease in the presence of vinblastine.  Permeation of daunomycin across Caco-2 cell monolayers was also higher from the basolateral to the apical side than vice versa.  Basolateral to apical permeation was decreased in the presence of SDZ PSC 833 and cyclosporin A.  Western blot anal. of Caco-2 cells with the monoclonal antibody C219 confirmed the presence of p-glycoprotein in the used cell system.  When the absorption of CyA in the gastrointestinal (GI)-tract of healthy volunteers was detd., a remarkable decrease of the plasma AUC could be obsd. dependent on the location of absorption in the rank order stomach>jejunum/ileum>colon.  The decrease in absorption exhibited a marked correlation (r = 0.994) to the expression of mRNA for p-glycoprotein over the GI-tract (stomach<jejunum<colon).  All data provide evidence that CyA is a substrate of p-glycoprotein in the GI-tract, which might explain the local differences and the high variability in cyclosporin absorption found in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXilC3zqeAg7Vg90H21EOLACvtfcHk0lic_-gT9lDKQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XkvVartrY%253D&md5=02465aba23808c65ec6ed98f4ceaaebc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1996.tb15612.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1996.tb15612.x%26sid%3Dliteratum%253Aachs%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DHuwyler%26aufirst%3DJ.%26aulast%3DGutmann%26aufirst%3DH.%26aulast%3DBeglinger%26aufirst%3DC.%26atitle%3DRelevance%2520of%2520p-glycoprotein%2520for%2520the%2520enteral%2520absorption%2520of%2520cyclosporin%2520A%253A%2520in%2520vitro%25E2%2580%2593in%2520vivo%2520correlation%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D118%26spage%3D1841%26epage%3D1847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Fatouros, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karpf, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullertz, A.</span><span> </span><span class="NLM_article-title">Clinical studies with oral lipid based formulations of poorly soluble compounds</span> <span class="citation_source-journal">Ther. Clin. Risk Manage.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=18472981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyjtL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=591-604&author=D.+M.+Fatourosauthor=D.+M.+Karpfauthor=F.+S.+Nielsenauthor=A.+Mullertz&title=Clinical+studies+with+oral+lipid+based+formulations+of+poorly+soluble+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical studies with oral lipid based formulations of poorly soluble compounds</span></div><div class="casAuthors">Fatouros, Dimitrios G.; Karpf, Ditte M.; Nielsen, Flemming S.; Mullertz, Anette</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-604</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  This work is an attempt to give an overview of the clin. data available on lipid based formulations.  Lipid and surfactant based formulations are recognized as a feasible approach to improve bioavailability of poorly sol. compds.  However not many clin. studies have been published so far.  Several drug products intended for oral administration have been marketed utilizing lipid and surfactant based formulations.  Sandimmune and Sandimmune Neoral (cyclosporin A, Novartis), Norvir (ritonavir), and Fortovase (saquinavir) have been formulated in self-emulsifying drug delivery systems (SEDDS).  This review summarizes published pharmacokinetic studies of orally administered lipid based formulations of poorly aq. sol. drugs in human subjects.  Special attention has been paid to the physicochem. characteristics of the formulations, when available and the impact of these properties on the in vivo performance of the formulation.  Equally important is the effect of concurrent food intake on the bioavailability of poorly sol. compds.  The effect of food on the bioavailability of compds. formulated in lipid and surfactant based formulations is also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOHIorI1YP8rVg90H21EOLACvtfcHk0lic_-gT9lDKQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyjtL7J&md5=1d57e5ca229b6c4b7888cb61c7ad49fb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFatouros%26aufirst%3DD.%2BM.%26aulast%3DKarpf%26aufirst%3DD.%2BM.%26aulast%3DNielsen%26aufirst%3DF.%2BS.%26aulast%3DMullertz%26aufirst%3DA.%26atitle%3DClinical%2520studies%2520with%2520oral%2520lipid%2520based%2520formulations%2520of%2520poorly%2520soluble%2520compounds%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2007%26volume%3D3%26spage%3D591%26epage%3D604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">El Tayar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallat, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunne, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gunsteren, W. F.</span><span> </span><span class="NLM_article-title">Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3757</span><span class="NLM_x">–</span> <span class="NLM_lpage">3764</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00076a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3757-3764&author=N.+El+Tayarauthor=A.+E.+Markauthor=P.+Vallatauthor=R.+M.+Brunneauthor=B.+Testaauthor=W.+F.+van+Gunsteren&title=Solvent-dependent+conformation+and+hydrogen-bonding+capacity+of+cyclosporin+A%3A+evidence+from+partition+coefficients+and+molecular+dynamics+simulations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm00076a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00076a002%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BTayar%26aufirst%3DN.%26aulast%3DMark%26aufirst%3DA.%2BE.%26aulast%3DVallat%26aufirst%3DP.%26aulast%3DBrunne%26aufirst%3DR.%2BM.%26aulast%3DTesta%26aufirst%3DB.%26aulast%3Dvan%2BGunsteren%26aufirst%3DW.%2BF.%26atitle%3DSolvent-dependent%2520conformation%2520and%2520hydrogen-bonding%2520capacity%2520of%2520cyclosporin%2520A%253A%2520evidence%2520from%2520partition%2520coefficients%2520and%2520molecular%2520dynamics%2520simulations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D3757%26epage%3D3764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Alex, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakenhut, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitlock, G. A.</span><span> </span><span class="NLM_article-title">Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">669</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1039%2Fc1md00093d" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=669-674&author=A.+Alexauthor=D.+S.+Millanauthor=M.+Perezauthor=F.+Wakenhutauthor=G.+A.+Whitlock&title=Intramolecular+hydrogen+bonding+to+improve+membrane+permeability+and+absorption+in+beyond+rule+of+five+chemical+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fc1md00093d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00093d%26sid%3Dliteratum%253Aachs%26aulast%3DAlex%26aufirst%3DA.%26aulast%3DMillan%26aufirst%3DD.%2BS.%26aulast%3DPerez%26aufirst%3DM.%26aulast%3DWakenhut%26aufirst%3DF.%26aulast%3DWhitlock%26aufirst%3DG.%2BA.%26atitle%3DIntramolecular%2520hydrogen%2520bonding%2520to%2520improve%2520membrane%2520permeability%2520and%2520absorption%2520in%2520beyond%2520rule%2520of%2520five%2520chemical%2520space%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D669%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Knipp, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Velde, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siahaan, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borchardt, R. T.</span><span> </span><span class="NLM_article-title">The effect of β-turn structure on the passive diffusion of peptides across Caco-2 cell monolayers</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1332</span><span class="NLM_x">–</span> <span class="NLM_lpage">1340</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=1332-1340&author=G.+T.+Knippauthor=G.+D.+Vander+Veldeauthor=T.+J.+Siahaanauthor=R.+T.+Borchardt&title=The+effect+of+%CE%B2-turn+structure+on+the+passive+diffusion+of+peptides+across+Caco-2+cell+monolayers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnipp%26aufirst%3DG.%2BT.%26aulast%3DVander%2BVelde%26aufirst%3DG.%2BD.%26aulast%3DSiahaan%26aufirst%3DT.%2BJ.%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26atitle%3DThe%2520effect%2520of%2520%25CE%25B2-turn%2520structure%2520on%2520the%2520passive%2520diffusion%2520of%2520peptides%2520across%2520Caco-2%2520cell%2520monolayers%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D1332%26epage%3D1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Okumu, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauletti, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Velde, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siahaan, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borchardt, R. T.</span><span> </span><span class="NLM_article-title">Effect of restricted conformational flexibility on the permeation of model hexapeptides across Caco-2 cell monolayers</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=169-175&author=F.+W.+Okumuauthor=G.+M.+Paulettiauthor=G.+D.+Vander+Veldeauthor=T.+J.+Siahaanauthor=R.+T.+Borchardt&title=Effect+of+restricted+conformational+flexibility+on+the+permeation+of+model+hexapeptides+across+Caco-2+cell+monolayers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkumu%26aufirst%3DF.%2BW.%26aulast%3DPauletti%26aufirst%3DG.%2BM.%26aulast%3DVander%2BVelde%26aufirst%3DG.%2BD.%26aulast%3DSiahaan%26aufirst%3DT.%2BJ.%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26atitle%3DEffect%2520of%2520restricted%2520conformational%2520flexibility%2520on%2520the%2520permeation%2520of%2520model%2520hexapeptides%2520across%2520Caco-2%2520cell%2520monolayers%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D169%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Rezai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalyanaraman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, M. P.</span><span> </span><span class="NLM_article-title">Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">14073</span><span class="NLM_x">–</span> <span class="NLM_lpage">14080</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja063076p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCmur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=14073-14080&author=T.+Rezaiauthor=J.+E.+Bockauthor=M.+V.+Zhouauthor=C.+Kalyanaramanauthor=R.+S.+Lokeyauthor=M.+P.+Jacobsen&title=Conformational+flexibility%2C+internal+hydrogen+bonding%2C+and+passive+membrane+permeability%3A+successful+in+silico+prediction+of+the+relative+permeabilities+of+cyclic+peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Flexibility, Internal Hydrogen Bonding, and Passive Membrane Permeability: Successful in Silico Prediction of the Relative Permeabilities of Cyclic Peptides</span></div><div class="casAuthors">Rezai, Taha; Bock, Jonathan E.; Zhou, Mai V.; Kalyanaraman, Chakrapani; Lokey, R. Scott; Jacobson, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">14073-14080</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report an atomistic phys. model for the passive membrane permeability of cyclic peptides.  The computational modeling was performed in advance of the expts. and did not involve the use of "training data".  The model explicitly treats the conformational flexibility of the peptides by extensive conformational sampling in low (membrane) and high (water) dielec. environments.  The passive membrane permeabilities of 11 cyclic peptides were obtained exptl. using a parallel artificial membrane permeability assay (PAMPA) and showed a linear correlation with the computational results with R2 = 0.96.  In general, the results support the hypothesis, already well established in the literature, that the ability to form internal hydrogen bonds is crit. for passive membrane permeability and can be the distinguishing factor among closely related compds., such as those studied here.  However, we have found that the no. of internal hydrogen bonds that can form in the membrane and the solvent-exposed polar surface area correlate more poorly with PAMPA permeability than our model, which quant. ests. the solvation free energy losses upon moving from high-dielec. water to the low-dielec. interior of a membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofxfL018o86rVg90H21EOLACvtfcHk0liwMsfc-51azQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCmur3I&md5=78d4b4082e6a72b288d4b6dac933ca35</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja063076p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja063076p%26sid%3Dliteratum%253Aachs%26aulast%3DRezai%26aufirst%3DT.%26aulast%3DBock%26aufirst%3DJ.%2BE.%26aulast%3DZhou%26aufirst%3DM.%2BV.%26aulast%3DKalyanaraman%26aufirst%3DC.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26aulast%3DJacobsen%26aufirst%3DM.%2BP.%26atitle%3DConformational%2520flexibility%252C%2520internal%2520hydrogen%2520bonding%252C%2520and%2520passive%2520membrane%2520permeability%253A%2520successful%2520in%2520silico%2520prediction%2520of%2520the%2520relative%2520permeabilities%2520of%2520cyclic%2520peptides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D14073%26epage%3D14080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Guimaraes, C. R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalaeva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span> </span><span class="NLM_article-title">Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci300010y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlGlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=882-890&author=C.+R.+W.+Guimaraesauthor=A.+M.+Mathiowetzauthor=M.+Shalaevaauthor=G.+Goetzauthor=S.+Liras&title=Use+of+3D+properties+to+characterize+beyond+rule-of-5+property+space+for+passive+permeation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Use of 3D Properties to Characterize Beyond Rule-of-5 Property Space for Passive Permeation</span></div><div class="casAuthors">Guimaraes, Cristiano R. W.; Mathiowetz, Alan M.; Shalaeva, Marina; Goetz, Gilles; Liras, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">882-890</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The application of conformationally dependent measures of size and polarity to characterize beyond rule-of-5 (Ro5) space for passive permeation was investigated.  Specifically, radius of gyration, an alternative to mol. wt., and three-dimensional polar surface area and the generalized Born/surface area dehydration free energy, alternatives to hydrogen-bond donor and acceptor counts, were computed on models of the permeating conformations of over 35 000 mols.  The resulting guidelines for size and polarity, described by the 3D properties, should aid the design of Ro5 violators with passive permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-wXo2cwYEvrVg90H21EOLACvtfcHk0ljjKlvnb9587g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlGlurc%253D&md5=823a9f943cbcdfa9cd2bdeb3a803a4eb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fci300010y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300010y%26sid%3Dliteratum%253Aachs%26aulast%3DGuimaraes%26aufirst%3DC.%2BR.%2BW.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DShalaeva%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DUse%2520of%25203D%2520properties%2520to%2520characterize%2520beyond%2520rule-of-5%2520property%2520space%2520for%2520passive%2520permeation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D882%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">White, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzelman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rand, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEwen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelev, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linington, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span> </span><span class="NLM_article-title">On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnchembio.664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=21946276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1anurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=810-817&author=T.+R.+Whiteauthor=C.+M.+Renzelmanauthor=A.+C.+Randauthor=T.+Rezaiauthor=C.+M.+McEwenauthor=V.+M.+Gelevauthor=R.+A.+Turnerauthor=R.+G.+Liningtonauthor=S.+S.+F.+Leungauthor=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=Y.+Zhangauthor=S.+Lirasauthor=D.+A.+Priceauthor=A.+M.+Mathiowetzauthor=M.+P.+Jacobsenauthor=R.+S.+Lokey&title=On-resin+N-methylation+of+cyclic+peptides+for+discovery+of+orally+bioavailable+scaffolds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds</span></div><div class="casAuthors">White, Tina R.; Renzelman, Chad M.; Rand, Arthur C.; Rezai, Taha; McEwen, Cayla M.; Gelev, Vladimir M.; Turner, Rushia A.; Linington, Roger G.; Leung, Siegfried S. F.; Kalgutkar, Amit S.; Bauman, Jonathan N.; Zhang, Yizhong; Liras, Spiros; Price, David A.; Mathiowetz, Alan M.; Jacobson, Matthew P.; Lokey, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">810-817</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Backbone N-methylation is common among peptide natural products and has a substantial impact on both the phys. properties and the conformational states of cyclic peptides.  However, the specific impact of N-methylation on passive membrane diffusion in cyclic peptides has not been investigated systematically.  Here we report a method for the selective, on-resin N-methylation of cyclic peptides to generate compds. with drug-like membrane permeability and oral bioavailability.  The selectivity and degree of N-methylation of the cyclic peptide was dependent on backbone stereochem., suggesting that conformation dictates the regiochem. of the N-methylation reaction.  The permeabilities of the N-Me variants were corroborated by computational studies on a 1024-member virtual library of N-Me cyclic peptides.  One of the most permeable compds., a cyclic hexapeptide (mol. mass = 755 Da) with three N-Me groups, showed an oral bioavailability of 28% in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreigsRodBtOLVg90H21EOLACvtfcHk0ljjKlvnb9587g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1anurjL&md5=6f9f01f4ab523bb46cc0198cc8f1c34e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.664%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DT.%2BR.%26aulast%3DRenzelman%26aufirst%3DC.%2BM.%26aulast%3DRand%26aufirst%3DA.%2BC.%26aulast%3DRezai%26aufirst%3DT.%26aulast%3DMcEwen%26aufirst%3DC.%2BM.%26aulast%3DGelev%26aufirst%3DV.%2BM.%26aulast%3DTurner%26aufirst%3DR.%2BA.%26aulast%3DLinington%26aufirst%3DR.%2BG.%26aulast%3DLeung%26aufirst%3DS.%2BS.%2BF.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DJacobsen%26aufirst%3DM.%2BP.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26atitle%3DOn-resin%2520N-methylation%2520of%2520cyclic%2520peptides%2520for%2520discovery%2520of%2520orally%2520bioavailable%2520scaffolds%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D810%26epage%3D817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Beck, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiran, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovadia, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span> </span><span class="NLM_article-title">Intestinal permeability of cyclic peptides: common key backbone motifs identified</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">12125</span><span class="NLM_x">–</span> <span class="NLM_lpage">12133</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja303200d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1Cisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=12125-12133&author=J.+G.+Beckauthor=J.+Chatterjeeauthor=B.+Lauferauthor=M.+U.+Kiranauthor=A.+O.+Frankauthor=S.+Neubauerauthor=O.+Ovadiaauthor=S.+Greenbergauthor=C.+Gilonauthor=A.+Hoffmanauthor=H.+Kessler&title=Intestinal+permeability+of+cyclic+peptides%3A+common+key+backbone+motifs+identified"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal Permeability of Cyclic Peptides: Common Key Backbone Motifs Identified</span></div><div class="casAuthors">Beck, Johannes G.; Chatterjee, Jayanta; Laufer, Burkhardt; Kiran, Marelli Udaya; Frank, Andreas O.; Neubauer, Stefanie; Ovadia, Oded; Greenberg, Sarit; Gilon, Chaim; Hoffman, Amnon; Kessler, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">12125-12133</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Insufficient oral bioavailability is considered as a key limitation for the widespread development of peptides as therapeutics.  While the oral bioavailability of small org. compds. is often estd. from simple rules, similar rules do not apply to peptides, and even the high oral bioavailability that is described for a small no. of peptides is not well understood.  Here we present two highly Caco-2 permeable template structures based on a library of 54 cyclo(-d-Ala-Ala5-) peptides with different N-methylation patterns.  The first all-trans template structure possesses two β-turns of type II along Ala6-d-Ala1 and Ala3-Ala4 and is only found for one peptide with two N-Me groups at d-Ala1 and Ala6 [NMe(1,6)].  The second single-cis template possesses a characteristic cis peptide bond preceding Ala5, which results in type VI β-turn geometry along Ala4-Ala5.  Although the second template structure is found in seven peptides carrying N-Me groups on Ala5, high Caco-2 permeability is only found for a subgroup of two of them [NMe(1,5) and NMe(1,2,4,5)], suggesting that N-methylation of d-Ala1 is a prerequisite for high permeability of the second template structure.  The structural similarity of the second template structure with the orally bioavailable somatostatin analog cyclo(-Pro-Phe-NMe-d-Trp-NMe-Lys-Thr-NMe-Phe-), and the striking resemblance with both β-turns of the orally bioavailable peptide cyclosporine A, suggests that the introduction of bioactive sequences on the highly Caco-2 permeable templates may result in potent orally bioavailable drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4AC8OVfXJMbVg90H21EOLACvtfcHk0ljjKlvnb9587g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1Cisbw%253D&md5=ecf4dc5aa62a8ebb7c5cc99e8009f528</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fja303200d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja303200d%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DJ.%2BG.%26aulast%3DChatterjee%26aufirst%3DJ.%26aulast%3DLaufer%26aufirst%3DB.%26aulast%3DKiran%26aufirst%3DM.%2BU.%26aulast%3DFrank%26aufirst%3DA.%2BO.%26aulast%3DNeubauer%26aufirst%3DS.%26aulast%3DOvadia%26aufirst%3DO.%26aulast%3DGreenberg%26aufirst%3DS.%26aulast%3DGilon%26aufirst%3DC.%26aulast%3DHoffman%26aufirst%3DA.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DIntestinal%2520permeability%2520of%2520cyclic%2520peptides%253A%2520common%2520key%2520backbone%2520motifs%2520identified%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D12125%26epage%3D12133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Zhanel, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dueck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoban, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vercaigne, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Embil, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlowsky, J. A.</span><span> </span><span class="NLM_article-title">Review of macrolides and ketolides. Focus on respiratory tract infections</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=443-498&author=G.+G.+Zhanelauthor=M.+Dueckauthor=D.+J.+Hobanauthor=L.+M.+Vercaigneauthor=J.+M.+Embilauthor=A.+S.+Ginauthor=J.+A.+Karlowsky&title=Review+of+macrolides+and+ketolides.+Focus+on+respiratory+tract+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DDueck%26aufirst%3DM.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26aulast%3DVercaigne%26aufirst%3DL.%2BM.%26aulast%3DEmbil%26aufirst%3DJ.%2BM.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DReview%2520of%2520macrolides%2520and%2520ketolides.%2520Focus%2520on%2520respiratory%2520tract%2520infections%26jtitle%3DDrugs%26date%3D2001%26volume%3D61%26spage%3D443%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Defining optimum lipophilicity and molecular weight ranges for drug candidates—molecular weight dependent lower logD limits based on permeability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2844</span><span class="NLM_x">–</span> <span class="NLM_lpage">2851</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2844-2851&author=M.+J.+Waring&title=Defining+optimum+lipophilicity+and+molecular+weight+ranges+for+drug+candidates%E2%80%94molecular+weight+dependent+lower+logD+limits+based+on+permeability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DDefining%2520optimum%2520lipophilicity%2520and%2520molecular%2520weight%2520ranges%2520for%2520drug%2520candidates%25E2%2580%2594molecular%2520weight%2520dependent%2520lower%2520logD%2520limits%2520based%2520on%2520permeability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2844%26epage%3D2851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Egan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merz, J., K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J. J.</span><span> </span><span class="NLM_article-title">Prediction of drug absorption using multivariate statistics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3877</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000292e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3867-3877&author=W.+J.+Eganauthor=J.%2C+K.+M.+Merzauthor=J.+J.+Baldwin&title=Prediction+of+drug+absorption+using+multivariate+statistics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Absorption Using Multivariate Statistics</span></div><div class="casAuthors">Egan, William J.; Merz, Kenneth M. Jr.; Baldwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3867-3877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Literature data on compds. both well- and poorly-absorbed in humans were used to build a statistical pattern recognition model of passive intestinal absorption.  Robust outlier detection was utilized to analyze the well-absorbed compds., some of which were intermingled with the poorly-absorbed compds. in the model space.  Outliers were identified as being actively transported.  The descriptors chosen for inclusion in the model were PSA and AlogP98, based on consideration of the phys. processes involved in membrane permeability and the interrelationships and redundancies between available descriptors.  These descriptors are quite straightforward for a medicinal chemist to interpret, enhancing the utility of the model.  Mol. wt., while often used in passive absorption models, was shown to be superfluous, as it is already a component of both PSA and AlogP98.  Extensive validation of the model on hundreds of known orally delivered drugs, "drug-like" mols., and Pharmacopeia, Inc. compds., which had been assayed for Caco-2 cell permeability, demonstrated a good rate of successful predictions (74-92%, depending on the dataset and exact criterion used).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZF9e_GNz8LVg90H21EOLACvtfcHk0lj1gwDvd52PGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D&md5=44f909ad1fd6187840921e7f07497b4e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm000292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000292e%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DW.%2BJ.%26aulast%3DMerz%26aufirst%3DJ.%252C%2BK.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520drug%2520absorption%2520using%2520multivariate%2520statistics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3867%26epage%3D3877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.-Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lj1gwDvd52PGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.-Y.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Marchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montecchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venturini, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascellan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brufani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellai, L.</span><span> </span><span class="NLM_article-title">4-Deoxypyrido[1′,2′:1,2]imidazo[5,4-<i>c</i>]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">960</span><span class="NLM_x">–</span> <span class="NLM_lpage">963</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00145a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1985&pages=960-963&author=E.+Marchiauthor=L.+Montecchiauthor=A.+P.+Venturiniauthor=G.+Mascellanauthor=M.+Brufaniauthor=L.+Cellai&title=4-Deoxypyrido%5B1%E2%80%B2%2C2%E2%80%B2%3A1%2C2%5Dimidazo%5B5%2C4-c%5Drifamycin+SV+derivatives.+A+new+series+of+semisynthetic+rifamycins+with+high+antibacterial+activity+and+low+gastroenteric+absorption"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm00145a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00145a020%26sid%3Dliteratum%253Aachs%26aulast%3DMarchi%26aufirst%3DE.%26aulast%3DMontecchi%26aufirst%3DL.%26aulast%3DVenturini%26aufirst%3DA.%2BP.%26aulast%3DMascellan%26aufirst%3DG.%26aulast%3DBrufani%26aufirst%3DM.%26aulast%3DCellai%26aufirst%3DL.%26atitle%3D4-Deoxypyrido%255B1%25E2%2580%25B2%252C2%25E2%2580%25B2%253A1%252C2%255Dimidazo%255B5%252C4-c%255Drifamycin%2520SV%2520derivatives.%2520A%2520new%2520series%2520of%2520semisynthetic%2520rifamycins%2520with%2520high%2520antibacterial%2520activity%2520and%2520low%2520gastroenteric%2520absorption%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1985%26volume%3D28%26spage%3D960%26epage%3D963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Brufani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerrini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedeli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaciago, A.</span><span> </span><span class="NLM_article-title">X-ray crystal structure of 4-deoxy-3′-bromopyrido[1′,2′-1,2]imidazo[5,4-<i>c</i>]rifamycin SV</span> <span class="citation_source-journal">J. Antibiot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1623</span><span class="NLM_x">–</span> <span class="NLM_lpage">1627</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1984&pages=1623-1627&author=M.+Brufaniauthor=L.+Cellaiauthor=S.+Cerriniauthor=W.+Fedeliauthor=E.+Marchiauthor=A.+Segreauthor=A.+Vaciago&title=X-ray+crystal+structure+of+4-deoxy-3%E2%80%B2-bromopyrido%5B1%E2%80%B2%2C2%E2%80%B2-1%2C2%5Dimidazo%5B5%2C4-c%5Drifamycin+SV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrufani%26aufirst%3DM.%26aulast%3DCellai%26aufirst%3DL.%26aulast%3DCerrini%26aufirst%3DS.%26aulast%3DFedeli%26aufirst%3DW.%26aulast%3DMarchi%26aufirst%3DE.%26aulast%3DSegre%26aufirst%3DA.%26aulast%3DVaciago%26aufirst%3DA.%26atitle%3DX-ray%2520crystal%2520structure%2520of%25204-deoxy-3%25E2%2580%25B2-bromopyrido%255B1%25E2%2580%25B2%252C2%25E2%2580%25B2-1%252C2%255Dimidazo%255B5%252C4-c%255Drifamycin%2520SV%26jtitle%3DJ.%2520Antibiot.%26date%3D1984%26volume%3D37%26spage%3D1623%26epage%3D1627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Pirsch, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deierhoi, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filo, R. S.</span><span> </span><span class="NLM_article-title">A comparison of tacrolimus (Fk506) and cyclosporine for immunosuppression after cadaveric renal transplantation</span> <span class="citation_source-journal">Transplantation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">983</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1997&pages=977-983&author=J.+D.+Pirschauthor=J.+Millerauthor=M.+H.+Deierhoiauthor=F.+Vincentiauthor=R.+S.+Filo&title=A+comparison+of+tacrolimus+%28Fk506%29+and+cyclosporine+for+immunosuppression+after+cadaveric+renal+transplantation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPirsch%26aufirst%3DJ.%2BD.%26aulast%3DMiller%26aufirst%3DJ.%26aulast%3DDeierhoi%26aufirst%3DM.%2BH.%26aulast%3DVincenti%26aufirst%3DF.%26aulast%3DFilo%26aufirst%3DR.%2BS.%26atitle%3DA%2520comparison%2520of%2520tacrolimus%2520%2528Fk506%2529%2520and%2520cyclosporine%2520for%2520immunosuppression%2520after%2520cadaveric%2520renal%2520transplantation%26jtitle%3DTransplantation%26date%3D1997%26volume%3D63%26spage%3D977%26epage%3D983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagaya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuchi, T.</span><span> </span><span class="NLM_article-title">Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients</span> <span class="citation_source-journal">Transplant. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1732</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.transproceed.2005.02.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Crs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=1730-1732&author=H.+Tadaauthor=N.+Tsuchiyaauthor=S.+Satohauthor=H.+Kagayaauthor=Z.+Liauthor=K.+Satoauthor=M.+Miuraauthor=T.+Suzukiauthor=T.+Katoauthor=T.+Habuchi&title=Impact+of+CYP3A5+and+MDR1%28ABCB1%29+C3435T+polymorphisms+on+the+pharmacokinetics+of+tacrolimus+in+renal+transplant+recipients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of CYP3A5 and MDR1(ABCB1) C3435T Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients</span></div><div class="casAuthors">Tada, H.; Tsuchiya, N.; Satoh, S.; Kagaya, H.; Li, Z.; Sato, K.; Miura, M.; Suzuki, T.; Kato, T.; Habuchi, T.</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation Proceedings</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1730-1732</span>CODEN:
                <span class="NLM_cas:coden">TRPPA8</span>;
        ISSN:<span class="NLM_cas:issn">0041-1345</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: The objective of this study was to assess the influence of CYP3A5 and MDR1 genetic polymorphisms on tacrolimus pharmacokinetics in Japanese renal transplant recipients.  Method: The pharmacokinetic parameters of tacrolimus were calcd. in steady-state on day 28 after transplantation.  Polymerase chain reaction-restriction fragment length polymorphism and direct sequence methods were used for CYP3A5 and MDR1 polymorphisms, resp.  Results: The dose-adjusted area under the concn.-time curve (AUC0-12) was significantly lower among CYP3A5*1 carriers than those bearing CYP3A5*3/*3. (0.570 ± 0.105 vs 0.865 ± 0.343 ng · h/mL per mg/kg, P = .00322).  The daily tacrolimus dose per body wt. was significantly higher in CYP3A5*1 carriers than those of CYP3A5*3/*3 carriers (0.271 ± 0.110 vs 0.150 ± 0.056 mg/kg, P = .00016).  In this study, a distinction was made between carriers of CYP3A5*1/*1+*1/*3 and CYP3A5*3/*3 to investigate the influence of the MDR1 C3435T mutation on tacrolimus pharmacokinetics.  The MDR1 C3435T polymorphisms did not affect any tacrolimus pharmacokinetic parameter in either group.  Conclusions: Renal transplant recipients who were CYP3A5*1 carriers required a higher dose of tacrolimus than CYP3A5*3/*3, indicating a significantly lower dose-adjusted AUC0-12 of tacrolimus.  In contrast, MDR1 C3435T polymorphism was not an important factor in tacrolimus pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVqlSm7oB1_LVg90H21EOLACvtfcHk0lj8KfbxVQv1OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Crs78%253D&md5=e9d8699142acbae23d5b6d435148a47d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.transproceed.2005.02.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.transproceed.2005.02.073%26sid%3Dliteratum%253Aachs%26aulast%3DTada%26aufirst%3DH.%26aulast%3DTsuchiya%26aufirst%3DN.%26aulast%3DSatoh%26aufirst%3DS.%26aulast%3DKagaya%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMiura%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DHabuchi%26aufirst%3DT.%26atitle%3DImpact%2520of%2520CYP3A5%2520and%2520MDR1%2528ABCB1%2529%2520C3435T%2520polymorphisms%2520on%2520the%2520pharmacokinetics%2520of%2520tacrolimus%2520in%2520renal%2520transplant%2520recipients%26jtitle%3DTransplant.%2520Proc.%26date%3D2005%26volume%3D37%26spage%3D1730%26epage%3D1732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Gottlieb, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahfa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrowietz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murrell, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortonne, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emady-Azar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, C. F.</span><span> </span><span class="NLM_article-title">Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1111%2Fj.1365-2133.2005.06661.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmslCjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2005&pages=1219-1227&author=A.+B.+Gottliebauthor=C.+E.+M.+Griffithsauthor=V.+C.+Hoauthor=M.+Lahfaauthor=U.+Mrowietzauthor=D.+F.+Murrellauthor=J.-P.+Ortonneauthor=G.+Toddauthor=R.+Cherillauthor=I.+Marksauthor=S.+Emady-Azarauthor=C.+F.+Paul&title=Oral+pimecrolimus+in+the+treatment+of+moderate+to+severe+chronic+plaque-type+psoriasis%3A+a+double-blind%2C+multicentre%2C+randomized%2C+dose-finding+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial</span></div><div class="casAuthors">Gottlieb, A. B.; Griffiths, C. E. M.; Ho, V. C.; Lahfa, M.; Mrowietz, U.; Murrell, D. F.; Ortonne, J.-P.; Todd, G.; Cherill, R.; Marks, I.; Emady-Azar, S.; Paul, C. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1219-1227</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">There is a need for safe and effective alternative treatments for patients with moderate to severe psoriasis.  Pimecrolimus is a calcineurin inhibitor that is being investigated in oral form for the treatment of psoriasis.  A double-blind, randomized, parallel-group, dose-finding study was performed.  Healthy adult outpatients with moderate to severe chronic plaque-type psoriasis (n = 143) were randomized to receive oral placebo or pimecrolimus 10 mg, 20 mg, or 30 mg twice daily (b.d.) for 12 wk.  The Psoriasis Area and Severity Index (PASI) was used to assess clin. severity of psoriasis.  Results were analyzed at weeks 7 (primary endpoint) and 13.  Safety was assessed by monitoring all adverse events, lab. investigations (blood chem., urinalysis, hematol.) and phys. examns.  The change from baseline in PASI at week 7 showed a dose-dependent effect.  The differences between each of the two higher doses of pimecrolimus and placebo were statistically significant (P < 0.001; ANOVA).  The mean percentage decreases from baseline in PASI in the placebo group and pimecrolimus 10 mg, 20 mg and 30 mg b.d. groups at week 7 were 3.1%, 22.2%, 51.3% and 54.0%, resp.  Most adverse events were of mild or moderate severity.  The only adverse event to show a dose-response relationship was a transient feeling of warmth.  No clin. relevant effects on lab. parameters were obsd., and no increase in skin infection with pimecrolimus was seen.  Oral pimecrolimus produces a dose-dependent redn. in psoriasis severity, with doses of 20 mg and 30 mg b.d. being the most effective and well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG9b2nLMRGF7Vg90H21EOLACvtfcHk0lipqyQvG_faaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmslCjtbw%253D&md5=64613bc1247cca8a798120aadabf6f98</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2005.06661.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2005.06661.x%26sid%3Dliteratum%253Aachs%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DHo%26aufirst%3DV.%2BC.%26aulast%3DLahfa%26aufirst%3DM.%26aulast%3DMrowietz%26aufirst%3DU.%26aulast%3DMurrell%26aufirst%3DD.%2BF.%26aulast%3DOrtonne%26aufirst%3DJ.-P.%26aulast%3DTodd%26aufirst%3DG.%26aulast%3DCherill%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DI.%26aulast%3DEmady-Azar%26aufirst%3DS.%26aulast%3DPaul%26aufirst%3DC.%2BF.%26atitle%3DOral%2520pimecrolimus%2520in%2520the%2520treatment%2520of%2520moderate%2520to%2520severe%2520chronic%2520plaque-type%2520psoriasis%253A%2520a%2520double-blind%252C%2520multicentre%252C%2520randomized%252C%2520dose-finding%2520trial%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2005%26volume%3D152%26spage%3D1219%26epage%3D1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Kirsner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffernan, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antaya, R.</span><span> </span><span class="NLM_article-title">Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids</span> <span class="citation_source-journal">Acta Derm.-Venereol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2340%2F00015555-0748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFGjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2010&pages=58-64&author=R.+S.+Kirsnerauthor=M.+P.+Heffernanauthor=R.+Antaya&title=Safety+and+efficacy+of+tacrolimus+ointment+versus+pimecrolimus+cream+in+the+treatment+of+patients+with+atopic+dermatitis+previously+treated+with+corticosteroids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids</span></div><div class="casAuthors">Kirsner, Robert S.; Heffernan, Michael P.; Antaya, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Dermato-Venereologica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-64</span>CODEN:
                <span class="NLM_cas:coden">ADVEA4</span>;
        ISSN:<span class="NLM_cas:issn">0001-5555</span>.
    
            (<span class="NLM_cas:orgname">Acta Dermato-Venereologica</span>)
        </div><div class="casAbstract">Adult and pediatric patients (n=347) with atopic dermatitis enrolled in three multicenter, randomized, 6-wk studies who had previously used steroids were analyzed to examine the null hypothesis that improvement in atopic dermatitis initiated after prior treatment with steroids eliminates any subsequent treatment differences between tacrolimus ointment and pimecrolimus cream.  Of these patients, 171 were randomized to tacrolimus ointment and 176 to pimecrolimus cream.  Based on improvement in the Eczema Area and Severity Index at the end of study, tacrolimus ointment was significantly more effective than pimecrolimus cream (p=0.0002).  Tacrolimus ointment was also significantly more effective than pimecrolimus cream at the end of study in all secondary end-points.  Overall, the frequency of adverse events was comparable between treatment groups (24.0% for tacrolimus ointment vs. 25.6% for pimecrolimus cream).  Tacrolimus ointment is more effective, with a similar safety profile, compared with pimecrolimus cream in patients with atopic dermatitis previously treated with topical corticosteroids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplVjvghalu6rVg90H21EOLACvtfcHk0lipqyQvG_faaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFGjs70%253D&md5=25de6664caa2f6b04e54fe7db96e9147</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2340%2F00015555-0748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2340%252F00015555-0748%26sid%3Dliteratum%253Aachs%26aulast%3DKirsner%26aufirst%3DR.%2BS.%26aulast%3DHeffernan%26aufirst%3DM.%2BP.%26aulast%3DAntaya%26aufirst%3DR.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tacrolimus%2520ointment%2520versus%2520pimecrolimus%2520cream%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520atopic%2520dermatitis%2520previously%2520treated%2520with%2520corticosteroids%26jtitle%3DActa%2520Derm.-Venereol.%26date%3D2010%26volume%3D90%26spage%3D58%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Ashcroft, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimmock, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garside, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, H. C.</span><span> </span><span class="NLM_article-title">Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials</span> <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">522</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1136%2Fbmj.38376.439653.D3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVOltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2005&pages=516-522&author=D.+M.+Ashcroftauthor=P.+Dimmockauthor=R.+Garsideauthor=K.+Steinauthor=H.+C.+Williams&title=Efficacy+and+tolerability+of+topical+pimecrolimus+and+tacrolimus+in+the+treatment+of+atopic+dermatitis%3A+meta-analysis+of+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials</span></div><div class="casAuthors">Ashcroft, Darren M.; Dimmock, Paul; Garside, Ruth; Stein, Ken; Williams, Hywel C.</div><div class="citationInfo"><span class="NLM_cas:title">BMJ [British Medical Journal]</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">7490</span>),
    <span class="NLM_cas:pages">516-522</span>CODEN:
                <span class="NLM_cas:coden">BMJBFE</span>;
        ISSN:<span class="NLM_cas:issn">0959-8146</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">To det. the efficacy and tolerability of topical pimecrolimus and tacrolimus compared with other treatments for atopic dermatitis, a systematic review and meta-anal were carried out on data from electronic searches of the Cochrane Library, Medline, and Embase regarding randomized controlled trials of topical pimecrolimus or tacrolimus reporting efficacy outcomes or tolerability.  Data extn. efficiency was detd. by investigators' global assessment of response, patients' global assessment of response; proportions of patients with flares of atopic dermatitis; and improvements in quality of life.  Tolerability was assessed by overall rates of withdrawal, withdrawal due to adverse events, and the proportions of patients with burning of the skin and skin infections.  A total of 4186 of 6897 participants in 25 randomized controlled trials received pimecrolimus or tacrolimus.  Both drugs were significantly more effective than a vehicle control.  Tacrolimus 0.1% was as effective as potent topical corticosteroids at 3 wk and more effective than combined treatment with hydrocortisone butyrate 0.1% (potent formulation used on trunk) plus hydrocortisone acetate 1% (weak formaulation used on face) at 12 wk (no. needed to treat (NNT) = 6).  Tacrolimus 0.1% was also more effective than hydrocortisone acetate 1% (NNT = 4).  In comparison, tacrolimus 0.03% was more effective than hydrocortisone acetate 1% (NNT = 5) but less effective than hydrocortisone butyrate 0.1% (NNT = -8).  Direct comparisons of tacrolimus 0.03% and tacrolimus 0.1% consistently favored the higher strength formulation, but efficacy differed significantly between the two strengths only after 12 wk' treatment (rate ratio 0.80, 95% confidence interval 0.65-0.99).  Pimecrolimus was far less effective than betamethasone valerate 0.1% (NNT = -3 at 3 wk).  Pimecrolimus and tacrolimus caused significantly more skin burning than topical corticosteroids.  Rates of skin infections in any of the comparisons did not differ.  Both topical pimecrolimus and topical tacrolimus are more effective than placebo treatments for atopic dermatitis, but in the absence of studies that show long term safety gains, any advantage over topical corticosteroids is unclear.  Topical tacrolimus is similar to potent topical corticosteroids and may have a place for long term use in patients with resistant atopic dermatitis on sites where side effects from topical corticosteroids might develop quickly.  In the absence of key comparisons with mild corticosteroids.  The clin. need for topical pimecrolimus is unclear.  The usefulness of either treatment in patients who have failed to respond adequately to topical corticosteroids is also unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJni_isqBqiLVg90H21EOLACvtfcHk0lipqyQvG_faaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVOltb0%253D&md5=bb0e0b6efd8de77dbedd2d88bb4e97b1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1136%2Fbmj.38376.439653.D3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.38376.439653.D3%26sid%3Dliteratum%253Aachs%26aulast%3DAshcroft%26aufirst%3DD.%2BM.%26aulast%3DDimmock%26aufirst%3DP.%26aulast%3DGarside%26aufirst%3DR.%26aulast%3DStein%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DH.%2BC.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520topical%2520pimecrolimus%2520and%2520tacrolimus%2520in%2520the%2520treatment%2520of%2520atopic%2520dermatitis%253A%2520meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DBr.%2520Med.%2520J.%26date%3D2005%26volume%3D330%26spage%3D516%26epage%3D522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aschauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aszódi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuetz, A.</span><span> </span><span class="NLM_article-title">Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.ijpharm.2003.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFeksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2004&pages=29-35&author=A.+Billichauthor=H.+Aschauerauthor=A.+Asz%C3%B3diauthor=A.+Stuetz&title=Percutaneous+absorption+of+drugs+used+in+atopic+eczema%3A+pimecrolimus+permeates+less+through+skin+than+corticosteroids+and+tacrolimus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus</span></div><div class="casAuthors">Billich, Andreas; Aschauer, Heinrich; Aszodi, Andras; Stuetz, Anton</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">For treatment of skin diseases with topical drugs, penetration of the agents into the relevant layers of the skin is required.  Permeation through the skin should, however, be kept to a min., in order to avoid the risk of systemic side effects.  Here we compared the in vitro skin penetration and permeation of two novel drugs used in the therapy of atopic eczema (pimecrolimus and tacrolimus) and three representative corticosteroids (betamethasone-17-valerate, clobetasol-17-propionate, and diflucortolone-21-valerate).  Drug concns. of pimecrolimus and corticosteroids in human skin were found to be in the same order of magnitude.  Permeation of pimecrolimus through human skin was, however, lower by factors of 70-110 as compared to the steroids.  When pimecrolimus was compared with tacrolimus in human, pig, or rat skin, similar concns. of the two compds. were measured in the skin, whereas permeation of pimecrolimus through skin was consistently lower by factors of 9-10.  Lipophilicity was found to be highest for pimecrolimus, its octanol-water distribution coeff. being higher by factors of 8 and 25-450 than that of tacrolimus and the corticosteroids, resp.  The low permeation of pimecrolimus may be explained by its higher lipophilicity (compared to tacrolimus and the corticosteroids) and higher mol. wt. (compared to steroids).  In conclusion, pimecrolimus appears to have a favorable skin penetration/permeation profile, featuring a low degree of percutaneous absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnrb11yhmBTbVg90H21EOLACvtfcHk0lipqyQvG_faaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFeksLs%253D&md5=dfa9d3ac6dad852c5c6330b374d6391f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2003.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2003.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DAschauer%26aufirst%3DH.%26aulast%3DAsz%25C3%25B3di%26aufirst%3DA.%26aulast%3DStuetz%26aufirst%3DA.%26atitle%3DPercutaneous%2520absorption%2520of%2520drugs%2520used%2520in%2520atopic%2520eczema%253A%2520pimecrolimus%2520permeates%2520less%2520through%2520skin%2520than%2520corticosteroids%2520and%2520tacrolimus%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2004%26volume%3D269%26spage%3D29%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Weiss, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fresneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moenius, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuetz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billich, A.</span><span> </span><span class="NLM_article-title">Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1812</span><span class="NLM_x">–</span> <span class="NLM_lpage">1818</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1812-1818&author=H.+M.+Weissauthor=M.+Fresneauauthor=T.+Moeniusauthor=A.+Stuetzauthor=A.+Billich&title=Binding+of+pimecrolimus+and+tacrolimus+to+skin+and+plasma+proteins%3A+implications+for+systemic+exposure+after+topical+application"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DH.%2BM.%26aulast%3DFresneau%26aufirst%3DM.%26aulast%3DMoenius%26aufirst%3DT.%26aulast%3DStuetz%26aufirst%3DA.%26aulast%3DBillich%26aufirst%3DA.%26atitle%3DBinding%2520of%2520pimecrolimus%2520and%2520tacrolimus%2520to%2520skin%2520and%2520plasma%2520proteins%253A%2520implications%2520for%2520systemic%2520exposure%2520after%2520topical%2520application%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1812%26epage%3D1818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Mahalati, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaha, B. D.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of sirolimus</span> <span class="citation_source-journal">Clin. Pharmacokinet .</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2165%2F00003088-200140080-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=11523724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsl2gsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=573-585&author=K.+Mahalatiauthor=B.+D.+Kaha&title=Clinical+pharmacokinetics+of+sirolimus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of sirolimus</span></div><div class="casAuthors">Mahalati, Kamran; Kahan, Barry D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-585</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Sirolimus (previously known as rapamycin), a macrocyclic lactone, is a potent immunosuppressive agent.  Sirolimus was recently approved by the US Food and Drug Administration, on the basis of 2 large, double-blind, prospective clin. trials, for use in kidney transplant recipients at a fixed dosage of 2 or 5 mg/day in addn. to full dosages of cyclosporin and prednisone.  However, despite the fixed dosage regimens used in these pivotal trials, pharmacokinetic and clin. data show that sirolimus is a crit.-dose drug requiring therapeutic drug monitoring to minimize drug-related toxicities and maximize efficacy.  Assays using high performance liq. chromatog. coupled to mass spectrometry, although cumbersome, are the gold std. for evaluating other commonly used assays, such as liq. chromatog. with UV detection, radioreceptor assay and microparticle enzyme immunoassay.  Sirolimus is available in oral soln. and tablet form.  It has poor oral absorption and distributes widely in tissues, displaying not only a wide inter- and intrapatient variability in drug clearance, but also less than optimal correlations between whole blood concns. and drug dose, demog. features or patient characteristics.  Furthermore, the crit. role of the cytochrome P 450 3A4 system for sirolimus biotransformation leads to extensive drug-drug interactions, among which are increases in cyclosporin concns.  Thus, sirolimus is now being used to reduce or eliminate exposure to cyclosporin or corticosteroids.  The long elimination half-life of sirolimus necessitates a loading dose but allows once daily administration, which is more convenient and thereby could help to improve patient compliance.  This review emphasizes the importance of blood concn. monitoring in optimizing the use of sirolimus.  The excellent correlation between steady-state trough concn. (at least 4 days after inception of, or change in, therapy) and area under the concn.-time curve makes the former a simple and reliable index for monitoring sirolimus exposure.  Target trough concn. ranges depend on the concomitant immunosuppressive regimen, but a range of 5 to 15 μg/L is appropriate if cyclosporin is being used at trough concns. of 75 to 150 μg/L.  Weekly monitoring is recommended for the first month and bi-weekly for the next month; thereafter, concn. measurements are necessary only if warranted clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFv9OHBSIUCLVg90H21EOLACvtfcHk0lgXt5TOhFdD5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsl2gsLc%253D&md5=728dec62ae02c9fc473f71f5f94f93aa</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2165%2F00003088-200140080-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200140080-00002%26sid%3Dliteratum%253Aachs%26aulast%3DMahalati%26aufirst%3DK.%26aulast%3DKaha%26aufirst%3DB.%2BD.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520sirolimus%26jtitle%3DClin.%2520Pharmacokinet%2520.%26date%3D2001%26volume%3D40%26spage%3D573%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Hudes, G. R.</span><span> </span><span class="NLM_article-title">Targeting mTOR in renal cell carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2313</span><span class="NLM_x">–</span> <span class="NLM_lpage">2320</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2009&pages=2313-2320&author=G.+R.+Hudes&title=Targeting+mTOR+in+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudes%26aufirst%3DG.%2BR.%26atitle%3DTargeting%2520mTOR%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DCancer%26date%3D2009%26volume%3D115%26spage%3D2313%26epage%3D2320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Buckner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forouzesh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkenblit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=334-342&author=J.+C.+Bucknerauthor=B.+Forouzeshauthor=C.+Erlichmanauthor=M.+Hidalgoauthor=J.+P.+Boniauthor=G.+Dukartauthor=A.+Berkenblitauthor=E.+K.+Rowinsky&title=Phase+I%2C+pharmacokinetic+study+of+temsirolimus+administered+orally+to+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuckner%26aufirst%3DJ.%2BC.%26aulast%3DForouzesh%26aufirst%3DB.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBoni%26aufirst%3DJ.%2BP.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DBerkenblit%26aufirst%3DA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DPhase%2520I%252C%2520pharmacokinetic%2520study%2520of%2520temsirolimus%2520administered%2520orally%2520to%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2010%26volume%3D28%26spage%3D334%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Burke, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, L. B.</span><span> </span><span class="NLM_article-title">Zotarolimus (ABT-578) eluting stents</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.addr.2006.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=16581153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD28Xltl2js74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=437-446&author=S.+E.+Burkeauthor=R.+E.+Kuntzauthor=L.+B.+Schwartz&title=Zotarolimus+%28ABT-578%29+eluting+stents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Zotarolimus (ABT-578) eluting stents</span></div><div class="casAuthors">Burke, Sandra E.; Kuntz, Richard E.; Schwartz, Lewis B.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">437-446</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Drug-eluting stents have revolutionized the field of interventional cardiol. and have provided a significant innovation for preventing coronary artery restenosis.  Polymer coatings that deliver anti-proliferative drugs to the vessel wall are key components of these revolutionary medical devices.  This article focuses on the development of stents which elute the potent anti-proliferative agent, zotarolimus, from a synthetic phosphorylcholine-based polymer known for its biocompatible profile.  Zotarolimus is the first drug developed specifically for local delivery from stents for the prevention of restenosis and was tested extensively to support this indication.  Clin. experience with the PC polymer is also extensive, since more than 120,000 patients were implanted to date with stents contg. this non-thrombogenic coating.  This review provides background on pre-clin. studies with zotarolimus, on the development of the biocompatible PC polymer and on the clin. trials conducted using 2 stent platforms which deliver this drug to patients with coronary artery disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2zuwfCTBaKrVg90H21EOLACvtfcHk0lgXt5TOhFdD5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xltl2js74%253D&md5=219c232c01f34e5f7b79f16f99e3e7b7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2006.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2006.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DS.%2BE.%26aulast%3DKuntz%26aufirst%3DR.%2BE.%26aulast%3DSchwartz%26aufirst%3DL.%2BB.%26atitle%3DZotarolimus%2520%2528ABT-578%2529%2520eluting%2520stents%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D437%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Kirchner, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier-Wiedenbach, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manns, M. P.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of everolimus</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2165%2F00003088-200443020-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=14748618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFGkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=83-95&author=G.+I.+Kirchnerauthor=I.+Meier-Wiedenbachauthor=M.+P.+Manns&title=Clinical+pharmacokinetics+of+everolimus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of everolimus</span></div><div class="casAuthors">Kirchner, Gabriele I.; Meier-Wiedenbach, Ivo; Manns, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-95</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Everolimus is an immunosuppressive macrolide bearing a stable 2-hydroxyethyl chain substitution at position 40 on the sirolimus (rapamycin) structure.  Everolimus, which has greater polarity than sirolimus, was developed in an attempt to improve the pharmacokinetic characteristics of sirolimus, particularly to increase its oral bioavailability.  Everolimus has a mechanism of action similar to that of sirolimus.  It blocks growth-driven transduction signals in the T-cell response to alloantigen and thus acts at a later stage than the calcineurin inhibitors ciclosporin and tacrolimus.  Everolimus and ciclosporin show synergism in immunosuppression both in vitro and in vivo and therefore the drugs are intended to be given in combination after solid organ transplantation.  The synergistic effect allows a dosage redn. that decreases adverse effects.  For the quantification of the pharmacokinetics of everolimus, nine different assays using high performance liq. chromatog. coupled to an electrospray mass spectrometer, and one ELISA, have been developed.  Oral everolimus is absorbed rapidly, and reaches peak concn. after 1.3-1.8 h.  Steady state is reached within 7 days, and steady-state peak and trough concns., and area under the concn.-time curve (AUC), are proportional to dosage.  In adults, everolimus pharmacokinetic characteristics do not differ according to age, wt. or sex, but bodyweight-adjusted dosages are necessary in children.  The interindividual pharmacokinetic variability of everolimus can be explained by different activities of the drug efflux pump P-glycoprotein and of metab. by cytochrome P 450 (CYP) 3A4, 3A5 and 2C8.  The crit. role of the CYP3A4 system for everolimus biotransformation leads to drug-drug interactions with other drugs metabolised by this cytochrome system.  In patients with hepatic impairment, the apparent clearance of everolimus is significantly lower than in healthy volunteers, and therefore the dosage of everolimus should be reduced by half in these patients.  The advantage of everolimus seems to be its lower nephrotoxicity in comparison with the std. immunosuppressants ciclosporin and tacrolimus.  Obsd. adverse effects with everolimus include hypertriglyceridemia, hypercholesterolemia, opportunistic infections, thrombocytopenia and leucocytopenia.  Because of the variable oral bioavailability and narrow therapeutic index of everolimus, blood concn. monitoring seems to be important.  The excellent correlation between steady-state trough concn. and AUC makes the former a simple and reliable index for monitoring everolimus exposure.  The target trough concn. of everolimus should range between 3 and 15 μg/l, in combination therapy with ciclosporin (trough concn. 100-300 μg/L) and prednisone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8TxYc6XZNTbVg90H21EOLACvtfcHk0ligDY56utZ4og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFGkurY%253D&md5=f2b26414d8364047fcce45ebbe687c6b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2165%2F00003088-200443020-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200443020-00002%26sid%3Dliteratum%253Aachs%26aulast%3DKirchner%26aufirst%3DG.%2BI.%26aulast%3DMeier-Wiedenbach%26aufirst%3DI.%26aulast%3DManns%26aufirst%3DM.%2BP.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520everolimus%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2004%26volume%3D43%26spage%3D83%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Canga, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieto, A. M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebana, M. J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieitez, J. J. G.</span><span> </span><span class="NLM_article-title">The pharmacokinetics and interactions of ivermectin in humans—a mini-review</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=42-46&author=A.+G.+Cangaauthor=A.+M.+S.+Prietoauthor=M.+J.+D.+Liebanaauthor=N.+F.+Martinezauthor=M.+S.+Vegaauthor=J.+J.+G.+Vieitez&title=The+pharmacokinetics+and+interactions+of+ivermectin+in+humans%E2%80%94a+mini-review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCanga%26aufirst%3DA.%2BG.%26aulast%3DPrieto%26aufirst%3DA.%2BM.%2BS.%26aulast%3DLiebana%26aufirst%3DM.%2BJ.%2BD.%26aulast%3DMartinez%26aufirst%3DN.%2BF.%26aulast%3DVega%26aufirst%3DM.%2BS.%26aulast%3DVieitez%26aufirst%3DJ.%2BJ.%2BG.%26atitle%3DThe%2520pharmacokinetics%2520and%2520interactions%2520of%2520ivermectin%2520in%2520humans%25E2%2580%2594a%2520mini-review%26jtitle%3DAAPS%2520J.%26date%3D2008%26volume%3D10%26spage%3D42%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Edwards, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingsdale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helsby, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breckenridge, A.</span><span> </span><span class="NLM_article-title">The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1988&pages=681-684&author=G.+Edwardsauthor=A.+Dingsdaleauthor=N.+Helsbyauthor=M.+L.+Ormeauthor=A.+Breckenridge&title=The+relative+systemic+availability+of+ivermectin+after+administration+as+capsule%2C+tablet%2C+and+oral+solution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DG.%26aulast%3DDingsdale%26aufirst%3DA.%26aulast%3DHelsby%26aufirst%3DN.%26aulast%3DOrme%26aufirst%3DM.%2BL.%26aulast%3DBreckenridge%26aufirst%3DA.%26atitle%3DThe%2520relative%2520systemic%2520availability%2520of%2520ivermectin%2520after%2520administration%2520as%2520capsule%252C%2520tablet%252C%2520and%2520oral%2520solution%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1988%26volume%3D35%26spage%3D681%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Hoveyda, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagnon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vézina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benakli, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaubien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saint-Louis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinault, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaseshan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foucher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchemin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhérer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, G. L.</span><span> </span><span class="NLM_article-title">Optimization of the potency and pharmacokinetic properties of macrocyclic ghrelin receptor agonist (part I): development of ulimorelin (TZP-101) from hit to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8305</span><span class="NLM_x">–</span> <span class="NLM_lpage">8320</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8305-8320&author=H.+R.+Hoveydaauthor=E.+Marsaultauthor=R.+Gagnonauthor=A.+P.+Mathieuauthor=M.+V%C3%A9zinaauthor=A.+Landryauthor=Z.+Wangauthor=K.+Benakliauthor=S.+Beaubienauthor=C.+Saint-Louisauthor=M.+Brassardauthor=J.-F.+Pinaultauthor=L.+Ouelletauthor=S.+Bhatauthor=M.+Ramaseshanauthor=X.+Pengauthor=L.+Foucherauthor=S.+Beaucheminauthor=P.+Bh%C3%A9rerauthor=D.+F.+Veberauthor=M.+L.+Petersonauthor=G.+L.+Fraser&title=Optimization+of+the+potency+and+pharmacokinetic+properties+of+macrocyclic+ghrelin+receptor+agonist+%28part+I%29%3A+development+of+ulimorelin+%28TZP-101%29+from+hit+to+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm2007062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007062%26sid%3Dliteratum%253Aachs%26aulast%3DHoveyda%26aufirst%3DH.%2BR.%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DGagnon%26aufirst%3DR.%26aulast%3DMathieu%26aufirst%3DA.%2BP.%26aulast%3DV%25C3%25A9zina%26aufirst%3DM.%26aulast%3DLandry%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBenakli%26aufirst%3DK.%26aulast%3DBeaubien%26aufirst%3DS.%26aulast%3DSaint-Louis%26aufirst%3DC.%26aulast%3DBrassard%26aufirst%3DM.%26aulast%3DPinault%26aufirst%3DJ.-F.%26aulast%3DOuellet%26aufirst%3DL.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DRamaseshan%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DFoucher%26aufirst%3DL.%26aulast%3DBeauchemin%26aufirst%3DS.%26aulast%3DBh%25C3%25A9rer%26aufirst%3DP.%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26aulast%3DFraser%26aufirst%3DG.%2BL.%26atitle%3DOptimization%2520of%2520the%2520potency%2520and%2520pharmacokinetic%2520properties%2520of%2520macrocyclic%2520ghrelin%2520receptor%2520agonist%2520%2528part%2520I%2529%253A%2520development%2520of%2520ulimorelin%2520%2528TZP-101%2529%2520from%2520hit%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8305%26epage%3D8320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Hosoe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mae, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konishi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamane, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2749</span><span class="NLM_x">–</span> <span class="NLM_lpage">2755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=2749-2755&author=K.+Hosoeauthor=T.+Maeauthor=E.+Konishiauthor=K.+Fujiiauthor=K.+Yamashitaauthor=T.+Yamaneauthor=T.+Hidakaauthor=T.+Ohashi&title=Pharmacokinetics+of+KRM-1648%2C+a+new+benzoxazinorifamycin%2C+in+rats+and+dogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHosoe%26aufirst%3DK.%26aulast%3DMae%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DE.%26aulast%3DFujii%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DK.%26aulast%3DYamane%26aufirst%3DT.%26aulast%3DHidaka%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520of%2520KRM-1648%252C%2520a%2520new%2520benzoxazinorifamycin%252C%2520in%2520rats%2520and%2520dogs%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D2749%26epage%3D2755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Chen, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caban, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, L.</span><span> </span><span class="NLM_article-title">Escalating single-dose safety and pharmacokinetics of rifalazil in healthy volunteers</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">M1103</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=M1103&author=Y.-X.+Chenauthor=B.+Cabanauthor=L.+Robertson&title=Escalating+single-dose+safety+and+pharmacokinetics+of+rifalazil+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-X.%26aulast%3DCaban%26aufirst%3DB.%26aulast%3DRobertson%26aufirst%3DL.%26atitle%3DEscalating%2520single-dose%2520safety%2520and%2520pharmacokinetics%2520of%2520rifalazil%2520in%2520healthy%2520volunteers%26jtitle%3DAAPS%2520J.%26date%3D2004%26volume%3D6%26spage%3DM1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Chen, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabana, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelis, A.</span><span> </span><span class="NLM_article-title">Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">849</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1177%2F0091270007300745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1Gitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=841-849&author=Y.-X.+Chenauthor=B.+Cabanaauthor=N.+Kivelauthor=A.+Michaelis&title=Effect+of+food+on+the+pharmacokinetics+of+rifalazil%2C+a+novel+antibacterial%2C+in+healthy+male+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers</span></div><div class="casAuthors">Chen, Y.-X.; Cabana, B.; Kivel, N.; Michaelis, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">841-849</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Rifalazil is a new antibiotic structurally related to rifampin but devoid of the metabolic liabilities typically assocd. with the rifamycin class of antibiotics.  A randomized, 3-way crossover study in healthy male volunteers (n = 12) investigated the safety and pharmacokinetics of a single 25-mg oral rifalazil dose administered under a std. breakfast contg. fat as 30% of calories, a high-fat breakfast contg. fat as 60% of calories, and an overnight fast of 10 h with a 21- to 28-day washout between doses.  Systemic exposure to rifalazil based on Cmax, AUC0-Tlast, and AUCa-∞ was increased progressively as the fat content of the test breakfast was increased from 30% to 60% compared with fasting.  The confidence intervals for both fat-contg. breakfasts are outside the limits of 80% to 125% allowed for food effect bioequivalence based on Cmax, AUC0-Tlast, and AUC0-∞.  This food effect may be a result of increased fractional absorption with increasing dietary fat content.  Another striking finding was the large redn. of the pharmacokinetic intersubject variability after rifalazil administration with food.  Rifalazil was safe and well tolerated under fed and fasted conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNFb9GmK4FnbVg90H21EOLACvtfcHk0lj9DIyocJJr8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1Gitrw%253D&md5=c5c274d7ade0d47d23c6fd28e3e42952</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1177%2F0091270007300745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270007300745%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-X.%26aulast%3DCabana%26aufirst%3DB.%26aulast%3DKivel%26aufirst%3DN.%26aulast%3DMichaelis%26aufirst%3DA.%26atitle%3DEffect%2520of%2520food%2520on%2520the%2520pharmacokinetics%2520of%2520rifalazil%252C%2520a%2520novel%2520antibacterial%252C%2520in%2520healthy%2520male%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D47%26spage%3D841%26epage%3D849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fetterly, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldston, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathews, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricart, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mays, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreisberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedrosian, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1200%2FJCO.2007.12.0345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=18202410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVGntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=361-367&author=M.+M.+Mitaauthor=A.+C.+Mitaauthor=Q.+S.+Chuauthor=E.+K.+Rowinskyauthor=G.+J.+Fetterlyauthor=M.+Goldstonauthor=A.+Patnaikauthor=L.+Mathewsauthor=A.+D.+Ricartauthor=T.+Maysauthor=H.+Knowlesauthor=V.+M.+Riveraauthor=J.+Kreisbergauthor=C.+L.+Bedrosianauthor=A.+W.+Tolcher&title=Phase+I+trial+of+the+novel+mammalian+target+of+rapamycin+inhibitor+deforolimus+%28AP23573%3B+MK-8669%29+administered+intravenously+daily+for+5+days+every+2+weeks+to+patients+with+advanced+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies</span></div><div class="casAuthors">Mita, Monica M.; Mita, Alain C.; Chu, Quincy S.; Rowinsky, Eric K.; Fetterly, Gerald J.; Goldston, Michelle; Patnaik, Amita; Mathews, Lesley; Ricart, Alejandro D.; Mays, Theresa; Knowles, Heather; Rivera, Victor M.; Kreisberg, Jeff; Bedrosian, Camille L.; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">This phase I trial was conducted to det. the safety, tolerability, pharmacokinetics, and pharmacodynamics of deforolimus (previously known as AP23573; MK-8669), a nonprodrug rapamycin analog, in patients with advanced solid malignancies.  Patients were treated using an accelerated titrn. design with sequential escalating flat doses of deforolimus administered as a 30-min i.v. infusion once daily for 5 consecutive days every 2 wk (QD×5) in a 28-day cycle.  Safety, pharmacokinetic, pharmacodynamic, and tumor response assessments were performed.  Thirty-two patients received at least one dose of deforolimus (3 to 28 mg/d).  Three dose-limiting toxicity events of grade 3 mouth sores were reported.  The max.-tolerated dose (MTD) was 18.75 mg/d.  Common treatment-related adverse events included reversible mouth sores and rash.  Whole-blood clearance increased with dose.  Pharmacodynamic analyses demonstrated mammalian target of rapamycin inhibition at all dose levels.  Four patients (one each with non-small-cell lung cancer, mixed mullerian tumor [carcinosarcoma], renal cell carcinoma, and Ewing sarcoma) experienced confirmed partial responses, and three addnl. patients had minor tumor regressions.  The MTD of this phase I trial using an accelerated titrn. design was detd. to be 18.75 mg/d.  Deforolimus was well tolerated and showed encouraging antitumor activity across a broad range of malignancies when administered i.v. on the QD×5 schedule.  On the basis of these overall results, a dose of 12.5 mg/d is being evaluated in phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy2ctnnQ5BdbVg90H21EOLACvtfcHk0lj9DIyocJJr8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVGntLk%253D&md5=ff21fcdb34fae88592e6e597204945b6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.12.0345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.12.0345%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DChu%26aufirst%3DQ.%2BS.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DGoldston%26aufirst%3DM.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DMathews%26aufirst%3DL.%26aulast%3DRicart%26aufirst%3DA.%2BD.%26aulast%3DMays%26aufirst%3DT.%26aulast%3DKnowles%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DKreisberg%26aufirst%3DJ.%26aulast%3DBedrosian%26aufirst%3DC.%2BL.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520novel%2520mammalian%2520target%2520of%2520rapamycin%2520inhibitor%2520deforolimus%2520%2528AP23573%253B%2520MK-8669%2529%2520administered%2520intravenously%2520daily%2520for%25205%2520days%2520every%25202%2520weeks%2520to%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Fetterly, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poplin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tap, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmona, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonemoto, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedrosian, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of oral deforolimus (AP23573, MK-8669)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">15S</span><span class="NLM_x">) </span> <span class="NLM_fpage">14555</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=14555&issue=15S&author=G.+J.+Fetterlyauthor=M.+M.+Mitaauthor=C.+D.+Brittenauthor=E.+Poplinauthor=W.+D.+Tapauthor=A.+Carmonaauthor=L.+Yonemotoauthor=C.+L.+Bedrosianauthor=E.+H.+Rubinauthor=A.+W.+Tolcher&title=Pharmacokinetics+of+oral+deforolimus+%28AP23573%2C+MK-8669%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DPoplin%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DCarmona%26aufirst%3DA.%26aulast%3DYonemoto%26aufirst%3DL.%26aulast%3DBedrosian%26aufirst%3DC.%2BL.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DPharmacokinetics%2520of%2520oral%2520deforolimus%2520%2528AP23573%252C%2520MK-8669%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3D15S%26spage%3D14555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Still, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schranz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, K.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1997</span><span class="NLM_x">–</span> <span class="NLM_lpage">2003</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=1997-2003&author=J.+G.+Stillauthor=J.+Schranzauthor=T.+P.+Degenhardtauthor=D.+Scottauthor=P.+Fernandesauthor=M.+J.+Gutierrezauthor=K.+Clark&title=Pharmacokinetics+of+solithromycin+%28CEM-101%29+after+single+or+multiple+oral+doses+and+effects+of+food+on+single-dose+bioavailability+in+healthy+adult+subjects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStill%26aufirst%3DJ.%2BG.%26aulast%3DSchranz%26aufirst%3DJ.%26aulast%3DDegenhardt%26aufirst%3DT.%2BP.%26aulast%3DScott%26aufirst%3DD.%26aulast%3DFernandes%26aufirst%3DP.%26aulast%3DGutierrez%26aufirst%3DM.%2BJ.%26aulast%3DClark%26aufirst%3DK.%26atitle%3DPharmacokinetics%2520of%2520solithromycin%2520%2528CEM-101%2529%2520after%2520single%2520or%2520multiple%2520oral%2520doses%2520and%2520effects%2520of%2520food%2520on%2520single-dose%2520bioavailability%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D1997%26epage%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Ross, D. B.</span><span> </span><span class="NLM_article-title">The FDA and the case of Ketek</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">1601</span><span class="NLM_x">–</span> <span class="NLM_lpage">1604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1056%2FNEJMp078032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=17442902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=1601-1604&author=D.+B.+Ross&title=The+FDA+and+the+case+of+Ketek"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: the FDA and the case of Ketek</span></div><div class="casAuthors">Ross, David B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1601-1604</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxg3oJZMs06LVg90H21EOLACvtfcHk0ljk23IIPZcR5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFCgtb4%253D&md5=f077976e1f2d38a66f7730fe4e6fb184</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1056%2FNEJMp078032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp078032%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DD.%2BB.%26atitle%3DThe%2520FDA%2520and%2520the%2520case%2520of%2520Ketek%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D1601%26epage%3D1604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scorneaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeill, Y.</span><span> </span><span class="NLM_article-title">SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=660-672&author=S.+Hopkinsauthor=B.+Scorneauxauthor=Z.+Huangauthor=M.+G.+Murrayauthor=S.+Wringauthor=C.+Smitleyauthor=R.+Harrisauthor=F.+Erdmannauthor=G.+Fischerauthor=Y.+Ribeill&title=SCY-635%2C+a+novel+nonimmunosuppressive+analog+of+cyclosporine+that+exhibits+potent+inhibition+of+hepatitis+C+virus+RNA+replication+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DScorneaux%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMurray%26aufirst%3DM.%2BG.%26aulast%3DWring%26aufirst%3DS.%26aulast%3DSmitley%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DErdmann%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DG.%26aulast%3DRibeill%26aufirst%3DY.%26atitle%3DSCY-635%252C%2520a%2520novel%2520nonimmunosuppressive%2520analog%2520of%2520cyclosporine%2520that%2520exhibits%2520potent%2520inhibition%2520of%2520hepatitis%2520C%2520virus%2520RNA%2520replication%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D660%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMassimo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sluder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scorneaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalczyk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeill, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baugh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P.</span><span> </span><span class="NLM_article-title">The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.jhep.2012.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22425702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XovV2nsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2012&pages=47-54&author=S.+Hopkinsauthor=B.+DiMassimoauthor=P.+Rusnakauthor=D.+Heumanauthor=J.+Lalezariauthor=A.+Sluderauthor=B.+Scorneauxauthor=S.+Mosierauthor=P.+Kowalczykauthor=Y.+Ribeillauthor=J.+Baughauthor=P.+Gallay&title=The+cyclophilin+inhibitor+SCY-635+suppresses+viral+replication+and+induces+endogenous+interferons+in+patients+with+chronic+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection</span></div><div class="casAuthors">Hopkins, Sam; DiMassimo, Betty; Rusnak, Pamela; Heuman, Douglas; Lalezari, Jacob; Sluder, Ann; Scorneaux, Bernard; Mosier, Sarah; Kowalczyk, Paul; Ribeill, Yves; Baugh, James; Gallay, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: SCY-635 is a non-immunosuppressive analog of cyclosporin A that inhibits cyclophilins A and B and hepatitis C virus (HCV) replication in vitro.  In a phase 1b multi-dose escalation study, we evaluated the safety, plasma pharmacokinetics, and antiviral activity of 15 days of monotherapy with SCY-635 in adults with chronic genotype 1 HCV infection.  Methods: Twenty adults with chronic HCV genotype 1 were randomized to SCY-635 oral doses of 100, 200, or 300 mg three times daily for 15 days.  Results: No dose-limiting clin. or lab. toxicities were identified.  On day 15, the mean decline in plasma viremia was 2.24 ± 1.74 log10 IU/mL with SCY-635 900 mg/d.  Individual antiviral responses correlated with host IL28B genotype.  Post hoc analyses indicated treatment with SCY-635 increased plasma protein concns. of interferon α (IFNα), IFNs λ1 and λ3, and 2'5' oligoadenylate synthetase 1 (2'5'OAS-1), with the greatest increases in IL28B CC and CT subjects.  Changes in plasma concns. for all markers were coincident with changes in the plasma concn. of SCY-635.  Peaks of IFNs α, λ1, and λ3 and 2'5'OAS-1 were obsd. within 2 h after drug administration.  In replicon cells, SCY-635 enhanced secretion of type I and type III IFNs and increased the expression of IFN-stimulated genes (ISG).  Conclusions: These studies establish clin. proof of concept for SCY-635 as a novel antiviral agent and suggest that restoration of the host innate immune response to chronic hepatitis C infection may represent a major mechanism through which cyclophilin inhibitors exert clin. antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOeLKHF7TNQLVg90H21EOLACvtfcHk0ljk23IIPZcR5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovV2nsLc%253D&md5=43dcadacaaef7efd63d3d823f53ad514</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DDiMassimo%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DP.%26aulast%3DHeuman%26aufirst%3DD.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DSluder%26aufirst%3DA.%26aulast%3DScorneaux%26aufirst%3DB.%26aulast%3DMosier%26aufirst%3DS.%26aulast%3DKowalczyk%26aufirst%3DP.%26aulast%3DRibeill%26aufirst%3DY.%26aulast%3DBaugh%26aufirst%3DJ.%26aulast%3DGallay%26aufirst%3DP.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520SCY-635%2520suppresses%2520viral%2520replication%2520and%2520induces%2520endogenous%2520interferons%2520in%2520patients%2520with%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D57%26spage%3D47%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Aspeslet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freitag, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepanier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naicker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneteman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatscoff, R.</span><span> </span><span class="NLM_article-title">ISATX247: a novel calcineurin inhibitor</span> <span class="citation_source-journal">Transplant. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2FS0041-1345%2800%2902325-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitV2nsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=1048-1051&author=L.+Aspesletauthor=D.+Freitagauthor=D.+Trepanierauthor=M.+Abelauthor=S.+Naickerauthor=N.+Knetemanauthor=R.+Fosterauthor=R.+Yatscoff&title=ISATX247%3A+a+novel+calcineurin+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">ISATX</span></div><div class="casAuthors">Aspeslet, L.; Freitag, D.; Trepanier, D.; Abel, M.; Naicker, S.; Kneteman, N.; Foster, R.; Yatscoff, R.</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation Proceedings</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1048-1051</span>CODEN:
                <span class="NLM_cas:coden">TRPPA8</span>;
        ISSN:<span class="NLM_cas:issn">0041-1345</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The toxicokinetics of ISATX247, a novel calcineurin inhibitor, were evaluated in rabbit, rat, and dog models.  The immunosuppressive activity of the drug was evaluated in vitro using a calcineurin assay and the in vivo potency was assessed in a heterotopic rat heart transplant model.  ISATX247 was shown to be more potent than cyclosporine in vitro and in vivo.  In the rat heterotopic heart transplant model, the drug prolonged graft survival threefold longer than cyclosporine.  ISATX247 showed significantly reduced renal side effects compared to cyclosporine, suggesting dissocn. between calcineurin inhibition and toxicity.  The results indicated that ISATX247 has a wider therapeutic index than cyclosporine and should offer a significant advantage over presently immunosuppressive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPSGbkQ0zET7Vg90H21EOLACvtfcHk0ljk23IIPZcR5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitV2nsbk%253D&md5=8cbf77dc19fdc60d4b96c8b1575c16a5</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0041-1345%2800%2902325-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0041-1345%252800%252902325-3%26sid%3Dliteratum%253Aachs%26aulast%3DAspeslet%26aufirst%3DL.%26aulast%3DFreitag%26aufirst%3DD.%26aulast%3DTrepanier%26aufirst%3DD.%26aulast%3DAbel%26aufirst%3DM.%26aulast%3DNaicker%26aufirst%3DS.%26aulast%3DKneteman%26aufirst%3DN.%26aulast%3DFoster%26aufirst%3DR.%26aulast%3DYatscoff%26aufirst%3DR.%26atitle%3DISATX247%253A%2520a%2520novel%2520calcineurin%2520inhibitor%26jtitle%3DTransplant.%2520Proc.%26date%3D2001%26volume%3D33%26spage%3D1048%26epage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Wasel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunynetz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guenther, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourcier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatscoff, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freitag, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, R. T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of ISA247 in a phase III randomized, multicenter, double-blind, placebo-controlled study</span> <span class="citation_source-journal">J. Am. Acad. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">P36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=P36&author=N.+Waselauthor=A.+Guptaauthor=Z.+Tomiauthor=R.+Kunynetzauthor=L.+Guentherauthor=M.+Bourcierauthor=R.+W.+Yatscoffauthor=P.+Mayoauthor=D.+Freitagauthor=R.+T.+Foster&title=Pharmacokinetics+and+pharmacodynamics+of+ISA247+in+a+phase+III+randomized%2C+multicenter%2C+double-blind%2C+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWasel%26aufirst%3DN.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DTomi%26aufirst%3DZ.%26aulast%3DKunynetz%26aufirst%3DR.%26aulast%3DGuenther%26aufirst%3DL.%26aulast%3DBourcier%26aufirst%3DM.%26aulast%3DYatscoff%26aufirst%3DR.%2BW.%26aulast%3DMayo%26aufirst%3DP.%26aulast%3DFreitag%26aufirst%3DD.%26aulast%3DFoster%26aufirst%3DR.%2BT.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520ISA247%2520in%2520a%2520phase%2520III%2520randomized%252C%2520multicenter%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2006%26volume%3D54%26spage%3DP36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Politano, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, R. G.</span><span> </span><span class="NLM_article-title">NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=20112172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnt1KgtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=225-236&author=A.+D.+Politanoauthor=R.+G.+Sawyer&title=NXL-103%2C+a+combination+of+flopristin+and+linopristin%2C+for+the+potential+treatment+of+bacterial+infections+including+community-acquired+pneumonia+and+MRSA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA</span></div><div class="casAuthors">Politano, Amani D.; Sawyer, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (BioMed Central)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-236</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">2040-3429</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Novexel is developing the novel, orally active, semisynthetic streptogramin NXL-103, which has potential therapeutic application in the treatment of community-acquired pneumonia, community- or hospital-acquired MRSA, vancomycin-resistant enterococcus, and acute bacterial skin and soft tissue infections.  NXL-103 is a combination of streptogramin A:streptogramin B components, initially developed in a 70:30 dose ratio.  In multiple in vitro studies, NXL-103 demonstrated potent activity against different types of bacteria, such as Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecium, Enterococcus faecalis, Haemophilus influenzae and Haemophilus parainfluenzae.  NXL-103 was not affected by the resistance profiles of bacteria against other commonly used antibiotics.  In phase I clin. trials, NXL-103 achieved bactericidal levels in plasma and was generally well tolerated, with side effects primarily on the gastrointestinal system.  The first phase II trial conducted to evaluate the efficacy of NXL-103 against community-acquired pneumonia revealed that the compd. was comparable with amoxicillin.  NXL-103 has promise to become an important agent in the treatment of community-acquired pneumonia and complex skin and soft tissue infections, pending further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZhaHyEQ-YPrVg90H21EOLACvtfcHk0ljgOkEwCHFQvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnt1KgtLw%253D&md5=c5c124478ed1f545d51103a2194249df</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolitano%26aufirst%3DA.%2BD.%26aulast%3DSawyer%26aufirst%3DR.%2BG.%26atitle%3DNXL-103%252C%2520a%2520combination%2520of%2520flopristin%2520and%2520linopristin%252C%2520for%2520the%2520potential%2520treatment%2520of%2520bacterial%2520infections%2520including%2520community-acquired%2520pneumonia%2520and%2520MRSA%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D11%26spage%3D225%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Malcolm, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belanger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butkiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheyas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1013-1020&author=B.+A.+Malcolmauthor=R.+Liuauthor=F.+Lahserauthor=S.+Agrawalauthor=B.+Belangerauthor=N.+Butkiewiczauthor=R.+Chaseauthor=F.+Gheyasauthor=A.+Hartauthor=D.+Heskauthor=P.+Ingravalloauthor=C.+Jiangauthor=R.+Kongauthor=J.+Luauthor=J.+Pichardoauthor=A.+Prongayauthor=A.+Skeltonauthor=X.+Tongauthor=S.+Venkatramanauthor=E.+Xiaauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=SCH+503034%2C+a+mechanism-based+inhibitor+of+hepatitis+C+virus+NS3+protease%2C+suppresses+polyprotein+maturation+and+enhances+the+antiviral+activity+of+alpha+interferon+in+replicon+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalcolm%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DLahser%26aufirst%3DF.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DBelanger%26aufirst%3DB.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DGheyas%26aufirst%3DF.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DSkelton%26aufirst%3DA.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DSCH%2520503034%252C%2520a%2520mechanism-based%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%2520protease%252C%2520suppresses%2520polyprotein%2520maturation%2520and%2520enhances%2520the%2520antiviral%2520activity%2520of%2520alpha%2520interferon%2520in%2520replicon%2520cells%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D1013%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almquist, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrn, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandorkar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinehart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalkeri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaczkowski, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span> </span><span class="NLM_article-title">Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">899</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=899-909&author=R.+B.+Perniauthor=S.+J.+Almquistauthor=R.+A.+Byrnauthor=G.+Chandorkarauthor=P.+R.+Chaturvediauthor=L.+F.+Courtneyauthor=C.+J.+Deckerauthor=K.+Dinehartauthor=C.+A.+Gatesauthor=S.+L.+Harbesonauthor=A.+Heiserauthor=G.+Kalkeriauthor=E.+Kolaczkowskiauthor=K.+Linauthor=Y.+P.+Luongauthor=B.+G.+Raoauthor=W.+P.+Taylorauthor=J.+A.+Thomsonauthor=R.+D.+Tungauthor=Y.+Weiauthor=A.+D.+Kwongauthor=C.+Lin&title=Preclinical+profile+of+VX-950%2C+a+potent%2C+selective%2C+and+orally+bioavailable+inhibitor+of+hepatitis+C+virus+NS3-4A+serine+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DAlmquist%26aufirst%3DS.%2BJ.%26aulast%3DByrn%26aufirst%3DR.%2BA.%26aulast%3DChandorkar%26aufirst%3DG.%26aulast%3DChaturvedi%26aufirst%3DP.%2BR.%26aulast%3DCourtney%26aufirst%3DL.%2BF.%26aulast%3DDecker%26aufirst%3DC.%2BJ.%26aulast%3DDinehart%26aufirst%3DK.%26aulast%3DGates%26aufirst%3DC.%2BA.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DHeiser%26aufirst%3DA.%26aulast%3DKalkeri%26aufirst%3DG.%26aulast%3DKolaczkowski%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLuong%26aufirst%3DY.%2BP.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DTaylor%26aufirst%3DW.%2BP.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DLin%26aufirst%3DC.%26atitle%3DPreclinical%2520profile%2520of%2520VX-950%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3-4A%2520serine%2520protease%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D899%26epage%3D909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span> </span><span class="NLM_article-title">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+Boesauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingley&title=An+NS3+protease+inhibitor+with+antiviral+effects+in+humans+infected+with+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0ljgOkEwCHFQvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DBoes%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26atitle%3DAn%2520NS3%2520protease%2520inhibitor%2520with%2520antiviral%2520effects%2520in%2520humans%2520infected%2520with%2520hepatitis%2520C%2520virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1002%2Fanie.200390347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1356-1360&author=Y.+S.+Tsantrizosauthor=G.+Bolgerauthor=P.+Bonneauauthor=D.+R.+Cameronauthor=N.+Goudreauauthor=G.+Kukoljauthor=S.+R.+LaPlanteauthor=M.+Llin%C3%A0s-Brunetauthor=H.+Narauthor=D.+Lamarre&title=Macrocyclic+inhibitors+of+the+NS3+protease+as+potential+therapeutic+agents+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span></div><div class="casAuthors">Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1356-1360</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed.  The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease.  The designed HCV inhibitor and its satd. analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay.  In addn., they are orally absorbed and stable to metabolic breakdown.  Thus, these compds. show many of the desirable properties of a druglike archetype and could lead t a clin. useful antiviral agent for the treatment of hepatitis C viral infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCij3shP5tmLVg90H21EOLACvtfcHk0lieOIqerd8W2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D&md5=e0a3c98ee0096bfc3d058bf0b92b81c3</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390347%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DMacrocyclic%2520inhibitors%2520of%2520the%2520NS3%2520protease%2520as%2520potential%2520therapeutic%2520agents%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D1356%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">M. Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador-Oden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wähling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickström, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamelink, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Vreken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pille, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of TMC435350</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4853</span><span class="NLM_x">–</span> <span class="NLM_lpage">4858</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4853-4858&author=P.+Raboissonauthor=H.+de+Kockauthor=%C3%85.+Rosenquistauthor=M.+M.+Nilssonauthor=L.+Salvador-Odenauthor=T.-I.+Linauthor=N.+Roueauthor=V.+Ivanovauthor=H.+W%C3%A4hlingauthor=K.+Wickstr%C3%B6mauthor=E.+Hamelinkauthor=M.+Edlundauthor=L.+Vrangauthor=S.+Vendevilleauthor=W.+Van+de+Vrekenauthor=D.+McGowanauthor=A.+Tahriauthor=L.+Huauthor=C.+Bouttonauthor=O.+Lenzauthor=F.+Delouvroyauthor=G.+Pilleauthor=D.+Surlerauxauthor=P.+Wigerinckauthor=B.+Samuelssonauthor=K.+Simmen&title=Structure%E2%80%93activity+relationship+study+on+a+novel+series+of+cyclopentane-containing+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3+protease+leading+to+the+discovery+of+TMC435350"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DM.%2BNilsson%26aufirst%3DM.%26aulast%3DSalvador-Oden%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DRoue%26aufirst%3DN.%26aulast%3DIvanov%26aufirst%3DV.%26aulast%3DW%25C3%25A4hling%26aufirst%3DH.%26aulast%3DWickstr%25C3%25B6m%26aufirst%3DK.%26aulast%3DHamelink%26aufirst%3DE.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DVan%2Bde%2BVreken%26aufirst%3DW.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBoutton%26aufirst%3DC.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DPille%26aufirst%3DG.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520study%2520on%2520a%2520novel%2520series%2520of%2520cyclopentane-containing%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520TMC435350%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4853%26epage%3D4858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbinnen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholliers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeiren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1377</span><span class="NLM_x">–</span> <span class="NLM_lpage">1385</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=1377-1385&author=T.+I.+Linauthor=O.+Lenzauthor=G.+Fanningauthor=T.+Verbinnenauthor=F.+Delouvroyauthor=A.+Scholliersauthor=K.+Vermeirenauthor=A.+Rosenquistauthor=M.+Edlundauthor=B.+Samuelssonauthor=L.+Vrangauthor=H.+de+Kockauthor=P.+Wigerinckauthor=P.+Raboissonauthor=K.+Simmen&title=In+vitro+activity+and+preclinical+profile+of+TMC435350%2C+a+potent+hepatitis+C+virus+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVerbinnen%26aufirst%3DT.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DVermeiren%26aufirst%3DK.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520activity%2520and%2520preclinical%2520profile%2520of%2520TMC435350%252C%2520a%2520potent%2520hepatitis%2520C%2520virus%2520protease%2520inhibitor%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D1377%26epage%3D1385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blatt, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patat, A.</span><span> </span><span class="NLM_article-title">A phase 1 study of the safety, tolerability, and pharmacokinetics of single ascending oral doses of the NS3/4A protease inhibitor ITMN-191 in healthy subjects</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1146A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1146A&author=W.+Z.+Bradfordauthor=C.+Rubinoauthor=S.+Porterauthor=A.+Forrestauthor=L.+M.+Blattauthor=A.+Patat&title=A+phase+1+study+of+the+safety%2C+tolerability%2C+and+pharmacokinetics+of+single+ascending+oral+doses+of+the+NS3%2F4A+protease+inhibitor+ITMN-191+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DRubino%26aufirst%3DC.%26aulast%3DPorter%26aufirst%3DS.%26aulast%3DForrest%26aufirst%3DA.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DPatat%26aufirst%3DA.%26atitle%3DA%2520phase%25201%2520study%2520of%2520the%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520single%2520ascending%2520oral%2520doses%2520of%2520the%2520NS3%252F4A%2520protease%2520inhibitor%2520ITMN-191%2520in%2520healthy%2520subjects%26jtitle%3DHepatology%26date%3D2008%26volume%3D48%26spage%3D1146A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Reddy, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blotner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, J. Q.</span><span> </span><span class="NLM_article-title">Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug–drug interaction study</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">457</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2165%2F11599700-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFaksbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=457-465&author=M.+B.+Reddyauthor=Y.+Chenauthor=J.+O.+Haznedarauthor=J.+Fretlandauthor=S.+Blotnerauthor=P.+Smithauthor=J.+Q.+Tran&title=Impact+of+low-dose+ritonavir+on+danoprevir+pharmacokinetics%3A+results+of+computer-based+simulations+and+a+clinical+drug%E2%80%93drug+interaction+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study</span></div><div class="casAuthors">Reddy, Micaela B.; Chen, Yuan; Haznedar, Joshua O.; Fretland, Jennifer; Blotner, Steven; Smith, Patrick; Tran, Jonathan Q.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">457-465</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">Background and Objective: Danoprevir, a potent, selective inhibitor of the hepatitis C virus (HCV) NS3/4A protease, is metabolized by cytochrome P 450 (CYP) 3A.  Clin. studies in HCV patients have shown a potential need for a high danoprevir daily dose and/or dosing frequency.  Ritonavir, an HIV-1 protease inhibitor (PI) and potent CYP3A inhibitor, is used as a pharmacokinetic enhancer at subtherapeutic doses in combination with other HIV PIs.  Coadministering danoprevir with ritonavir as a pharmacokinetic enhancer could allow reduced danoprevir doses and/or dosing frequency.  Here we evaluate the impact of ritonavir on danoprevir pharmacokinetics.  Methods: The effects of low-dose ritonavir on danoprevir pharmacokinetics were simulated using Simcyp, a population-based simulator.  Following results from this drug-drug interaction (DDI) model, a crossover study was performed in healthy volunteers to investigate the effects of acute and repeat dosing of low-dose ritonavir on danoprevir single-dose pharmacokinetics.  Volunteers received a single oral dose of danoprevir 100 mg in a fixed sequence as follows: alone, and on the first day and the last day of 10-day dosing with ritonavir 100 mg every 12 h.  Results: The initial DDI model predicted that following multiple dosing of ritonavir 100 mg every 12 h for 10 days, the danoprevir area under the plasma concn.-time curve (AUC) from time zero to 24 h and max. plasma drug concn. (Cmax) would increase by about 3.9- and 3.2-fold, resp.  The clin. results at day 10 of ritonavir dosing showed that the plasma drug concn. at 12 h postdose, AUC from time zero to infinity and Cmax of danoprevir increased by approx. 42-fold, 5.5-fold and 3.2-fold, resp., compared with danoprevir alone.  The DDI model was refined with the clin. data and sensitivity analyses were performed to better understand factors impacting the ritonavir-danoprevir interaction.  Conclusion: DDI model simulations predicted that danoprevir exposures could be successfully enhanced with ritonavir coadministration, and that a clin. study confirming this result was warranted.  The clin. results demonstrate that low-dose ritonavir enhances the pharmacokinetic profile of low-dose danoprevir such that overall danoprevir exposures can be reduced while sustaining danoprevir trough concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP0vJez0knArVg90H21EOLACvtfcHk0ljMMhNU8FDdxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFaksbjI&md5=8691b68cbf95355ec2eb651aee412e88</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2165%2F11599700-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11599700-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BB.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHaznedar%26aufirst%3DJ.%2BO.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DBlotner%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DJ.%2BQ.%26atitle%3DImpact%2520of%2520low-dose%2520ritonavir%2520on%2520danoprevir%2520pharmacokinetics%253A%2520results%2520of%2520computer-based%2520simulations%2520and%2520a%2520clinical%2520drug%25E2%2580%2593drug%2520interaction%2520study%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D457%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">Molecular modeling based approach to potent P2–P4 macrocyclic inhibitors of hepatitis C NS3/4a protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">4607</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja711120r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=4607-4609&author=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=J.+W.+Butcherauthor=S.+S.+Carrollauthor=J.+DiMuzioauthor=C.+Fandozziauthor=K.+F.+Gilbertauthor=S.-S.+Maoauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=M.+Stahlhutauthor=B.-L.+Wanauthor=D.+B.+Olsenauthor=J.+P.+Vacca&title=Molecular+modeling+based+approach+to+potent+P2%E2%80%93P4+macrocyclic+inhibitors+of+hepatitis+C+NS3%2F4a+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fja711120r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja711120r%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMolecular%2520modeling%2520based%2520approach%2520to%2520potent%2520P2%25E2%2580%2593P4%2520macrocyclic%2520inhibitors%2520of%2520hepatitis%2520C%2520NS3%252F4a%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D4607%26epage%3D4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2463</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9015526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2443-2463&author=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=M.+T.+Ruddauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=J.+W.+Butcherauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=M.+K.+Hollowayauthor=J.+Swestockauthor=B.-L.+Wanauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=S.+W.+Ludmererauthor=S.-S.+Maoauthor=M.+W.+Stahlhutauthor=C.+M.+Fandozziauthor=N.+Trainorauthor=D.+B.+Olsenauthor=J.+P.+Vaccaauthor=N.+J.+Liverton&title=Discovery+of+vaniprevir+%28MK-7009%29%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">McCauley, John A.; McIntyre, Charles J.; Rudd, Michael T.; Nguyen, Kevin T.; Romano, Joseph J.; Butcher, John W.; Gilbert, Kevin F.; Bush, Kimberly J.; Holloway, M. Katharine; Swestock, John; Wan, Bang-Lin; Carroll, Steven S.; DiMuzio, Jillian M.; Graham, Donald J.; Ludmerer, Steven W.; Mao, Shi-Shan; Stahlhut, Mark W.; Fandozzi, Christine M.; Trainor, Nicole; Olsen, David B.; Vacca, Joseph P.; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2443-2463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a mol.-modeling derived strategy.  Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compds. via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate vaniprevir, MK-7009, which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2CVs9I1H_7Vg90H21EOLACvtfcHk0ljMMhNU8FDdxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D&md5=dc820c588d5482f6913091a87eaf9af1</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm9015526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015526%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520vaniprevir%2520%2528MK-7009%2529%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2443%26epage%3D2463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazuda, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4a protease</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=305-311&author=N.+J.+Livertonauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=C.+Fandozziauthor=D.+J.+Grahamauthor=D.+J.+Hazudaauthor=M.+K.+Hollowayauthor=S.+W.+Ludmererauthor=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=D.+B.+Olsenauthor=M.+T.+Ruddauthor=M.+Stahlhutauthor=J.+P.+Vacca&title=MK-7009%2C+a+potent+and+selective+inhibitor+of+hepatitis+C+virus+NS3%2F4a+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMK-7009%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D305%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claudio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Filippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazuda, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span> </span><span class="NLM_article-title">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4161</span><span class="NLM_x">–</span> <span class="NLM_lpage">4167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1128%2FAAC.00324-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22615282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4161-4167&author=V.+Summaauthor=S.+W.+Ludmererauthor=J.+A.+McCauleyauthor=C.+Fandozziauthor=C.+Burleinauthor=G.+Claudioauthor=P.+J.+Colemanauthor=J.+M.+DiMuzioauthor=M.+Ferraraauthor=M.+Di+Filippoauthor=A.+T.+Gatesauthor=D.+J.+Grahamauthor=S.+Harperauthor=D.+J.+Hazudaauthor=C.+McHaleauthor=E.+Monteagudoauthor=V.+Pucciauthor=M.+Rowleyauthor=M.+T.+Ruddauthor=A.+Sorianoauthor=M.+W.+Stahlhutauthor=J.+P.+Vaccaauthor=D.+B.+Olsenauthor=N.+J.+Livertonauthor=S.+S.+Carroll&title=MK-5172%2C+a+selective+inhibitor+of+hepatitis+C+virus+NS3%2F4a+protease+with+broad+activity+across+genotypes+and+resistant+variants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span></div><div class="casAuthors">Summa, Vincenzo; Ludmerer, Steven W.; McCauley, John A.; Fandozzi, Christine; Burlein, Christine; Claudio, Giuliano; Coleman, Paul J.; DiMuzio, Jillian M.; Ferrara, Marco; Di Filippo, Marcello; Gates, Adam T.; Graham, Donald J.; Harper, Steven; Hazuda, Daria J.; McHale, Carolyn; Monteagudo, Edith; Pucci, Vincenzo; Rowley, Michael; Rudd, Michael T.; Soriano, Aileen; Stahlhut, Mark W.; Vacca, Joseph P.; Olsen, David B.; Liverton, Nigel J.; Carroll, Steven S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4161-4167</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections.  Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes for future agents to be used in combinations without interferon.  In this communication, we report the preclin. profile of MK-5172, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clin. development.  The compd. demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors.  In replicon selections, MK-5172 exerted high selective pressure, which yielded few resistant colonies.  In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing.  When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppressed viral load between 4 to 5 logs at a dose of 1 mg/kg of body wt. twice daily (b.i.d.) for 7 days.  Based on its preclin. profile, MK-5172 is anticipated to be broadly active against multiple HCV genotypes and clin. important resistance variants and highly suited for incorporation into newer all-oral regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomXxLJMTmWqrVg90H21EOLACvtfcHk0lgOGc61_-Hpww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF&md5=8874f9279917137113e429cda31c1bba</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1128%2FAAC.00324-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00324-12%26sid%3Dliteratum%253Aachs%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DClaudio%26aufirst%3DG.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DGates%26aufirst%3DA.%2BT.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26atitle%3DMK-5172%252C%2520a%2520selective%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520with%2520broad%2520activity%2520across%2520genotypes%2520and%2520resistant%2520variants%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4161%26epage%3D4167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Last, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Steen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4437</span><span class="NLM_x">–</span> <span class="NLM_lpage">4443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4437-4443&author=S.+Vendevilleauthor=T.+I.+Linauthor=L.+Huauthor=A.+Tahriauthor=D.+McGowanauthor=M.+D.+Cummingsauthor=K.+Amssomsauthor=M.+Canardauthor=S.+Lastauthor=I.+Van+den+Steenauthor=B.+Devogelaereauthor=M.+C.+Rouanauthor=L.+Vijgenauthor=J.+M.+Berkeauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=G.+Fanningauthor=K.+Van+Emelenauthor=O.+Nyanguileauthor=K.+Simmenauthor=P.+Raboisson&title=Finger+loop+inhibitors+of+the+HCV+NS5b+polymerase.+Part+II.+Optimization+of+tetracyclic+indole-based+macrocycle+leading+to+the+discovery+of+TMC647055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DCanard%26aufirst%3DM.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DVan%2Bden%2BSteen%26aufirst%3DI.%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DFinger%2520loop%2520inhibitors%2520of%2520the%2520HCV%2520NS5b%2520polymerase.%2520Part%2520II.%2520Optimization%2520of%2520tetracyclic%2520indole-based%2520macrocycle%2520leading%2520to%2520the%2520discovery%2520of%2520TMC647055%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4437%26epage%3D4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span> </span><span class="NLM_article-title">TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4676</span><span class="NLM_x">–</span> <span class="NLM_lpage">4684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4676-4684&author=B.+Devogelaereauthor=J.+M.+Berkeauthor=L.+Vijgenauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=O.+Nyanguileauthor=A.+Tahriauthor=K.+Amssomsauthor=O.+Lenzauthor=M.+D.+Cummingsauthor=R.+F.+Claytonauthor=S.+Vendevilleauthor=P.+Raboissonauthor=K.+A.+Simmenauthor=G.+C.+Fanningauthor=T.+I.+Lin&title=TMC647055%2C+a+potent+nonnucleoside+hepatitis+C+virus+NS5B+polymerase+inhibitor+with+cross-genotypic+coverage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DClayton%26aufirst%3DR.%2BF.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%2BA.%26aulast%3DFanning%26aufirst%3DG.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BI.%26atitle%3DTMC647055%252C%2520a%2520potent%2520nonnucleoside%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%2520inhibitor%2520with%2520cross-genotypic%2520coverage%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4676%26epage%3D4684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.-H.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2FFms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.-H.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252FFms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Younes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romaguera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeister, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neelapu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro Faria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span> </span><span class="NLM_article-title">Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4161</span><span class="NLM_x">–</span> <span class="NLM_lpage">4167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1200%2FJCO.2012.42.5223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVanug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=4161-4167&author=A.+Younesauthor=J.+Romagueraauthor=M.+Fanaleauthor=P.+McLaughlinauthor=F.+Hagemeisterauthor=A.+Copelandauthor=S.+Neelapuauthor=L.+Kwakauthor=J.+Shahauthor=S.+de+Castro+Fariaauthor=S.+Hartauthor=J.+Woodauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+Zhu&title=Phase+I+study+of+a+novel+oral+Janus+kinase+2+inhibitor%2C+SB1518%2C+in+patients+with+relapsed+lymphoma%3A+evidence+of+clinical+and+biologic+activity+in+multiple+lymphoma+subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes</span></div><div class="casAuthors">Younes, Anas; Romaguera, Jorge; Fanale, Michelle; McLaughlin, Peter; Hagemeister, Frederick; Copeland, Amanda; Neelapu, Sattva; Kwak, Larry; Shah, Jatin; Faria, Silvana de Castro; Hart, Stefan; Wood, Jeanette; Jayaraman, Ramesh; Ethirajulu, Kantharaj; Zhu, Joy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4161-4167</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose. The Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) pathway plays an important role in the pathogenesis of hematol. malignancies.  We conducted a phase I dose-finding and pharmacokinetic/pharmacodynamic study of SB1518, a potent JAK2 inhibitor, in patients with relapsed lymphoma.  Patients and Methods. Patients with relapsed or refractory Hodgkin or non-Hodgkin lymphoma of any type except Burkitt's or CNS lymphoma were enrolled.  Patient cohorts received escalating doses of SB1518 orally once daily for 28-day cycles.  Response was evaluated after 8 wk.  Results. Thirty-four patients received doses of 100 to 600 mg/d.  The max. tolerated dose was not reached.  Treatment was well tolerated, with mostly grade 1 and 2 toxicities.  Gastrointestinal toxicities were the most common treatment-related events.  Cytopenias were infrequent and modest.  Pharmacol. active concns. were achieved at all doses.  Dose-related linear increases in area under the concn.-time curve were seen on day 1, with no significant accumulation on day 15.  Mean terminal half-life was 1 to 4 days, and mean time to peak concn. ranged from 5 to 9 h.  SB1518 inhibited JAK2 signaling at 4 h postdose at all levels.  Increases in fms-like tyrosine kinase-3 (FLT-3) ligand, reflecting FLT-3 inhibition, were seen in most patients.  There were three partial responses (≥ 300 mg/d) and 15 patients with stable disease (SD), with most responses lasting longer than 2 mo.  Seven of 13 SDs had tumor redns. of 4% to 46%.  Conclusion. SB1518 has encouraging activity in relapsed lymphoma, providing the first proof-of-principle of the potential therapeutic value of targeting the JAK/STAT pathway in lymphoma in the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptMRuMQba1fbVg90H21EOLACvtfcHk0lgynBbG7nKexQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVanug%253D%253D&md5=4d209b73c02421bd732d2257d616521b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.5223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.5223%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DRomaguera%26aufirst%3DJ.%26aulast%3DFanale%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DP.%26aulast%3DHagemeister%26aufirst%3DF.%26aulast%3DCopeland%26aufirst%3DA.%26aulast%3DNeelapu%26aufirst%3DS.%26aulast%3DKwak%26aufirst%3DL.%26aulast%3DShah%26aufirst%3DJ.%26aulast%3Dde%2BCastro%2BFaria%26aufirst%3DS.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520study%2520of%2520a%2520novel%2520oral%2520Janus%2520kinase%25202%2520inhibitor%252C%2520SB1518%252C%2520in%2520patients%2520with%2520relapsed%2520lymphoma%253A%2520evidence%2520of%2520clinical%2520and%2520biologic%2520activity%2520in%2520multiple%2520lymphoma%2520subtypes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D4161%26epage%3D4167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">4123</span><span class="NLM_x">–</span> <span class="NLM_lpage">4134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=4123-4134&author=B.+Madanauthor=K.+C.+Gohauthor=S.+Hartauthor=A.+D.+Williamauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+M.+Wood&title=SB1578%2C+a+novel+inhibitor+of+JAK2%2C+FLT3%2C+and+c-Fms+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DSB1578%252C%2520a%2520novel%2520inhibitor%2520of%2520JAK2%252C%2520FLT3%252C%2520and%2520c-Fms%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26spage%3D4123%26epage%3D4134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span> </span><span class="NLM_article-title">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">J Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1007%2Fs00894-012-1528-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22820730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=119-130&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=H.+Nagarajauthor=M.+Williamsauthor=H.+Wangauthor=A.+Leeauthor=E.+Sunauthor=E.+L.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+nitrogen-linked+macrocyclic+kinase+inhibitors+leading+to+the+clinical+candidate+SB1317%2FTG02%2C+a+potent+inhibitor+of+cyclin+dependant+kinases+%28CDKs%29%2C+Janus+kinase+2+%28JAK2%29%2C+and+Fms-like+tyrosine+kinase-3+%28FLT3%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Poulsen, Anders; William, Anthony; Blanchard, Stephanie; Nagaraj, Harish; Williams, Meredith; Wang, Haishan; Lee, Angeline; Sun, Eric; Teo, Ee-Ling; Tan, Evelyn; Goh, Kee Chuan; Dymock, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-130</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A high-throughput screen against Aurora A kinase revealed several promising submicromolar pyrimidine-aniline leads.  The bioactive conformation found by docking these leads into the Aurora A ATP-binding site had a semicircular shape.  Macrocycle formation was proposed to achieve novelty and selectivity via ring-closing metathesis of a diene precursor.  The nature of the optimal linker and its size was directed by docking.  In a kinase panel screen, selected macrocycles were active on other kinase targets, mainly FLT3, JAK2, and CDKs.  These compds. then became leads in a CDK/FLT3/JAK2 inhibitor project.  Macrocycles with a basic nitrogen in the linker form a salt bridge with Asp86 in CDK2 and Asp698 in FLT3.  Interaction with this residue explains the obsd. selectivity.  The Asp86 residue is conserved in most CDKs, resulting in potent pan-CDK inhibition by these compds.  Optimized macrocycles generally have good DMPK properties, and are efficacious in mouse models of cancer.  Compd. 5 (SB1317/TG02), a pan-CDK/FLT3/JAK2 inhibitor, was selected for preclin. development, and is now in phase 1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnGiv82CuwbVg90H21EOLACvtfcHk0liGVBrmNoNVjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D&md5=3f65c0a7f61329cabb9e85656a2c3dcf</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs00894-012-1528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-012-1528-7%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520nitrogen-linked%2520macrocyclic%2520kinase%2520inhibitors%2520leading%2520to%2520the%2520clinical%2520candidate%2520SB1317%252FTG02%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin%2520dependant%2520kinases%2520%2528CDKs%2529%252C%2520Janus%2520kinase%25202%2520%2528JAK2%2529%252C%2520and%2520Fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26spage%3D119%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span> </span><span class="NLM_article-title">Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2174%2F187231212800229336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=33-42&author=M.+K.+Pashaauthor=R.+Jayaramanauthor=V.+P.+Reddyauthor=P.+Yeoauthor=E.+Gohauthor=A.+Williamsauthor=K.+C.+Gohauthor=E.+Kantharaj&title=Preclinical+metabolism+and+pharmacokinetics+of+SB1317+%28TG02%29%2C+a+potent+CDK%2FJAK2%2FFLT3+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor</span></div><div class="casAuthors">Pasha, Mohammed Khalid; Jayaraman, Ramesh; Reddy, Venkatesh Pilla; Yeo, Pauline; Goh, Evelyn; Williams, Anthony; Goh, Kee Chuan; Kantharaj, Ethirajulu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">SB1317 (TG02) is a novel small mol. potent CDK/JAK2/FLT3 inhibitor.  To evaluate full potential of this development candidate, we conducted drug metab. and pharmacokinetic studies of this novel anti-cancer agent.  SB1317 was sol., highly permeable in Caco-2 cells, and showed >99% binding to plasma from mice, dog and humans.  It was metabolically stable in human and dog liver microsomes relative to mouse and rat.  SB1317 was mainly metabolized by CYP3A4 and CY1A2 in vitro.  SB1317 did not inhibit any of the major human CYPs in vitro except CYP2D6 (IC50 = 1 μM).  SB1317 did not significantly induce CYP1A and CYP3A4 in human hepatocytes in vitro.  The metabolic profiles in liver microsomes from preclin. species were qual. similar to humans.  In pharmacokinetic studies SB1317 showed moderate to high systemic clearance (relative to liver blood flow), high vol. of distribution (>0.6 L/kg), oral bioavailability of 24%, ∼4 and 37% in mice, rats and dogs, resp.; and extensive tissue distribution in mice.  The favorable ADME of SB1317 supported its preclin. development as an oral drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIusZ0BdJyPbVg90H21EOLACvtfcHk0liGVBrmNoNVjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2gsb8%253D&md5=fbc9c2d6453202c5130db50ed1df75c3</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2174%2F187231212800229336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231212800229336%26sid%3Dliteratum%253Aachs%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DV.%2BP.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DKantharaj%26aufirst%3DE.%26atitle%3DPreclinical%2520metabolism%2520and%2520pharmacokinetics%2520of%2520SB1317%2520%2528TG02%2529%252C%2520a%2520potent%2520CDK%252FJAK2%252FFLT3%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2012%26volume%3D6%26spage%3D33%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Konings, I. R. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jonge, M. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Gaast, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Beijsterveldt, L. E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellemans, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span> </span><span class="NLM_article-title">Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">992</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fsj.bjc.6605867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=987-992&author=I.+R.+H.+M.+Koningsauthor=M.+J.+A.+de+Jongeauthor=H.+Burgerauthor=A.+van+der+Gaastauthor=L.+E.+C.+van+Beijsterveldtauthor=H.+Winklerauthor=J.+Verweijauthor=Z.+Yuanauthor=P.+Hellemansauthor=F.+A.+L.+M.+Eskens&title=Phase+I+and+pharmacological+study+of+the+broad-spectrum+tyrosine+kinase+inhibitor+JNJ-26483327+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours</span></div><div class="casAuthors">Konings, I. R. H. M.; de Jonge, M. J. A.; Burger, H.; van der Gaast, A.; van Beijsterveldt, L. E. C.; Winkler, H.; Verweij, J.; Yuan, Z.; Hellemans, P.; Eskens, F. A. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: JNJ-26483327 is an oral, potent, multi-targeted tyrosine kinase inhibitor, inhibiting kinases of epidermal growth factor receptor (EGFR)-1, -2 and -4, rearranged during transfection (RET) receptor, vascular endothelial growth factor receptor (VEGFR)-3 and Src family (Lyn, Fyn, Yes) at low nanomolar concns.  This phase I, accelerated titrn. study assessed max. tolerated dose, safety, pharmacokinetics and pharmacodynamic effects of JNJ-26483327.  Methods: Nineteen patients with advanced cancers received JNJ-26483327 continuous twice daily (BID) in escalating dose cohorts ranging from 100 to 2100 mg.  Pharmacodynamic effects were assessed in paired skin biopsies and blood.  Results: JNJ-26483327 was well tolerated in doses up to 1500 mg BID, with target-inhibition-related toxicity such as diarrhea and skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue.  At 2100 mg, two episodes of dose-limiting toxicity were obsd., consisting of grade 3 anorexia and a combination of grade 3 anorexia and fatigue, resp.  Pharmacokinetics were dose proportional up to 1500 mg in which plasma levels were obtained showing anti-tumor activity in xenograft mouse models.  Pharmacodynamic anal. did not show a substantial effect on expression of Ki-67, p27kip1, phosphorylated mitogen-activated protein kinase, phosphorylated Akt and EGFR, and serum levels of sVEGFR-2, VEGF-C and VEGF-D remained unchanged.  Stable disease was noted in six patients (32%).  Conclusion: JNJ-26483327 is well tolerated and shows a predictable pharmacokinetic profile; the recommended dose for further studies is 1500 mg BID.  British Journal of Cancer (2010) 103, 987-992; doi:10.1038/sj.bjc.6605867 www.bjcancer.com Published online 7 Sept. 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP2g2VkUKueLVg90H21EOLACvtfcHk0liGVBrmNoNVjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrbL&md5=5f8f04fc2656ce1ec6c55e5ee4c870c6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605867%26sid%3Dliteratum%253Aachs%26aulast%3DKonings%26aufirst%3DI.%2BR.%2BH.%2BM.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3Dvan%2Bder%2BGaast%26aufirst%3DA.%26aulast%3Dvan%2BBeijsterveldt%26aufirst%3DL.%2BE.%2BC.%26aulast%3DWinkler%26aufirst%3DH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26atitle%3DPhase%2520I%2520and%2520pharmacological%2520study%2520of%2520the%2520broad-spectrum%2520tyrosine%2520kinase%2520inhibitor%2520JNJ-26483327%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer.%26date%3D2010%26volume%3D103%26spage%3D987%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Hughes, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fobian, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilles, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger-Burke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wager, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4875</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0li62OuWbA2hZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':[],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 340 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">SahaIshika</span><span class="NLM_role">Graduate Student Researcher</span><a class="email" href="/cdn-cgi/l/email-protection#751c061d1c1e1406141d1435125b001619145b101100"><span class="nobrWithWbr"><span class="__cf_email__" data-cfemail="026b716a6b696371636a6342652c">[email protected]</span><wbr></wbr>ucla.<wbr></wbr>edu</span></a><span class="hlFld-ContribAuthor ">HarranPatrick G.</span><span class="NLM_role">D.J. & J.M. Cram Chair in Organic Chemistry</span><a class="email" href="/cdn-cgi/l/email-protection#a5cdc4d7d7c4cbe5c6cdc0c88bd0c6c9c48bc0c1d0"><span class="nobrWithWbr"><span class="__cf_email__" data-cfemail="7a121b08081b143a19121f1754">[email protected]</span><wbr></wbr>ucla.<wbr></wbr>edu</span></a>Dr. Jonathan Bohmann, Department of Pharmaceuticals and Bioengineering, Southwest Research Institute, <div class="author-comment"><p class="first last">A great introduction to the topic of virtual screening, which is often seen as a black box.  It does a good job weaving a lot of material together. The molecular simulation community has needed a book like this for a long time. It is honest about the pitfalls of VS while pointing to reasons why VS is needed and the positive impacts on early drug discovery programs, where resources are generally scarce.</p></div><span class="NLM_string-name hlFld-ContribAuthor">Ryan Gumpper, Postdoctoral Researcher, University of North Carolina at Chapel Hill</span><div class="author-comment"><p class="first last">I would recommend this work to young graduate students starting in the field and anyone who is interested in expanding their knowledge in the field.</p></div>. </span><span class="cited-content_cbyCitation_article-title">Virtual Screening for Chemists. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1021/acsinfocus.7e5001" title="DOI URL">https://doi.org/10.1021/acsinfocus.7e5001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfocus.7e5001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfocus.7e5001%26sid%3Dliteratum%253Aachs%26atitle%3DVirtual%252BScreening%252Bfor%252BChemists%26aulast%3DSaha%26aufirst%3DIshika%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dongjae Lee, Sungjin Lee, Jieun Choi, Yoo-Kyung Song, Min Ju Kim, Dae-Seop Shin, Myung Ae Bae, Yong-Chul Kim, Chin-Ju Park, Kyeong-Ryoon Lee, Jun-Ho Choi, <span class="NLM_string-name hlFld-ContribAuthor">Jiwon Seo</span>. </span><span class="cited-content_cbyCitation_article-title">Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8272-8286. <a href="https://doi.org/10.1021/acs.jmedchem.1c00211" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00211</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00211%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInterplay%252Bamong%252BConformation%25252C%252BIntramolecular%252BHydrogen%252BBonds%25252C%252Band%252BChameleonicity%252Bin%252Bthe%252BMembrane%252BPermeability%252Band%252BCyclophilin%252BA%252BBinding%252Bof%252BMacrocyclic%252BPeptide%252BCyclosporin%252BO%252BDerivatives%26aulast%3DLee%26aufirst%3DDongjae%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04022021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8272%26epage%3D8286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sanja Koštrun, Andrea Fajdetić, Dijana Pešić, Karmen Brajša, Vlatka Bencetić Mihaljević, Dubravko Jelić, Adriana Petrinić Grba, Ivaylo Elenkov, Renata Rupčić, Samra Kapić, Ivana Ozimec Landek, Kristina Butković, Ana Grgičević, Dinko Žiher, Ana Čikoš, Jasna Padovan, Gordon Saxty, Kevin Dack, Haakan Bladh, Tine Skak-Nielsen, Simon Feldbaek Nielsen, Maja Lambert, <span class="NLM_string-name hlFld-ContribAuthor">Martin Stahlhut</span>. </span><span class="cited-content_cbyCitation_article-title">Macrolide Inspired Macrocycles as Modulators of the IL-17A/IL-17RA Interaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8354-8383. <a href="https://doi.org/10.1021/acs.jmedchem.1c00327" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00327</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00327%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMacrolide%252BInspired%252BMacrocycles%252Bas%252BModulators%252Bof%252Bthe%252BIL-17A%25252FIL-17RA%252BInteraction%26aulast%3DKo%25C5%25A1trun%26aufirst%3DSanja%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D22022021%26date%3D08062021%26volume%3D64%26issue%3D12%26spage%3D8354%26epage%3D8383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christian Comeau, Benjamin Ries, Thomas Stadelmann, Jacob Tremblay, Sylvain Poulet, Ulrike Fröhlich, Jérôme Côté, Pierre-Luc Boudreault, Rabeb Mouna Derbali, Philippe Sarret, Michel Grandbois, Grégoire Leclair, Sereina Riniker, <span class="NLM_string-name hlFld-ContribAuthor">Éric Marsault</span>. </span><span class="cited-content_cbyCitation_article-title">Modulation of the Passive Permeability of Semipeptidic Macrocycles: N- and C-Methylations Fine-Tune Conformation and Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 5365-5383. <a href="https://doi.org/10.1021/acs.jmedchem.0c02036" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02036%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DModulation%252Bof%252Bthe%252BPassive%252BPermeability%252Bof%252BSemipeptidic%252BMacrocycles%25253A%252BN-%252Band%252BC-Methylations%252BFine-Tune%252BConformation%252Band%252BProperties%26aulast%3DComeau%26aufirst%3DChristian%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23112020%26date%3D22032021%26volume%3D64%26issue%3D9%26spage%3D5365%26epage%3D5383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael Bauder, Christian Meyners, Patrick L. Purder, Stephanie Merz, Wisely Oki Sugiarto, Andreas M. Voll, Tim Heymann, <span class="NLM_string-name hlFld-ContribAuthor">Felix Hausch</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3320-3349. <a href="https://doi.org/10.1021/acs.jmedchem.0c02195" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02195%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Bof%252BHigh-Affinity%252BMacrocyclic%252BFKBP51%252BInhibitors%26aulast%3DBauder%26aufirst%3DMichael%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19122020%26date%3D05032021%26volume%3D64%26issue%3D6%26spage%3D3320%26epage%3D3349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paula C. Ortet, Samantha N. Muellers, Lauren A. Viarengo-Baker, Kristina Streu, Blair R. Szymczyna, Aaron B. Beeler, Karen N. Allen, <span class="NLM_string-name hlFld-ContribAuthor">Adrian Whitty</span>. </span><span class="cited-content_cbyCitation_article-title">Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (10)
                                     , 3779-3793. <a href="https://doi.org/10.1021/jacs.0c09799" title="DOI URL">https://doi.org/10.1021/jacs.0c09799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c09799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c09799%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DRecapitulating%252Bthe%252BBinding%252BAffinity%252Bof%252BNrf2%252Bfor%252BKEAP1%252Bin%252Ba%252BCyclic%252BHeptapeptide%25252C%252BGuided%252Bby%252BNMR%25252C%252BX-ray%252BCrystallography%25252C%252Band%252BMachine%252BLearning%26aulast%3DOrtet%26aufirst%3DPaula%2BC.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D13092020%26date%3D08032021%26volume%3D143%26issue%3D10%26spage%3D3779%26epage%3D3793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lucian Chan, Geoffrey R. Hutchison, <span class="NLM_string-name hlFld-ContribAuthor">Garrett M. Morris</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding Ring Puckering in Small Molecules and Cyclic Peptides. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2021,</strong> <em>61 </em>
                                    (2)
                                     , 743-755. <a href="https://doi.org/10.1021/acs.jcim.0c01144" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c01144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c01144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c01144%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DUnderstanding%252BRing%252BPuckering%252Bin%252BSmall%252BMolecules%252Band%252BCyclic%252BPeptides%26aulast%3DChan%26aufirst%3DLucian%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D01102020%26date%3D05022021%26volume%3D61%26issue%3D2%26spage%3D743%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ling-Gui Liu, Yan-Mei Sun, Ze-Yu Liu, Yu-Hui Liao, Lei Zeng, Yong Ye, <span class="NLM_string-name hlFld-ContribAuthor">Hai-Yang Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Halogenated Gallium Corroles:DNA Interaction and Photodynamic Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2021,</strong> <em>60 </em>
                                    (4)
                                     , 2234-2245. <a href="https://doi.org/10.1021/acs.inorgchem.0c03016" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.0c03016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.0c03016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.0c03016%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DHalogenated%252BGallium%252BCorroles%25253ADNA%252BInteraction%252Band%252BPhotodynamic%252BAntitumor%252BActivity%26aulast%3DLiu%26aufirst%3DLing-Gui%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D11102020%26date%3D22012021%26volume%3D60%26issue%3D4%26spage%3D2234%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amber L. H. Gray, Carlos A. Steren, Isaac W. Haynes, Guillermo A. Bermejo, Filippo Favretto, Markus Zweckstetter, <span class="NLM_string-name hlFld-ContribAuthor">Thanh D. Do</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Flexibility of Cyclosporine A Is Mediated by Amide Cis–Trans Isomerization and the Chameleonic Roles of Calcium. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2021,</strong> <em>125 </em>
                                    (5)
                                     , 1378-1391. <a href="https://doi.org/10.1021/acs.jpcb.0c11152" title="DOI URL">https://doi.org/10.1021/acs.jpcb.0c11152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.0c11152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.0c11152%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DStructural%252BFlexibility%252Bof%252BCyclosporine%252BA%252BIs%252BMediated%252Bby%252BAmide%252BCis%2525E2%252580%252593Trans%252BIsomerization%252Band%252Bthe%252BChameleonic%252BRoles%252Bof%252BCalcium%26aulast%3DGray%26aufirst%3DAmber%2BL.%2BH.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D14122020%26date%3D01022021%26volume%3D125%26issue%3D5%26spage%3D1378%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Atilio Reyes Romero, Angel Jonathan Ruiz-Moreno, Matthew R. Groves, Marco Velasco-Velázquez, <span class="NLM_string-name hlFld-ContribAuthor">Alexander Dömling</span>. </span><span class="cited-content_cbyCitation_article-title">Benchmark of Generic Shapes for Macrocycles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (12)
                                     , 6298-6313. <a href="https://doi.org/10.1021/acs.jcim.0c01038" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c01038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c01038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c01038%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DBenchmark%252Bof%252BGeneric%252BShapes%252Bfor%252BMacrocycles%26aulast%3DReyes%2BRomero%26aufirst%3DAtilio%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D02092020%26date%3D03122020%26volume%3D60%26issue%3D12%26spage%3D6298%26epage%3D6313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Masakazu Nakadai, <span class="NLM_string-name hlFld-ContribAuthor">Shuta Tomida</span>. </span><span class="cited-content_cbyCitation_article-title">Diameter Is a Key 3D Characteristic for Assessments of Efficient Inhibitors of Protein–Protein Interactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (10)
                                     , 4785-4790. <a href="https://doi.org/10.1021/acs.jcim.0c00607" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00607</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00607%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiameter%252BIs%252Ba%252BKey%252B3D%252BCharacteristic%252Bfor%252BAssessments%252Bof%252BEfficient%252BInhibitors%252Bof%252BProtein%2525E2%252580%252593Protein%252BInteractions%26aulast%3DNakadai%26aufirst%3DMasakazu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01062020%26date%3D01092020%26date%3D18082020%26volume%3D60%26issue%3D10%26spage%3D4785%26epage%3D4790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dan Sindhikara, Michael Wagner, Paraskevi Gkeka, Stefan Güssregen, Garima Tiwari, Gerhard Hessler, Engin Yapici, Ziyu Li, <span class="NLM_string-name hlFld-ContribAuthor">Andreas Evers</span>. </span><span class="cited-content_cbyCitation_article-title">Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 12100-12115. <a href="https://doi.org/10.1021/acs.jmedchem.0c01500" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01500</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01500%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAutomated%252BDesign%252Bof%252BMacrocycles%252Bfor%252BTherapeutic%252BApplications%25253A%252BFrom%252BSmall%252BMolecules%252Bto%252BPeptides%252Band%252BProteins%26aulast%3DSindhikara%26aufirst%3DDan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27082020%26date%3D05102020%26volume%3D63%26issue%3D20%26spage%3D12100%26epage%3D12115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anna S. Kamenik, Johannes Kraml, Florian Hofer, Franz Waibl, Patrick K. Quoika, Ursula Kahler, Michael Schauperl, <span class="NLM_string-name hlFld-ContribAuthor">Klaus R. Liedl</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocycle Cell Permeability Measured by Solvation Free Energies in Polar and Apolar Environments. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (7)
                                     , 3508-3517. <a href="https://doi.org/10.1021/acs.jcim.0c00280" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00280%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMacrocycle%252BCell%252BPermeability%252BMeasured%252Bby%252BSolvation%252BFree%252BEnergies%252Bin%252BPolar%252Band%252BApolar%252BEnvironments%26aulast%3DKamenik%26aufirst%3DAnna%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19032020%26date%3D29062020%26date%3D18062020%26volume%3D60%26issue%3D7%26spage%3D3508%26epage%3D3517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paul C. D. Hawkins, <span class="NLM_string-name hlFld-ContribAuthor">Stanislaw Wlodek</span>. </span><span class="cited-content_cbyCitation_article-title">Decisions with Confidence: Application to the Conformation Sampling of Molecules in the Solid State. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (7)
                                     , 3518-3533. <a href="https://doi.org/10.1021/acs.jcim.0c00358" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00358</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00358%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDecisions%252Bwith%252BConfidence%25253A%252BApplication%252Bto%252Bthe%252BConformation%252BSampling%252Bof%252BMolecules%252Bin%252Bthe%252BSolid%252BState%26aulast%3DHawkins%26aufirst%3DPaul%2BC.%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10042020%26date%3D10072020%26date%3D23062020%26volume%3D60%26issue%3D7%26spage%3D3518%26epage%3D3533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Antoine Le Roux, Émilie Blaise, Pierre-Luc Boudreault, Christian Comeau, Annie Doucet, Marilena Giarrusso, Marie-Pierre Collin, Thomas Neubauer, Florian Kölling, Andreas H. Göller, Lea Seep, Dieudonné T. Tshitenge, Matthias Wittwer, Maximilian Kullmann, Alexander Hillisch, Joachim Mittendorf, <span class="NLM_string-name hlFld-ContribAuthor">Eric Marsault</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–Permeability Relationship of Semipeptidic Macrocycles—Understanding and Optimizing Passive Permeability and Efflux Ratio. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 6774-6783. <a href="https://doi.org/10.1021/acs.jmedchem.0c00013" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00013%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Permeability%252BRelationship%252Bof%252BSemipeptidic%252BMacrocycles%2525E2%252580%252594Understanding%252Band%252BOptimizing%252BPassive%252BPermeability%252Band%252BEfflux%252BRatio%26aulast%3DLe%2BRoux%26aufirst%3DAntoine%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15012020%26date%3D30062020%26date%3D26052020%26volume%3D63%26issue%3D13%26spage%3D6774%26epage%3D6783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jonathan A. Spencer, Ian R. Baldwin, Nick Barton, Chun-Wa Chung, Máire A. Convery, Christopher D. Edwards, Craig Jamieson, David N. Mallett, James E. Rowedder, Paul Rowland, Daniel A. Thomas, <span class="NLM_string-name hlFld-ContribAuthor">Charlotte J. Hardy</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (7)
                                     , 1386-1391. <a href="https://doi.org/10.1021/acsmedchemlett.0c00061" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00061%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252BDevelopment%252Bof%252Ba%252BMacrocyclic%252BSeries%252BTargeting%252BPhosphoinositide%252B3-Kinase%252B%2525CE%2525B4%26aulast%3DSpencer%26aufirst%3DJonathan%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D03062020%26date%3D18062020%26date%3D03062020%26volume%3D11%26issue%3D7%26spage%3D1386%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Leandro Simonetti, <span class="NLM_string-name hlFld-ContribAuthor">Ylva Ivarsson</span>. </span><span class="cited-content_cbyCitation_article-title">Genetically Encoded Cyclic Peptide Phage Display Libraries. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2020,</strong> <em>6 </em>
                                    (3)
                                     , 336-338. <a href="https://doi.org/10.1021/acscentsci.0c00087" title="DOI URL">https://doi.org/10.1021/acscentsci.0c00087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.0c00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.0c00087%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DGenetically%252BEncoded%252BCyclic%252BPeptide%252BPhage%252BDisplay%252BLibraries%26aulast%3DSimonetti%26aufirst%3DLeandro%26date%3D2020%26date%3D2020%26date%3D24022020%26volume%3D6%26issue%3D3%26spage%3D336%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maria-Jesus Blanco, <span class="NLM_string-name hlFld-ContribAuthor">Kevin M. Gardinier</span>. </span><span class="cited-content_cbyCitation_article-title">New Chemical Modalities and Strategic Thinking in Early Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 228-231. <a href="https://doi.org/10.1021/acsmedchemlett.9b00582" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00582</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00582%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNew%252BChemical%252BModalities%252Band%252BStrategic%252BThinking%252Bin%252BEarly%252BDrug%252BDiscovery%26aulast%3DBlanco%26aufirst%3DMaria-Jesus%26date%3D2020%26date%3D2020%26date%3D14012020%26volume%3D11%26issue%3D3%26spage%3D228%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jie Yang, Vladimir O. Talibov, Stefan Peintner, Claire Rhee, Vasanthanathan Poongavanam, Matthis Geitmann, Matteo Rossi Sebastiano, Bernd Simon, Janosch Hennig, Doreen Dobritzsch, U. Helena Danielson, <span class="NLM_string-name hlFld-ContribAuthor">Jan Kihlberg</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocyclic Peptides Uncover a Novel Binding Mode for Reversible Inhibitors of LSD1. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (8)
                                     , 3979-3995. <a href="https://doi.org/10.1021/acsomega.9b03493" title="DOI URL">https://doi.org/10.1021/acsomega.9b03493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03493%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DMacrocyclic%252BPeptides%252BUncover%252Ba%252BNovel%252BBinding%252BMode%252Bfor%252BReversible%252BInhibitors%252Bof%252BLSD1%26aulast%3DYang%26aufirst%3DJie%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19102019%26date%3D30012020%26date%3D17022020%26volume%3D5%26issue%3D8%26spage%3D3979%26epage%3D3995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Radka Houštecká, Martin Hadzima, Jindřich Fanfrlík, Jiří Brynda, Lenka Pallová, Iva Hánová, Helena Mertlíková-Kaiserová, Martin Lepšík, Martin Horn, Martin Smrčina, Pavel Majer, <span class="NLM_string-name hlFld-ContribAuthor">Michael Mareš</span>. </span><span class="cited-content_cbyCitation_article-title">Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure–Activity Relationship and Binding Mode Analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (4)
                                     , 1576-1596. <a href="https://doi.org/10.1021/acs.jmedchem.9b01351" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01351</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01351%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBiomimetic%252BMacrocyclic%252BInhibitors%252Bof%252BHuman%252BCathepsin%252BD%25253A%252BStructure%2525E2%252580%252593Activity%252BRelationship%252Band%252BBinding%252BMode%252BAnalysis%26aulast%3DHou%25C5%25A1teck%25C3%25A1%26aufirst%3DRadka%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D30082019%26date%3D13022020%26date%3D31012020%26volume%3D63%26issue%3D4%26spage%3D1576%26epage%3D1596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dimitrios G. Tsalikis, <span class="NLM_string-name hlFld-ContribAuthor">Vlasis G. Mavrantzas</span>. </span><span class="cited-content_cbyCitation_article-title">Size and Diffusivity of Polymer Rings in Linear Polymer Matrices: The Key Role of Threading Events. </span><span class="cited-content_cbyCitation_journal-name">Macromolecules</span><span> <strong>2020,</strong> <em>53 </em>
                                    (3)
                                     , 803-820. <a href="https://doi.org/10.1021/acs.macromol.9b02099" title="DOI URL">https://doi.org/10.1021/acs.macromol.9b02099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.macromol.9b02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.macromol.9b02099%26sid%3Dliteratum%253Aachs%26jtitle%3DMacromolecules%26atitle%3DSize%252Band%252BDiffusivity%252Bof%252BPolymer%252BRings%252Bin%252BLinear%252BPolymer%252BMatrices%25253A%252BThe%252BKey%252BRole%252Bof%252BThreading%252BEvents%26aulast%3DTsalikis%26aufirst%3DDimitrios%2BG.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D03102019%26date%3D26122019%26date%3D17012020%26volume%3D53%26issue%3D3%26spage%3D803%26epage%3D820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Cheng Peng, Yoseph Atilaw, Jinan Wang, Zhijian Xu, Vasanthanathan Poongavanam, Jiye Shi, Jan Kihlberg, Weiliang Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Máté Erdélyi</span>. </span><span class="cited-content_cbyCitation_article-title">Conformation of the Macrocyclic Drug Lorlatinib in Polar and Nonpolar Environments: A MD Simulation and NMR Study. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (26)
                                     , 22245-22250. <a href="https://doi.org/10.1021/acsomega.9b03797" title="DOI URL">https://doi.org/10.1021/acsomega.9b03797</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03797%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DConformation%252Bof%252Bthe%252BMacrocyclic%252BDrug%252BLorlatinib%252Bin%252BPolar%252Band%252BNonpolar%252BEnvironments%25253A%252BA%252BMD%252BSimulation%252Band%252BNMR%252BStudy%26aulast%3DPeng%26aufirst%3DCheng%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07112019%26date%3D26112019%26date%3D16122019%26volume%3D4%26issue%3D26%26spage%3D22245%26epage%3D22250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Olga Cruz-López, Carolin Temps, Beatrice Longo, Samuel H. Myers, Francisco Franco-Montalban, <span class="NLM_string-name hlFld-ContribAuthor">Asier Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (25)
                                     , 21620-21626. <a href="https://doi.org/10.1021/acsomega.9b03525" title="DOI URL">https://doi.org/10.1021/acsomega.9b03525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03525%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252Ba%252BClick-Assembled%252B18-Atom%252BMacrocycle%252BThat%252BDisplays%252BSelective%252BAXL%252BKinase%252BInhibitory%252BActivity%26aulast%3DCruz-L%25C3%25B3pez%26aufirst%3DOlga%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22102019%26date%3D14112019%26date%3D03122019%26volume%3D4%26issue%3D25%26spage%3D21620%26epage%3D21626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christopher
J. M. Brown, Michael P. Gotsbacher, Jason P. Holland, <span class="NLM_string-name hlFld-ContribAuthor">Rachel Codd</span>. </span><span class="cited-content_cbyCitation_article-title">endo-Hydroxamic Acid Monomers for the Assembly of a Suite of Non-native Dimeric Macrocyclic Siderophores Using Metal-Templated Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (20)
                                     , 13591-13603. <a href="https://doi.org/10.1021/acs.inorgchem.9b00878" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.9b00878</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.9b00878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.9b00878%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3Dendo-Hydroxamic%252BAcid%252BMonomers%252Bfor%252Bthe%252BAssembly%252Bof%252Ba%252BSuite%252Bof%252BNon-native%252BDimeric%252BMacrocyclic%252BSiderophores%252BUsing%252BMetal-Templated%252BSynthesis%26aulast%3DBrown%26aufirst%3DChristopher%2BJ.%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27032019%26date%3D05062019%26volume%3D58%26issue%3D20%26spage%3D13591%26epage%3D13603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yichao Huang, Mareike Margarete Wiedmann, <span class="NLM_string-name hlFld-ContribAuthor">Hiroaki Suga</span>. </span><span class="cited-content_cbyCitation_article-title">RNA Display Methods for the Discovery of Bioactive Macrocycles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (17)
                                     , 10360-10391. <a href="https://doi.org/10.1021/acs.chemrev.8b00430" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00430</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00430%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DRNA%252BDisplay%252BMethods%252Bfor%252Bthe%252BDiscovery%252Bof%252BBioactive%252BMacrocycles%26aulast%3DHuang%26aufirst%3DYichao%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D08072018%26date%3D05112018%26volume%3D119%26issue%3D17%26spage%3D10360%26epage%3D10391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Solomon
D. Appavoo, Sungjoon Huh, Diego B. Diaz, <span class="NLM_string-name hlFld-ContribAuthor">Andrei K. Yudin</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational Control of Macrocycles by Remote Structural Modification. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (17)
                                     , 9724-9752. <a href="https://doi.org/10.1021/acs.chemrev.8b00742" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00742</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00742%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DConformational%252BControl%252Bof%252BMacrocycles%252Bby%252BRemote%252BStructural%252BModification%26aulast%3DAppavoo%26aufirst%3DSolomon%2BD.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D03122018%26date%3D14082019%26volume%3D119%26issue%3D17%26spage%3D9724%26epage%3D9752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Leslie Reguera, <span class="NLM_string-name hlFld-ContribAuthor">Daniel G. Rivera</span>. </span><span class="cited-content_cbyCitation_article-title">Multicomponent Reaction Toolbox for Peptide Macrocyclization and Stapling. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (17)
                                     , 9836-9860. <a href="https://doi.org/10.1021/acs.chemrev.8b00744" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00744%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DMulticomponent%252BReaction%252BToolbox%252Bfor%252BPeptide%252BMacrocyclization%252Band%252BStapling%26aulast%3DReguera%26aufirst%3DLeslie%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D04122018%26date%3D16042019%26volume%3D119%26issue%3D17%26spage%3D9836%26epage%3D9860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kim T. Mortensen, Thomas J. Osberger, Thomas A. King, Hannah F. Sore, <span class="NLM_string-name hlFld-ContribAuthor">David R. Spring</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies for the Diversity-Oriented Synthesis of Macrocycles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (17)
                                     , 10288-10317. <a href="https://doi.org/10.1021/acs.chemrev.9b00084" title="DOI URL">https://doi.org/10.1021/acs.chemrev.9b00084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.9b00084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.9b00084%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DStrategies%252Bfor%252Bthe%252BDiversity-Oriented%252BSynthesis%252Bof%252BMacrocycles%26aulast%3DMortensen%26aufirst%3DKim%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D04022019%26date%3D20062019%26volume%3D119%26issue%3D17%26spage%3D10288%26epage%3D10317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maxwell D. Cummings, <span class="NLM_string-name hlFld-ContribAuthor">Sivakumar Sekharan</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6843-6853. <a href="https://doi.org/10.1021/acs.jmedchem.8b01985" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01985%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BMacrocycle%252BDesign%252Bin%252BSmall-Molecule%252BDrug%252BDiscovery%252Band%252BSimple%252BMetrics%252BTo%252BIdentify%252BOpportunities%252Bfor%252BMacrocyclization%252Bof%252BSmall-Molecule%252BLigands%26aulast%3DCummings%26aufirst%3DMaxwell%2BD.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D18122018%26date%3D22032019%26date%3D12032019%26volume%3D62%26issue%3D15%26spage%3D6843%26epage%3D6853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Satoshi Ono, Matthew R. Naylor, Chad E. Townsend, Chieko Okumura, Okimasa Okada, <span class="NLM_string-name hlFld-ContribAuthor">R. Scott Lokey</span>. </span><span class="cited-content_cbyCitation_article-title">Conformation and Permeability: Cyclic Hexapeptide Diastereomers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (6)
                                     , 2952-2963. <a href="https://doi.org/10.1021/acs.jcim.9b00217" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00217%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DConformation%252Band%252BPermeability%25253A%252BCyclic%252BHexapeptide%252BDiastereomers%26aulast%3DOno%26aufirst%3DSatoshi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13032019%26date%3D08052019%26date%3D01052019%26volume%3D59%26issue%3D6%26spage%3D2952%26epage%3D2963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chad M. Beneker, Magdalini Rovoli, George Kontopidis, Michael Röring, Simeon Galda, Sandra Braun, Tilman Brummer, <span class="NLM_string-name hlFld-ContribAuthor">Campbell McInnes</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 3886-3897. <a href="https://doi.org/10.1021/acs.jmedchem.8b01288" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01288%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BType-IV%252BInhibitors%252Bof%252BBRAF%252BKinase%252BThat%252BBlock%252BDimerization%252Band%252BOvercome%252BParadoxical%252BMEK%25252FERK%252BActivation%26aulast%3DBeneker%26aufirst%3DChad%2BM.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D14082018%26date%3D12042019%26volume%3D62%26issue%3D8%26spage%3D3886%26epage%3D3897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kathleen A. Farley, Ye Che, Armando Navarro-Vázquez, Chris Limberakis, Dennis Anderson, Jiangli Yan, Michael Shapiro, Veerabahu Shanmugasundaram, <span class="NLM_string-name hlFld-ContribAuthor">Roberto R. Gil</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclic Peptide Design Guided by Residual Dipolar Couplings, J-Couplings, and Intramolecular Hydrogen Bond Analysis. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (8)
                                     , 4803-4813. <a href="https://doi.org/10.1021/acs.joc.8b02811" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02811%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCyclic%252BPeptide%252BDesign%252BGuided%252Bby%252BResidual%252BDipolar%252BCouplings%25252C%252BJ-Couplings%25252C%252Band%252BIntramolecular%252BHydrogen%252BBond%252BAnalysis%26aulast%3DFarley%26aufirst%3DKathleen%2BA.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D02112018%26date%3D15012019%26date%3D03012019%26volume%3D84%26issue%3D8%26spage%3D4803%26epage%3D4813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kirsten Deprey, Lukas Becker, Joshua Kritzer, <span class="NLM_string-name hlFld-ContribAuthor">Andreas Plückthun</span>. </span><span class="cited-content_cbyCitation_article-title">Trapped! A Critical Evaluation of Methods for Measuring Total Cellular Uptake versus Cytosolic Localization. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (4)
                                     , 1006-1027. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00112" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00112%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DTrapped%252521%252BA%252BCritical%252BEvaluation%252Bof%252BMethods%252Bfor%252BMeasuring%252BTotal%252BCellular%252BUptake%252Bversus%252BCytosolic%252BLocalization%26aulast%3DDeprey%26aufirst%3DKirsten%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D11022019%26date%3D14032019%26date%3D05042019%26date%3D18032019%26volume%3D30%26issue%3D4%26spage%3D1006%26epage%3D1027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard Trilles, Dmitri Beglov, Qiujia Chen, Hongzhen He, Randall Wireman, April Reed, Spandan Chennamadhavuni, James S. Panek, Lauren E. Brown, Sandor Vajda, John A. Porco, Jr., Mark R. Kelley, <span class="NLM_string-name hlFld-ContribAuthor">Millie M. Georgiadis</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Macrocyclic Inhibitors of Apurinic/Apyrimidinic Endonuclease 1. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (4)
                                     , 1971-1988. <a href="https://doi.org/10.1021/acs.jmedchem.8b01529" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01529%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BMacrocyclic%252BInhibitors%252Bof%252BApurinic%25252FApyrimidinic%252BEndonuclease%252B1%26aulast%3DTrilles%26aufirst%3DRichard%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D01102018%26date%3D06022019%26date%3D17012019%26volume%3D62%26issue%3D4%26spage%3D1971%26epage%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Constantinos G. Neochoritis, Ting Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Alexander Dömling</span>. </span><span class="cited-content_cbyCitation_article-title">Tetrazoles via Multicomponent Reactions. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (3)
                                     , 1970-2042. <a href="https://doi.org/10.1021/acs.chemrev.8b00564" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00564%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DTetrazoles%252Bvia%252BMulticomponent%252BReactions%26aulast%3DNeochoritis%26aufirst%3DConstantinos%2BG.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D13092018%26date%3D01022019%26volume%3D119%26issue%3D3%26spage%3D1970%26epage%3D2042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Catherine Fagundez, Diver Sellanes, Stella Peña, Laura Scarone, Anna C. C. Aguiar, Juliana O. de Souza, Rafael V. C. Guido, Lindsay Stewart, Vanessa Yardley, Sabine Ottilie, Elizabeth A. Winzeler, Francisco-J. Gamo, Laura M. Sanz, <span class="NLM_string-name hlFld-ContribAuthor">Gloria L. Serra</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Profiling, and in Vivo Evaluation of Cyclopeptides Containing N-Methyl Amino Acids as Antiplasmodial Agents. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     , 137-141. <a href="https://doi.org/10.1021/acsmedchemlett.8b00543" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00543</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00543%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%25252C%252BProfiling%25252C%252Band%252Bin%252BVivo%252BEvaluation%252Bof%252BCyclopeptides%252BContaining%252BN-Methyl%252BAmino%252BAcids%252Bas%252BAntiplasmodial%252BAgents%26aulast%3DFagundez%26aufirst%3DCatherine%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10112018%26date%3D26122018%26date%3D31122018%26date%3D26122018%26volume%3D10%26issue%3D1%26spage%3D137%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Robert    Dugger </span><span class="hlFld-ContribAuthor "> Bryan    Li    </span><span class="hlFld-ContribAuthor "> Paul    Richardson </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 27-59. <a href="https://doi.org/10.1021/bk-2019-1332.ch002" title="DOI URL">https://doi.org/10.1021/bk-2019-1332.ch002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2019-1332.ch002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2019-1332.ch002%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BLorlatinib%25253A%252BA%252BMacrocyclic%252BInhibitor%252Bof%252BEML4-ALK%252Bfor%252Bthe%252BTreatment%252Bof%252BNSCLC%26aulast%3DDugger%26aufirst%3DRobert%26date%3D2019%26date%3D2019%26spage%3D27%26epage%3D59%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B2%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2019%26date%3D2019%26volume%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christoph Ernst, Julia Sindlinger, Dirk Schwarzer, Pierre Koch, <span class="NLM_string-name hlFld-ContribAuthor">Frank M. Boeckler</span>. </span><span class="cited-content_cbyCitation_article-title">The Symmetric Tetravalent Sulfhydryl-Specific Linker NATBA Facilitates a Combinatorial “Tool Kit” Strategy for Phage Display-Based Selection of Functionalized Bicyclic Peptides. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (10)
                                     , 12361-12368. <a href="https://doi.org/10.1021/acsomega.8b01814" title="DOI URL">https://doi.org/10.1021/acsomega.8b01814</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b01814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b01814%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DThe%252BSymmetric%252BTetravalent%252BSulfhydryl-Specific%252BLinker%252BNATBA%252BFacilitates%252Ba%252BCombinatorial%252B%2525E2%252580%25259CTool%252BKit%2525E2%252580%25259D%252BStrategy%252Bfor%252BPhage%252BDisplay-Based%252BSelection%252Bof%252BFunctionalized%252BBicyclic%252BPeptides%26aulast%3DErnst%26aufirst%3DChristoph%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D30072018%26date%3D17092018%26volume%3D3%26issue%3D10%26spage%3D12361%26epage%3D12368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eric Valeur, <span class="NLM_string-name hlFld-ContribAuthor">Patrick Jimonet</span>. </span><span class="cited-content_cbyCitation_article-title">New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9004-9029. <a href="https://doi.org/10.1021/acs.jmedchem.8b00378" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00378</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00378%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252BModalities%25252C%252BTechnologies%25252C%252Band%252BPartnerships%252Bin%252BProbe%252Band%252BLead%252BGeneration%25253A%252BEnabling%252Ba%252BMode-of-Action%252BCentric%252BParadigm%26aulast%3DValeur%26aufirst%3DEric%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09032018%26date%3D13062018%26date%3D31052018%26volume%3D61%26issue%3D20%26spage%3D9004%26epage%3D9029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vasanthanathan Poongavanam, Emma Danelius, Stefan Peintner, Lilian Alcaraz, Giulia Caron, Maxwell D. Cummings, Stanislaw Wlodek, Mate Erdelyi, Paul C. D. Hawkins, Giuseppe Ermondi, <span class="NLM_string-name hlFld-ContribAuthor">Jan Kihlberg</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (9)
                                     , 11742-11757. <a href="https://doi.org/10.1021/acsomega.8b01379" title="DOI URL">https://doi.org/10.1021/acsomega.8b01379</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b01379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b01379%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DConformational%252BSampling%252Bof%252BMacrocyclic%252BDrugs%252Bin%252BDifferent%252BEnvironments%25253A%252BCan%252BWe%252BFind%252Bthe%252BRelevant%252BConformations%25253F%26aulast%3DPoongavanam%26aufirst%3DVasanthanathan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19062018%26date%3D04092018%26volume%3D3%26issue%3D9%26spage%3D11742%26epage%3D11757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maria
Julia Mora, Renée Onnainty, <span class="NLM_string-name hlFld-ContribAuthor">Gladys Ester Granero</span>. </span><span class="cited-content_cbyCitation_article-title">Comparative Oral Drug Classification Systems: Acetazolamide, Azithromycin, Clopidogrel, and Efavirenz Case Studies. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2018,</strong> <em>15 </em>
                                    (8)
                                     , 3187-3196. <a href="https://doi.org/10.1021/acs.molpharmaceut.8b00274" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.8b00274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.8b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.8b00274%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DComparative%252BOral%252BDrug%252BClassification%252BSystems%25253A%252BAcetazolamide%25252C%252BAzithromycin%25252C%252BClopidogrel%25252C%252Band%252BEfavirenz%252BCase%252BStudies%26aulast%3DMora%26aufirst%3DMaria%2BJulia%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D14032018%26date%3D21062018%26date%3D18062018%26date%3D03072018%26date%3D21062018%26volume%3D15%26issue%3D8%26spage%3D3187%26epage%3D3196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anna S. Kamenik, Uta Lessel, Julian E. Fuchs, Thomas Fox, <span class="NLM_string-name hlFld-ContribAuthor">Klaus R. Liedl</span>. </span><span class="cited-content_cbyCitation_article-title">Peptidic Macrocycles - Conformational Sampling and Thermodynamic Characterization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2018,</strong> <em>58 </em>
                                    (5)
                                     , 982-992. <a href="https://doi.org/10.1021/acs.jcim.8b00097" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00097</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00097%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DPeptidic%252BMacrocycles%252B-%252BConformational%252BSampling%252Band%252BThermodynamic%252BCharacterization%26aulast%3DKamenik%26aufirst%3DAnna%2BS.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19022018%26date%3D20042018%26date%3D13042018%26volume%3D58%26issue%3D5%26spage%3D982%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matteo Rossi Sebastiano, Bradley C. Doak, Maria Backlund, Vasanthanathan Poongavanam, Björn Over, Giuseppe Ermondi, Giulia Caron, Pär Matsson, <span class="NLM_string-name hlFld-ContribAuthor">Jan Kihlberg</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (9)
                                     , 4189-4202. <a href="https://doi.org/10.1021/acs.jmedchem.8b00347" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00347</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00347%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DImpact%252Bof%252BDynamically%252BExposed%252BPolarity%252Bon%252BPermeability%252Band%252BSolubility%252Bof%252BChameleonic%252BDrugs%252BBeyond%252Bthe%252BRule%252Bof%252B5%26aulast%3DRossi%2BSebastiano%26aufirst%3DMatteo%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04032018%26date%3D16042018%26date%3D02042018%26volume%3D61%26issue%3D9%26spage%3D4189%26epage%3D4202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dušan Petrović, Ansgar Bokel, Matthew Allan, Vlada B. Urlacher, <span class="NLM_string-name hlFld-ContribAuthor">Birgit Strodel</span>. </span><span class="cited-content_cbyCitation_article-title">Simulation-Guided Design of Cytochrome P450 for Chemo- and Regioselective Macrocyclic Oxidation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2018,</strong> <em>58 </em>
                                    (4)
                                     , 848-858. <a href="https://doi.org/10.1021/acs.jcim.8b00043" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00043%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DSimulation-Guided%252BDesign%252Bof%252BCytochrome%252BP450%252Bfor%252BChemo-%252Band%252BRegioselective%252BMacrocyclic%252BOxidation%26aulast%3DPetrovi%25C4%2587%26aufirst%3DDu%25C5%25A1an%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D25012018%26date%3D23032018%26date%3D09032018%26volume%3D58%26issue%3D4%26spage%3D848%26epage%3D858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David A. DeGoey, Hui-Ju Chen, Philip B. Cox, <span class="NLM_string-name hlFld-ContribAuthor">Michael D. Wendt</span>. </span><span class="cited-content_cbyCitation_article-title">Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 2636-2651. <a href="https://doi.org/10.1021/acs.jmedchem.7b00717" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBeyond%252Bthe%252BRule%252Bof%252B5%25253A%252BLessons%252BLearned%252Bfrom%252BAbbVie%2525E2%252580%252599s%252BDrugs%252Band%252BCompound%252BCollection%26aulast%3DDeGoey%26aufirst%3DDavid%2BA.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D15052017%26date%3D27092017%26date%3D19092017%26volume%3D61%26issue%3D7%26spage%3D2636%26epage%3D2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniel
P. Teufel, Gavin Bennett, Helen Harrison, Katerine van Rietschoten, Silvia Pavan, Catherine Stace, François Le Floch, Tine Van Bergen, Elke Vermassen, Philippe Barbeaux, Tjing-Tjing Hu, Jean H. M. Feyen, <span class="NLM_string-name hlFld-ContribAuthor">Marc Vanhove</span>. </span><span class="cited-content_cbyCitation_article-title">Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 2823-2836. <a href="https://doi.org/10.1021/acs.jmedchem.7b01625" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01625</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01625%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStable%252Band%252BLong-Lasting%25252C%252BNovel%252BBicyclic%252BPeptide%252BPlasma%252BKallikrein%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BDiabetic%252BMacular%252BEdema%26aulast%3DTeufel%26aufirst%3DDaniel%2BP.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D14112017%26date%3D15032018%26date%3D08032018%26volume%3D61%26issue%3D7%26spage%3D2823%26epage%3D2836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Catherine Fagundez, Diver Sellanes, <span class="NLM_string-name hlFld-ContribAuthor">Gloria Serra</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Cyclic Peptides as Potential Anti-Malarials. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2018,</strong> <em>20 </em>
                                    (4)
                                     , 212-219. <a href="https://doi.org/10.1021/acscombsci.7b00154" title="DOI URL">https://doi.org/10.1021/acscombsci.7b00154</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.7b00154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.7b00154%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DSynthesis%252Bof%252BCyclic%252BPeptides%252Bas%252BPotential%252BAnti-Malarials%26aulast%3DFagundez%26aufirst%3DCatherine%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D2018%26date%3D22102017%26date%3D03022018%26date%3D26022018%26date%3D15022018%26volume%3D20%26issue%3D4%26spage%3D212%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Masato Kaneda, Shinsuke Inuki, Hiroaki Ohno, <span class="NLM_string-name hlFld-ContribAuthor">Shinya Oishi</span>. </span><span class="cited-content_cbyCitation_article-title">Total Synthesis and Stereochemical Revision of Stereocalpin A: Mirror-Image Approach for Stereochemical Assignments of the Peptide–Polyketide Macrocycle. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (6)
                                     , 3047-3060. <a href="https://doi.org/10.1021/acs.joc.8b00118" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00118%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTotal%252BSynthesis%252Band%252BStereochemical%252BRevision%252Bof%252BStereocalpin%252BA%25253A%252BMirror-Image%252BApproach%252Bfor%252BStereochemical%252BAssignments%252Bof%252Bthe%252BPeptide%2525E2%252580%252593Polyketide%252BMacrocycle%26aulast%3DKaneda%26aufirst%3DMasato%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15012018%26date%3D27022018%26date%3D22022018%26volume%3D83%26issue%3D6%26spage%3D3047%26epage%3D3060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jan Řezáč, Daniel Bím, Ondrej Gutten, <span class="NLM_string-name hlFld-ContribAuthor">Lubomír Rulíšek</span>. </span><span class="cited-content_cbyCitation_article-title">Toward Accurate Conformational Energies of Smaller Peptides and Medium-Sized Macrocycles: MPCONF196 Benchmark Energy Data Set. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Theory and Computation</span><span> <strong>2018,</strong> <em>14 </em>
                                    (3)
                                     , 1254-1266. <a href="https://doi.org/10.1021/acs.jctc.7b01074" title="DOI URL">https://doi.org/10.1021/acs.jctc.7b01074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jctc.7b01074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jctc.7b01074%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Theory%2520and%2520Computation%26atitle%3DToward%252BAccurate%252BConformational%252BEnergies%252Bof%252BSmaller%252BPeptides%252Band%252BMedium-Sized%252BMacrocycles%25253A%252BMPCONF196%252BBenchmark%252BEnergy%252BData%252BSet%26aulast%3D%25C5%2598ez%25C3%25A1%25C4%258D%26aufirst%3DJan%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D24102017%26date%3D02032018%26date%3D20022018%26volume%3D14%26issue%3D3%26spage%3D1254%26epage%3D1266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolyn S.  Higman</span>, <span class="hlFld-ContribAuthor ">Daniel L.  Nascimento</span>, <span class="hlFld-ContribAuthor ">Benjamin J.  Ireland</span>, <span class="hlFld-ContribAuthor ">Stephan  Audörsch</span>, <span class="hlFld-ContribAuthor ">Gwendolyn A.  Bailey</span>, <span class="hlFld-ContribAuthor ">Robert  McDonald</span>, and <span class="hlFld-ContribAuthor ">Deryn E.  Fogg</span>  . </span><span class="cited-content_cbyCitation_article-title">Chelate-Assisted Ring-Closing Metathesis: A Strategy for Accelerating Macrocyclization at Ambient Temperatures. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (5)
                                     , 1604-1607. <a href="https://doi.org/10.1021/jacs.7b13257" title="DOI URL">https://doi.org/10.1021/jacs.7b13257</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b13257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b13257%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DChelate-Assisted%252BRing-Closing%252BMetathesis%25253A%252BA%252BStrategy%252Bfor%252BAccelerating%252BMacrocyclization%252Bat%252BAmbient%252BTemperatures%26aulast%3DHigman%26aufirst%3DCarolyn%2BS.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D15122017%26date%3D24012018%26date%3D07022018%26date%3D18012018%26volume%3D140%26issue%3D5%26spage%3D1604%26epage%3D1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ondrej  Gutten</span>, <span class="hlFld-ContribAuthor ">Daniel  Bím</span>, <span class="hlFld-ContribAuthor ">Jan  Řezáč</span>, and <span class="hlFld-ContribAuthor ">Lubomír  Rulíšek</span>  . </span><span class="cited-content_cbyCitation_article-title">Macrocycle Conformational Sampling by DFT-D3/COSMO-RS Methodology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2018,</strong> <em>58 </em>
                                    (1)
                                     , 48-60. <a href="https://doi.org/10.1021/acs.jcim.7b00453" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00453</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00453%26sid%3Dliteratum%253Aachs%26aulast%3DWatts%26aufirst%3DK.%2BS.%26atitle%3DMacrocycle%2520Conformational%2520Sampling%2520with%2520MacroModel%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D2680%26epage%3D2696%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMacrocycle%252BConformational%252BSampling%252Bby%252BDFT-D3%25252FCOSMO-RS%252BMethodology%26aulast%3DGutten%26aufirst%3DOndrej%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D27072017%26date%3D18122017%26date%3D22012018%26date%3D28112017%26volume%3D58%26issue%3D1%26spage%3D48%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhengrong  Zhu</span>, <span class="hlFld-ContribAuthor ">Alex  Shaginian</span>, <span class="hlFld-ContribAuthor ">LaShadric C.  Grady</span>, <span class="hlFld-ContribAuthor ">Thomas  O’Keeffe</span>, <span class="hlFld-ContribAuthor ">Xiangguo E.  Shi</span>, <span class="hlFld-ContribAuthor ">Christopher P.  Davie</span>, <span class="hlFld-ContribAuthor ">Graham L.  Simpson</span>, <span class="hlFld-ContribAuthor ">Jeffrey A.  Messer</span>, <span class="hlFld-ContribAuthor ">Ghotas  Evindar</span>, <span class="hlFld-ContribAuthor ">Robert N.  Bream</span>, <span class="hlFld-ContribAuthor ">Praew P.  Thansandote</span>, <span class="hlFld-ContribAuthor ">Naomi R.  Prentice</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Mason</span>, and <span class="hlFld-ContribAuthor ">Sandeep  Pal</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Application of a DNA-Encoded Macrocyclic Peptide Library. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (1)
                                     , 53-59. <a href="https://doi.org/10.1021/acschembio.7b00852" title="DOI URL">https://doi.org/10.1021/acschembio.7b00852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.7b00852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.7b00852%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDesign%252Band%252BApplication%252Bof%252Ba%252BDNA-Encoded%252BMacrocyclic%252BPeptide%252BLibrary%26aulast%3DZhu%26aufirst%3DZhengrong%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D28092017%26date%3D29112017%26date%3D04122017%26date%3D19012018%26date%3D29112017%26volume%3D13%26issue%3D1%26spage%3D53%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia  Estrada-Ortiz</span>, <span class="hlFld-ContribAuthor ">Constantinos G.  Neochoritis</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Twarda-Clapa</span>, <span class="hlFld-ContribAuthor ">Bogdan  Musielak</span>, <span class="hlFld-ContribAuthor ">Tad A.  Holak</span>, and <span class="hlFld-ContribAuthor ">Alexander  Dömling</span>  . </span><span class="cited-content_cbyCitation_article-title">Artificial Macrocycles as Potent p53–MDM2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (10)
                                     , 1025-1030. <a href="https://doi.org/10.1021/acsmedchemlett.7b00219" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00219%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DArtificial%252BMacrocycles%252Bas%252BPotent%252Bp53%2525E2%252580%252593MDM2%252BInhibitors%26aulast%3DEstrada-Ortiz%26aufirst%3DNatalia%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D23052017%26date%3D20092017%26date%3D25092017%26date%3D12102017%26date%3D20092017%26volume%3D8%26issue%3D10%26spage%3D1025%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya  Chen</span>, <span class="hlFld-ContribAuthor ">Christina  de Bruyn Kops</span>, and <span class="hlFld-ContribAuthor ">Johannes  Kirchmair</span>  . </span><span class="cited-content_cbyCitation_article-title">Data Resources for the Computer-Guided Discovery of Bioactive Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (9)
                                     , 2099-2111. <a href="https://doi.org/10.1021/acs.jcim.7b00341" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00341</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00341%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DData%252BResources%252Bfor%252Bthe%252BComputer-Guided%252BDiscovery%252Bof%252BBioactive%252BNatural%252BProducts%26aulast%3DChen%26aufirst%3DYa%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07062017%26date%3D30082017%26date%3D25092017%26volume%3D57%26issue%3D9%26spage%3D2099%26epage%3D2111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Sindhikara</span>, <span class="hlFld-ContribAuthor ">Steven A.  Spronk</span>, <span class="hlFld-ContribAuthor ">Tyler  Day</span>, <span class="hlFld-ContribAuthor ">Ken  Borrelli</span>, <span class="hlFld-ContribAuthor ">Daniel L.  Cheney</span>, and <span class="hlFld-ContribAuthor ">Shana L.  Posy</span>  . </span><span class="cited-content_cbyCitation_article-title">Improving Accuracy, Diversity, and Speed with Prime Macrocycle Conformational Sampling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (8)
                                     , 1881-1894. <a href="https://doi.org/10.1021/acs.jcim.7b00052" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00052%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DImproving%252BAccuracy%25252C%252BDiversity%25252C%252Band%252BSpeed%252Bwith%252BPrime%252BMacrocycle%252BConformational%252BSampling%26aulast%3DSindhikara%26aufirst%3DDan%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D27012017%26date%3D08082017%26date%3D28082017%26date%3D20072017%26volume%3D57%26issue%3D8%26spage%3D1881%26epage%3D1894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaycie  Deyle</span>, <span class="hlFld-ContribAuthor ">Xu-Dong  Kong</span>, and <span class="hlFld-ContribAuthor ">Christian  Heinis</span>  . </span><span class="cited-content_cbyCitation_article-title">Phage Selection of Cyclic Peptides for Application in Research and Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Accounts of Chemical Research</span><span> <strong>2017,</strong> <em>50 </em>
                                    (8)
                                     , 1866-1874. <a href="https://doi.org/10.1021/acs.accounts.7b00184" title="DOI URL">https://doi.org/10.1021/acs.accounts.7b00184</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.accounts.7b00184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.accounts.7b00184%26sid%3Dliteratum%253Aachs%26jtitle%3DAccounts%2520of%2520Chemical%2520Research%26atitle%3DPhage%252BSelection%252Bof%252BCyclic%252BPeptides%252Bfor%252BApplication%252Bin%252BResearch%252Band%252BDrug%252BDevelopment%26aulast%3DDeyle%26aufirst%3DKaycie%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D13042017%26date%3D18072017%26date%3D15082017%26volume%3D50%26issue%3D8%26spage%3D1866%26epage%3D1874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel S.  Nielsen</span>, <span class="hlFld-ContribAuthor ">Nicholas E.  Shepherd</span>, <span class="hlFld-ContribAuthor ">Weijun  Xu</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Lucke</span>, <span class="hlFld-ContribAuthor ">Martin J.  Stoermer</span>, and <span class="hlFld-ContribAuthor ">David P.  Fairlie</span>  . </span><span class="cited-content_cbyCitation_article-title">Orally Absorbed Cyclic Peptides. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2017,</strong> <em>117 </em>
                                    (12)
                                     , 8094-8128. <a href="https://doi.org/10.1021/acs.chemrev.6b00838" title="DOI URL">https://doi.org/10.1021/acs.chemrev.6b00838</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.6b00838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.6b00838%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DOrally%252BAbsorbed%252BCyclic%252BPeptides%26aulast%3DNielsen%26aufirst%3DDaniel%2BS.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D20122016%26date%3D25052017%26date%3D28062017%26volume%3D117%26issue%3D12%26spage%3D8094%26epage%3D8128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojie  Lu</span>, <span class="hlFld-ContribAuthor ">Lijun  Fan</span>, <span class="hlFld-ContribAuthor ">Christopher B.  Phelps</span>, <span class="hlFld-ContribAuthor ">Christopher P.  Davie</span>, and <span class="hlFld-ContribAuthor ">Christine P.  Donahue</span>  . </span><span class="cited-content_cbyCitation_article-title">Ruthenium Promoted On-DNA Ring-Closing Metathesis and Cross-Metathesis. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (6)
                                     , 1625-1629. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00292" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00292%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DRuthenium%252BPromoted%252BOn-DNA%252BRing-Closing%252BMetathesis%252Band%252BCross-Metathesis%26aulast%3DLu%26aufirst%3DXiaojie%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D24052017%26date%3D04062017%26date%3D09062017%26date%3D21062017%26date%3D05062017%26volume%3D28%26issue%3D6%26spage%3D1625%26epage%3D1629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kelly  Maurent</span>, <span class="hlFld-ContribAuthor ">Corinne  Vanucci-Bacqué</span>, <span class="hlFld-ContribAuthor ">Nathalie  Saffon-Merceron</span>, <span class="hlFld-ContribAuthor ">Michel  Baltas</span>, and <span class="hlFld-ContribAuthor ">Florence  Bedos-Belval</span>  . </span><span class="cited-content_cbyCitation_article-title">Total Synthesis of Tedarene A. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2017,</strong> <em>80 </em>
                                    (5)
                                     , 1623-1630. <a href="https://doi.org/10.1021/acs.jnatprod.7b00199" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.7b00199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.7b00199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.7b00199%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DTotal%252BSynthesis%252Bof%252BTedarene%252BA%26aulast%3DMaurent%26aufirst%3DKelly%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07032017%26date%3D02052017%26date%3D26052017%26volume%3D80%26issue%3D5%26spage%3D1623%26epage%3D1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-Philippe  Krieger</span>, <span class="hlFld-ContribAuthor ">Dominique  Lesuisse</span>, <span class="hlFld-ContribAuthor ">Gino  Ricci</span>, <span class="hlFld-ContribAuthor ">Marc-Antoine  Perrin</span>, <span class="hlFld-ContribAuthor ">Christophe  Meyer</span>, and <span class="hlFld-ContribAuthor ">Janine  Cossy</span>  . </span><span class="cited-content_cbyCitation_article-title">Rhodium(III)-Catalyzed C–H Activation/Heterocyclization as a Macrocyclization Strategy. Synthesis of Macrocyclic Pyridones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (10)
                                     , 2706-2709. <a href="https://doi.org/10.1021/acs.orglett.7b01051" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b01051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b01051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b01051%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRhodium%252528III%252529-Catalyzed%252BC%2525E2%252580%252593H%252BActivation%25252FHeterocyclization%252Bas%252Ba%252BMacrocyclization%252BStrategy.%252BSynthesis%252Bof%252BMacrocyclic%252BPyridones%26aulast%3DKrieger%26aufirst%3DJean-Philippe%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07042017%26date%3D09052017%26date%3D19052017%26volume%3D19%26issue%3D10%26spage%3D2706%26epage%3D2709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan  Booth</span>, <span class="hlFld-ContribAuthor ">Christina-Nicoleta  Alexandru-Crivac</span>, <span class="hlFld-ContribAuthor ">Kirstie A.  Rickaby</span>, <span class="hlFld-ContribAuthor ">Ada F.  Nneoyiegbe</span>, <span class="hlFld-ContribAuthor ">Ugochukwu  Umeobika</span>, <span class="hlFld-ContribAuthor ">Andrew R.  McEwan</span>, <span class="hlFld-ContribAuthor ">Laurent  Trembleau</span>, <span class="hlFld-ContribAuthor ">Marcel  Jaspars</span>, <span class="hlFld-ContribAuthor ">Wael E.  Houssen</span>, and <span class="hlFld-ContribAuthor ">Dmitrii V.  Shalashilin</span>  . </span><span class="cited-content_cbyCitation_article-title">A Blind Test of Computational Technique for Predicting the Likelihood of Peptide Sequences to Cyclize. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (10)
                                     , 2310-2315. <a href="https://doi.org/10.1021/acs.jpclett.7b00848" title="DOI URL">https://doi.org/10.1021/acs.jpclett.7b00848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpclett.7b00848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpclett.7b00848%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520Letters%26atitle%3DA%252BBlind%252BTest%252Bof%252BComputational%252BTechnique%252Bfor%252BPredicting%252Bthe%252BLikelihood%252Bof%252BPeptide%252BSequences%252Bto%252BCyclize%26aulast%3DBooth%26aufirst%3DJonathan%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07042017%26date%3D05052017%26date%3D10052017%26date%3D18052017%26date%3D05052017%26volume%3D8%26issue%3D10%26spage%3D2310%26epage%3D2315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amber M.  Johnson</span> and <span class="hlFld-ContribAuthor ">Eric V.  Anslyn</span>  . </span><span class="cited-content_cbyCitation_article-title">Reversible Macrocyclization of Peptides with a Conjugate Acceptor. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (7)
                                     , 1654-1657. <a href="https://doi.org/10.1021/acs.orglett.7b00451" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b00451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b00451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b00451%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DReversible%252BMacrocyclization%252Bof%252BPeptides%252Bwith%252Ba%252BConjugate%252BAcceptor%26aulast%3DJohnson%26aufirst%3DAmber%2BM.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D14022017%26date%3D10032017%26date%3D07042017%26volume%3D19%26issue%3D7%26spage%3D1654%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergei V.  Voitekhovich</span>, <span class="hlFld-ContribAuthor ">Alexander S.  Lyakhov</span>, <span class="hlFld-ContribAuthor ">Ludmila S.  Ivashkevich</span>, <span class="hlFld-ContribAuthor ">Sara  Schmorl</span>, <span class="hlFld-ContribAuthor ">Berthold  Kersting</span>, and <span class="hlFld-ContribAuthor ">Oleg A.  Ivashkevich</span>  . </span><span class="cited-content_cbyCitation_article-title">The First Characterized Coordination Compounds of Macrocyclic Ligands Including Incorporated Tetrazole Rings. </span><span class="cited-content_cbyCitation_journal-name">Crystal Growth & Design</span><span> <strong>2017,</strong> <em>17 </em>
                                    (4)
                                     , 1796-1805. <a href="https://doi.org/10.1021/acs.cgd.6b01775" title="DOI URL">https://doi.org/10.1021/acs.cgd.6b01775</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.cgd.6b01775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.cgd.6b01775%26sid%3Dliteratum%253Aachs%26jtitle%3DCrystal%2520Growth%2520%2526%2520Design%26atitle%3DThe%252BFirst%252BCharacterized%252BCoordination%252BCompounds%252Bof%252BMacrocyclic%252BLigands%252BIncluding%252BIncorporated%252BTetrazole%252BRings%26aulast%3DVoitekhovich%26aufirst%3DSergei%2BV.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D2017%26date%3D07122016%26date%3D21022017%26date%3D10032017%26date%3D05042017%26date%3D01032017%26volume%3D17%26issue%3D4%26spage%3D1796%26epage%3D1805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William  Tieu</span>, <span class="hlFld-ContribAuthor ">Tulip  Lifa</span>, <span class="hlFld-ContribAuthor ">Andrew  Katsifis</span>, and <span class="hlFld-ContribAuthor ">Rachel  Codd</span>  . </span><span class="cited-content_cbyCitation_article-title">Octadentate Zirconium(IV)-Loaded Macrocycles with Varied Stoichiometry Assembled From Hydroxamic Acid Monomers using Metal-Templated Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2017,</strong> <em>56 </em>
                                    (6)
                                     , 3719-3728. <a href="https://doi.org/10.1021/acs.inorgchem.7b00362" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.7b00362</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.7b00362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.7b00362%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DOctadentate%252BZirconium%252528IV%252529-Loaded%252BMacrocycles%252Bwith%252BVaried%252BStoichiometry%252BAssembled%252BFrom%252BHydroxamic%252BAcid%252BMonomers%252Busing%252BMetal-Templated%252BSynthesis%26aulast%3DTieu%26aufirst%3DWilliam%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D09022017%26date%3D28022017%26date%3D20032017%26volume%3D56%26issue%3D6%26spage%3D3719%26epage%3D3728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Liu</span> and <span class="hlFld-ContribAuthor ">Ying-Yeung  Yeung</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Macrocyclic Ketones through Catalyst-Free Electrophilic Halogen-Mediated Semipinacol Rearrangement: Application to the Total Synthesis of (±)-Muscone. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (6)
                                     , 1422-1425. <a href="https://doi.org/10.1021/acs.orglett.7b00350" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b00350</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b00350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b00350%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BMacrocyclic%252BKetones%252Bthrough%252BCatalyst-Free%252BElectrophilic%252BHalogen-Mediated%252BSemipinacol%252BRearrangement%25253A%252BApplication%252Bto%252Bthe%252BTotal%252BSynthesis%252Bof%252B%252528%2525C2%2525B1%252529-Muscone%26aulast%3DLiu%26aufirst%3DYi%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D03022017%26date%3D28022017%26date%3D17032017%26volume%3D19%26issue%3D6%26spage%3D1422%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiba  Alogheli</span>, <span class="hlFld-ContribAuthor ">Gustav  Olanders</span>, <span class="hlFld-ContribAuthor ">Wesley  Schaal</span>, <span class="hlFld-ContribAuthor ">Peter  Brandt</span>, and <span class="hlFld-ContribAuthor ">Anders  Karlén</span>  . </span><span class="cited-content_cbyCitation_article-title">Docking of Macrocycles: Comparing Rigid and Flexible Docking in Glide. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (2)
                                     , 190-202. <a href="https://doi.org/10.1021/acs.jcim.6b00443" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00443%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDocking%252Bof%252BMacrocycles%25253A%252BComparing%252BRigid%252Band%252BFlexible%252BDocking%252Bin%252BGlide%26aulast%3DAlogheli%26aufirst%3DHiba%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D01082016%26date%3D02022017%26date%3D27022017%26date%3D12012017%26volume%3D57%26issue%3D2%26spage%3D190%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James R.  Corte</span>, <span class="hlFld-ContribAuthor ">Tianan  Fang</span>, <span class="hlFld-ContribAuthor ">Honey  Osuna</span>, <span class="hlFld-ContribAuthor ">Donald J. P.  Pinto</span>, <span class="hlFld-ContribAuthor ">Karen A.  Rossi</span>, <span class="hlFld-ContribAuthor ">Joseph E.  Myers, Jr.</span>, <span class="hlFld-ContribAuthor ">Steven  Sheriff</span>, <span class="hlFld-ContribAuthor ">Zhen  Lou</span>, <span class="hlFld-ContribAuthor ">Joanna J.  Zheng</span>, <span class="hlFld-ContribAuthor ">Timothy W.  Harper</span>, <span class="hlFld-ContribAuthor ">Jeffrey M.  Bozarth</span>, <span class="hlFld-ContribAuthor ">Yiming  Wu</span>, <span class="hlFld-ContribAuthor ">Joseph M.  Luettgen</span>, <span class="hlFld-ContribAuthor ">Dietmar A.  Seiffert</span>, <span class="hlFld-ContribAuthor ">Carl P.  Decicco</span>, <span class="hlFld-ContribAuthor ">Ruth R.  Wexler</span>, and <span class="hlFld-ContribAuthor ">Mimi L.  Quan</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (3)
                                     , 1060-1075. <a href="https://doi.org/10.1021/acs.jmedchem.6b01460" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01460</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01460%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Bof%252BMacrocyclic%252BFactor%252BXIa%252BInhibitors%25253A%252BDiscovery%252Bof%252Bthe%252BMacrocyclic%252BAmide%252BLinker%26aulast%3DCorte%26aufirst%3DJames%2BR.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D04102016%26date%3D31012017%26date%3D09022017%26date%3D13012017%26volume%3D60%26issue%3D3%26spage%3D1060%26epage%3D1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Weihe  Zhang</span>, <span class="hlFld-ContribAuthor ">Michael A.  Stashko</span>, <span class="hlFld-ContribAuthor ">James  Nichols</span>, <span class="hlFld-ContribAuthor ">Michael J.  Miley</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Norris-Drouin</span>, <span class="hlFld-ContribAuthor ">Zhilong  Chen</span>, <span class="hlFld-ContribAuthor ">Mischa  Machius</span>, <span class="hlFld-ContribAuthor ">Deborah  DeRyckere</span>, <span class="hlFld-ContribAuthor ">Edgar  Wood</span>, <span class="hlFld-ContribAuthor ">Douglas K.  Graham</span>, <span class="hlFld-ContribAuthor ">H. Shelton  Earp</span>, <span class="hlFld-ContribAuthor ">Dmitri  Kireev</span>, and <span class="hlFld-ContribAuthor ">Stephen V.  Frye</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (12)
                                     , 1044-1049. <a href="https://doi.org/10.1021/acsmedchemlett.6b00221" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00221%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNovel%252BMacrocyclic%252BMer%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DWang%26aufirst%3DXiaodong%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26052016%26date%3D13092016%26date%3D21092016%26date%3D08122016%26date%3D13092016%26volume%3D7%26issue%3D12%26spage%3D1044%26epage%3D1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akihiro  Furukawa</span>, <span class="hlFld-ContribAuthor ">Chad E.  Townsend</span>, <span class="hlFld-ContribAuthor ">Joshua  Schwochert</span>, <span class="hlFld-ContribAuthor ">Cameron R.  Pye</span>, <span class="hlFld-ContribAuthor ">Maria A.  Bednarek</span>, and <span class="hlFld-ContribAuthor ">R. Scott  Lokey</span>  . </span><span class="cited-content_cbyCitation_article-title">Passive Membrane Permeability in Cyclic Peptomer Scaffolds Is Robust to Extensive Variation in Side Chain Functionality and Backbone Geometry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (20)
                                     , 9503-9512. <a href="https://doi.org/10.1021/acs.jmedchem.6b01246" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01246</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01246%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPassive%252BMembrane%252BPermeability%252Bin%252BCyclic%252BPeptomer%252BScaffolds%252BIs%252BRobust%252Bto%252BExtensive%252BVariation%252Bin%252BSide%252BChain%252BFunctionality%252Band%252BBackbone%252BGeometry%26aulast%3DFurukawa%26aufirst%3DAkihiro%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D17082016%26date%3D11102016%26date%3D27102016%26date%3D03102016%26volume%3D59%26issue%3D20%26spage%3D9503%26epage%3D9512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroshi  Sato</span>, <span class="hlFld-ContribAuthor ">Masahito  Yoshida</span>, <span class="hlFld-ContribAuthor ">Hayato  Murase</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Nakagawa</span>, and <span class="hlFld-ContribAuthor ">Takayuki  Doi</span>  . </span><span class="cited-content_cbyCitation_article-title">Combinatorial Solid-Phase Synthesis and Biological Evaluation of Cyclodepsipeptide Destruxin B as a Negative Regulator for Osteoclast Morphology. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2016,</strong> <em>18 </em>
                                    (9)
                                     , 590-595. <a href="https://doi.org/10.1021/acscombsci.6b00076" title="DOI URL">https://doi.org/10.1021/acscombsci.6b00076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.6b00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.6b00076%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DCombinatorial%252BSolid-Phase%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BCyclodepsipeptide%252BDestruxin%252BB%252Bas%252Ba%252BNegative%252BRegulator%252Bfor%252BOsteoclast%252BMorphology%26aulast%3DSato%26aufirst%3DHiroshi%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D30052016%26date%3D25072016%26date%3D18082016%26date%3D12092016%26date%3D04082016%26volume%3D18%26issue%3D9%26spage%3D590%26epage%3D595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brett A.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Graham F.  Smith</span>, and <span class="hlFld-ContribAuthor ">Nunzio  Sciammetta</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Cyclic Peptidomimetics via a Pd-Catalyzed Macroamination Reaction. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2016,</strong> <em>18 </em>
                                    (16)
                                     , 4072-4075. <a href="https://doi.org/10.1021/acs.orglett.6b01961" title="DOI URL">https://doi.org/10.1021/acs.orglett.6b01961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.6b01961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.6b01961%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BCyclic%252BPeptidomimetics%252Bvia%252Ba%252BPd-Catalyzed%252BMacroamination%252BReaction%26aulast%3DHopkins%26aufirst%3DBrett%2BA.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D06072016%26date%3D10082016%26date%3D19082016%26volume%3D18%26issue%3D16%26spage%3D4072%26epage%3D4075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jennifer L.  Hickey</span>, <span class="hlFld-ContribAuthor ">Serge  Zaretsky</span>, <span class="hlFld-ContribAuthor ">Megan A.  St. Denis</span>, <span class="hlFld-ContribAuthor ">Sai  Kumar Chakka</span>, <span class="hlFld-ContribAuthor ">M. Monzur  Morshed</span>, <span class="hlFld-ContribAuthor ">Conor C. G.  Scully</span>, <span class="hlFld-ContribAuthor ">Andrew L.  Roughton</span>, and <span class="hlFld-ContribAuthor ">Andrei K.  Yudin</span>  . </span><span class="cited-content_cbyCitation_article-title">Passive Membrane Permeability of Macrocycles Can Be Controlled by Exocyclic Amide Bonds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (11)
                                     , 5368-5376. <a href="https://doi.org/10.1021/acs.jmedchem.6b00222" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00222</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00222%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPassive%252BMembrane%252BPermeability%252Bof%252BMacrocycles%252BCan%252BBe%252BControlled%252Bby%252BExocyclic%252BAmide%252BBonds%26aulast%3DHickey%26aufirst%3DJennifer%2BL.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11022016%26date%3D19052016%26date%3D09062016%26date%3D27042016%26volume%3D59%26issue%3D11%26spage%3D5368%26epage%3D5376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Djadé I.  Soumana</span>, <span class="hlFld-ContribAuthor ">Nese  Kurt Yilmaz</span>, <span class="hlFld-ContribAuthor ">Kristina L.  Prachanronarong</span>, <span class="hlFld-ContribAuthor ">Cihan  Aydin</span>, <span class="hlFld-ContribAuthor ">Akbar  Ali</span>, and <span class="hlFld-ContribAuthor ">Celia A.  Schiffer</span>  . </span><span class="cited-content_cbyCitation_article-title">Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (4)
                                     , 900-909. <a href="https://doi.org/10.1021/acschembio.5b00647" title="DOI URL">https://doi.org/10.1021/acschembio.5b00647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.5b00647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.5b00647%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DStructural%252Band%252BThermodynamic%252BEffects%252Bof%252BMacrocyclization%252Bin%252BHCV%252BNS3%25252F4A%252BInhibitor%252BMK-5172%26aulast%3DSoumana%26aufirst%3DDjad%25C3%25A9%2BI.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D11082015%26date%3D18122015%26date%3D06012016%26date%3D15042016%26date%3D18122015%26volume%3D11%26issue%3D4%26spage%3D900%26epage%3D909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor J.  Cee</span>, <span class="hlFld-ContribAuthor ">Frank  Chavez, Jr.</span>, <span class="hlFld-ContribAuthor ">Bradley  Herberich</span>, <span class="hlFld-ContribAuthor ">Brian A.  Lanman</span>, <span class="hlFld-ContribAuthor ">Liping H.  Pettus</span>, <span class="hlFld-ContribAuthor ">Anthony B.  Reed</span>, <span class="hlFld-ContribAuthor ">Bin  Wu</span>, <span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Jie  Chen</span>, <span class="hlFld-ContribAuthor ">Dean  Hickman</span>, <span class="hlFld-ContribAuthor ">Jimmy  Laszlo, III</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Lee</span>, <span class="hlFld-ContribAuthor ">Nadia  Guerrero</span>, <span class="hlFld-ContribAuthor ">Bethany K.  Mattson</span>, <span class="hlFld-ContribAuthor ">Yen  Nguyen</span>, <span class="hlFld-ContribAuthor ">Christopher  Mohr</span>, <span class="hlFld-ContribAuthor ">Karen  Rex</span>, <span class="hlFld-ContribAuthor ">Christine E.  Sastri</span>, <span class="hlFld-ContribAuthor ">Paul  Wang</span>, <span class="hlFld-ContribAuthor ">Qiong  Wu</span>, <span class="hlFld-ContribAuthor ">Tian  Wu</span>, <span class="hlFld-ContribAuthor ">Yang  Xu</span>, <span class="hlFld-ContribAuthor ">Yihong  Zhou</span>, <span class="hlFld-ContribAuthor ">Jeffrey T.  Winston</span>, <span class="hlFld-ContribAuthor ">J. Russell  Lipford</span>, <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>, and <span class="hlFld-ContribAuthor ">Hui-Ling  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (4)
                                     , 408-412. <a href="https://doi.org/10.1021/acsmedchemlett.5b00403" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00403%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252BMacrocyclic%252BQuinoxaline-pyrrolo-dihydropiperidinones%252Bas%252BPotent%252BPim-1%25252F2%252BKinase%252BInhibitors%26aulast%3DCee%26aufirst%3DVictor%2BJ.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D14102015%26date%3D08022016%26date%3D12022016%26date%3D14042016%26volume%3D7%26issue%3D4%26spage%3D408%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bradley C.  Doak</span>, <span class="hlFld-ContribAuthor ">Jie  Zheng</span>, <span class="hlFld-ContribAuthor ">Doreen  Dobritzsch</span>, and <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>  . </span><span class="cited-content_cbyCitation_article-title">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (6)
                                     , 2312-2327. <a href="https://doi.org/10.1021/acs.jmedchem.5b01286" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01286</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01286%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHow%252BBeyond%252BRule%252Bof%252B5%252BDrugs%252Band%252BClinical%252BCandidates%252BBind%252Bto%252BTheir%252BTargets%26aulast%3DDoak%26aufirst%3DBradley%2BC.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D18082015%26date%3D30102015%26date%3D24032016%26date%3D12102015%26volume%3D59%26issue%3D6%26spage%3D2312%26epage%3D2327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vishnu C.  Damalanka</span>, <span class="hlFld-ContribAuthor ">Yunjeong  Kim</span>, <span class="hlFld-ContribAuthor ">Kevin R.  Alliston</span>, <span class="hlFld-ContribAuthor ">Pathum M.  Weerawarna</span>, <span class="hlFld-ContribAuthor ">Anushka C.  Galasiti Kankanamalage</span>, <span class="hlFld-ContribAuthor ">Gerald H.  Lushington</span>, <span class="hlFld-ContribAuthor ">Nurjahan  Mehzabeen</span>, <span class="hlFld-ContribAuthor ">Kevin P.  Battaile</span>, <span class="hlFld-ContribAuthor ">Scott  Lovell</span>, <span class="hlFld-ContribAuthor ">Kyeong-Ok  Chang</span>, and <span class="hlFld-ContribAuthor ">William C.  Groutas</span>  . </span><span class="cited-content_cbyCitation_article-title">Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 1899-1913. <a href="https://doi.org/10.1021/acs.jmedchem.5b01464" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01464</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01464%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOxadiazole-Based%252BCell%252BPermeable%252BMacrocyclic%252BTransition%252BState%252BInhibitors%252Bof%252BNorovirus%252B3CL%252BProtease%26aulast%3DDamalanka%26aufirst%3DVishnu%2BC.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D19092015%26date%3D08022016%26date%3D10032016%26date%3D29012016%26volume%3D59%26issue%3D5%26spage%3D1899%26epage%3D1913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danmeng  Luo</span>, <span class="hlFld-ContribAuthor ">Qi-Yin  Chen</span>, and <span class="hlFld-ContribAuthor ">Hendrik  Luesch</span>  . </span><span class="cited-content_cbyCitation_article-title">Total Synthesis of the Potent Marine-Derived Elastase Inhibitor Lyngbyastatin 7 and in Vitro Biological Evaluation in Model Systems for Pulmonary Diseases. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (2)
                                     , 532-544. <a href="https://doi.org/10.1021/acs.joc.5b02386" title="DOI URL">https://doi.org/10.1021/acs.joc.5b02386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b02386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b02386%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTotal%252BSynthesis%252Bof%252Bthe%252BPotent%252BMarine-Derived%252BElastase%252BInhibitor%252BLyngbyastatin%252B7%252Band%252Bin%252BVitro%252BBiological%252BEvaluation%252Bin%252BModel%252BSystems%252Bfor%252BPulmonary%252BDiseases%26aulast%3DLuo%26aufirst%3DDanmeng%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D14102015%26date%3D28122015%26date%3D15012016%26volume%3D81%26issue%3D2%26spage%3D532%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunjeong  Kim</span>, <span class="hlFld-ContribAuthor ">Anushka C.  Galasiti Kankanamalage</span>, <span class="hlFld-ContribAuthor ">Kyeong-Ok  Chang</span>, and <span class="hlFld-ContribAuthor ">William C.  Groutas</span>  . </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Norovirus Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (24)
                                     , 9438-9450. <a href="https://doi.org/10.1021/acs.jmedchem.5b00762" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00762%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BNorovirus%252BTherapeutics%26aulast%3DKim%26aufirst%3DYunjeong%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D19052015%26date%3D17082015%26date%3D24122015%26date%3D10082015%26volume%3D58%26issue%3D24%26spage%3D9438%26epage%3D9450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">George P.  Liao</span>, <span class="hlFld-ContribAuthor ">Eman M. M.  Abdelraheem</span>, <span class="hlFld-ContribAuthor ">Constantinos G.  Neochoritis</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kurpiewska</span>, <span class="hlFld-ContribAuthor ">Justyna  Kalinowska-Tłuścik</span>, <span class="hlFld-ContribAuthor ">David C.  McGowan</span>, and <span class="hlFld-ContribAuthor ">Alexander  Dömling</span>  . </span><span class="cited-content_cbyCitation_article-title">Versatile Multicomponent Reaction Macrocycle Synthesis Using α-Isocyano-ω-carboxylic Acids. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2015,</strong> <em>17 </em>
                                    (20)
                                     , 4980-4983. <a href="https://doi.org/10.1021/acs.orglett.5b02419" title="DOI URL">https://doi.org/10.1021/acs.orglett.5b02419</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.5b02419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.5b02419%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DVersatile%252BMulticomponent%252BReaction%252BMacrocycle%252BSynthesis%252BUsing%252B%2525CE%2525B1-Isocyano-%2525CF%252589-carboxylic%252BAcids%26aulast%3DLiao%26aufirst%3DGeorge%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D22082015%26date%3D06102015%26date%3D16102015%26volume%3D17%26issue%3D20%26spage%3D4980%26epage%3D4983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew T.  Bockus</span>, <span class="hlFld-ContribAuthor ">Joshua A.  Schwochert</span>, <span class="hlFld-ContribAuthor ">Cameron R.  Pye</span>, <span class="hlFld-ContribAuthor ">Chad E.  Townsend</span>, <span class="hlFld-ContribAuthor ">Vong  Sok</span>, <span class="hlFld-ContribAuthor ">Maria A.  Bednarek</span>, and <span class="hlFld-ContribAuthor ">R. Scott  Lokey</span>  . </span><span class="cited-content_cbyCitation_article-title">Going Out on a Limb: Delineating The Effects of β-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (18)
                                     , 7409-7418. <a href="https://doi.org/10.1021/acs.jmedchem.5b00919" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00919</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00919%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGoing%252BOut%252Bon%252Ba%252BLimb%25253A%252BDelineating%252BThe%252BEffects%252Bof%252B%2525CE%2525B2-Branching%25252C%252BN-Methylation%25252C%252Band%252BSide%252BChain%252BSize%252Bon%252Bthe%252BPassive%252BPermeability%25252C%252BSolubility%25252C%252Band%252BFlexibility%252Bof%252BSanguinamide%252BA%252BAnalogues%26aulast%3DBockus%26aufirst%3DAndrew%2BT.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D15062015%26date%3D02092015%26date%3D24092015%26date%3D26082015%26volume%3D58%26issue%3D18%26spage%3D7409%26epage%3D7418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vicente  Martí-Centelles</span>, <span class="hlFld-ContribAuthor ">Mrituanjay D.  Pandey</span>, <span class="hlFld-ContribAuthor ">M. Isabel  Burguete</span>, and <span class="hlFld-ContribAuthor ">Santiago V.  Luis</span>  . </span><span class="cited-content_cbyCitation_article-title">Macrocyclization Reactions: The Importance of Conformational, Configurational, and Template-Induced Preorganization. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2015,</strong> <em>115 </em>
                                    (16)
                                     , 8736-8834. <a href="https://doi.org/10.1021/acs.chemrev.5b00056" title="DOI URL">https://doi.org/10.1021/acs.chemrev.5b00056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.5b00056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.5b00056%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DMacrocyclization%252BReactions%25253A%252BThe%252BImportance%252Bof%252BConformational%25252C%252BConfigurational%25252C%252Band%252BTemplate-Induced%252BPreorganization%26aulast%3DMart%25C3%25AD-Centelles%26aufirst%3DVicente%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D29012015%26date%3D06082015%26date%3D26082015%26volume%3D115%26issue%3D16%26spage%3D8736%26epage%3D8834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. Scott  Priestley</span>, <span class="hlFld-ContribAuthor ">Daniel L.  Cheney</span>, <span class="hlFld-ContribAuthor ">Indawati  DeLucca</span>, <span class="hlFld-ContribAuthor ">Anzhi  Wei</span>, <span class="hlFld-ContribAuthor ">Joseph M.  Luettgen</span>, <span class="hlFld-ContribAuthor ">Alan R.  Rendina</span>, <span class="hlFld-ContribAuthor ">Pancras C.  Wong</span>, and <span class="hlFld-ContribAuthor ">Ruth R.  Wexler</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (15)
                                     , 6225-6236. <a href="https://doi.org/10.1021/acs.jmedchem.5b00788" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00788%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Bof%252BMacrocyclic%252BCoagulation%252BFactor%252BVIIa%252BInhibitors%26aulast%3DPriestley%26aufirst%3DE.%2BScott%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D22052015%26date%3D28072015%26date%3D13082015%26date%3D07072015%26volume%3D58%26issue%3D15%26spage%3D6225%26epage%3D6236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aldrin V.  Vasco</span>, <span class="hlFld-ContribAuthor ">Carlos S.  Pérez</span>, <span class="hlFld-ContribAuthor ">Fidel E.  Morales</span>, <span class="hlFld-ContribAuthor ">Hilda E.  Garay</span>, <span class="hlFld-ContribAuthor ">Dimitar  Vasilev</span>, <span class="hlFld-ContribAuthor ">José A.  Gavín</span>, <span class="hlFld-ContribAuthor ">Ludger A.  Wessjohann</span>, and <span class="hlFld-ContribAuthor ">Daniel G.  Rivera</span>  . </span><span class="cited-content_cbyCitation_article-title">Macrocyclization of Peptide Side Chains by the Ugi Reaction: Achieving Peptide Folding and Exocyclic N-Functionalization in One Shot. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>80 </em>
                                    (13)
                                     , 6697-6707. <a href="https://doi.org/10.1021/acs.joc.5b00858" title="DOI URL">https://doi.org/10.1021/acs.joc.5b00858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b00858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b00858%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMacrocyclization%252Bof%252BPeptide%252BSide%252BChains%252Bby%252Bthe%252BUgi%252BReaction%25253A%252BAchieving%252BPeptide%252BFolding%252Band%252BExocyclic%252BN-Functionalization%252Bin%252BOne%252BShot%26aulast%3DVasco%26aufirst%3DAldrin%2BV.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D17042015%26date%3D17062015%26date%3D02072015%26date%3D01062015%26volume%3D80%26issue%3D13%26spage%3D6697%26epage%3D6707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew T.  Bockus</span>, <span class="hlFld-ContribAuthor ">Katrina W.  Lexa</span>, <span class="hlFld-ContribAuthor ">Cameron R.  Pye</span>, <span class="hlFld-ContribAuthor ">Amit S.  Kalgutkar</span>, <span class="hlFld-ContribAuthor ">Jarret W.  Gardner</span>, <span class="hlFld-ContribAuthor ">Kathryn C. R.  Hund</span>, <span class="hlFld-ContribAuthor ">William M.  Hewitt</span>, <span class="hlFld-ContribAuthor ">Joshua A.  Schwochert</span>, <span class="hlFld-ContribAuthor ">Emerson  Glassey</span>, <span class="hlFld-ContribAuthor ">David A.  Price</span>, <span class="hlFld-ContribAuthor ">Alan M.  Mathiowetz</span>, <span class="hlFld-ContribAuthor ">Spiros  Liras</span>, <span class="hlFld-ContribAuthor ">Matthew P.  Jacobson</span>, and <span class="hlFld-ContribAuthor ">R. Scott  Lokey</span>  . </span><span class="cited-content_cbyCitation_article-title">Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (11)
                                     , 4581-4589. <a href="https://doi.org/10.1021/acs.jmedchem.5b00128" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00128</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00128%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProbing%252Bthe%252BPhysicochemical%252BBoundaries%252Bof%252BCell%252BPermeability%252Band%252BOral%252BBioavailability%252Bin%252BLipophilic%252BMacrocycles%252BInspired%252Bby%252BNatural%252BProducts%26aulast%3DBockus%26aufirst%3DAndrew%2BT.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D22012015%26date%3D20052015%26date%3D11062015%26date%3D07052015%26volume%3D58%26issue%3D11%26spage%3D4581%26epage%3D4589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brett R.  Beno</span>, <span class="hlFld-ContribAuthor ">Kap-Sun  Yeung</span>, <span class="hlFld-ContribAuthor ">Michael D.  Bartberger</span>, <span class="hlFld-ContribAuthor ">Lewis D.  Pennington</span>, and <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (11)
                                     , 4383-4438. <a href="https://doi.org/10.1021/jm501853m" title="DOI URL">https://doi.org/10.1021/jm501853m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501853m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSurvey%252Bof%252Bthe%252BRole%252Bof%252BNoncovalent%252BSulfur%252BInteractions%252Bin%252BDrug%252BDesign%26aulast%3DBeno%26aufirst%3DBrett%2BR.%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D01122014%26date%3D03032015%26date%3D11062015%26volume%3D58%26issue%3D11%26spage%3D4383%26epage%3D4438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. C.  Nicolaou</span>, <span class="hlFld-ContribAuthor ">Christian  Nilewski</span>, <span class="hlFld-ContribAuthor ">Christopher R. H.  Hale</span>, <span class="hlFld-ContribAuthor ">Christopher F.  Ahles</span>, <span class="hlFld-ContribAuthor ">Chiao An  Chiu</span>, <span class="hlFld-ContribAuthor ">Christian  Ebner</span>, <span class="hlFld-ContribAuthor ">Abdelatif  ElMarrouni</span>, <span class="hlFld-ContribAuthor ">Lifeng  Yang</span>, <span class="hlFld-ContribAuthor ">Katherine  Stiles</span>, and <span class="hlFld-ContribAuthor ">Deepak  Nagrath</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Dimeric Furanoid Macroheterocycles: Discovery of New Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2015,</strong> <em>137 </em>
                                    (14)
                                     , 4766-4770. <a href="https://doi.org/10.1021/jacs.5b00141" title="DOI URL">https://doi.org/10.1021/jacs.5b00141</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.5b00141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.5b00141%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BDimeric%252BFuranoid%252BMacroheterocycles%25253A%252BDiscovery%252Bof%252BNew%252BAnticancer%252BAgents%26aulast%3DNicolaou%26aufirst%3DK.%2BC.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D09012015%26date%3D01042015%26date%3D15042015%26volume%3D137%26issue%3D14%26spage%3D4766%26epage%3D4770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tulip  Lifa</span>, <span class="hlFld-ContribAuthor ">William  Tieu</span>, <span class="hlFld-ContribAuthor ">Rosalie K.  Hocking</span>, and <span class="hlFld-ContribAuthor ">Rachel  Codd</span>  . </span><span class="cited-content_cbyCitation_article-title">Forward and Reverse (Retro) Iron(III) or Gallium(III) Desferrioxamine E and Ring-Expanded Analogues Prepared Using Metal-Templated Synthesis from endo-Hydroxamic Acid Monomers. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2015,</strong> <em>54 </em>
                                    (7)
                                     , 3573-3583. <a href="https://doi.org/10.1021/acs.inorgchem.5b00141" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.5b00141</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.5b00141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.5b00141%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DForward%252Band%252BReverse%252B%252528Retro%252529%252BIron%252528III%252529%252Bor%252BGallium%252528III%252529%252BDesferrioxamine%252BE%252Band%252BRing-Expanded%252BAnalogues%252BPrepared%252BUsing%252BMetal-Templated%252BSynthesis%252Bfrom%252Bendo-Hydroxamic%252BAcid%252BMonomers%26aulast%3DLifa%26aufirst%3DTulip%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D21012015%26date%3D19032015%26date%3D06042015%26volume%3D54%26issue%3D7%26spage%3D3573%26epage%3D3583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hengbin  Wang</span>, <span class="hlFld-ContribAuthor ">Solymar  Negretti</span>, <span class="hlFld-ContribAuthor ">Allison R.  Knauff</span>, and <span class="hlFld-ContribAuthor ">John  Montgomery</span>  . </span><span class="cited-content_cbyCitation_article-title">Exo-Selective Reductive Macrocyclization of Ynals. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2015,</strong> <em>17 </em>
                                    (6)
                                     , 1493-1496. <a href="https://doi.org/10.1021/acs.orglett.5b00381" title="DOI URL">https://doi.org/10.1021/acs.orglett.5b00381</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.5b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.5b00381%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DExo-Selective%252BReductive%252BMacrocyclization%252Bof%252BYnals%26aulast%3DWang%26aufirst%3DHengbin%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D05022015%26date%3D06032015%26date%3D20032015%26volume%3D17%26issue%3D6%26spage%3D1493%26epage%3D1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jon J. G.  Winter</span>, <span class="hlFld-ContribAuthor ">Malcolm  Anderson</span>, <span class="hlFld-ContribAuthor ">Kevin  Blades</span>, <span class="hlFld-ContribAuthor ">Claire  Brassington</span>, <span class="hlFld-ContribAuthor ">Alexander L.  Breeze</span>, <span class="hlFld-ContribAuthor ">Christine  Chresta</span>, <span class="hlFld-ContribAuthor ">Kevin  Embrey</span>, <span class="hlFld-ContribAuthor ">Gary  Fairley</span>, <span class="hlFld-ContribAuthor ">Paul  Faulder</span>, <span class="hlFld-ContribAuthor ">M. Raymond V.  Finlay</span>, <span class="hlFld-ContribAuthor ">Jason G.  Kettle</span>, <span class="hlFld-ContribAuthor ">Thorsten  Nowak</span>, <span class="hlFld-ContribAuthor ">Ross  Overman</span>, <span class="hlFld-ContribAuthor ">S. Joe  Patel</span>, <span class="hlFld-ContribAuthor ">Paula  Perkins</span>, <span class="hlFld-ContribAuthor ">Loredana  Spadola</span>, <span class="hlFld-ContribAuthor ">Jonathan  Tart</span>, <span class="hlFld-ContribAuthor ">Julie A.  Tucker</span>, and <span class="hlFld-ContribAuthor ">Gail  Wrigley</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (5)
                                     , 2265-2274. <a href="https://doi.org/10.1021/jm501660t" title="DOI URL">https://doi.org/10.1021/jm501660t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501660t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501660t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BBinding%252BSites%252Bon%252Bthe%252BRas%25253ASOS%252BComplex%252BCan%252BBe%252BExploited%252Bfor%252BInhibition%252Bof%252BRas%252BActivation%26aulast%3DWinter%26aufirst%3DJon%2BJ.%2BG.%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D28102014%26date%3D26022015%26date%3D12032015%26date%3D19022015%26volume%3D58%26issue%3D5%26spage%3D2265%26epage%3D2274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.  Vasudevan</span>, <span class="hlFld-ContribAuthor ">K.  Kashinath</span>, and <span class="hlFld-ContribAuthor ">D. Srinivasa  Reddy</span>  . </span><span class="cited-content_cbyCitation_article-title">Total Synthesis of Deoxy-solomonamide B by Mimicking Biogenesis. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2014,</strong> <em>16 </em>
                                    (23)
                                     , 6148-6151. <a href="https://doi.org/10.1021/ol503011g" title="DOI URL">https://doi.org/10.1021/ol503011g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol503011g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol503011g%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DTotal%252BSynthesis%252Bof%252BDeoxy-solomonamide%252BB%252Bby%252BMimicking%252BBiogenesis%26aulast%3DVasudevan%26aufirst%3DN.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D13102014%26date%3D13112014%26date%3D05122014%26volume%3D16%26issue%3D23%26spage%3D6148%26epage%3D6151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoph  Nitsche</span>, <span class="hlFld-ContribAuthor ">Steven  Holloway</span>, <span class="hlFld-ContribAuthor ">Tanja  Schirmeister</span>, and <span class="hlFld-ContribAuthor ">Christian D.  Klein</span>  . </span><span class="cited-content_cbyCitation_article-title">Biochemistry and Medicinal Chemistry of the Dengue Virus Protease. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2014,</strong> <em>114 </em>
                                    (22)
                                     , 11348-11381. <a href="https://doi.org/10.1021/cr500233q" title="DOI URL">https://doi.org/10.1021/cr500233q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cr500233q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcr500233q%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DBiochemistry%252Band%252BMedicinal%252BChemistry%252Bof%252Bthe%252BDengue%252BVirus%252BProtease%26aulast%3DNitsche%26aufirst%3DChristoph%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D28042014%26date%3D30092014%26date%3D26112014%26volume%3D114%26issue%3D22%26spage%3D11348%26epage%3D11381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy A.  Hill</span>, <span class="hlFld-ContribAuthor ">Rink-Jan  Lohman</span>, <span class="hlFld-ContribAuthor ">Huy N.  Hoang</span>, <span class="hlFld-ContribAuthor ">Daniel S.  Nielsen</span>, <span class="hlFld-ContribAuthor ">Conor C. G.  Scully</span>, <span class="hlFld-ContribAuthor ">W. Mei  Kok</span>, <span class="hlFld-ContribAuthor ">Ligong  Liu</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Lucke</span>, <span class="hlFld-ContribAuthor ">Martin J.  Stoermer</span>, <span class="hlFld-ContribAuthor ">Christina I.  Schroeder</span>, <span class="hlFld-ContribAuthor ">Stephanie  Chaousis</span>, <span class="hlFld-ContribAuthor ">Barbara  Colless</span>, <span class="hlFld-ContribAuthor ">Paul V.  Bernhardt</span>, <span class="hlFld-ContribAuthor ">David J.  Edmonds</span>, <span class="hlFld-ContribAuthor ">David A.  Griffith</span>, <span class="hlFld-ContribAuthor ">Charles J.  Rotter</span>, <span class="hlFld-ContribAuthor ">Roger B.  Ruggeri</span>, <span class="hlFld-ContribAuthor ">David A.  Price</span>, <span class="hlFld-ContribAuthor ">Spiros  Liras</span>, <span class="hlFld-ContribAuthor ">David J.  Craik</span>, and <span class="hlFld-ContribAuthor ">David P.  Fairlie</span>  . </span><span class="cited-content_cbyCitation_article-title">Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally Absorbed. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (10)
                                     , 1148-1151. <a href="https://doi.org/10.1021/ml5002823" title="DOI URL">https://doi.org/10.1021/ml5002823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml5002823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml5002823%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCyclic%252BPenta-%252Band%252BHexaleucine%252BPeptides%252Bwithout%252BN-Methylation%252BAre%252BOrally%252BAbsorbed%26aulast%3DHill%26aufirst%3DTimothy%2BA.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D11072014%26date%3D04082014%26date%3D07082014%26date%3D09102014%26date%3D04082014%26volume%3D5%26issue%3D10%26spage%3D1148%26epage%3D1151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tamam  El-Elimat</span>, <span class="hlFld-ContribAuthor ">Huzefa A.  Raja</span>, <span class="hlFld-ContribAuthor ">Cynthia S.  Day</span>, <span class="hlFld-ContribAuthor ">Wei-Lun  Chen</span>, <span class="hlFld-ContribAuthor ">Steven M.  Swanson</span>, and <span class="hlFld-ContribAuthor ">Nicholas H.  Oberlies</span>  . </span><span class="cited-content_cbyCitation_article-title">Greensporones: Resorcylic Acid Lactones from an Aquatic Halenospora sp.. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2014,</strong> <em>77 </em>
                                    (9)
                                     , 2088-2098. <a href="https://doi.org/10.1021/np500497r" title="DOI URL">https://doi.org/10.1021/np500497r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/np500497r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fnp500497r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DGreensporones%25253A%252BResorcylic%252BAcid%252BLactones%252Bfrom%252Ban%252BAquatic%252BHalenospora%252Bsp.%26aulast%3DEl-Elimat%26aufirst%3DTamam%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18062014%26date%3D05082014%26date%3D26092014%26volume%3D77%26issue%3D9%26spage%3D2088%26epage%3D2098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paola  Agrigento</span>, <span class="hlFld-ContribAuthor ">Fernando  Albericio</span>, <span class="hlFld-ContribAuthor ">Sylvie  Chamoin</span>, <span class="hlFld-ContribAuthor ">Isabelle  Dacquignies</span>, <span class="hlFld-ContribAuthor ">Halil  Koc</span>, and <span class="hlFld-ContribAuthor ">Martin  Eberle</span>  . </span><span class="cited-content_cbyCitation_article-title">Facile and Mild Synthesis of Linear and Cyclic Peptides via Thioesters. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2014,</strong> <em>16 </em>
                                    (15)
                                     , 3922-3925. <a href="https://doi.org/10.1021/ol501669n" title="DOI URL">https://doi.org/10.1021/ol501669n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol501669n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol501669n%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DFacile%252Band%252BMild%252BSynthesis%252Bof%252BLinear%252Band%252BCyclic%252BPeptides%252Bvia%252BThioesters%26aulast%3DAgrigento%26aufirst%3DPaola%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D10062014%26date%3D17072014%26date%3D01082014%26volume%3D16%26issue%3D15%26spage%3D3922%26epage%3D3925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ted W.  Johnson</span>, <span class="hlFld-ContribAuthor ">Paul F.  Richardson</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Alexei  Brooun</span>, <span class="hlFld-ContribAuthor ">Benjamin J.  Burke</span>, <span class="hlFld-ContribAuthor ">Michael R.  Collins</span>, <span class="hlFld-ContribAuthor ">J. Jean  Cui</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Ya-Li  Deng</span>, <span class="hlFld-ContribAuthor ">Dac  Dinh</span>, <span class="hlFld-ContribAuthor ">Lars D.  Engstrom</span>, <span class="hlFld-ContribAuthor ">Mingying  He</span>, <span class="hlFld-ContribAuthor ">Jacqui  Hoffman</span>, <span class="hlFld-ContribAuthor ">Robert L.  Hoffman</span>, <span class="hlFld-ContribAuthor ">Qinhua  Huang</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Hieu  Lam</span>, <span class="hlFld-ContribAuthor ">Justine L.  Lam</span>, <span class="hlFld-ContribAuthor ">Phuong T.  Le</span>, <span class="hlFld-ContribAuthor ">Laura  Lingardo</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Michele  McTigue</span>, <span class="hlFld-ContribAuthor ">Cynthia L.  Palmer</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Graham L.  Smith</span>, <span class="hlFld-ContribAuthor ">Albert E.  Stewart</span>, <span class="hlFld-ContribAuthor ">Sergei  Timofeevski</span>, <span class="hlFld-ContribAuthor ">Huichun  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinjiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Helen Y.  Zou</span>, and <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (11)
                                     , 4720-4744. <a href="https://doi.org/10.1021/jm500261q" title="DOI URL">https://doi.org/10.1021/jm500261q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500261q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%25252810R%252529-7-Amino-12-fluoro-2%25252C10%25252C16-trimethyl-15-oxo-10%25252C15%25252C16%25252C17-tetrahydro-2H-8%25252C4-%252528metheno%252529pyrazolo%25255B4%25252C3-h%25255D%25255B2%25252C5%25252C11%25255D-benzoxadiazacyclotetradecine-3-carbonitrile%252B%252528PF-06463922%252529%25252C%252Ba%252BMacrocyclic%252BInhibitor%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252Band%252Bc-ros%252BOncogene%252B1%252B%252528ROS1%252529%252Bwith%252BPreclinical%252BBrain%252BExposure%252Band%252BBroad-Spectrum%252BPotency%252Bagainst%252BALK-Resistant%252BMutations%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D17022014%26date%3D03062014%26date%3D12062014%26date%3D13052014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth A.  Ilardi</span>, <span class="hlFld-ContribAuthor ">Edon  Vitaku</span>, and <span class="hlFld-ContribAuthor ">Jon T.  Njardarson</span>  . </span><span class="cited-content_cbyCitation_article-title">Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (7)
                                     , 2832-2842. <a href="https://doi.org/10.1021/jm401375q" title="DOI URL">https://doi.org/10.1021/jm401375q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401375q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401375q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DData-Mining%252Bfor%252BSulfur%252Band%252BFluorine%25253A%252BAn%252BEvaluation%252Bof%252BPharmaceuticals%252BTo%252BReveal%252BOpportunities%252Bfor%252BDrug%252BDesign%252Band%252BDiscovery%26aulast%3DIlardi%26aufirst%3DElizabeth%2BA.%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D06092013%26date%3D29102013%26date%3D10042014%26date%3D08102013%26volume%3D57%26issue%3D7%26spage%3D2832%26epage%3D2842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cyril  Portmann</span>, <span class="hlFld-ContribAuthor ">Simon  Sieber</span>, <span class="hlFld-ContribAuthor ">Silvan  Wirthensohn</span>, <span class="hlFld-ContribAuthor ">Judith F.  Blom</span>, <span class="hlFld-ContribAuthor ">Laeticia  Da Silva</span>, <span class="hlFld-ContribAuthor ">Emilie  Baudat</span>, <span class="hlFld-ContribAuthor ">Marcel  Kaiser</span>, <span class="hlFld-ContribAuthor ">Reto  Brun</span>, and <span class="hlFld-ContribAuthor ">Karl  Gademann</span>  . </span><span class="cited-content_cbyCitation_article-title">Balgacyclamides, Antiplasmodial Heterocyclic Peptides from Microcystis aeruguinosa EAWAG 251. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2014,</strong> <em>77 </em>
                                    (3)
                                     , 557-562. <a href="https://doi.org/10.1021/np400814w" title="DOI URL">https://doi.org/10.1021/np400814w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/np400814w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fnp400814w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DBalgacyclamides%25252C%252BAntiplasmodial%252BHeterocyclic%252BPeptides%252Bfrom%252BMicrocystis%252Baeruguinosa%252BEAWAG%252B251%26aulast%3DPortmann%26aufirst%3DCyril%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D01102013%26date%3D06012014%26date%3D28032014%26volume%3D77%26issue%3D3%26spage%3D557%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Björn  Over</span>, <span class="hlFld-ContribAuthor ">Patrick  McCarren</span>, <span class="hlFld-ContribAuthor ">Per  Artursson</span>, <span class="hlFld-ContribAuthor ">Michael  Foley</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Giordanetto</span>, <span class="hlFld-ContribAuthor ">Gunnar  Grönberg</span>, <span class="hlFld-ContribAuthor ">Constanze  Hilgendorf</span>, <span class="hlFld-ContribAuthor ">Maurice D.  Lee, IV</span>, <span class="hlFld-ContribAuthor ">Pär  Matsson</span>, <span class="hlFld-ContribAuthor ">Giovanni  Muncipinto</span>, <span class="hlFld-ContribAuthor ">Mélanie  Pellisson</span>, <span class="hlFld-ContribAuthor ">Matthew W. D.  Perry</span>, <span class="hlFld-ContribAuthor ">Richard  Svensson</span>, <span class="hlFld-ContribAuthor ">Jeremy R.  Duvall</span>, and <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>  . </span><span class="cited-content_cbyCitation_article-title">Impact of Stereospecific Intramolecular Hydrogen Bonding on Cell Permeability and Physicochemical Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (6)
                                     , 2746-2754. <a href="https://doi.org/10.1021/jm500059t" title="DOI URL">https://doi.org/10.1021/jm500059t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500059t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500059t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DImpact%252Bof%252BStereospecific%252BIntramolecular%252BHydrogen%252BBonding%252Bon%252BCell%252BPermeability%252Band%252BPhysicochemical%252BProperties%26aulast%3DOver%26aufirst%3DBj%25C3%25B6rn%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D12012014%26date%3D26022014%26date%3D27032014%26date%3D13022014%26volume%3D57%26issue%3D6%26spage%3D2746%26epage%3D2754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nis  Halland</span>, <span class="hlFld-ContribAuthor ">Horst  Blum</span>, <span class="hlFld-ContribAuthor ">Christian  Buning</span>, <span class="hlFld-ContribAuthor ">Markus  Kohlmann</span>, and <span class="hlFld-ContribAuthor ">Andreas  Lindenschmidt</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Macrocycles As Highly Active Integrin α2β1 Antagonists. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (2)
                                     , 193-198. <a href="https://doi.org/10.1021/ml4004556" title="DOI URL">https://doi.org/10.1021/ml4004556</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml4004556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml4004556%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252BMacrocycles%252BAs%252BHighly%252BActive%252BIntegrin%252B%2525CE%2525B12%2525CE%2525B21%252BAntagonists%26aulast%3DHalland%26aufirst%3DNis%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D12112013%26date%3D08012014%26date%3D10012014%26date%3D13022014%26volume%3D5%26issue%3D2%26spage%3D193%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm400887j&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm400887j%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-2%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=340&amp;pagesCount=4&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0016.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Distribution of oral (green bars, <i>N</i> = 19) and parenteral (red bars, <i>N</i> = 49) macrocyclic drugs across different therapeutic indications (a) and chemical classes (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Distribution of oral (green bar) and parenteral (red bars, <i>N</i> = 29) macrocyclic peptide drugs across different subclasses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Distribution of oral (green bars) and parenteral (red bars) ansamycin and macrolide drugs across different subclasses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Calculated lipophilicity (a, cLogP), polar surface area (b, PSA), and number of hydrogen bond donors (c, HBD) as a function of molecular weight (MW) for oral macrocyclic drugs from the macrolide (cyan) and ansamycin (magenta) classes. Cyclosporin A (black) has been included for comparison.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Daily dose (mg) versus oral bioavailabities (%) for macrocyclic drugs administered orally. Colors indicate the corresponding chemical class (black, cyclic peptide = cyclosporin A; cyan, macrolide; magenta, ansamycin).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Distribution of oral (green bars, <i>N</i> = 15) and parenteral (red bars, <i>N</i> = 20) macrocyclic compounds in clinical development across different therapeutic areas (a) and chemical classes (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Lipophilicity (a, cLogP), polar surface area (b, PSA), and the number of hydrogen bond donors (c, HBD) as a function of molecular weight (MW) for oral macrocycles in clinical studies. Clinical candidates come from the macrolide (cyan), ansamycin (magenta), “de novo designed” (green), and cyclic peptide (black) classes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/medium/jm-2013-00887j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lipophilicity (a, cLogP), polar surface area (b, PSA), and hydrogen bond donor count (c, HBD) as a function of molecular weight (MW) for macrocycles in clinical development and registered macrocyclic drugs. Macrocycles administered orally are in green, and those given parenterally are in red. Solid black boxes indicate preferred molecular property space for oral small molecules (MW < 500, cLogP < 5, PSA < 140, HBD < 5). Dashed black boxes indicate preferred molecular property space for oral macrocycles (MW < 1000, cLogP < 10, PSA < 250, HBD < 5). Cyclosporin A and two analogues in clinical development are the only oral macrocycles outside the dashed space.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-2/jm400887j/production/images/large/jm-2013-00887j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400887j&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78724" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78724" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 87 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Surade, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blundell, T. L.</span><span> </span><span class="NLM_article-title">Structural biology and drug discovery of difficult targets: the limits of ligandability</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.chembiol.2011.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22284353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=42-50&author=S.+Suradeauthor=T.+L.+Blundell&title=Structural+biology+and+drug+discovery+of+difficult+targets%3A+the+limits+of+ligandability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability</span></div><div class="casAuthors">Surade, Sachin; Blundell, Tom L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Over the past decade, researchers in the pharmaceutical industry and academia have made retrospective analyses of successful drug campaigns in order to establish "rules" to guide the selection of new target proteins.  They have identified features that are considered undesirable and some that make targets "unligandable.".  This review focuses on the factors that make targets difficult: featureless binding sites, the lack of hydrogen-bond donors and acceptors, the presence of metal ions, the need for adaptive changes in conformation, and the lipophilicity of residues at the protein-ligand interface.  Protein-protein interfaces of multiprotein assemblies share many of these undesirable features, although those that involve concerted binding and folding in their assembly have better defined pockets or grooves, and these can provide opportunities for identifying hits and for lead optimization.  In some protein-protein interfaces conformational changes-often involving rearrangement of large side chains such as those of tyrosine, tryptophan, or arginine-are required to configure an appropriate binding site, and this may require tethering of the ligands until higher affinity is achieved.  In many enzymes, larger conformational rearrangements are required to form the binding site, and these can make fragment-based approaches particularly difficult.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqCA_OH6VRoLVg90H21EOLACvtfcHk0lh5ujfVjXHdtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crsbc%253D&md5=646b6cad327b44785848375383ca90ea</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DSurade%26aufirst%3DS.%26aulast%3DBlundell%26aufirst%3DT.%2BL.%26atitle%3DStructural%2520biology%2520and%2520drug%2520discovery%2520of%2520difficult%2520targets%253A%2520the%2520limits%2520of%2520ligandability%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D42%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lh5ujfVjXHdtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=191-200&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D11%26spage%3D191%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hann, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span> </span><span class="NLM_article-title">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnrd3701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22543468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=355-365&author=M.+M.+Hannauthor=G.+M.+Keseru&title=Finding+the+sweet+spot%3A+the+role+of+nature+and+nurture+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the sweet spot: the role of nature and nurture in medicinal chemistry</span></div><div class="casAuthors">Hann, Michael M.; Keserue, Gyoergy M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Given its position at the heart of small-mol. drug discovery, medicinal chem. has an important role in tackling the well-known productivity challenges in pharmaceutical research and development.  In recent years, extensive analyses of successful and failed discovery compds. and drug candidates have improved our understanding of the role of physicochem. properties in drug attrition.  Based on the clarified challenges in finding the 'sweet spot' in medicinal chem. programs, we suggest that this goal can be achieved through a combination of first identifying chem. starting points with appropriate 'nature' and then rigorously 'nurturing' them during lead optimization.  Here, we discuss scientific, strategic, organizational and cultural considerations for medicinal chem. practices, with the aim of promoting more effective use of what is already known, as well as a wider appreciation of the risks of pursuing suboptimal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrURciGjB2A3LVg90H21EOLACvtfcHk0lh5ujfVjXHdtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1GqsLY%253D&md5=90170e3f4e69e52bfa38667df380516a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd3701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3701%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DFinding%2520the%2520sweet%2520spot%253A%2520the%2520role%2520of%2520nature%2520and%2520nurture%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D355%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Mallinson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Macrocycles in new drug discovery</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.4155%2Ffmc.12.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22857532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCht7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1409-1438&author=J.+Mallinsonauthor=I.+Collins&title=Macrocycles+in+new+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles in new drug discovery</span></div><div class="casAuthors">Mallinson, Jamie; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1409-1438</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of drug-like macrocycles is emerging as an exciting area of medicinal chem., with several recent examples highlighting the favorable changes in biol. and physicochem. properties that macrocyclization can afford.  Natural product macrocycles and their synthetic derivs. have long been clin. useful and attention is now being focused on the wider use of macrocyclic scaffolds in medicinal chem. in the search for new drugs for increasingly challenging targets.  With the increasing awareness of concepts of drug-likeness and the dangers of mol. obesity', functionalized macrocyclic scaffolds could provide a way to generate ligand-efficient mols. with enhanced properties.  In this review we will sep. discuss the effects of macrocyclization upon potency, selectivity and physicochem. properties, concg. on recent case histories in oncol. drug discovery.  Addnl., we will highlight selected advances in the synthesis of macrocycles and provide an outlook on the future use of macrocyclic scaffolds in medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSrzcbKW7Tc7Vg90H21EOLACvtfcHk0ljlBADS_bL5yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCht7rO&md5=63ad275af92ac89ae6b36c5071b578f8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.93%26sid%3Dliteratum%253Aachs%26aulast%3DMallinson%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMacrocycles%2520in%2520new%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1409%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Driggers, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrett, N. F.</span><span> </span><span class="NLM_article-title">The exploration of macrocycles for drug discovery—an underexploited structural class</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+F.+Terrett&title=The+exploration+of+macrocycles+for+drug+discovery%E2%80%94an+underexploited+structural+class"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BF.%26atitle%3DThe%2520exploration%2520of%2520macrocycles%2520for%2520drug%2520discovery%25E2%2580%2594an%2520underexploited%2520structural%2520class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">DeLorbe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clements, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiddon, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. F.</span><span> </span><span class="NLM_article-title">Thermodynamic and structural effects of macrocyclic constraints in protein-ligand interactions</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">448</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml100142y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A280%3ADC%252BC2srmt1OisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=448-452&author=J.+E.+DeLorbeauthor=J.+H.+Clementsauthor=B.+B.+Whiddonauthor=S.+F.+Martin&title=Thermodynamic+and+structural+effects+of+macrocyclic+constraints+in+protein-ligand+interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Thermodynamic and Structural Effects of Macrocyclization as a Constraining Method in Protein-Ligand Interactions</span></div><div class="casAuthors">Delorbe John E; Clements John H; Whiddon Benjamin B; Martin Stephen F</div><div class="citationInfo"><span class="NLM_cas:title">ACS medicinal chemistry letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">448-452</span>
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    </div><div class="casAbstract">The thermodynamic and structural effects of macrocyclization as a tactic for stabilizing the biologically-active conformation of Grb2 SH2 binding peptides were investigated using isothermal titration calorimetry and x-ray crystallography. 23-Membered macrocycles containing the sequence pYVN were slightly more potent than their linear controls; however, preorganization did not necessarily eventuate in a more favorable binding entropy.  Structures of complexes of macrocycle 7 and its acyclic control 8 are similar except for differences in relative orientations of corresponding atoms in the linking moieties of 7 and 8.  There are no differences in the number of direct or water-mediated protein-ligand contacts that might account for the less favorable binding enthalpy of 7; however, an intramolecular hydrogen bond between the pY and pY+3 residues in 8 that is absent in 7 may be a factor.  These studies highlight the difficulties associated with correlating energetics and structure in protein-ligand interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdL3gvK7FnJAwxfk_AGB-EfW6udTcc2eYyBVjJzZ8Zjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srmt1OisA%253D%253D&md5=bec2aeb7e9127f0f6310dbccf2663c76</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fml100142y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100142y%26sid%3Dliteratum%253Aachs%26aulast%3DDeLorbe%26aufirst%3DJ.%2BE.%26aulast%3DClements%26aufirst%3DJ.%2BH.%26aulast%3DWhiddon%26aufirst%3DB.%2BB.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DThermodynamic%2520and%2520structural%2520effects%2520of%2520macrocyclic%2520constraints%2520in%2520protein-ligand%2520interactions%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D448%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Bogdan, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span> </span><span class="NLM_article-title">Comparison of diffusion coefficients for matched pairs of macrocyclic and linear molecules over a drug-like molecular weight range</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">7727</span><span class="NLM_x">–</span> <span class="NLM_lpage">7733</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=7727-7733&author=A.+R.+Bogdanauthor=N.+L.+Daviesauthor=K.+James&title=Comparison+of+diffusion+coefficients+for+matched+pairs+of+macrocyclic+and+linear+molecules+over+a+drug-like+molecular+weight+range"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBogdan%26aufirst%3DA.%2BR.%26aulast%3DDavies%26aufirst%3DN.%2BL.%26aulast%3DJames%26aufirst%3DK.%26atitle%3DComparison%2520of%2520diffusion%2520coefficients%2520for%2520matched%2520pairs%2520of%2520macrocyclic%2520and%2520linear%2520molecules%2520over%2520a%2520drug-like%2520molecular%2520weight%2520range%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D7727%26epage%3D7733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Marsault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. L.</span><span> </span><span class="NLM_article-title">Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macocycles in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1961</span><span class="NLM_x">–</span> <span class="NLM_lpage">2004</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1012374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1961-2004&author=E.+Marsaultauthor=M.+L.+Peterson&title=Macrocycles+are+great+cycles%3A+applications%2C+opportunities%2C+and+challenges+of+synthetic+macocycles+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm1012374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012374%26sid%3Dliteratum%253Aachs%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26atitle%3DMacrocycles%2520are%2520great%2520cycles%253A%2520applications%252C%2520opportunities%252C%2520and%2520challenges%2520of%2520synthetic%2520macocycles%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1961%26epage%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Schreiber, S. L.</span><span> </span><span class="NLM_article-title">Molecular diversity by design</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">457</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2F457153a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=19129834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=457&publication_year=2009&pages=153-154&author=S.+L.+Schreiber&title=Molecular+diversity+by+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular diversity by design</span></div><div class="casAuthors">Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">457</span>
        (<span class="NLM_cas:issue">7226</span>),
    <span class="NLM_cas:pages">153-154</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many org. syntheses are target-oriented - each multi-step route is designed to make just one compd.  But now a diversity-oriented synthesis can make 80 different mol. skeletons in just a few steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNnW8LJ03ahbVg90H21EOLACvtfcHk0lhI3lOvIbrKqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlSgug%253D%253D&md5=2ddc5e57f47d2e83598e644fb0259245</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F457153a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F457153a%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DMolecular%2520diversity%2520by%2520design%26jtitle%3DNature%26date%3D2009%26volume%3D457%26spage%3D153%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Terrett, N. F.</span><span> </span><span class="NLM_article-title">Methods for the synthesis of macrocycle libraries for drug discovery</span> <span class="citation_source-journal">Drug Discovery Today: Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e97</span><span class="NLM_x">–</span> <span class="NLM_lpage">e104</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.ddtec.2010.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVegsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=e97-e104&author=N.+F.+Terrett&title=Methods+for+the+synthesis+of+macrocycle+libraries+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for the synthesis of macrocycle libraries for drug discovery</span></div><div class="casAuthors">Terrett, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">E97-E104</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Macrocyclic compds. are found widely in nature where they fulfill numerous specific functions.  However, they have been generally under-exploited as drug mols., as they are larger than more conventional rule-of-five (Lepinski's rule of five) compliant mols. and their synthesis and screening has been considered a challenge.  Consequently most pharmaceutical companies have very few macrocyclic compds. in their screening files and, yet, these compds. can have potent and selective pharmacol. activity, and exhibit drug-like properties such as cell membrane permeability and oral bioavailability.  To permit the further investigation of macrocyclic drugs, several groups have developed diverse methods for the rapid synthesis and screening of macrocyclic libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMnUro57zsW7Vg90H21EOLACvtfcHk0lhI3lOvIbrKqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVegsLY%253D&md5=e7968c6c505322bcf07f9d2a3558be1f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2010.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2010.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DTerrett%26aufirst%3DN.%2BF.%26atitle%3DMethods%2520for%2520the%2520synthesis%2520of%2520macrocycle%2520libraries%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2010%26volume%3D7%26spage%3De97%26epage%3De104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Obrecht, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevalier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moehle, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, J. A.</span><span> </span><span class="NLM_article-title">β-Hairpin protein epitope mimetic technology in drug discovery</span> <span class="citation_source-journal">Drug Discovery Today: Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e63</span><span class="NLM_x">–</span> <span class="NLM_lpage">e69</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=e63-e69&author=D.+Obrechtauthor=E.+Chevalierauthor=K.+Moehleauthor=J.+A.+Robinson&title=%CE%B2-Hairpin+protein+epitope+mimetic+technology+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObrecht%26aufirst%3DD.%26aulast%3DChevalier%26aufirst%3DE.%26aulast%3DMoehle%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DJ.%2BA.%26atitle%3D%25CE%25B2-Hairpin%2520protein%2520epitope%2520mimetic%2520technology%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2011%26volume%3D9%26spage%3De63%26epage%3De69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kotz, J.</span><span> </span><span class="NLM_article-title">Bringing macrocycles full circle</span>.  <span class="citation_source-journal">SciBX</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span>, DOI: <span class="refDoi"> DOI: 10.1038/scibx.2012.1176</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fscibx.2012.1176" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&author=J.+Kotz&title=Bringing+macrocycles+full+circle&doi=10.1038%2Fscibx.2012.1176"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fscibx.2012.1176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fscibx.2012.1176%26sid%3Dliteratum%253Aachs%26aulast%3DKotz%26aufirst%3DJ.%26atitle%3DBringing%2520macrocycles%2520full%2520circle%26jtitle%3DSciBX%26date%3D2012%26volume%3D5%26doi%3D10.1038%2Fscibx.2012.1176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Scannell, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanckley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, B.</span><span> </span><span class="NLM_article-title">Diagnosing the decline in pharmaceutical R&D efficiency</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&author=J.+W.+Scannellauthor=A.+Blanckleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+decline+in+pharmaceutical+R%26D+efficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0litWvvExnFluw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%2BW.%26aulast%3DBlanckley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520decline%2520in%2520pharmaceutical%2520R%2526D%2520efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D191%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Bunnage, M. E.</span><span> </span><span class="NLM_article-title">Getting pharmaceutical R&D back on track</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnchembio.581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=21587251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtF2lur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=335-339&author=M.+E.+Bunnage&title=Getting+pharmaceutical+R%26D+back+on+track"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Getting pharmaceutical R&D back on target</span></div><div class="casAuthors">Bunnage, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">335-339</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry is in a period of crisis due to the low no. of new drug approvals relative to the high levels of R&D investment.  It is argued here that improving the quality of target selection is the single most important factor to transform industry productivity and bring innovative new medicines to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyfBkdRkjR8LVg90H21EOLACvtfcHk0litWvvExnFluw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtF2lur4%253D&md5=458abeefd10325afc74b5ced717d3b40</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.581%26sid%3Dliteratum%253Aachs%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26atitle%3DGetting%2520pharmaceutical%2520R%2526D%2520back%2520on%2520track%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D335%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Knox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frolkis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banco, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neveu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djoumbou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, D. S.</span><span> </span><span class="NLM_article-title">DrugBank 3.0: a comprehensive resource for “omics” research on drugs</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">D1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">D1041</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=D1035-D1041&author=C.+Knoxauthor=V.+Lawauthor=T.+Jewisonauthor=P.+Liuauthor=S.+Lyauthor=A.+Frolkisauthor=A.+Ponauthor=K.+Bancoauthor=C.+Makauthor=V.+Neveuauthor=Y.+Djoumbouauthor=R.+Eisnerauthor=A.+C.+Guoauthor=D.+S.+Wishart&title=DrugBank+3.0%3A+a+comprehensive+resource+for+%E2%80%9Comics%E2%80%9D+research+on+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DC.%26aulast%3DLaw%26aufirst%3DV.%26aulast%3DJewison%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DLy%26aufirst%3DS.%26aulast%3DFrolkis%26aufirst%3DA.%26aulast%3DPon%26aufirst%3DA.%26aulast%3DBanco%26aufirst%3DK.%26aulast%3DMak%26aufirst%3DC.%26aulast%3DNeveu%26aufirst%3DV.%26aulast%3DDjoumbou%26aufirst%3DY.%26aulast%3DEisner%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DA.%2BC.%26aulast%3DWishart%26aufirst%3DD.%2BS.%26atitle%3DDrugBank%25203.0%253A%2520a%2520comprehensive%2520resource%2520for%2520%25E2%2580%259Comics%25E2%2580%259D%2520research%2520on%2520drugs%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2011%26volume%3D39%26spage%3DD1035%26epage%3DD1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span>Thomson Reuters Integrity. <a href="http://integrity.prous.com" class="extLink">http://integrity.prous.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Thomson+Reuters+Integrity.+http%3A%2F%2Fintegrity.prous.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span>About GOSTAR. <a href="http://gostardb.com/gostar/doc/HyperlinkDownloadPDF.pdf" class="extLink">http://gostardb.com/gostar/doc/HyperlinkDownloadPDF.pdf</a> (accessed in April,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=About+GOSTAR.+http%3A%2F%2Fgostardb.com%2Fgostar%2Fdoc%2FHyperlinkDownloadPDF.pdf+%28accessed+in+April%2C+2013%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Cumming, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirrette, A.</span><span> </span><span class="NLM_article-title">Better compounds faster: the development and exploitation of a desktop predictive chemistry toolkit</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span><span class="NLM_x">–</span> <span class="NLM_lpage">927</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=923-927&author=J.+G.+Cummingauthor=J.+Winterauthor=A.+Poirrette&title=Better+compounds+faster%3A+the+development+and+exploitation+of+a+desktop+predictive+chemistry+toolkit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DWinter%26aufirst%3DJ.%26aulast%3DPoirrette%26aufirst%3DA.%26atitle%3DBetter%2520compounds%2520faster%253A%2520the%2520development%2520and%2520exploitation%2520of%2520a%2520desktop%2520predictive%2520chemistry%2520toolkit%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D923%26epage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="note"><p class="first last">In this analysis drugs were annotated as oral if they were administered orally and required systemic exposure to exert their effect. Drugs delivered by all other routes were classified as parenteral. Drugs delivered orally that exert their pharmacological action in the gastrointestinal tract, without the need for systemic absorption, were included in the parenteral class.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span>Adis. <a href="http://www.springer.com/adis/databases?SGWID=0-1749113-0-0-0" class="extLink">http://www.springer.com/adis/databases?SGWID=0-1749113-0-0-0</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Adis.+http%3A%2F%2Fwww.springer.com%2Fadis%2Fdatabases%3FSGWID%3D0-1749113-0-0-0."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ptachcinski, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burckart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataramanan, R.</span><span> </span><span class="NLM_article-title">Cyclosporine</span> <span class="citation_source-journal">Drug Intell. Clin. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=3882378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADyaL2MXht1CqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1985&pages=90-100&author=R.+J.+Ptachcinskiauthor=G.+J.+Burckartauthor=R.+Venkataramanan&title=Cyclosporine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporine</span></div><div class="casAuthors">Ptachcinski, Richard J.; Burckart, Gilbert J.; Venkataramanan, Raman</div><div class="citationInfo"><span class="NLM_cas:title">Drug Intelligence & Clinical Pharmacy</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">90-100</span>CODEN:
                <span class="NLM_cas:coden">DICPBB</span>;
        ISSN:<span class="NLM_cas:issn">0012-6578</span>.
    </div><div class="casAbstract">A review with 114 refs. of the pharmacol., pharmacokinetics, clin. use, toxicity, and drug interaction of the immunosuppressant, cyclosporin  [79217-60-0].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDc8LUB5zyULVg90H21EOLACvtfcHk0licG36PwSV4-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXht1CqsLg%253D&md5=3344619d849b258dc951e3ea35b6e5c1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPtachcinski%26aufirst%3DR.%2BJ.%26aulast%3DBurckart%26aufirst%3DG.%2BJ.%26aulast%3DVenkataramanan%26aufirst%3DR.%26atitle%3DCyclosporine%26jtitle%3DDrug%2520Intell.%2520Clin.%2520Pharm.%26date%3D1985%26volume%3D19%26spage%3D90%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Fahr, A.</span><span> </span><span class="NLM_article-title">Cyclosporin clinical pharmacokinetics</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">495</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1993&pages=472-495&author=A.+Fahr&title=Cyclosporin+clinical+pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahr%26aufirst%3DA.%26atitle%3DCyclosporin%2520clinical%2520pharmacokinetics%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1993%26volume%3D24%26spage%3D472%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Fricker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huwyler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beglinger, C.</span><span> </span><span class="NLM_article-title">Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro–in vivo correlation</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">1841</span><span class="NLM_x">–</span> <span class="NLM_lpage">1847</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1111%2Fj.1476-5381.1996.tb15612.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=8842452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADyaK28XkvVartrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=1841-1847&author=G.+Frickerauthor=J.+Dreweauthor=J.+Huwylerauthor=H.+Gutmannauthor=C.+Beglinger&title=Relevance+of+p-glycoprotein+for+the+enteral+absorption+of+cyclosporin+A%3A+in+vitro%E2%80%93in+vivo+correlation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation</span></div><div class="casAuthors">Fricker, G.; Drewe, J.; Huwyler, J.; Gutmann, H.; Beglinger, C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1841-1847</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The interaction of cyclosporin A (CyA) with p-glycoprotein during intestinal uptake was investigated by a combination of in vitro expts. with human Caco-2 cells and an intubation study in healthy volunteers.  CyA uptake into the cells was not saturable and exhibited only a low, temp. sensitivity, suggesting passive diffusion.  When the permeation of CyA across Caco-2 monolayers from the apical to the basolateral side was detd., overall transport had an apparently saturable component up to a concn. of 1 μM.  At higher concns. permeation increased over-proportionally.  Calcn. of the kinetic parameters of apical to basolateral permeation suggested a diffusional process with a KD of 0.5 μl min-1 per filter, which was overlayed by an active system in basolateral to apical direction with a KM of 3.8 μM and a Jmax of 6.5 picomol min-1 per filter.  CyA permeation was significantly higher when the drug was given from the basolateral side as compared to the permeation from the apical side.  Apical to basolateral transport of CyA was increased in the presence of vinblastine, daunomycin and a non-immunosuppressive CyA-deriv.  All compds. inhibit p-glycoprotein-mediated transport processes.  Basolateral to apical permeation of CyA showed a dose-dependent decrease in the presence of vinblastine.  Permeation of daunomycin across Caco-2 cell monolayers was also higher from the basolateral to the apical side than vice versa.  Basolateral to apical permeation was decreased in the presence of SDZ PSC 833 and cyclosporin A.  Western blot anal. of Caco-2 cells with the monoclonal antibody C219 confirmed the presence of p-glycoprotein in the used cell system.  When the absorption of CyA in the gastrointestinal (GI)-tract of healthy volunteers was detd., a remarkable decrease of the plasma AUC could be obsd. dependent on the location of absorption in the rank order stomach>jejunum/ileum>colon.  The decrease in absorption exhibited a marked correlation (r = 0.994) to the expression of mRNA for p-glycoprotein over the GI-tract (stomach<jejunum<colon).  All data provide evidence that CyA is a substrate of p-glycoprotein in the GI-tract, which might explain the local differences and the high variability in cyclosporin absorption found in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXilC3zqeAg7Vg90H21EOLACvtfcHk0licG36PwSV4-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XkvVartrY%253D&md5=02465aba23808c65ec6ed98f4ceaaebc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1996.tb15612.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1996.tb15612.x%26sid%3Dliteratum%253Aachs%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DDrewe%26aufirst%3DJ.%26aulast%3DHuwyler%26aufirst%3DJ.%26aulast%3DGutmann%26aufirst%3DH.%26aulast%3DBeglinger%26aufirst%3DC.%26atitle%3DRelevance%2520of%2520p-glycoprotein%2520for%2520the%2520enteral%2520absorption%2520of%2520cyclosporin%2520A%253A%2520in%2520vitro%25E2%2580%2593in%2520vivo%2520correlation%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D118%26spage%3D1841%26epage%3D1847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Fatouros, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karpf, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullertz, A.</span><span> </span><span class="NLM_article-title">Clinical studies with oral lipid based formulations of poorly soluble compounds</span> <span class="citation_source-journal">Ther. Clin. Risk Manage.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=18472981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyjtL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=591-604&author=D.+M.+Fatourosauthor=D.+M.+Karpfauthor=F.+S.+Nielsenauthor=A.+Mullertz&title=Clinical+studies+with+oral+lipid+based+formulations+of+poorly+soluble+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical studies with oral lipid based formulations of poorly soluble compounds</span></div><div class="casAuthors">Fatouros, Dimitrios G.; Karpf, Ditte M.; Nielsen, Flemming S.; Mullertz, Anette</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-604</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  This work is an attempt to give an overview of the clin. data available on lipid based formulations.  Lipid and surfactant based formulations are recognized as a feasible approach to improve bioavailability of poorly sol. compds.  However not many clin. studies have been published so far.  Several drug products intended for oral administration have been marketed utilizing lipid and surfactant based formulations.  Sandimmune and Sandimmune Neoral (cyclosporin A, Novartis), Norvir (ritonavir), and Fortovase (saquinavir) have been formulated in self-emulsifying drug delivery systems (SEDDS).  This review summarizes published pharmacokinetic studies of orally administered lipid based formulations of poorly aq. sol. drugs in human subjects.  Special attention has been paid to the physicochem. characteristics of the formulations, when available and the impact of these properties on the in vivo performance of the formulation.  Equally important is the effect of concurrent food intake on the bioavailability of poorly sol. compds.  The effect of food on the bioavailability of compds. formulated in lipid and surfactant based formulations is also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOHIorI1YP8rVg90H21EOLACvtfcHk0lhKPzIxANdJhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyjtL7J&md5=1d57e5ca229b6c4b7888cb61c7ad49fb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFatouros%26aufirst%3DD.%2BM.%26aulast%3DKarpf%26aufirst%3DD.%2BM.%26aulast%3DNielsen%26aufirst%3DF.%2BS.%26aulast%3DMullertz%26aufirst%3DA.%26atitle%3DClinical%2520studies%2520with%2520oral%2520lipid%2520based%2520formulations%2520of%2520poorly%2520soluble%2520compounds%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2007%26volume%3D3%26spage%3D591%26epage%3D604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">El Tayar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallat, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunne, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gunsteren, W. F.</span><span> </span><span class="NLM_article-title">Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3757</span><span class="NLM_x">–</span> <span class="NLM_lpage">3764</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00076a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3757-3764&author=N.+El+Tayarauthor=A.+E.+Markauthor=P.+Vallatauthor=R.+M.+Brunneauthor=B.+Testaauthor=W.+F.+van+Gunsteren&title=Solvent-dependent+conformation+and+hydrogen-bonding+capacity+of+cyclosporin+A%3A+evidence+from+partition+coefficients+and+molecular+dynamics+simulations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm00076a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00076a002%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BTayar%26aufirst%3DN.%26aulast%3DMark%26aufirst%3DA.%2BE.%26aulast%3DVallat%26aufirst%3DP.%26aulast%3DBrunne%26aufirst%3DR.%2BM.%26aulast%3DTesta%26aufirst%3DB.%26aulast%3Dvan%2BGunsteren%26aufirst%3DW.%2BF.%26atitle%3DSolvent-dependent%2520conformation%2520and%2520hydrogen-bonding%2520capacity%2520of%2520cyclosporin%2520A%253A%2520evidence%2520from%2520partition%2520coefficients%2520and%2520molecular%2520dynamics%2520simulations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D3757%26epage%3D3764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Alex, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakenhut, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitlock, G. A.</span><span> </span><span class="NLM_article-title">Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">669</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1039%2Fc1md00093d" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=669-674&author=A.+Alexauthor=D.+S.+Millanauthor=M.+Perezauthor=F.+Wakenhutauthor=G.+A.+Whitlock&title=Intramolecular+hydrogen+bonding+to+improve+membrane+permeability+and+absorption+in+beyond+rule+of+five+chemical+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fc1md00093d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00093d%26sid%3Dliteratum%253Aachs%26aulast%3DAlex%26aufirst%3DA.%26aulast%3DMillan%26aufirst%3DD.%2BS.%26aulast%3DPerez%26aufirst%3DM.%26aulast%3DWakenhut%26aufirst%3DF.%26aulast%3DWhitlock%26aufirst%3DG.%2BA.%26atitle%3DIntramolecular%2520hydrogen%2520bonding%2520to%2520improve%2520membrane%2520permeability%2520and%2520absorption%2520in%2520beyond%2520rule%2520of%2520five%2520chemical%2520space%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D669%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Knipp, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Velde, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siahaan, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borchardt, R. T.</span><span> </span><span class="NLM_article-title">The effect of β-turn structure on the passive diffusion of peptides across Caco-2 cell monolayers</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1332</span><span class="NLM_x">–</span> <span class="NLM_lpage">1340</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=1332-1340&author=G.+T.+Knippauthor=G.+D.+Vander+Veldeauthor=T.+J.+Siahaanauthor=R.+T.+Borchardt&title=The+effect+of+%CE%B2-turn+structure+on+the+passive+diffusion+of+peptides+across+Caco-2+cell+monolayers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnipp%26aufirst%3DG.%2BT.%26aulast%3DVander%2BVelde%26aufirst%3DG.%2BD.%26aulast%3DSiahaan%26aufirst%3DT.%2BJ.%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26atitle%3DThe%2520effect%2520of%2520%25CE%25B2-turn%2520structure%2520on%2520the%2520passive%2520diffusion%2520of%2520peptides%2520across%2520Caco-2%2520cell%2520monolayers%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D1332%26epage%3D1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Okumu, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauletti, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Velde, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siahaan, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borchardt, R. T.</span><span> </span><span class="NLM_article-title">Effect of restricted conformational flexibility on the permeation of model hexapeptides across Caco-2 cell monolayers</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">175</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=169-175&author=F.+W.+Okumuauthor=G.+M.+Paulettiauthor=G.+D.+Vander+Veldeauthor=T.+J.+Siahaanauthor=R.+T.+Borchardt&title=Effect+of+restricted+conformational+flexibility+on+the+permeation+of+model+hexapeptides+across+Caco-2+cell+monolayers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkumu%26aufirst%3DF.%2BW.%26aulast%3DPauletti%26aufirst%3DG.%2BM.%26aulast%3DVander%2BVelde%26aufirst%3DG.%2BD.%26aulast%3DSiahaan%26aufirst%3DT.%2BJ.%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26atitle%3DEffect%2520of%2520restricted%2520conformational%2520flexibility%2520on%2520the%2520permeation%2520of%2520model%2520hexapeptides%2520across%2520Caco-2%2520cell%2520monolayers%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D169%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Rezai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalyanaraman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, M. P.</span><span> </span><span class="NLM_article-title">Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">14073</span><span class="NLM_x">–</span> <span class="NLM_lpage">14080</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja063076p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCmur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=14073-14080&author=T.+Rezaiauthor=J.+E.+Bockauthor=M.+V.+Zhouauthor=C.+Kalyanaramanauthor=R.+S.+Lokeyauthor=M.+P.+Jacobsen&title=Conformational+flexibility%2C+internal+hydrogen+bonding%2C+and+passive+membrane+permeability%3A+successful+in+silico+prediction+of+the+relative+permeabilities+of+cyclic+peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Flexibility, Internal Hydrogen Bonding, and Passive Membrane Permeability: Successful in Silico Prediction of the Relative Permeabilities of Cyclic Peptides</span></div><div class="casAuthors">Rezai, Taha; Bock, Jonathan E.; Zhou, Mai V.; Kalyanaraman, Chakrapani; Lokey, R. Scott; Jacobson, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">14073-14080</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report an atomistic phys. model for the passive membrane permeability of cyclic peptides.  The computational modeling was performed in advance of the expts. and did not involve the use of "training data".  The model explicitly treats the conformational flexibility of the peptides by extensive conformational sampling in low (membrane) and high (water) dielec. environments.  The passive membrane permeabilities of 11 cyclic peptides were obtained exptl. using a parallel artificial membrane permeability assay (PAMPA) and showed a linear correlation with the computational results with R2 = 0.96.  In general, the results support the hypothesis, already well established in the literature, that the ability to form internal hydrogen bonds is crit. for passive membrane permeability and can be the distinguishing factor among closely related compds., such as those studied here.  However, we have found that the no. of internal hydrogen bonds that can form in the membrane and the solvent-exposed polar surface area correlate more poorly with PAMPA permeability than our model, which quant. ests. the solvation free energy losses upon moving from high-dielec. water to the low-dielec. interior of a membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofxfL018o86rVg90H21EOLACvtfcHk0lhKPzIxANdJhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCmur3I&md5=78d4b4082e6a72b288d4b6dac933ca35</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja063076p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja063076p%26sid%3Dliteratum%253Aachs%26aulast%3DRezai%26aufirst%3DT.%26aulast%3DBock%26aufirst%3DJ.%2BE.%26aulast%3DZhou%26aufirst%3DM.%2BV.%26aulast%3DKalyanaraman%26aufirst%3DC.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26aulast%3DJacobsen%26aufirst%3DM.%2BP.%26atitle%3DConformational%2520flexibility%252C%2520internal%2520hydrogen%2520bonding%252C%2520and%2520passive%2520membrane%2520permeability%253A%2520successful%2520in%2520silico%2520prediction%2520of%2520the%2520relative%2520permeabilities%2520of%2520cyclic%2520peptides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D14073%26epage%3D14080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Guimaraes, C. R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalaeva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span> </span><span class="NLM_article-title">Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci300010y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlGlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=882-890&author=C.+R.+W.+Guimaraesauthor=A.+M.+Mathiowetzauthor=M.+Shalaevaauthor=G.+Goetzauthor=S.+Liras&title=Use+of+3D+properties+to+characterize+beyond+rule-of-5+property+space+for+passive+permeation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Use of 3D Properties to Characterize Beyond Rule-of-5 Property Space for Passive Permeation</span></div><div class="casAuthors">Guimaraes, Cristiano R. W.; Mathiowetz, Alan M.; Shalaeva, Marina; Goetz, Gilles; Liras, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">882-890</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The application of conformationally dependent measures of size and polarity to characterize beyond rule-of-5 (Ro5) space for passive permeation was investigated.  Specifically, radius of gyration, an alternative to mol. wt., and three-dimensional polar surface area and the generalized Born/surface area dehydration free energy, alternatives to hydrogen-bond donor and acceptor counts, were computed on models of the permeating conformations of over 35 000 mols.  The resulting guidelines for size and polarity, described by the 3D properties, should aid the design of Ro5 violators with passive permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-wXo2cwYEvrVg90H21EOLACvtfcHk0ljVVz9DZhCOnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlGlurc%253D&md5=823a9f943cbcdfa9cd2bdeb3a803a4eb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fci300010y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300010y%26sid%3Dliteratum%253Aachs%26aulast%3DGuimaraes%26aufirst%3DC.%2BR.%2BW.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DShalaeva%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DUse%2520of%25203D%2520properties%2520to%2520characterize%2520beyond%2520rule-of-5%2520property%2520space%2520for%2520passive%2520permeation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D882%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">White, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzelman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rand, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEwen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelev, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linington, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span> </span><span class="NLM_article-title">On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnchembio.664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=21946276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1anurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=810-817&author=T.+R.+Whiteauthor=C.+M.+Renzelmanauthor=A.+C.+Randauthor=T.+Rezaiauthor=C.+M.+McEwenauthor=V.+M.+Gelevauthor=R.+A.+Turnerauthor=R.+G.+Liningtonauthor=S.+S.+F.+Leungauthor=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=Y.+Zhangauthor=S.+Lirasauthor=D.+A.+Priceauthor=A.+M.+Mathiowetzauthor=M.+P.+Jacobsenauthor=R.+S.+Lokey&title=On-resin+N-methylation+of+cyclic+peptides+for+discovery+of+orally+bioavailable+scaffolds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds</span></div><div class="casAuthors">White, Tina R.; Renzelman, Chad M.; Rand, Arthur C.; Rezai, Taha; McEwen, Cayla M.; Gelev, Vladimir M.; Turner, Rushia A.; Linington, Roger G.; Leung, Siegfried S. F.; Kalgutkar, Amit S.; Bauman, Jonathan N.; Zhang, Yizhong; Liras, Spiros; Price, David A.; Mathiowetz, Alan M.; Jacobson, Matthew P.; Lokey, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">810-817</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Backbone N-methylation is common among peptide natural products and has a substantial impact on both the phys. properties and the conformational states of cyclic peptides.  However, the specific impact of N-methylation on passive membrane diffusion in cyclic peptides has not been investigated systematically.  Here we report a method for the selective, on-resin N-methylation of cyclic peptides to generate compds. with drug-like membrane permeability and oral bioavailability.  The selectivity and degree of N-methylation of the cyclic peptide was dependent on backbone stereochem., suggesting that conformation dictates the regiochem. of the N-methylation reaction.  The permeabilities of the N-Me variants were corroborated by computational studies on a 1024-member virtual library of N-Me cyclic peptides.  One of the most permeable compds., a cyclic hexapeptide (mol. mass = 755 Da) with three N-Me groups, showed an oral bioavailability of 28% in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreigsRodBtOLVg90H21EOLACvtfcHk0ljVVz9DZhCOnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1anurjL&md5=6f9f01f4ab523bb46cc0198cc8f1c34e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.664%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DT.%2BR.%26aulast%3DRenzelman%26aufirst%3DC.%2BM.%26aulast%3DRand%26aufirst%3DA.%2BC.%26aulast%3DRezai%26aufirst%3DT.%26aulast%3DMcEwen%26aufirst%3DC.%2BM.%26aulast%3DGelev%26aufirst%3DV.%2BM.%26aulast%3DTurner%26aufirst%3DR.%2BA.%26aulast%3DLinington%26aufirst%3DR.%2BG.%26aulast%3DLeung%26aufirst%3DS.%2BS.%2BF.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DJacobsen%26aufirst%3DM.%2BP.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26atitle%3DOn-resin%2520N-methylation%2520of%2520cyclic%2520peptides%2520for%2520discovery%2520of%2520orally%2520bioavailable%2520scaffolds%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D810%26epage%3D817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Beck, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiran, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ovadia, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span> </span><span class="NLM_article-title">Intestinal permeability of cyclic peptides: common key backbone motifs identified</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">12125</span><span class="NLM_x">–</span> <span class="NLM_lpage">12133</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja303200d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1Cisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=12125-12133&author=J.+G.+Beckauthor=J.+Chatterjeeauthor=B.+Lauferauthor=M.+U.+Kiranauthor=A.+O.+Frankauthor=S.+Neubauerauthor=O.+Ovadiaauthor=S.+Greenbergauthor=C.+Gilonauthor=A.+Hoffmanauthor=H.+Kessler&title=Intestinal+permeability+of+cyclic+peptides%3A+common+key+backbone+motifs+identified"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal Permeability of Cyclic Peptides: Common Key Backbone Motifs Identified</span></div><div class="casAuthors">Beck, Johannes G.; Chatterjee, Jayanta; Laufer, Burkhardt; Kiran, Marelli Udaya; Frank, Andreas O.; Neubauer, Stefanie; Ovadia, Oded; Greenberg, Sarit; Gilon, Chaim; Hoffman, Amnon; Kessler, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">12125-12133</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Insufficient oral bioavailability is considered as a key limitation for the widespread development of peptides as therapeutics.  While the oral bioavailability of small org. compds. is often estd. from simple rules, similar rules do not apply to peptides, and even the high oral bioavailability that is described for a small no. of peptides is not well understood.  Here we present two highly Caco-2 permeable template structures based on a library of 54 cyclo(-d-Ala-Ala5-) peptides with different N-methylation patterns.  The first all-trans template structure possesses two β-turns of type II along Ala6-d-Ala1 and Ala3-Ala4 and is only found for one peptide with two N-Me groups at d-Ala1 and Ala6 [NMe(1,6)].  The second single-cis template possesses a characteristic cis peptide bond preceding Ala5, which results in type VI β-turn geometry along Ala4-Ala5.  Although the second template structure is found in seven peptides carrying N-Me groups on Ala5, high Caco-2 permeability is only found for a subgroup of two of them [NMe(1,5) and NMe(1,2,4,5)], suggesting that N-methylation of d-Ala1 is a prerequisite for high permeability of the second template structure.  The structural similarity of the second template structure with the orally bioavailable somatostatin analog cyclo(-Pro-Phe-NMe-d-Trp-NMe-Lys-Thr-NMe-Phe-), and the striking resemblance with both β-turns of the orally bioavailable peptide cyclosporine A, suggests that the introduction of bioactive sequences on the highly Caco-2 permeable templates may result in potent orally bioavailable drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4AC8OVfXJMbVg90H21EOLACvtfcHk0lhFDm1LaXCT3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1Cisbw%253D&md5=ecf4dc5aa62a8ebb7c5cc99e8009f528</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fja303200d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja303200d%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DJ.%2BG.%26aulast%3DChatterjee%26aufirst%3DJ.%26aulast%3DLaufer%26aufirst%3DB.%26aulast%3DKiran%26aufirst%3DM.%2BU.%26aulast%3DFrank%26aufirst%3DA.%2BO.%26aulast%3DNeubauer%26aufirst%3DS.%26aulast%3DOvadia%26aufirst%3DO.%26aulast%3DGreenberg%26aufirst%3DS.%26aulast%3DGilon%26aufirst%3DC.%26aulast%3DHoffman%26aufirst%3DA.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DIntestinal%2520permeability%2520of%2520cyclic%2520peptides%253A%2520common%2520key%2520backbone%2520motifs%2520identified%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D12125%26epage%3D12133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Zhanel, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dueck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoban, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vercaigne, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Embil, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlowsky, J. A.</span><span> </span><span class="NLM_article-title">Review of macrolides and ketolides. Focus on respiratory tract infections</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=443-498&author=G.+G.+Zhanelauthor=M.+Dueckauthor=D.+J.+Hobanauthor=L.+M.+Vercaigneauthor=J.+M.+Embilauthor=A.+S.+Ginauthor=J.+A.+Karlowsky&title=Review+of+macrolides+and+ketolides.+Focus+on+respiratory+tract+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DDueck%26aufirst%3DM.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26aulast%3DVercaigne%26aufirst%3DL.%2BM.%26aulast%3DEmbil%26aufirst%3DJ.%2BM.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DReview%2520of%2520macrolides%2520and%2520ketolides.%2520Focus%2520on%2520respiratory%2520tract%2520infections%26jtitle%3DDrugs%26date%3D2001%26volume%3D61%26spage%3D443%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Defining optimum lipophilicity and molecular weight ranges for drug candidates—molecular weight dependent lower logD limits based on permeability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2844</span><span class="NLM_x">–</span> <span class="NLM_lpage">2851</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2844-2851&author=M.+J.+Waring&title=Defining+optimum+lipophilicity+and+molecular+weight+ranges+for+drug+candidates%E2%80%94molecular+weight+dependent+lower+logD+limits+based+on+permeability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DDefining%2520optimum%2520lipophilicity%2520and%2520molecular%2520weight%2520ranges%2520for%2520drug%2520candidates%25E2%2580%2594molecular%2520weight%2520dependent%2520lower%2520logD%2520limits%2520based%2520on%2520permeability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2844%26epage%3D2851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Egan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merz, J., K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J. J.</span><span> </span><span class="NLM_article-title">Prediction of drug absorption using multivariate statistics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3877</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000292e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3867-3877&author=W.+J.+Eganauthor=J.%2C+K.+M.+Merzauthor=J.+J.+Baldwin&title=Prediction+of+drug+absorption+using+multivariate+statistics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Absorption Using Multivariate Statistics</span></div><div class="casAuthors">Egan, William J.; Merz, Kenneth M. Jr.; Baldwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3867-3877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Literature data on compds. both well- and poorly-absorbed in humans were used to build a statistical pattern recognition model of passive intestinal absorption.  Robust outlier detection was utilized to analyze the well-absorbed compds., some of which were intermingled with the poorly-absorbed compds. in the model space.  Outliers were identified as being actively transported.  The descriptors chosen for inclusion in the model were PSA and AlogP98, based on consideration of the phys. processes involved in membrane permeability and the interrelationships and redundancies between available descriptors.  These descriptors are quite straightforward for a medicinal chemist to interpret, enhancing the utility of the model.  Mol. wt., while often used in passive absorption models, was shown to be superfluous, as it is already a component of both PSA and AlogP98.  Extensive validation of the model on hundreds of known orally delivered drugs, "drug-like" mols., and Pharmacopeia, Inc. compds., which had been assayed for Caco-2 cell permeability, demonstrated a good rate of successful predictions (74-92%, depending on the dataset and exact criterion used).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZF9e_GNz8LVg90H21EOLACvtfcHk0lhFDm1LaXCT3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D&md5=44f909ad1fd6187840921e7f07497b4e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm000292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000292e%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DW.%2BJ.%26aulast%3DMerz%26aufirst%3DJ.%252C%2BK.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520drug%2520absorption%2520using%2520multivariate%2520statistics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3867%26epage%3D3877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.-Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lhFDm1LaXCT3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.-Y.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Marchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montecchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venturini, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascellan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brufani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellai, L.</span><span> </span><span class="NLM_article-title">4-Deoxypyrido[1′,2′:1,2]imidazo[5,4-<i>c</i>]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">960</span><span class="NLM_x">–</span> <span class="NLM_lpage">963</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00145a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1985&pages=960-963&author=E.+Marchiauthor=L.+Montecchiauthor=A.+P.+Venturiniauthor=G.+Mascellanauthor=M.+Brufaniauthor=L.+Cellai&title=4-Deoxypyrido%5B1%E2%80%B2%2C2%E2%80%B2%3A1%2C2%5Dimidazo%5B5%2C4-c%5Drifamycin+SV+derivatives.+A+new+series+of+semisynthetic+rifamycins+with+high+antibacterial+activity+and+low+gastroenteric+absorption"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm00145a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00145a020%26sid%3Dliteratum%253Aachs%26aulast%3DMarchi%26aufirst%3DE.%26aulast%3DMontecchi%26aufirst%3DL.%26aulast%3DVenturini%26aufirst%3DA.%2BP.%26aulast%3DMascellan%26aufirst%3DG.%26aulast%3DBrufani%26aufirst%3DM.%26aulast%3DCellai%26aufirst%3DL.%26atitle%3D4-Deoxypyrido%255B1%25E2%2580%25B2%252C2%25E2%2580%25B2%253A1%252C2%255Dimidazo%255B5%252C4-c%255Drifamycin%2520SV%2520derivatives.%2520A%2520new%2520series%2520of%2520semisynthetic%2520rifamycins%2520with%2520high%2520antibacterial%2520activity%2520and%2520low%2520gastroenteric%2520absorption%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1985%26volume%3D28%26spage%3D960%26epage%3D963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Brufani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cellai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerrini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedeli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaciago, A.</span><span> </span><span class="NLM_article-title">X-ray crystal structure of 4-deoxy-3′-bromopyrido[1′,2′-1,2]imidazo[5,4-<i>c</i>]rifamycin SV</span> <span class="citation_source-journal">J. Antibiot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1623</span><span class="NLM_x">–</span> <span class="NLM_lpage">1627</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1984&pages=1623-1627&author=M.+Brufaniauthor=L.+Cellaiauthor=S.+Cerriniauthor=W.+Fedeliauthor=E.+Marchiauthor=A.+Segreauthor=A.+Vaciago&title=X-ray+crystal+structure+of+4-deoxy-3%E2%80%B2-bromopyrido%5B1%E2%80%B2%2C2%E2%80%B2-1%2C2%5Dimidazo%5B5%2C4-c%5Drifamycin+SV"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrufani%26aufirst%3DM.%26aulast%3DCellai%26aufirst%3DL.%26aulast%3DCerrini%26aufirst%3DS.%26aulast%3DFedeli%26aufirst%3DW.%26aulast%3DMarchi%26aufirst%3DE.%26aulast%3DSegre%26aufirst%3DA.%26aulast%3DVaciago%26aufirst%3DA.%26atitle%3DX-ray%2520crystal%2520structure%2520of%25204-deoxy-3%25E2%2580%25B2-bromopyrido%255B1%25E2%2580%25B2%252C2%25E2%2580%25B2-1%252C2%255Dimidazo%255B5%252C4-c%255Drifamycin%2520SV%26jtitle%3DJ.%2520Antibiot.%26date%3D1984%26volume%3D37%26spage%3D1623%26epage%3D1627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Pirsch, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deierhoi, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filo, R. S.</span><span> </span><span class="NLM_article-title">A comparison of tacrolimus (Fk506) and cyclosporine for immunosuppression after cadaveric renal transplantation</span> <span class="citation_source-journal">Transplantation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">983</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1997&pages=977-983&author=J.+D.+Pirschauthor=J.+Millerauthor=M.+H.+Deierhoiauthor=F.+Vincentiauthor=R.+S.+Filo&title=A+comparison+of+tacrolimus+%28Fk506%29+and+cyclosporine+for+immunosuppression+after+cadaveric+renal+transplantation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPirsch%26aufirst%3DJ.%2BD.%26aulast%3DMiller%26aufirst%3DJ.%26aulast%3DDeierhoi%26aufirst%3DM.%2BH.%26aulast%3DVincenti%26aufirst%3DF.%26aulast%3DFilo%26aufirst%3DR.%2BS.%26atitle%3DA%2520comparison%2520of%2520tacrolimus%2520%2528Fk506%2529%2520and%2520cyclosporine%2520for%2520immunosuppression%2520after%2520cadaveric%2520renal%2520transplantation%26jtitle%3DTransplantation%26date%3D1997%26volume%3D63%26spage%3D977%26epage%3D983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagaya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuchi, T.</span><span> </span><span class="NLM_article-title">Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients</span> <span class="citation_source-journal">Transplant. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1732</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.transproceed.2005.02.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Crs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=1730-1732&author=H.+Tadaauthor=N.+Tsuchiyaauthor=S.+Satohauthor=H.+Kagayaauthor=Z.+Liauthor=K.+Satoauthor=M.+Miuraauthor=T.+Suzukiauthor=T.+Katoauthor=T.+Habuchi&title=Impact+of+CYP3A5+and+MDR1%28ABCB1%29+C3435T+polymorphisms+on+the+pharmacokinetics+of+tacrolimus+in+renal+transplant+recipients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of CYP3A5 and MDR1(ABCB1) C3435T Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients</span></div><div class="casAuthors">Tada, H.; Tsuchiya, N.; Satoh, S.; Kagaya, H.; Li, Z.; Sato, K.; Miura, M.; Suzuki, T.; Kato, T.; Habuchi, T.</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation Proceedings</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1730-1732</span>CODEN:
                <span class="NLM_cas:coden">TRPPA8</span>;
        ISSN:<span class="NLM_cas:issn">0041-1345</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: The objective of this study was to assess the influence of CYP3A5 and MDR1 genetic polymorphisms on tacrolimus pharmacokinetics in Japanese renal transplant recipients.  Method: The pharmacokinetic parameters of tacrolimus were calcd. in steady-state on day 28 after transplantation.  Polymerase chain reaction-restriction fragment length polymorphism and direct sequence methods were used for CYP3A5 and MDR1 polymorphisms, resp.  Results: The dose-adjusted area under the concn.-time curve (AUC0-12) was significantly lower among CYP3A5*1 carriers than those bearing CYP3A5*3/*3. (0.570 ± 0.105 vs 0.865 ± 0.343 ng · h/mL per mg/kg, P = .00322).  The daily tacrolimus dose per body wt. was significantly higher in CYP3A5*1 carriers than those of CYP3A5*3/*3 carriers (0.271 ± 0.110 vs 0.150 ± 0.056 mg/kg, P = .00016).  In this study, a distinction was made between carriers of CYP3A5*1/*1+*1/*3 and CYP3A5*3/*3 to investigate the influence of the MDR1 C3435T mutation on tacrolimus pharmacokinetics.  The MDR1 C3435T polymorphisms did not affect any tacrolimus pharmacokinetic parameter in either group.  Conclusions: Renal transplant recipients who were CYP3A5*1 carriers required a higher dose of tacrolimus than CYP3A5*3/*3, indicating a significantly lower dose-adjusted AUC0-12 of tacrolimus.  In contrast, MDR1 C3435T polymorphism was not an important factor in tacrolimus pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVqlSm7oB1_LVg90H21EOLACvtfcHk0lgOHOdLN8WW_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Crs78%253D&md5=e9d8699142acbae23d5b6d435148a47d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.transproceed.2005.02.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.transproceed.2005.02.073%26sid%3Dliteratum%253Aachs%26aulast%3DTada%26aufirst%3DH.%26aulast%3DTsuchiya%26aufirst%3DN.%26aulast%3DSatoh%26aufirst%3DS.%26aulast%3DKagaya%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMiura%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DHabuchi%26aufirst%3DT.%26atitle%3DImpact%2520of%2520CYP3A5%2520and%2520MDR1%2528ABCB1%2529%2520C3435T%2520polymorphisms%2520on%2520the%2520pharmacokinetics%2520of%2520tacrolimus%2520in%2520renal%2520transplant%2520recipients%26jtitle%3DTransplant.%2520Proc.%26date%3D2005%26volume%3D37%26spage%3D1730%26epage%3D1732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Gottlieb, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahfa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrowietz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murrell, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortonne, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emady-Azar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, C. F.</span><span> </span><span class="NLM_article-title">Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1111%2Fj.1365-2133.2005.06661.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmslCjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2005&pages=1219-1227&author=A.+B.+Gottliebauthor=C.+E.+M.+Griffithsauthor=V.+C.+Hoauthor=M.+Lahfaauthor=U.+Mrowietzauthor=D.+F.+Murrellauthor=J.-P.+Ortonneauthor=G.+Toddauthor=R.+Cherillauthor=I.+Marksauthor=S.+Emady-Azarauthor=C.+F.+Paul&title=Oral+pimecrolimus+in+the+treatment+of+moderate+to+severe+chronic+plaque-type+psoriasis%3A+a+double-blind%2C+multicentre%2C+randomized%2C+dose-finding+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial</span></div><div class="casAuthors">Gottlieb, A. B.; Griffiths, C. E. M.; Ho, V. C.; Lahfa, M.; Mrowietz, U.; Murrell, D. F.; Ortonne, J.-P.; Todd, G.; Cherill, R.; Marks, I.; Emady-Azar, S.; Paul, C. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1219-1227</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">There is a need for safe and effective alternative treatments for patients with moderate to severe psoriasis.  Pimecrolimus is a calcineurin inhibitor that is being investigated in oral form for the treatment of psoriasis.  A double-blind, randomized, parallel-group, dose-finding study was performed.  Healthy adult outpatients with moderate to severe chronic plaque-type psoriasis (n = 143) were randomized to receive oral placebo or pimecrolimus 10 mg, 20 mg, or 30 mg twice daily (b.d.) for 12 wk.  The Psoriasis Area and Severity Index (PASI) was used to assess clin. severity of psoriasis.  Results were analyzed at weeks 7 (primary endpoint) and 13.  Safety was assessed by monitoring all adverse events, lab. investigations (blood chem., urinalysis, hematol.) and phys. examns.  The change from baseline in PASI at week 7 showed a dose-dependent effect.  The differences between each of the two higher doses of pimecrolimus and placebo were statistically significant (P < 0.001; ANOVA).  The mean percentage decreases from baseline in PASI in the placebo group and pimecrolimus 10 mg, 20 mg and 30 mg b.d. groups at week 7 were 3.1%, 22.2%, 51.3% and 54.0%, resp.  Most adverse events were of mild or moderate severity.  The only adverse event to show a dose-response relationship was a transient feeling of warmth.  No clin. relevant effects on lab. parameters were obsd., and no increase in skin infection with pimecrolimus was seen.  Oral pimecrolimus produces a dose-dependent redn. in psoriasis severity, with doses of 20 mg and 30 mg b.d. being the most effective and well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG9b2nLMRGF7Vg90H21EOLACvtfcHk0lgOHOdLN8WW_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmslCjtbw%253D&md5=64613bc1247cca8a798120aadabf6f98</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2005.06661.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2005.06661.x%26sid%3Dliteratum%253Aachs%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DHo%26aufirst%3DV.%2BC.%26aulast%3DLahfa%26aufirst%3DM.%26aulast%3DMrowietz%26aufirst%3DU.%26aulast%3DMurrell%26aufirst%3DD.%2BF.%26aulast%3DOrtonne%26aufirst%3DJ.-P.%26aulast%3DTodd%26aufirst%3DG.%26aulast%3DCherill%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DI.%26aulast%3DEmady-Azar%26aufirst%3DS.%26aulast%3DPaul%26aufirst%3DC.%2BF.%26atitle%3DOral%2520pimecrolimus%2520in%2520the%2520treatment%2520of%2520moderate%2520to%2520severe%2520chronic%2520plaque-type%2520psoriasis%253A%2520a%2520double-blind%252C%2520multicentre%252C%2520randomized%252C%2520dose-finding%2520trial%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2005%26volume%3D152%26spage%3D1219%26epage%3D1227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Kirsner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffernan, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antaya, R.</span><span> </span><span class="NLM_article-title">Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids</span> <span class="citation_source-journal">Acta Derm.-Venereol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2340%2F00015555-0748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFGjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2010&pages=58-64&author=R.+S.+Kirsnerauthor=M.+P.+Heffernanauthor=R.+Antaya&title=Safety+and+efficacy+of+tacrolimus+ointment+versus+pimecrolimus+cream+in+the+treatment+of+patients+with+atopic+dermatitis+previously+treated+with+corticosteroids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids</span></div><div class="casAuthors">Kirsner, Robert S.; Heffernan, Michael P.; Antaya, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Dermato-Venereologica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-64</span>CODEN:
                <span class="NLM_cas:coden">ADVEA4</span>;
        ISSN:<span class="NLM_cas:issn">0001-5555</span>.
    
            (<span class="NLM_cas:orgname">Acta Dermato-Venereologica</span>)
        </div><div class="casAbstract">Adult and pediatric patients (n=347) with atopic dermatitis enrolled in three multicenter, randomized, 6-wk studies who had previously used steroids were analyzed to examine the null hypothesis that improvement in atopic dermatitis initiated after prior treatment with steroids eliminates any subsequent treatment differences between tacrolimus ointment and pimecrolimus cream.  Of these patients, 171 were randomized to tacrolimus ointment and 176 to pimecrolimus cream.  Based on improvement in the Eczema Area and Severity Index at the end of study, tacrolimus ointment was significantly more effective than pimecrolimus cream (p=0.0002).  Tacrolimus ointment was also significantly more effective than pimecrolimus cream at the end of study in all secondary end-points.  Overall, the frequency of adverse events was comparable between treatment groups (24.0% for tacrolimus ointment vs. 25.6% for pimecrolimus cream).  Tacrolimus ointment is more effective, with a similar safety profile, compared with pimecrolimus cream in patients with atopic dermatitis previously treated with topical corticosteroids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplVjvghalu6rVg90H21EOLACvtfcHk0liH-UK28pMo9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFGjs70%253D&md5=25de6664caa2f6b04e54fe7db96e9147</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2340%2F00015555-0748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2340%252F00015555-0748%26sid%3Dliteratum%253Aachs%26aulast%3DKirsner%26aufirst%3DR.%2BS.%26aulast%3DHeffernan%26aufirst%3DM.%2BP.%26aulast%3DAntaya%26aufirst%3DR.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tacrolimus%2520ointment%2520versus%2520pimecrolimus%2520cream%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520atopic%2520dermatitis%2520previously%2520treated%2520with%2520corticosteroids%26jtitle%3DActa%2520Derm.-Venereol.%26date%3D2010%26volume%3D90%26spage%3D58%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Ashcroft, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimmock, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garside, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, H. C.</span><span> </span><span class="NLM_article-title">Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials</span> <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">522</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1136%2Fbmj.38376.439653.D3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVOltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2005&pages=516-522&author=D.+M.+Ashcroftauthor=P.+Dimmockauthor=R.+Garsideauthor=K.+Steinauthor=H.+C.+Williams&title=Efficacy+and+tolerability+of+topical+pimecrolimus+and+tacrolimus+in+the+treatment+of+atopic+dermatitis%3A+meta-analysis+of+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials</span></div><div class="casAuthors">Ashcroft, Darren M.; Dimmock, Paul; Garside, Ruth; Stein, Ken; Williams, Hywel C.</div><div class="citationInfo"><span class="NLM_cas:title">BMJ [British Medical Journal]</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">7490</span>),
    <span class="NLM_cas:pages">516-522</span>CODEN:
                <span class="NLM_cas:coden">BMJBFE</span>;
        ISSN:<span class="NLM_cas:issn">0959-8146</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">To det. the efficacy and tolerability of topical pimecrolimus and tacrolimus compared with other treatments for atopic dermatitis, a systematic review and meta-anal were carried out on data from electronic searches of the Cochrane Library, Medline, and Embase regarding randomized controlled trials of topical pimecrolimus or tacrolimus reporting efficacy outcomes or tolerability.  Data extn. efficiency was detd. by investigators' global assessment of response, patients' global assessment of response; proportions of patients with flares of atopic dermatitis; and improvements in quality of life.  Tolerability was assessed by overall rates of withdrawal, withdrawal due to adverse events, and the proportions of patients with burning of the skin and skin infections.  A total of 4186 of 6897 participants in 25 randomized controlled trials received pimecrolimus or tacrolimus.  Both drugs were significantly more effective than a vehicle control.  Tacrolimus 0.1% was as effective as potent topical corticosteroids at 3 wk and more effective than combined treatment with hydrocortisone butyrate 0.1% (potent formulation used on trunk) plus hydrocortisone acetate 1% (weak formaulation used on face) at 12 wk (no. needed to treat (NNT) = 6).  Tacrolimus 0.1% was also more effective than hydrocortisone acetate 1% (NNT = 4).  In comparison, tacrolimus 0.03% was more effective than hydrocortisone acetate 1% (NNT = 5) but less effective than hydrocortisone butyrate 0.1% (NNT = -8).  Direct comparisons of tacrolimus 0.03% and tacrolimus 0.1% consistently favored the higher strength formulation, but efficacy differed significantly between the two strengths only after 12 wk' treatment (rate ratio 0.80, 95% confidence interval 0.65-0.99).  Pimecrolimus was far less effective than betamethasone valerate 0.1% (NNT = -3 at 3 wk).  Pimecrolimus and tacrolimus caused significantly more skin burning than topical corticosteroids.  Rates of skin infections in any of the comparisons did not differ.  Both topical pimecrolimus and topical tacrolimus are more effective than placebo treatments for atopic dermatitis, but in the absence of studies that show long term safety gains, any advantage over topical corticosteroids is unclear.  Topical tacrolimus is similar to potent topical corticosteroids and may have a place for long term use in patients with resistant atopic dermatitis on sites where side effects from topical corticosteroids might develop quickly.  In the absence of key comparisons with mild corticosteroids.  The clin. need for topical pimecrolimus is unclear.  The usefulness of either treatment in patients who have failed to respond adequately to topical corticosteroids is also unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJni_isqBqiLVg90H21EOLACvtfcHk0liH-UK28pMo9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVOltb0%253D&md5=bb0e0b6efd8de77dbedd2d88bb4e97b1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1136%2Fbmj.38376.439653.D3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.38376.439653.D3%26sid%3Dliteratum%253Aachs%26aulast%3DAshcroft%26aufirst%3DD.%2BM.%26aulast%3DDimmock%26aufirst%3DP.%26aulast%3DGarside%26aufirst%3DR.%26aulast%3DStein%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DH.%2BC.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520topical%2520pimecrolimus%2520and%2520tacrolimus%2520in%2520the%2520treatment%2520of%2520atopic%2520dermatitis%253A%2520meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DBr.%2520Med.%2520J.%26date%3D2005%26volume%3D330%26spage%3D516%26epage%3D522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aschauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aszódi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuetz, A.</span><span> </span><span class="NLM_article-title">Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.ijpharm.2003.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFeksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2004&pages=29-35&author=A.+Billichauthor=H.+Aschauerauthor=A.+Asz%C3%B3diauthor=A.+Stuetz&title=Percutaneous+absorption+of+drugs+used+in+atopic+eczema%3A+pimecrolimus+permeates+less+through+skin+than+corticosteroids+and+tacrolimus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus</span></div><div class="casAuthors">Billich, Andreas; Aschauer, Heinrich; Aszodi, Andras; Stuetz, Anton</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-35</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">For treatment of skin diseases with topical drugs, penetration of the agents into the relevant layers of the skin is required.  Permeation through the skin should, however, be kept to a min., in order to avoid the risk of systemic side effects.  Here we compared the in vitro skin penetration and permeation of two novel drugs used in the therapy of atopic eczema (pimecrolimus and tacrolimus) and three representative corticosteroids (betamethasone-17-valerate, clobetasol-17-propionate, and diflucortolone-21-valerate).  Drug concns. of pimecrolimus and corticosteroids in human skin were found to be in the same order of magnitude.  Permeation of pimecrolimus through human skin was, however, lower by factors of 70-110 as compared to the steroids.  When pimecrolimus was compared with tacrolimus in human, pig, or rat skin, similar concns. of the two compds. were measured in the skin, whereas permeation of pimecrolimus through skin was consistently lower by factors of 9-10.  Lipophilicity was found to be highest for pimecrolimus, its octanol-water distribution coeff. being higher by factors of 8 and 25-450 than that of tacrolimus and the corticosteroids, resp.  The low permeation of pimecrolimus may be explained by its higher lipophilicity (compared to tacrolimus and the corticosteroids) and higher mol. wt. (compared to steroids).  In conclusion, pimecrolimus appears to have a favorable skin penetration/permeation profile, featuring a low degree of percutaneous absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnrb11yhmBTbVg90H21EOLACvtfcHk0liH-UK28pMo9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFeksLs%253D&md5=dfa9d3ac6dad852c5c6330b374d6391f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2003.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2003.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DAschauer%26aufirst%3DH.%26aulast%3DAsz%25C3%25B3di%26aufirst%3DA.%26aulast%3DStuetz%26aufirst%3DA.%26atitle%3DPercutaneous%2520absorption%2520of%2520drugs%2520used%2520in%2520atopic%2520eczema%253A%2520pimecrolimus%2520permeates%2520less%2520through%2520skin%2520than%2520corticosteroids%2520and%2520tacrolimus%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2004%26volume%3D269%26spage%3D29%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Weiss, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fresneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moenius, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuetz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billich, A.</span><span> </span><span class="NLM_article-title">Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1812</span><span class="NLM_x">–</span> <span class="NLM_lpage">1818</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1812-1818&author=H.+M.+Weissauthor=M.+Fresneauauthor=T.+Moeniusauthor=A.+Stuetzauthor=A.+Billich&title=Binding+of+pimecrolimus+and+tacrolimus+to+skin+and+plasma+proteins%3A+implications+for+systemic+exposure+after+topical+application"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DH.%2BM.%26aulast%3DFresneau%26aufirst%3DM.%26aulast%3DMoenius%26aufirst%3DT.%26aulast%3DStuetz%26aufirst%3DA.%26aulast%3DBillich%26aufirst%3DA.%26atitle%3DBinding%2520of%2520pimecrolimus%2520and%2520tacrolimus%2520to%2520skin%2520and%2520plasma%2520proteins%253A%2520implications%2520for%2520systemic%2520exposure%2520after%2520topical%2520application%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1812%26epage%3D1818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Mahalati, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaha, B. D.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of sirolimus</span> <span class="citation_source-journal">Clin. Pharmacokinet .</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2165%2F00003088-200140080-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=11523724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmsl2gsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=573-585&author=K.+Mahalatiauthor=B.+D.+Kaha&title=Clinical+pharmacokinetics+of+sirolimus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of sirolimus</span></div><div class="casAuthors">Mahalati, Kamran; Kahan, Barry D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-585</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Sirolimus (previously known as rapamycin), a macrocyclic lactone, is a potent immunosuppressive agent.  Sirolimus was recently approved by the US Food and Drug Administration, on the basis of 2 large, double-blind, prospective clin. trials, for use in kidney transplant recipients at a fixed dosage of 2 or 5 mg/day in addn. to full dosages of cyclosporin and prednisone.  However, despite the fixed dosage regimens used in these pivotal trials, pharmacokinetic and clin. data show that sirolimus is a crit.-dose drug requiring therapeutic drug monitoring to minimize drug-related toxicities and maximize efficacy.  Assays using high performance liq. chromatog. coupled to mass spectrometry, although cumbersome, are the gold std. for evaluating other commonly used assays, such as liq. chromatog. with UV detection, radioreceptor assay and microparticle enzyme immunoassay.  Sirolimus is available in oral soln. and tablet form.  It has poor oral absorption and distributes widely in tissues, displaying not only a wide inter- and intrapatient variability in drug clearance, but also less than optimal correlations between whole blood concns. and drug dose, demog. features or patient characteristics.  Furthermore, the crit. role of the cytochrome P 450 3A4 system for sirolimus biotransformation leads to extensive drug-drug interactions, among which are increases in cyclosporin concns.  Thus, sirolimus is now being used to reduce or eliminate exposure to cyclosporin or corticosteroids.  The long elimination half-life of sirolimus necessitates a loading dose but allows once daily administration, which is more convenient and thereby could help to improve patient compliance.  This review emphasizes the importance of blood concn. monitoring in optimizing the use of sirolimus.  The excellent correlation between steady-state trough concn. (at least 4 days after inception of, or change in, therapy) and area under the concn.-time curve makes the former a simple and reliable index for monitoring sirolimus exposure.  Target trough concn. ranges depend on the concomitant immunosuppressive regimen, but a range of 5 to 15 μg/L is appropriate if cyclosporin is being used at trough concns. of 75 to 150 μg/L.  Weekly monitoring is recommended for the first month and bi-weekly for the next month; thereafter, concn. measurements are necessary only if warranted clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFv9OHBSIUCLVg90H21EOLACvtfcHk0ljd0HJpwql1cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmsl2gsLc%253D&md5=728dec62ae02c9fc473f71f5f94f93aa</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2165%2F00003088-200140080-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200140080-00002%26sid%3Dliteratum%253Aachs%26aulast%3DMahalati%26aufirst%3DK.%26aulast%3DKaha%26aufirst%3DB.%2BD.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520sirolimus%26jtitle%3DClin.%2520Pharmacokinet%2520.%26date%3D2001%26volume%3D40%26spage%3D573%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Hudes, G. R.</span><span> </span><span class="NLM_article-title">Targeting mTOR in renal cell carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2313</span><span class="NLM_x">–</span> <span class="NLM_lpage">2320</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2009&pages=2313-2320&author=G.+R.+Hudes&title=Targeting+mTOR+in+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHudes%26aufirst%3DG.%2BR.%26atitle%3DTargeting%2520mTOR%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DCancer%26date%3D2009%26volume%3D115%26spage%3D2313%26epage%3D2320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Buckner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forouzesh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkenblit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=334-342&author=J.+C.+Bucknerauthor=B.+Forouzeshauthor=C.+Erlichmanauthor=M.+Hidalgoauthor=J.+P.+Boniauthor=G.+Dukartauthor=A.+Berkenblitauthor=E.+K.+Rowinsky&title=Phase+I%2C+pharmacokinetic+study+of+temsirolimus+administered+orally+to+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuckner%26aufirst%3DJ.%2BC.%26aulast%3DForouzesh%26aufirst%3DB.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBoni%26aufirst%3DJ.%2BP.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DBerkenblit%26aufirst%3DA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DPhase%2520I%252C%2520pharmacokinetic%2520study%2520of%2520temsirolimus%2520administered%2520orally%2520to%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2010%26volume%3D28%26spage%3D334%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Burke, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, L. B.</span><span> </span><span class="NLM_article-title">Zotarolimus (ABT-578) eluting stents</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.addr.2006.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=16581153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD28Xltl2js74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=437-446&author=S.+E.+Burkeauthor=R.+E.+Kuntzauthor=L.+B.+Schwartz&title=Zotarolimus+%28ABT-578%29+eluting+stents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Zotarolimus (ABT-578) eluting stents</span></div><div class="casAuthors">Burke, Sandra E.; Kuntz, Richard E.; Schwartz, Lewis B.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">437-446</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Drug-eluting stents have revolutionized the field of interventional cardiol. and have provided a significant innovation for preventing coronary artery restenosis.  Polymer coatings that deliver anti-proliferative drugs to the vessel wall are key components of these revolutionary medical devices.  This article focuses on the development of stents which elute the potent anti-proliferative agent, zotarolimus, from a synthetic phosphorylcholine-based polymer known for its biocompatible profile.  Zotarolimus is the first drug developed specifically for local delivery from stents for the prevention of restenosis and was tested extensively to support this indication.  Clin. experience with the PC polymer is also extensive, since more than 120,000 patients were implanted to date with stents contg. this non-thrombogenic coating.  This review provides background on pre-clin. studies with zotarolimus, on the development of the biocompatible PC polymer and on the clin. trials conducted using 2 stent platforms which deliver this drug to patients with coronary artery disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2zuwfCTBaKrVg90H21EOLACvtfcHk0ljd0HJpwql1cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xltl2js74%253D&md5=219c232c01f34e5f7b79f16f99e3e7b7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2006.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2006.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DS.%2BE.%26aulast%3DKuntz%26aufirst%3DR.%2BE.%26aulast%3DSchwartz%26aufirst%3DL.%2BB.%26atitle%3DZotarolimus%2520%2528ABT-578%2529%2520eluting%2520stents%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D437%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Kirchner, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier-Wiedenbach, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manns, M. P.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of everolimus</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2165%2F00003088-200443020-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=14748618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFGkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=83-95&author=G.+I.+Kirchnerauthor=I.+Meier-Wiedenbachauthor=M.+P.+Manns&title=Clinical+pharmacokinetics+of+everolimus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of everolimus</span></div><div class="casAuthors">Kirchner, Gabriele I.; Meier-Wiedenbach, Ivo; Manns, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-95</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Everolimus is an immunosuppressive macrolide bearing a stable 2-hydroxyethyl chain substitution at position 40 on the sirolimus (rapamycin) structure.  Everolimus, which has greater polarity than sirolimus, was developed in an attempt to improve the pharmacokinetic characteristics of sirolimus, particularly to increase its oral bioavailability.  Everolimus has a mechanism of action similar to that of sirolimus.  It blocks growth-driven transduction signals in the T-cell response to alloantigen and thus acts at a later stage than the calcineurin inhibitors ciclosporin and tacrolimus.  Everolimus and ciclosporin show synergism in immunosuppression both in vitro and in vivo and therefore the drugs are intended to be given in combination after solid organ transplantation.  The synergistic effect allows a dosage redn. that decreases adverse effects.  For the quantification of the pharmacokinetics of everolimus, nine different assays using high performance liq. chromatog. coupled to an electrospray mass spectrometer, and one ELISA, have been developed.  Oral everolimus is absorbed rapidly, and reaches peak concn. after 1.3-1.8 h.  Steady state is reached within 7 days, and steady-state peak and trough concns., and area under the concn.-time curve (AUC), are proportional to dosage.  In adults, everolimus pharmacokinetic characteristics do not differ according to age, wt. or sex, but bodyweight-adjusted dosages are necessary in children.  The interindividual pharmacokinetic variability of everolimus can be explained by different activities of the drug efflux pump P-glycoprotein and of metab. by cytochrome P 450 (CYP) 3A4, 3A5 and 2C8.  The crit. role of the CYP3A4 system for everolimus biotransformation leads to drug-drug interactions with other drugs metabolised by this cytochrome system.  In patients with hepatic impairment, the apparent clearance of everolimus is significantly lower than in healthy volunteers, and therefore the dosage of everolimus should be reduced by half in these patients.  The advantage of everolimus seems to be its lower nephrotoxicity in comparison with the std. immunosuppressants ciclosporin and tacrolimus.  Obsd. adverse effects with everolimus include hypertriglyceridemia, hypercholesterolemia, opportunistic infections, thrombocytopenia and leucocytopenia.  Because of the variable oral bioavailability and narrow therapeutic index of everolimus, blood concn. monitoring seems to be important.  The excellent correlation between steady-state trough concn. and AUC makes the former a simple and reliable index for monitoring everolimus exposure.  The target trough concn. of everolimus should range between 3 and 15 μg/l, in combination therapy with ciclosporin (trough concn. 100-300 μg/L) and prednisone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8TxYc6XZNTbVg90H21EOLACvtfcHk0lgvfQQ1V-r1lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFGkurY%253D&md5=f2b26414d8364047fcce45ebbe687c6b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2165%2F00003088-200443020-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200443020-00002%26sid%3Dliteratum%253Aachs%26aulast%3DKirchner%26aufirst%3DG.%2BI.%26aulast%3DMeier-Wiedenbach%26aufirst%3DI.%26aulast%3DManns%26aufirst%3DM.%2BP.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520everolimus%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2004%26volume%3D43%26spage%3D83%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Canga, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieto, A. M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebana, M. J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieitez, J. J. G.</span><span> </span><span class="NLM_article-title">The pharmacokinetics and interactions of ivermectin in humans—a mini-review</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=42-46&author=A.+G.+Cangaauthor=A.+M.+S.+Prietoauthor=M.+J.+D.+Liebanaauthor=N.+F.+Martinezauthor=M.+S.+Vegaauthor=J.+J.+G.+Vieitez&title=The+pharmacokinetics+and+interactions+of+ivermectin+in+humans%E2%80%94a+mini-review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCanga%26aufirst%3DA.%2BG.%26aulast%3DPrieto%26aufirst%3DA.%2BM.%2BS.%26aulast%3DLiebana%26aufirst%3DM.%2BJ.%2BD.%26aulast%3DMartinez%26aufirst%3DN.%2BF.%26aulast%3DVega%26aufirst%3DM.%2BS.%26aulast%3DVieitez%26aufirst%3DJ.%2BJ.%2BG.%26atitle%3DThe%2520pharmacokinetics%2520and%2520interactions%2520of%2520ivermectin%2520in%2520humans%25E2%2580%2594a%2520mini-review%26jtitle%3DAAPS%2520J.%26date%3D2008%26volume%3D10%26spage%3D42%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Edwards, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingsdale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helsby, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breckenridge, A.</span><span> </span><span class="NLM_article-title">The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1988&pages=681-684&author=G.+Edwardsauthor=A.+Dingsdaleauthor=N.+Helsbyauthor=M.+L.+Ormeauthor=A.+Breckenridge&title=The+relative+systemic+availability+of+ivermectin+after+administration+as+capsule%2C+tablet%2C+and+oral+solution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DG.%26aulast%3DDingsdale%26aufirst%3DA.%26aulast%3DHelsby%26aufirst%3DN.%26aulast%3DOrme%26aufirst%3DM.%2BL.%26aulast%3DBreckenridge%26aufirst%3DA.%26atitle%3DThe%2520relative%2520systemic%2520availability%2520of%2520ivermectin%2520after%2520administration%2520as%2520capsule%252C%2520tablet%252C%2520and%2520oral%2520solution%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1988%26volume%3D35%26spage%3D681%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Hoveyda, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsault, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagnon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vézina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benakli, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaubien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saint-Louis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinault, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaseshan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foucher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchemin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhérer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, G. L.</span><span> </span><span class="NLM_article-title">Optimization of the potency and pharmacokinetic properties of macrocyclic ghrelin receptor agonist (part I): development of ulimorelin (TZP-101) from hit to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8305</span><span class="NLM_x">–</span> <span class="NLM_lpage">8320</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8305-8320&author=H.+R.+Hoveydaauthor=E.+Marsaultauthor=R.+Gagnonauthor=A.+P.+Mathieuauthor=M.+V%C3%A9zinaauthor=A.+Landryauthor=Z.+Wangauthor=K.+Benakliauthor=S.+Beaubienauthor=C.+Saint-Louisauthor=M.+Brassardauthor=J.-F.+Pinaultauthor=L.+Ouelletauthor=S.+Bhatauthor=M.+Ramaseshanauthor=X.+Pengauthor=L.+Foucherauthor=S.+Beaucheminauthor=P.+Bh%C3%A9rerauthor=D.+F.+Veberauthor=M.+L.+Petersonauthor=G.+L.+Fraser&title=Optimization+of+the+potency+and+pharmacokinetic+properties+of+macrocyclic+ghrelin+receptor+agonist+%28part+I%29%3A+development+of+ulimorelin+%28TZP-101%29+from+hit+to+clinic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm2007062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007062%26sid%3Dliteratum%253Aachs%26aulast%3DHoveyda%26aufirst%3DH.%2BR.%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DGagnon%26aufirst%3DR.%26aulast%3DMathieu%26aufirst%3DA.%2BP.%26aulast%3DV%25C3%25A9zina%26aufirst%3DM.%26aulast%3DLandry%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBenakli%26aufirst%3DK.%26aulast%3DBeaubien%26aufirst%3DS.%26aulast%3DSaint-Louis%26aufirst%3DC.%26aulast%3DBrassard%26aufirst%3DM.%26aulast%3DPinault%26aufirst%3DJ.-F.%26aulast%3DOuellet%26aufirst%3DL.%26aulast%3DBhat%26aufirst%3DS.%26aulast%3DRamaseshan%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DFoucher%26aufirst%3DL.%26aulast%3DBeauchemin%26aufirst%3DS.%26aulast%3DBh%25C3%25A9rer%26aufirst%3DP.%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26aulast%3DFraser%26aufirst%3DG.%2BL.%26atitle%3DOptimization%2520of%2520the%2520potency%2520and%2520pharmacokinetic%2520properties%2520of%2520macrocyclic%2520ghrelin%2520receptor%2520agonist%2520%2528part%2520I%2529%253A%2520development%2520of%2520ulimorelin%2520%2528TZP-101%2529%2520from%2520hit%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8305%26epage%3D8320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Hosoe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mae, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konishi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamane, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2749</span><span class="NLM_x">–</span> <span class="NLM_lpage">2755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=2749-2755&author=K.+Hosoeauthor=T.+Maeauthor=E.+Konishiauthor=K.+Fujiiauthor=K.+Yamashitaauthor=T.+Yamaneauthor=T.+Hidakaauthor=T.+Ohashi&title=Pharmacokinetics+of+KRM-1648%2C+a+new+benzoxazinorifamycin%2C+in+rats+and+dogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHosoe%26aufirst%3DK.%26aulast%3DMae%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DE.%26aulast%3DFujii%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DK.%26aulast%3DYamane%26aufirst%3DT.%26aulast%3DHidaka%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520of%2520KRM-1648%252C%2520a%2520new%2520benzoxazinorifamycin%252C%2520in%2520rats%2520and%2520dogs%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D2749%26epage%3D2755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Chen, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caban, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, L.</span><span> </span><span class="NLM_article-title">Escalating single-dose safety and pharmacokinetics of rifalazil in healthy volunteers</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">M1103</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=M1103&author=Y.-X.+Chenauthor=B.+Cabanauthor=L.+Robertson&title=Escalating+single-dose+safety+and+pharmacokinetics+of+rifalazil+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-X.%26aulast%3DCaban%26aufirst%3DB.%26aulast%3DRobertson%26aufirst%3DL.%26atitle%3DEscalating%2520single-dose%2520safety%2520and%2520pharmacokinetics%2520of%2520rifalazil%2520in%2520healthy%2520volunteers%26jtitle%3DAAPS%2520J.%26date%3D2004%26volume%3D6%26spage%3DM1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Chen, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabana, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelis, A.</span><span> </span><span class="NLM_article-title">Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">849</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1177%2F0091270007300745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1Gitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=841-849&author=Y.-X.+Chenauthor=B.+Cabanaauthor=N.+Kivelauthor=A.+Michaelis&title=Effect+of+food+on+the+pharmacokinetics+of+rifalazil%2C+a+novel+antibacterial%2C+in+healthy+male+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of food on the pharmacokinetics of rifalazil, a novel antibacterial, in healthy male volunteers</span></div><div class="casAuthors">Chen, Y.-X.; Cabana, B.; Kivel, N.; Michaelis, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">841-849</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Rifalazil is a new antibiotic structurally related to rifampin but devoid of the metabolic liabilities typically assocd. with the rifamycin class of antibiotics.  A randomized, 3-way crossover study in healthy male volunteers (n = 12) investigated the safety and pharmacokinetics of a single 25-mg oral rifalazil dose administered under a std. breakfast contg. fat as 30% of calories, a high-fat breakfast contg. fat as 60% of calories, and an overnight fast of 10 h with a 21- to 28-day washout between doses.  Systemic exposure to rifalazil based on Cmax, AUC0-Tlast, and AUCa-∞ was increased progressively as the fat content of the test breakfast was increased from 30% to 60% compared with fasting.  The confidence intervals for both fat-contg. breakfasts are outside the limits of 80% to 125% allowed for food effect bioequivalence based on Cmax, AUC0-Tlast, and AUC0-∞.  This food effect may be a result of increased fractional absorption with increasing dietary fat content.  Another striking finding was the large redn. of the pharmacokinetic intersubject variability after rifalazil administration with food.  Rifalazil was safe and well tolerated under fed and fasted conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNFb9GmK4FnbVg90H21EOLACvtfcHk0likpZjW35mDAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1Gitrw%253D&md5=c5c274d7ade0d47d23c6fd28e3e42952</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1177%2F0091270007300745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270007300745%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-X.%26aulast%3DCabana%26aufirst%3DB.%26aulast%3DKivel%26aufirst%3DN.%26aulast%3DMichaelis%26aufirst%3DA.%26atitle%3DEffect%2520of%2520food%2520on%2520the%2520pharmacokinetics%2520of%2520rifalazil%252C%2520a%2520novel%2520antibacterial%252C%2520in%2520healthy%2520male%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2007%26volume%3D47%26spage%3D841%26epage%3D849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fetterly, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldston, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathews, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricart, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mays, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreisberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedrosian, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1200%2FJCO.2007.12.0345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=18202410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVGntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=361-367&author=M.+M.+Mitaauthor=A.+C.+Mitaauthor=Q.+S.+Chuauthor=E.+K.+Rowinskyauthor=G.+J.+Fetterlyauthor=M.+Goldstonauthor=A.+Patnaikauthor=L.+Mathewsauthor=A.+D.+Ricartauthor=T.+Maysauthor=H.+Knowlesauthor=V.+M.+Riveraauthor=J.+Kreisbergauthor=C.+L.+Bedrosianauthor=A.+W.+Tolcher&title=Phase+I+trial+of+the+novel+mammalian+target+of+rapamycin+inhibitor+deforolimus+%28AP23573%3B+MK-8669%29+administered+intravenously+daily+for+5+days+every+2+weeks+to+patients+with+advanced+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies</span></div><div class="casAuthors">Mita, Monica M.; Mita, Alain C.; Chu, Quincy S.; Rowinsky, Eric K.; Fetterly, Gerald J.; Goldston, Michelle; Patnaik, Amita; Mathews, Lesley; Ricart, Alejandro D.; Mays, Theresa; Knowles, Heather; Rivera, Victor M.; Kreisberg, Jeff; Bedrosian, Camille L.; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">This phase I trial was conducted to det. the safety, tolerability, pharmacokinetics, and pharmacodynamics of deforolimus (previously known as AP23573; MK-8669), a nonprodrug rapamycin analog, in patients with advanced solid malignancies.  Patients were treated using an accelerated titrn. design with sequential escalating flat doses of deforolimus administered as a 30-min i.v. infusion once daily for 5 consecutive days every 2 wk (QD×5) in a 28-day cycle.  Safety, pharmacokinetic, pharmacodynamic, and tumor response assessments were performed.  Thirty-two patients received at least one dose of deforolimus (3 to 28 mg/d).  Three dose-limiting toxicity events of grade 3 mouth sores were reported.  The max.-tolerated dose (MTD) was 18.75 mg/d.  Common treatment-related adverse events included reversible mouth sores and rash.  Whole-blood clearance increased with dose.  Pharmacodynamic analyses demonstrated mammalian target of rapamycin inhibition at all dose levels.  Four patients (one each with non-small-cell lung cancer, mixed mullerian tumor [carcinosarcoma], renal cell carcinoma, and Ewing sarcoma) experienced confirmed partial responses, and three addnl. patients had minor tumor regressions.  The MTD of this phase I trial using an accelerated titrn. design was detd. to be 18.75 mg/d.  Deforolimus was well tolerated and showed encouraging antitumor activity across a broad range of malignancies when administered i.v. on the QD×5 schedule.  On the basis of these overall results, a dose of 12.5 mg/d is being evaluated in phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy2ctnnQ5BdbVg90H21EOLACvtfcHk0likpZjW35mDAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVGntLk%253D&md5=ff21fcdb34fae88592e6e597204945b6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.12.0345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.12.0345%26sid%3Dliteratum%253Aachs%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DChu%26aufirst%3DQ.%2BS.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DGoldston%26aufirst%3DM.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DMathews%26aufirst%3DL.%26aulast%3DRicart%26aufirst%3DA.%2BD.%26aulast%3DMays%26aufirst%3DT.%26aulast%3DKnowles%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DKreisberg%26aufirst%3DJ.%26aulast%3DBedrosian%26aufirst%3DC.%2BL.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520novel%2520mammalian%2520target%2520of%2520rapamycin%2520inhibitor%2520deforolimus%2520%2528AP23573%253B%2520MK-8669%2529%2520administered%2520intravenously%2520daily%2520for%25205%2520days%2520every%25202%2520weeks%2520to%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Fetterly, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poplin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tap, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmona, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonemoto, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedrosian, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of oral deforolimus (AP23573, MK-8669)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">15S</span><span class="NLM_x">) </span> <span class="NLM_fpage">14555</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=14555&issue=15S&author=G.+J.+Fetterlyauthor=M.+M.+Mitaauthor=C.+D.+Brittenauthor=E.+Poplinauthor=W.+D.+Tapauthor=A.+Carmonaauthor=L.+Yonemotoauthor=C.+L.+Bedrosianauthor=E.+H.+Rubinauthor=A.+W.+Tolcher&title=Pharmacokinetics+of+oral+deforolimus+%28AP23573%2C+MK-8669%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFetterly%26aufirst%3DG.%2BJ.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DPoplin%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DCarmona%26aufirst%3DA.%26aulast%3DYonemoto%26aufirst%3DL.%26aulast%3DBedrosian%26aufirst%3DC.%2BL.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DPharmacokinetics%2520of%2520oral%2520deforolimus%2520%2528AP23573%252C%2520MK-8669%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3D15S%26spage%3D14555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Still, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schranz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, K.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1997</span><span class="NLM_x">–</span> <span class="NLM_lpage">2003</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=1997-2003&author=J.+G.+Stillauthor=J.+Schranzauthor=T.+P.+Degenhardtauthor=D.+Scottauthor=P.+Fernandesauthor=M.+J.+Gutierrezauthor=K.+Clark&title=Pharmacokinetics+of+solithromycin+%28CEM-101%29+after+single+or+multiple+oral+doses+and+effects+of+food+on+single-dose+bioavailability+in+healthy+adult+subjects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStill%26aufirst%3DJ.%2BG.%26aulast%3DSchranz%26aufirst%3DJ.%26aulast%3DDegenhardt%26aufirst%3DT.%2BP.%26aulast%3DScott%26aufirst%3DD.%26aulast%3DFernandes%26aufirst%3DP.%26aulast%3DGutierrez%26aufirst%3DM.%2BJ.%26aulast%3DClark%26aufirst%3DK.%26atitle%3DPharmacokinetics%2520of%2520solithromycin%2520%2528CEM-101%2529%2520after%2520single%2520or%2520multiple%2520oral%2520doses%2520and%2520effects%2520of%2520food%2520on%2520single-dose%2520bioavailability%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D1997%26epage%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Ross, D. B.</span><span> </span><span class="NLM_article-title">The FDA and the case of Ketek</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">1601</span><span class="NLM_x">–</span> <span class="NLM_lpage">1604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1056%2FNEJMp078032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=17442902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=1601-1604&author=D.+B.+Ross&title=The+FDA+and+the+case+of+Ketek"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: the FDA and the case of Ketek</span></div><div class="casAuthors">Ross, David B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1601-1604</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxg3oJZMs06LVg90H21EOLACvtfcHk0lhGOKYg5pWvDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFCgtb4%253D&md5=f077976e1f2d38a66f7730fe4e6fb184</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1056%2FNEJMp078032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp078032%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DD.%2BB.%26atitle%3DThe%2520FDA%2520and%2520the%2520case%2520of%2520Ketek%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D1601%26epage%3D1604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scorneaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeill, Y.</span><span> </span><span class="NLM_article-title">SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=660-672&author=S.+Hopkinsauthor=B.+Scorneauxauthor=Z.+Huangauthor=M.+G.+Murrayauthor=S.+Wringauthor=C.+Smitleyauthor=R.+Harrisauthor=F.+Erdmannauthor=G.+Fischerauthor=Y.+Ribeill&title=SCY-635%2C+a+novel+nonimmunosuppressive+analog+of+cyclosporine+that+exhibits+potent+inhibition+of+hepatitis+C+virus+RNA+replication+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DScorneaux%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DMurray%26aufirst%3DM.%2BG.%26aulast%3DWring%26aufirst%3DS.%26aulast%3DSmitley%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DR.%26aulast%3DErdmann%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DG.%26aulast%3DRibeill%26aufirst%3DY.%26atitle%3DSCY-635%252C%2520a%2520novel%2520nonimmunosuppressive%2520analog%2520of%2520cyclosporine%2520that%2520exhibits%2520potent%2520inhibition%2520of%2520hepatitis%2520C%2520virus%2520RNA%2520replication%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D660%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Hopkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMassimo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sluder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scorneaux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalczyk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeill, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baugh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P.</span><span> </span><span class="NLM_article-title">The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.jhep.2012.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22425702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XovV2nsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2012&pages=47-54&author=S.+Hopkinsauthor=B.+DiMassimoauthor=P.+Rusnakauthor=D.+Heumanauthor=J.+Lalezariauthor=A.+Sluderauthor=B.+Scorneauxauthor=S.+Mosierauthor=P.+Kowalczykauthor=Y.+Ribeillauthor=J.+Baughauthor=P.+Gallay&title=The+cyclophilin+inhibitor+SCY-635+suppresses+viral+replication+and+induces+endogenous+interferons+in+patients+with+chronic+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection</span></div><div class="casAuthors">Hopkins, Sam; DiMassimo, Betty; Rusnak, Pamela; Heuman, Douglas; Lalezari, Jacob; Sluder, Ann; Scorneaux, Bernard; Mosier, Sarah; Kowalczyk, Paul; Ribeill, Yves; Baugh, James; Gallay, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: SCY-635 is a non-immunosuppressive analog of cyclosporin A that inhibits cyclophilins A and B and hepatitis C virus (HCV) replication in vitro.  In a phase 1b multi-dose escalation study, we evaluated the safety, plasma pharmacokinetics, and antiviral activity of 15 days of monotherapy with SCY-635 in adults with chronic genotype 1 HCV infection.  Methods: Twenty adults with chronic HCV genotype 1 were randomized to SCY-635 oral doses of 100, 200, or 300 mg three times daily for 15 days.  Results: No dose-limiting clin. or lab. toxicities were identified.  On day 15, the mean decline in plasma viremia was 2.24 ± 1.74 log10 IU/mL with SCY-635 900 mg/d.  Individual antiviral responses correlated with host IL28B genotype.  Post hoc analyses indicated treatment with SCY-635 increased plasma protein concns. of interferon α (IFNα), IFNs λ1 and λ3, and 2'5' oligoadenylate synthetase 1 (2'5'OAS-1), with the greatest increases in IL28B CC and CT subjects.  Changes in plasma concns. for all markers were coincident with changes in the plasma concn. of SCY-635.  Peaks of IFNs α, λ1, and λ3 and 2'5'OAS-1 were obsd. within 2 h after drug administration.  In replicon cells, SCY-635 enhanced secretion of type I and type III IFNs and increased the expression of IFN-stimulated genes (ISG).  Conclusions: These studies establish clin. proof of concept for SCY-635 as a novel antiviral agent and suggest that restoration of the host innate immune response to chronic hepatitis C infection may represent a major mechanism through which cyclophilin inhibitors exert clin. antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOeLKHF7TNQLVg90H21EOLACvtfcHk0lhGOKYg5pWvDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovV2nsLc%253D&md5=43dcadacaaef7efd63d3d823f53ad514</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DDiMassimo%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DP.%26aulast%3DHeuman%26aufirst%3DD.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DSluder%26aufirst%3DA.%26aulast%3DScorneaux%26aufirst%3DB.%26aulast%3DMosier%26aufirst%3DS.%26aulast%3DKowalczyk%26aufirst%3DP.%26aulast%3DRibeill%26aufirst%3DY.%26aulast%3DBaugh%26aufirst%3DJ.%26aulast%3DGallay%26aufirst%3DP.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520SCY-635%2520suppresses%2520viral%2520replication%2520and%2520induces%2520endogenous%2520interferons%2520in%2520patients%2520with%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D57%26spage%3D47%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Aspeslet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freitag, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepanier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naicker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneteman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatscoff, R.</span><span> </span><span class="NLM_article-title">ISATX247: a novel calcineurin inhibitor</span> <span class="citation_source-journal">Transplant. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2FS0041-1345%2800%2902325-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitV2nsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=1048-1051&author=L.+Aspesletauthor=D.+Freitagauthor=D.+Trepanierauthor=M.+Abelauthor=S.+Naickerauthor=N.+Knetemanauthor=R.+Fosterauthor=R.+Yatscoff&title=ISATX247%3A+a+novel+calcineurin+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">ISATX</span></div><div class="casAuthors">Aspeslet, L.; Freitag, D.; Trepanier, D.; Abel, M.; Naicker, S.; Kneteman, N.; Foster, R.; Yatscoff, R.</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation Proceedings</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1048-1051</span>CODEN:
                <span class="NLM_cas:coden">TRPPA8</span>;
        ISSN:<span class="NLM_cas:issn">0041-1345</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The toxicokinetics of ISATX247, a novel calcineurin inhibitor, were evaluated in rabbit, rat, and dog models.  The immunosuppressive activity of the drug was evaluated in vitro using a calcineurin assay and the in vivo potency was assessed in a heterotopic rat heart transplant model.  ISATX247 was shown to be more potent than cyclosporine in vitro and in vivo.  In the rat heterotopic heart transplant model, the drug prolonged graft survival threefold longer than cyclosporine.  ISATX247 showed significantly reduced renal side effects compared to cyclosporine, suggesting dissocn. between calcineurin inhibition and toxicity.  The results indicated that ISATX247 has a wider therapeutic index than cyclosporine and should offer a significant advantage over presently immunosuppressive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPSGbkQ0zET7Vg90H21EOLACvtfcHk0lhv5v6GNikuaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitV2nsbk%253D&md5=8cbf77dc19fdc60d4b96c8b1575c16a5</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0041-1345%2800%2902325-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0041-1345%252800%252902325-3%26sid%3Dliteratum%253Aachs%26aulast%3DAspeslet%26aufirst%3DL.%26aulast%3DFreitag%26aufirst%3DD.%26aulast%3DTrepanier%26aufirst%3DD.%26aulast%3DAbel%26aufirst%3DM.%26aulast%3DNaicker%26aufirst%3DS.%26aulast%3DKneteman%26aufirst%3DN.%26aulast%3DFoster%26aufirst%3DR.%26aulast%3DYatscoff%26aufirst%3DR.%26atitle%3DISATX247%253A%2520a%2520novel%2520calcineurin%2520inhibitor%26jtitle%3DTransplant.%2520Proc.%26date%3D2001%26volume%3D33%26spage%3D1048%26epage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Wasel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunynetz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guenther, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourcier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatscoff, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freitag, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, R. T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of ISA247 in a phase III randomized, multicenter, double-blind, placebo-controlled study</span> <span class="citation_source-journal">J. Am. Acad. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">P36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=P36&author=N.+Waselauthor=A.+Guptaauthor=Z.+Tomiauthor=R.+Kunynetzauthor=L.+Guentherauthor=M.+Bourcierauthor=R.+W.+Yatscoffauthor=P.+Mayoauthor=D.+Freitagauthor=R.+T.+Foster&title=Pharmacokinetics+and+pharmacodynamics+of+ISA247+in+a+phase+III+randomized%2C+multicenter%2C+double-blind%2C+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWasel%26aufirst%3DN.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DTomi%26aufirst%3DZ.%26aulast%3DKunynetz%26aufirst%3DR.%26aulast%3DGuenther%26aufirst%3DL.%26aulast%3DBourcier%26aufirst%3DM.%26aulast%3DYatscoff%26aufirst%3DR.%2BW.%26aulast%3DMayo%26aufirst%3DP.%26aulast%3DFreitag%26aufirst%3DD.%26aulast%3DFoster%26aufirst%3DR.%2BT.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520ISA247%2520in%2520a%2520phase%2520III%2520randomized%252C%2520multicenter%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2006%26volume%3D54%26spage%3DP36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Politano, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, R. G.</span><span> </span><span class="NLM_article-title">NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=20112172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnt1KgtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=225-236&author=A.+D.+Politanoauthor=R.+G.+Sawyer&title=NXL-103%2C+a+combination+of+flopristin+and+linopristin%2C+for+the+potential+treatment+of+bacterial+infections+including+community-acquired+pneumonia+and+MRSA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA</span></div><div class="casAuthors">Politano, Amani D.; Sawyer, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (BioMed Central)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-236</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">2040-3429</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Novexel is developing the novel, orally active, semisynthetic streptogramin NXL-103, which has potential therapeutic application in the treatment of community-acquired pneumonia, community- or hospital-acquired MRSA, vancomycin-resistant enterococcus, and acute bacterial skin and soft tissue infections.  NXL-103 is a combination of streptogramin A:streptogramin B components, initially developed in a 70:30 dose ratio.  In multiple in vitro studies, NXL-103 demonstrated potent activity against different types of bacteria, such as Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecium, Enterococcus faecalis, Haemophilus influenzae and Haemophilus parainfluenzae.  NXL-103 was not affected by the resistance profiles of bacteria against other commonly used antibiotics.  In phase I clin. trials, NXL-103 achieved bactericidal levels in plasma and was generally well tolerated, with side effects primarily on the gastrointestinal system.  The first phase II trial conducted to evaluate the efficacy of NXL-103 against community-acquired pneumonia revealed that the compd. was comparable with amoxicillin.  NXL-103 has promise to become an important agent in the treatment of community-acquired pneumonia and complex skin and soft tissue infections, pending further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZhaHyEQ-YPrVg90H21EOLACvtfcHk0lhv5v6GNikuaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnt1KgtLw%253D&md5=c5c124478ed1f545d51103a2194249df</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolitano%26aufirst%3DA.%2BD.%26aulast%3DSawyer%26aufirst%3DR.%2BG.%26atitle%3DNXL-103%252C%2520a%2520combination%2520of%2520flopristin%2520and%2520linopristin%252C%2520for%2520the%2520potential%2520treatment%2520of%2520bacterial%2520infections%2520including%2520community-acquired%2520pneumonia%2520and%2520MRSA%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D11%26spage%3D225%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Malcolm, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belanger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butkiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheyas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1013-1020&author=B.+A.+Malcolmauthor=R.+Liuauthor=F.+Lahserauthor=S.+Agrawalauthor=B.+Belangerauthor=N.+Butkiewiczauthor=R.+Chaseauthor=F.+Gheyasauthor=A.+Hartauthor=D.+Heskauthor=P.+Ingravalloauthor=C.+Jiangauthor=R.+Kongauthor=J.+Luauthor=J.+Pichardoauthor=A.+Prongayauthor=A.+Skeltonauthor=X.+Tongauthor=S.+Venkatramanauthor=E.+Xiaauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=SCH+503034%2C+a+mechanism-based+inhibitor+of+hepatitis+C+virus+NS3+protease%2C+suppresses+polyprotein+maturation+and+enhances+the+antiviral+activity+of+alpha+interferon+in+replicon+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalcolm%26aufirst%3DB.%2BA.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DLahser%26aufirst%3DF.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DBelanger%26aufirst%3DB.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DGheyas%26aufirst%3DF.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DSkelton%26aufirst%3DA.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DE.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DSCH%2520503034%252C%2520a%2520mechanism-based%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%2520protease%252C%2520suppresses%2520polyprotein%2520maturation%2520and%2520enhances%2520the%2520antiviral%2520activity%2520of%2520alpha%2520interferon%2520in%2520replicon%2520cells%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D1013%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Perni, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almquist, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrn, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandorkar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinehart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalkeri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolaczkowski, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span> </span><span class="NLM_article-title">Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">899</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=899-909&author=R.+B.+Perniauthor=S.+J.+Almquistauthor=R.+A.+Byrnauthor=G.+Chandorkarauthor=P.+R.+Chaturvediauthor=L.+F.+Courtneyauthor=C.+J.+Deckerauthor=K.+Dinehartauthor=C.+A.+Gatesauthor=S.+L.+Harbesonauthor=A.+Heiserauthor=G.+Kalkeriauthor=E.+Kolaczkowskiauthor=K.+Linauthor=Y.+P.+Luongauthor=B.+G.+Raoauthor=W.+P.+Taylorauthor=J.+A.+Thomsonauthor=R.+D.+Tungauthor=Y.+Weiauthor=A.+D.+Kwongauthor=C.+Lin&title=Preclinical+profile+of+VX-950%2C+a+potent%2C+selective%2C+and+orally+bioavailable+inhibitor+of+hepatitis+C+virus+NS3-4A+serine+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DAlmquist%26aufirst%3DS.%2BJ.%26aulast%3DByrn%26aufirst%3DR.%2BA.%26aulast%3DChandorkar%26aufirst%3DG.%26aulast%3DChaturvedi%26aufirst%3DP.%2BR.%26aulast%3DCourtney%26aufirst%3DL.%2BF.%26aulast%3DDecker%26aufirst%3DC.%2BJ.%26aulast%3DDinehart%26aufirst%3DK.%26aulast%3DGates%26aufirst%3DC.%2BA.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DHeiser%26aufirst%3DA.%26aulast%3DKalkeri%26aufirst%3DG.%26aulast%3DKolaczkowski%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLuong%26aufirst%3DY.%2BP.%26aulast%3DRao%26aufirst%3DB.%2BG.%26aulast%3DTaylor%26aufirst%3DW.%2BP.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DLin%26aufirst%3DC.%26atitle%3DPreclinical%2520profile%2520of%2520VX-950%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3-4A%2520serine%2520protease%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D899%26epage%3D909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span> </span><span class="NLM_article-title">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+Boesauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingley&title=An+NS3+protease+inhibitor+with+antiviral+effects+in+humans+infected+with+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0lgIH1M5Kmiffg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DBoes%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26atitle%3DAn%2520NS3%2520protease%2520inhibitor%2520with%2520antiviral%2520effects%2520in%2520humans%2520infected%2520with%2520hepatitis%2520C%2520virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1002%2Fanie.200390347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1356-1360&author=Y.+S.+Tsantrizosauthor=G.+Bolgerauthor=P.+Bonneauauthor=D.+R.+Cameronauthor=N.+Goudreauauthor=G.+Kukoljauthor=S.+R.+LaPlanteauthor=M.+Llin%C3%A0s-Brunetauthor=H.+Narauthor=D.+Lamarre&title=Macrocyclic+inhibitors+of+the+NS3+protease+as+potential+therapeutic+agents+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span></div><div class="casAuthors">Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1356-1360</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed.  The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease.  The designed HCV inhibitor and its satd. analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay.  In addn., they are orally absorbed and stable to metabolic breakdown.  Thus, these compds. show many of the desirable properties of a druglike archetype and could lead t a clin. useful antiviral agent for the treatment of hepatitis C viral infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCij3shP5tmLVg90H21EOLACvtfcHk0lgIH1M5Kmiffg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D&md5=e0a3c98ee0096bfc3d058bf0b92b81c3</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390347%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DMacrocyclic%2520inhibitors%2520of%2520the%2520NS3%2520protease%2520as%2520potential%2520therapeutic%2520agents%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D1356%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">M. Nilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvador-Oden, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roue, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wähling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickström, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamelink, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Vreken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pille, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of TMC435350</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4853</span><span class="NLM_x">–</span> <span class="NLM_lpage">4858</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4853-4858&author=P.+Raboissonauthor=H.+de+Kockauthor=%C3%85.+Rosenquistauthor=M.+M.+Nilssonauthor=L.+Salvador-Odenauthor=T.-I.+Linauthor=N.+Roueauthor=V.+Ivanovauthor=H.+W%C3%A4hlingauthor=K.+Wickstr%C3%B6mauthor=E.+Hamelinkauthor=M.+Edlundauthor=L.+Vrangauthor=S.+Vendevilleauthor=W.+Van+de+Vrekenauthor=D.+McGowanauthor=A.+Tahriauthor=L.+Huauthor=C.+Bouttonauthor=O.+Lenzauthor=F.+Delouvroyauthor=G.+Pilleauthor=D.+Surlerauxauthor=P.+Wigerinckauthor=B.+Samuelssonauthor=K.+Simmen&title=Structure%E2%80%93activity+relationship+study+on+a+novel+series+of+cyclopentane-containing+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3+protease+leading+to+the+discovery+of+TMC435350"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DRosenquist%26aufirst%3D%25C3%2585.%26aulast%3DM.%2BNilsson%26aufirst%3DM.%26aulast%3DSalvador-Oden%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.-I.%26aulast%3DRoue%26aufirst%3DN.%26aulast%3DIvanov%26aufirst%3DV.%26aulast%3DW%25C3%25A4hling%26aufirst%3DH.%26aulast%3DWickstr%25C3%25B6m%26aufirst%3DK.%26aulast%3DHamelink%26aufirst%3DE.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DVan%2Bde%2BVreken%26aufirst%3DW.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBoutton%26aufirst%3DC.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DPille%26aufirst%3DG.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520study%2520on%2520a%2520novel%2520series%2520of%2520cyclopentane-containing%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520TMC435350%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4853%26epage%3D4858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verbinnen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delouvroy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholliers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeiren, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kock, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span> </span><span class="NLM_article-title">In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1377</span><span class="NLM_x">–</span> <span class="NLM_lpage">1385</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=1377-1385&author=T.+I.+Linauthor=O.+Lenzauthor=G.+Fanningauthor=T.+Verbinnenauthor=F.+Delouvroyauthor=A.+Scholliersauthor=K.+Vermeirenauthor=A.+Rosenquistauthor=M.+Edlundauthor=B.+Samuelssonauthor=L.+Vrangauthor=H.+de+Kockauthor=P.+Wigerinckauthor=P.+Raboissonauthor=K.+Simmen&title=In+vitro+activity+and+preclinical+profile+of+TMC435350%2C+a+potent+hepatitis+C+virus+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVerbinnen%26aufirst%3DT.%26aulast%3DDelouvroy%26aufirst%3DF.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DVermeiren%26aufirst%3DK.%26aulast%3DRosenquist%26aufirst%3DA.%26aulast%3DEdlund%26aufirst%3DM.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DVrang%26aufirst%3DL.%26aulast%3Dde%2BKock%26aufirst%3DH.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%26atitle%3DIn%2520vitro%2520activity%2520and%2520preclinical%2520profile%2520of%2520TMC435350%252C%2520a%2520potent%2520hepatitis%2520C%2520virus%2520protease%2520inhibitor%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D1377%26epage%3D1385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blatt, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patat, A.</span><span> </span><span class="NLM_article-title">A phase 1 study of the safety, tolerability, and pharmacokinetics of single ascending oral doses of the NS3/4A protease inhibitor ITMN-191 in healthy subjects</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1146A</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=1146A&author=W.+Z.+Bradfordauthor=C.+Rubinoauthor=S.+Porterauthor=A.+Forrestauthor=L.+M.+Blattauthor=A.+Patat&title=A+phase+1+study+of+the+safety%2C+tolerability%2C+and+pharmacokinetics+of+single+ascending+oral+doses+of+the+NS3%2F4A+protease+inhibitor+ITMN-191+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DRubino%26aufirst%3DC.%26aulast%3DPorter%26aufirst%3DS.%26aulast%3DForrest%26aufirst%3DA.%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26aulast%3DPatat%26aufirst%3DA.%26atitle%3DA%2520phase%25201%2520study%2520of%2520the%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520single%2520ascending%2520oral%2520doses%2520of%2520the%2520NS3%252F4A%2520protease%2520inhibitor%2520ITMN-191%2520in%2520healthy%2520subjects%26jtitle%3DHepatology%26date%3D2008%26volume%3D48%26spage%3D1146A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Reddy, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznedar, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blotner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, J. Q.</span><span> </span><span class="NLM_article-title">Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug–drug interaction study</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">457</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2165%2F11599700-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFaksbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=457-465&author=M.+B.+Reddyauthor=Y.+Chenauthor=J.+O.+Haznedarauthor=J.+Fretlandauthor=S.+Blotnerauthor=P.+Smithauthor=J.+Q.+Tran&title=Impact+of+low-dose+ritonavir+on+danoprevir+pharmacokinetics%3A+results+of+computer-based+simulations+and+a+clinical+drug%E2%80%93drug+interaction+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study</span></div><div class="casAuthors">Reddy, Micaela B.; Chen, Yuan; Haznedar, Joshua O.; Fretland, Jennifer; Blotner, Steven; Smith, Patrick; Tran, Jonathan Q.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">457-465</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">Background and Objective: Danoprevir, a potent, selective inhibitor of the hepatitis C virus (HCV) NS3/4A protease, is metabolized by cytochrome P 450 (CYP) 3A.  Clin. studies in HCV patients have shown a potential need for a high danoprevir daily dose and/or dosing frequency.  Ritonavir, an HIV-1 protease inhibitor (PI) and potent CYP3A inhibitor, is used as a pharmacokinetic enhancer at subtherapeutic doses in combination with other HIV PIs.  Coadministering danoprevir with ritonavir as a pharmacokinetic enhancer could allow reduced danoprevir doses and/or dosing frequency.  Here we evaluate the impact of ritonavir on danoprevir pharmacokinetics.  Methods: The effects of low-dose ritonavir on danoprevir pharmacokinetics were simulated using Simcyp, a population-based simulator.  Following results from this drug-drug interaction (DDI) model, a crossover study was performed in healthy volunteers to investigate the effects of acute and repeat dosing of low-dose ritonavir on danoprevir single-dose pharmacokinetics.  Volunteers received a single oral dose of danoprevir 100 mg in a fixed sequence as follows: alone, and on the first day and the last day of 10-day dosing with ritonavir 100 mg every 12 h.  Results: The initial DDI model predicted that following multiple dosing of ritonavir 100 mg every 12 h for 10 days, the danoprevir area under the plasma concn.-time curve (AUC) from time zero to 24 h and max. plasma drug concn. (Cmax) would increase by about 3.9- and 3.2-fold, resp.  The clin. results at day 10 of ritonavir dosing showed that the plasma drug concn. at 12 h postdose, AUC from time zero to infinity and Cmax of danoprevir increased by approx. 42-fold, 5.5-fold and 3.2-fold, resp., compared with danoprevir alone.  The DDI model was refined with the clin. data and sensitivity analyses were performed to better understand factors impacting the ritonavir-danoprevir interaction.  Conclusion: DDI model simulations predicted that danoprevir exposures could be successfully enhanced with ritonavir coadministration, and that a clin. study confirming this result was warranted.  The clin. results demonstrate that low-dose ritonavir enhances the pharmacokinetic profile of low-dose danoprevir such that overall danoprevir exposures can be reduced while sustaining danoprevir trough concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP0vJez0knArVg90H21EOLACvtfcHk0lj1lrDXiflx5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFaksbjI&md5=8691b68cbf95355ec2eb651aee412e88</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2165%2F11599700-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11599700-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BB.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHaznedar%26aufirst%3DJ.%2BO.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DBlotner%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DJ.%2BQ.%26atitle%3DImpact%2520of%2520low-dose%2520ritonavir%2520on%2520danoprevir%2520pharmacokinetics%253A%2520results%2520of%2520computer-based%2520simulations%2520and%2520a%2520clinical%2520drug%25E2%2580%2593drug%2520interaction%2520study%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D457%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">Molecular modeling based approach to potent P2–P4 macrocyclic inhibitors of hepatitis C NS3/4a protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">4607</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja711120r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=4607-4609&author=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=J.+W.+Butcherauthor=S.+S.+Carrollauthor=J.+DiMuzioauthor=C.+Fandozziauthor=K.+F.+Gilbertauthor=S.-S.+Maoauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=M.+Stahlhutauthor=B.-L.+Wanauthor=D.+B.+Olsenauthor=J.+P.+Vacca&title=Molecular+modeling+based+approach+to+potent+P2%E2%80%93P4+macrocyclic+inhibitors+of+hepatitis+C+NS3%2F4a+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fja711120r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja711120r%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMolecular%2520modeling%2520based%2520approach%2520to%2520potent%2520P2%25E2%2580%2593P4%2520macrocyclic%2520inhibitors%2520of%2520hepatitis%2520C%2520NS3%252F4a%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D4607%26epage%3D4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swestock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span> </span><span class="NLM_article-title">Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2463</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9015526" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2443-2463&author=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=M.+T.+Ruddauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=J.+W.+Butcherauthor=K.+F.+Gilbertauthor=K.+J.+Bushauthor=M.+K.+Hollowayauthor=J.+Swestockauthor=B.-L.+Wanauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=D.+J.+Grahamauthor=S.+W.+Ludmererauthor=S.-S.+Maoauthor=M.+W.+Stahlhutauthor=C.+M.+Fandozziauthor=N.+Trainorauthor=D.+B.+Olsenauthor=J.+P.+Vaccaauthor=N.+J.+Liverton&title=Discovery+of+vaniprevir+%28MK-7009%29%2C+a+macrocyclic+hepatitis+C+virus+NS3%2F4a+protease+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">McCauley, John A.; McIntyre, Charles J.; Rudd, Michael T.; Nguyen, Kevin T.; Romano, Joseph J.; Butcher, John W.; Gilbert, Kevin F.; Bush, Kimberly J.; Holloway, M. Katharine; Swestock, John; Wan, Bang-Lin; Carroll, Steven S.; DiMuzio, Jillian M.; Graham, Donald J.; Ludmerer, Steven W.; Mao, Shi-Shan; Stahlhut, Mark W.; Fandozzi, Christine M.; Trainor, Nicole; Olsen, David B.; Vacca, Joseph P.; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2443-2463</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a mol.-modeling derived strategy.  Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compds. via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate vaniprevir, MK-7009, which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_2CVs9I1H_7Vg90H21EOLACvtfcHk0lh4ngHMDvNu2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitV2gsr8%253D&md5=dc820c588d5482f6913091a87eaf9af1</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm9015526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9015526%26sid%3Dliteratum%253Aachs%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DSwestock%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520vaniprevir%2520%2528MK-7009%2529%252C%2520a%2520macrocyclic%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2443%26epage%3D2463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazuda, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4a protease</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=305-311&author=N.+J.+Livertonauthor=S.+S.+Carrollauthor=J.+M.+DiMuzioauthor=C.+Fandozziauthor=D.+J.+Grahamauthor=D.+J.+Hazudaauthor=M.+K.+Hollowayauthor=S.+W.+Ludmererauthor=J.+A.+McCauleyauthor=C.+J.+McIntyreauthor=D.+B.+Olsenauthor=M.+T.+Ruddauthor=M.+Stahlhutauthor=J.+P.+Vacca&title=MK-7009%2C+a+potent+and+selective+inhibitor+of+hepatitis+C+virus+NS3%2F4a+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMK-7009%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D305%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Summa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludmerer, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claudio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Filippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazuda, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pucci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span> </span><span class="NLM_article-title">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4161</span><span class="NLM_x">–</span> <span class="NLM_lpage">4167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1128%2FAAC.00324-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22615282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4161-4167&author=V.+Summaauthor=S.+W.+Ludmererauthor=J.+A.+McCauleyauthor=C.+Fandozziauthor=C.+Burleinauthor=G.+Claudioauthor=P.+J.+Colemanauthor=J.+M.+DiMuzioauthor=M.+Ferraraauthor=M.+Di+Filippoauthor=A.+T.+Gatesauthor=D.+J.+Grahamauthor=S.+Harperauthor=D.+J.+Hazudaauthor=C.+McHaleauthor=E.+Monteagudoauthor=V.+Pucciauthor=M.+Rowleyauthor=M.+T.+Ruddauthor=A.+Sorianoauthor=M.+W.+Stahlhutauthor=J.+P.+Vaccaauthor=D.+B.+Olsenauthor=N.+J.+Livertonauthor=S.+S.+Carroll&title=MK-5172%2C+a+selective+inhibitor+of+hepatitis+C+virus+NS3%2F4a+protease+with+broad+activity+across+genotypes+and+resistant+variants"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span></div><div class="casAuthors">Summa, Vincenzo; Ludmerer, Steven W.; McCauley, John A.; Fandozzi, Christine; Burlein, Christine; Claudio, Giuliano; Coleman, Paul J.; DiMuzio, Jillian M.; Ferrara, Marco; Di Filippo, Marcello; Gates, Adam T.; Graham, Donald J.; Harper, Steven; Hazuda, Daria J.; McHale, Carolyn; Monteagudo, Edith; Pucci, Vincenzo; Rowley, Michael; Rudd, Michael T.; Soriano, Aileen; Stahlhut, Mark W.; Vacca, Joseph P.; Olsen, David B.; Liverton, Nigel J.; Carroll, Steven S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4161-4167</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections.  Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes for future agents to be used in combinations without interferon.  In this communication, we report the preclin. profile of MK-5172, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clin. development.  The compd. demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors.  In replicon selections, MK-5172 exerted high selective pressure, which yielded few resistant colonies.  In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing.  When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppressed viral load between 4 to 5 logs at a dose of 1 mg/kg of body wt. twice daily (b.i.d.) for 7 days.  Based on its preclin. profile, MK-5172 is anticipated to be broadly active against multiple HCV genotypes and clin. important resistance variants and highly suited for incorporation into newer all-oral regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomXxLJMTmWqrVg90H21EOLACvtfcHk0lh4ngHMDvNu2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF&md5=8874f9279917137113e429cda31c1bba</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1128%2FAAC.00324-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00324-12%26sid%3Dliteratum%253Aachs%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DClaudio%26aufirst%3DG.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DGates%26aufirst%3DA.%2BT.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26atitle%3DMK-5172%252C%2520a%2520selective%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%252F4a%2520protease%2520with%2520broad%2520activity%2520across%2520genotypes%2520and%2520resistant%2520variants%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4161%26epage%3D4167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Last, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Steen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span> </span><span class="NLM_article-title">Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4437</span><span class="NLM_x">–</span> <span class="NLM_lpage">4443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4437-4443&author=S.+Vendevilleauthor=T.+I.+Linauthor=L.+Huauthor=A.+Tahriauthor=D.+McGowanauthor=M.+D.+Cummingsauthor=K.+Amssomsauthor=M.+Canardauthor=S.+Lastauthor=I.+Van+den+Steenauthor=B.+Devogelaereauthor=M.+C.+Rouanauthor=L.+Vijgenauthor=J.+M.+Berkeauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=G.+Fanningauthor=K.+Van+Emelenauthor=O.+Nyanguileauthor=K.+Simmenauthor=P.+Raboisson&title=Finger+loop+inhibitors+of+the+HCV+NS5b+polymerase.+Part+II.+Optimization+of+tetracyclic+indole-based+macrocycle+leading+to+the+discovery+of+TMC647055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DCanard%26aufirst%3DM.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DVan%2Bden%2BSteen%26aufirst%3DI.%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DRouan%26aufirst%3DM.%2BC.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DFinger%2520loop%2520inhibitors%2520of%2520the%2520HCV%2520NS5b%2520polymerase.%2520Part%2520II.%2520Optimization%2520of%2520tetracyclic%2520indole-based%2520macrocycle%2520leading%2520to%2520the%2520discovery%2520of%2520TMC647055%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4437%26epage%3D4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Devogelaere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijgen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehertogh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleiren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Helm, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyanguile, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amssoms, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendeville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raboisson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. I.</span><span> </span><span class="NLM_article-title">TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4676</span><span class="NLM_x">–</span> <span class="NLM_lpage">4684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4676-4684&author=B.+Devogelaereauthor=J.+M.+Berkeauthor=L.+Vijgenauthor=P.+Dehertoghauthor=E.+Fransenauthor=E.+Cleirenauthor=L.+van+der+Helmauthor=O.+Nyanguileauthor=A.+Tahriauthor=K.+Amssomsauthor=O.+Lenzauthor=M.+D.+Cummingsauthor=R.+F.+Claytonauthor=S.+Vendevilleauthor=P.+Raboissonauthor=K.+A.+Simmenauthor=G.+C.+Fanningauthor=T.+I.+Lin&title=TMC647055%2C+a+potent+nonnucleoside+hepatitis+C+virus+NS5B+polymerase+inhibitor+with+cross-genotypic+coverage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDevogelaere%26aufirst%3DB.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DDehertogh%26aufirst%3DP.%26aulast%3DFransen%26aufirst%3DE.%26aulast%3DCleiren%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BHelm%26aufirst%3DL.%26aulast%3DNyanguile%26aufirst%3DO.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DLenz%26aufirst%3DO.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DClayton%26aufirst%3DR.%2BF.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DSimmen%26aufirst%3DK.%2BA.%26aulast%3DFanning%26aufirst%3DG.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BI.%26atitle%3DTMC647055%252C%2520a%2520potent%2520nonnucleoside%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%2520inhibitor%2520with%2520cross-genotypic%2520coverage%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4676%26epage%3D4684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.-H.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2FFms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.-H.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252FFms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Younes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romaguera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeister, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neelapu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Castro Faria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span> </span><span class="NLM_article-title">Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4161</span><span class="NLM_x">–</span> <span class="NLM_lpage">4167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1200%2FJCO.2012.42.5223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVanug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=4161-4167&author=A.+Younesauthor=J.+Romagueraauthor=M.+Fanaleauthor=P.+McLaughlinauthor=F.+Hagemeisterauthor=A.+Copelandauthor=S.+Neelapuauthor=L.+Kwakauthor=J.+Shahauthor=S.+de+Castro+Fariaauthor=S.+Hartauthor=J.+Woodauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+Zhu&title=Phase+I+study+of+a+novel+oral+Janus+kinase+2+inhibitor%2C+SB1518%2C+in+patients+with+relapsed+lymphoma%3A+evidence+of+clinical+and+biologic+activity+in+multiple+lymphoma+subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes</span></div><div class="casAuthors">Younes, Anas; Romaguera, Jorge; Fanale, Michelle; McLaughlin, Peter; Hagemeister, Frederick; Copeland, Amanda; Neelapu, Sattva; Kwak, Larry; Shah, Jatin; Faria, Silvana de Castro; Hart, Stefan; Wood, Jeanette; Jayaraman, Ramesh; Ethirajulu, Kantharaj; Zhu, Joy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4161-4167</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose. The Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) pathway plays an important role in the pathogenesis of hematol. malignancies.  We conducted a phase I dose-finding and pharmacokinetic/pharmacodynamic study of SB1518, a potent JAK2 inhibitor, in patients with relapsed lymphoma.  Patients and Methods. Patients with relapsed or refractory Hodgkin or non-Hodgkin lymphoma of any type except Burkitt's or CNS lymphoma were enrolled.  Patient cohorts received escalating doses of SB1518 orally once daily for 28-day cycles.  Response was evaluated after 8 wk.  Results. Thirty-four patients received doses of 100 to 600 mg/d.  The max. tolerated dose was not reached.  Treatment was well tolerated, with mostly grade 1 and 2 toxicities.  Gastrointestinal toxicities were the most common treatment-related events.  Cytopenias were infrequent and modest.  Pharmacol. active concns. were achieved at all doses.  Dose-related linear increases in area under the concn.-time curve were seen on day 1, with no significant accumulation on day 15.  Mean terminal half-life was 1 to 4 days, and mean time to peak concn. ranged from 5 to 9 h.  SB1518 inhibited JAK2 signaling at 4 h postdose at all levels.  Increases in fms-like tyrosine kinase-3 (FLT-3) ligand, reflecting FLT-3 inhibition, were seen in most patients.  There were three partial responses (≥ 300 mg/d) and 15 patients with stable disease (SD), with most responses lasting longer than 2 mo.  Seven of 13 SDs had tumor redns. of 4% to 46%.  Conclusion. SB1518 has encouraging activity in relapsed lymphoma, providing the first proof-of-principle of the potential therapeutic value of targeting the JAK/STAT pathway in lymphoma in the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptMRuMQba1fbVg90H21EOLACvtfcHk0lhJMqK8JdX76Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVanug%253D%253D&md5=4d209b73c02421bd732d2257d616521b</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.5223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.5223%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DRomaguera%26aufirst%3DJ.%26aulast%3DFanale%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DP.%26aulast%3DHagemeister%26aufirst%3DF.%26aulast%3DCopeland%26aufirst%3DA.%26aulast%3DNeelapu%26aufirst%3DS.%26aulast%3DKwak%26aufirst%3DL.%26aulast%3DShah%26aufirst%3DJ.%26aulast%3Dde%2BCastro%2BFaria%26aufirst%3DS.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520study%2520of%2520a%2520novel%2520oral%2520Janus%2520kinase%25202%2520inhibitor%252C%2520SB1518%252C%2520in%2520patients%2520with%2520relapsed%2520lymphoma%253A%2520evidence%2520of%2520clinical%2520and%2520biologic%2520activity%2520in%2520multiple%2520lymphoma%2520subtypes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D4161%26epage%3D4167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">4123</span><span class="NLM_x">–</span> <span class="NLM_lpage">4134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=4123-4134&author=B.+Madanauthor=K.+C.+Gohauthor=S.+Hartauthor=A.+D.+Williamauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+M.+Wood&title=SB1578%2C+a+novel+inhibitor+of+JAK2%2C+FLT3%2C+and+c-Fms+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DSB1578%252C%2520a%2520novel%2520inhibitor%2520of%2520JAK2%252C%2520FLT3%252C%2520and%2520c-Fms%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26spage%3D4123%26epage%3D4134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span> </span><span class="NLM_article-title">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">J Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1007%2Fs00894-012-1528-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=22820730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=119-130&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=H.+Nagarajauthor=M.+Williamsauthor=H.+Wangauthor=A.+Leeauthor=E.+Sunauthor=E.+L.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+nitrogen-linked+macrocyclic+kinase+inhibitors+leading+to+the+clinical+candidate+SB1317%2FTG02%2C+a+potent+inhibitor+of+cyclin+dependant+kinases+%28CDKs%29%2C+Janus+kinase+2+%28JAK2%29%2C+and+Fms-like+tyrosine+kinase-3+%28FLT3%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Poulsen, Anders; William, Anthony; Blanchard, Stephanie; Nagaraj, Harish; Williams, Meredith; Wang, Haishan; Lee, Angeline; Sun, Eric; Teo, Ee-Ling; Tan, Evelyn; Goh, Kee Chuan; Dymock, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-130</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A high-throughput screen against Aurora A kinase revealed several promising submicromolar pyrimidine-aniline leads.  The bioactive conformation found by docking these leads into the Aurora A ATP-binding site had a semicircular shape.  Macrocycle formation was proposed to achieve novelty and selectivity via ring-closing metathesis of a diene precursor.  The nature of the optimal linker and its size was directed by docking.  In a kinase panel screen, selected macrocycles were active on other kinase targets, mainly FLT3, JAK2, and CDKs.  These compds. then became leads in a CDK/FLT3/JAK2 inhibitor project.  Macrocycles with a basic nitrogen in the linker form a salt bridge with Asp86 in CDK2 and Asp698 in FLT3.  Interaction with this residue explains the obsd. selectivity.  The Asp86 residue is conserved in most CDKs, resulting in potent pan-CDK inhibition by these compds.  Optimized macrocycles generally have good DMPK properties, and are efficacious in mouse models of cancer.  Compd. 5 (SB1317/TG02), a pan-CDK/FLT3/JAK2 inhibitor, was selected for preclin. development, and is now in phase 1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnGiv82CuwbVg90H21EOLACvtfcHk0lhJMqK8JdX76Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D&md5=3f65c0a7f61329cabb9e85656a2c3dcf</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs00894-012-1528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-012-1528-7%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520nitrogen-linked%2520macrocyclic%2520kinase%2520inhibitors%2520leading%2520to%2520the%2520clinical%2520candidate%2520SB1317%252FTG02%252C%2520a%2520potent%2520inhibitor%2520of%2520cyclin%2520dependant%2520kinases%2520%2528CDKs%2529%252C%2520Janus%2520kinase%25202%2520%2528JAK2%2529%252C%2520and%2520Fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26spage%3D119%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span> </span><span class="NLM_article-title">Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor</span> <span class="citation_source-journal">Drug Metab. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.2174%2F187231212800229336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=33-42&author=M.+K.+Pashaauthor=R.+Jayaramanauthor=V.+P.+Reddyauthor=P.+Yeoauthor=E.+Gohauthor=A.+Williamsauthor=K.+C.+Gohauthor=E.+Kantharaj&title=Preclinical+metabolism+and+pharmacokinetics+of+SB1317+%28TG02%29%2C+a+potent+CDK%2FJAK2%2FFLT3+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor</span></div><div class="casAuthors">Pasha, Mohammed Khalid; Jayaraman, Ramesh; Reddy, Venkatesh Pilla; Yeo, Pauline; Goh, Evelyn; Williams, Anthony; Goh, Kee Chuan; Kantharaj, Ethirajulu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">SB1317 (TG02) is a novel small mol. potent CDK/JAK2/FLT3 inhibitor.  To evaluate full potential of this development candidate, we conducted drug metab. and pharmacokinetic studies of this novel anti-cancer agent.  SB1317 was sol., highly permeable in Caco-2 cells, and showed >99% binding to plasma from mice, dog and humans.  It was metabolically stable in human and dog liver microsomes relative to mouse and rat.  SB1317 was mainly metabolized by CYP3A4 and CY1A2 in vitro.  SB1317 did not inhibit any of the major human CYPs in vitro except CYP2D6 (IC50 = 1 μM).  SB1317 did not significantly induce CYP1A and CYP3A4 in human hepatocytes in vitro.  The metabolic profiles in liver microsomes from preclin. species were qual. similar to humans.  In pharmacokinetic studies SB1317 showed moderate to high systemic clearance (relative to liver blood flow), high vol. of distribution (>0.6 L/kg), oral bioavailability of 24%, ∼4 and 37% in mice, rats and dogs, resp.; and extensive tissue distribution in mice.  The favorable ADME of SB1317 supported its preclin. development as an oral drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIusZ0BdJyPbVg90H21EOLACvtfcHk0lhJMqK8JdX76Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2gsb8%253D&md5=fbc9c2d6453202c5130db50ed1df75c3</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2174%2F187231212800229336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231212800229336%26sid%3Dliteratum%253Aachs%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DV.%2BP.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DKantharaj%26aufirst%3DE.%26atitle%3DPreclinical%2520metabolism%2520and%2520pharmacokinetics%2520of%2520SB1317%2520%2528TG02%2529%252C%2520a%2520potent%2520CDK%252FJAK2%252FFLT3%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2012%26volume%3D6%26spage%3D33%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Konings, I. R. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jonge, M. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Gaast, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Beijsterveldt, L. E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellemans, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span> </span><span class="NLM_article-title">Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">992</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1038%2Fsj.bjc.6605867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=987-992&author=I.+R.+H.+M.+Koningsauthor=M.+J.+A.+de+Jongeauthor=H.+Burgerauthor=A.+van+der+Gaastauthor=L.+E.+C.+van+Beijsterveldtauthor=H.+Winklerauthor=J.+Verweijauthor=Z.+Yuanauthor=P.+Hellemansauthor=F.+A.+L.+M.+Eskens&title=Phase+I+and+pharmacological+study+of+the+broad-spectrum+tyrosine+kinase+inhibitor+JNJ-26483327+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours</span></div><div class="casAuthors">Konings, I. R. H. M.; de Jonge, M. J. A.; Burger, H.; van der Gaast, A.; van Beijsterveldt, L. E. C.; Winkler, H.; Verweij, J.; Yuan, Z.; Hellemans, P.; Eskens, F. A. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: JNJ-26483327 is an oral, potent, multi-targeted tyrosine kinase inhibitor, inhibiting kinases of epidermal growth factor receptor (EGFR)-1, -2 and -4, rearranged during transfection (RET) receptor, vascular endothelial growth factor receptor (VEGFR)-3 and Src family (Lyn, Fyn, Yes) at low nanomolar concns.  This phase I, accelerated titrn. study assessed max. tolerated dose, safety, pharmacokinetics and pharmacodynamic effects of JNJ-26483327.  Methods: Nineteen patients with advanced cancers received JNJ-26483327 continuous twice daily (BID) in escalating dose cohorts ranging from 100 to 2100 mg.  Pharmacodynamic effects were assessed in paired skin biopsies and blood.  Results: JNJ-26483327 was well tolerated in doses up to 1500 mg BID, with target-inhibition-related toxicity such as diarrhea and skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue.  At 2100 mg, two episodes of dose-limiting toxicity were obsd., consisting of grade 3 anorexia and a combination of grade 3 anorexia and fatigue, resp.  Pharmacokinetics were dose proportional up to 1500 mg in which plasma levels were obtained showing anti-tumor activity in xenograft mouse models.  Pharmacodynamic anal. did not show a substantial effect on expression of Ki-67, p27kip1, phosphorylated mitogen-activated protein kinase, phosphorylated Akt and EGFR, and serum levels of sVEGFR-2, VEGF-C and VEGF-D remained unchanged.  Stable disease was noted in six patients (32%).  Conclusion: JNJ-26483327 is well tolerated and shows a predictable pharmacokinetic profile; the recommended dose for further studies is 1500 mg BID.  British Journal of Cancer (2010) 103, 987-992; doi:10.1038/sj.bjc.6605867 www.bjcancer.com Published online 7 Sept. 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP2g2VkUKueLVg90H21EOLACvtfcHk0lizC2TVKCF9Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrbL&md5=5f8f04fc2656ce1ec6c55e5ee4c870c6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605867%26sid%3Dliteratum%253Aachs%26aulast%3DKonings%26aufirst%3DI.%2BR.%2BH.%2BM.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3Dvan%2Bder%2BGaast%26aufirst%3DA.%26aulast%3Dvan%2BBeijsterveldt%26aufirst%3DL.%2BE.%2BC.%26aulast%3DWinkler%26aufirst%3DH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26atitle%3DPhase%2520I%2520and%2520pharmacological%2520study%2520of%2520the%2520broad-spectrum%2520tyrosine%2520kinase%2520inhibitor%2520JNJ-26483327%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer.%26date%3D2010%26volume%3D103%26spage%3D987%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Hughes, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fobian, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilles, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger-Burke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wager, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4875</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm400887j&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm400887j&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm400887j&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0lizC2TVKCF9Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i26"><a href="/doi/suppl/10.1021/jm400887j">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_35061"></div></div></div></div></div><hr /></hr><p class="last">A description of the methods used for assembly of the data sets of marketed macrocyclic drugs and macrocycles in clinical development; tables listing the name, structure, chemical class and subclass, therapeutic area, route of administration (oral or parenteral), average human daily dose, human bioavailability and physical chemical properties (HBD, PSA, MW and cLogP) for the members of the two data sets; a figure describing the relationship between human oral bioavailability and MW, cLogP, PSA, and the number of HBDs, respectively, for macrolide, ansamycin, and cyclic peptide macrocyclic drugs. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400887j/suppl_file/jm400887j_si_001.pdf">jm400887j_si_001.pdf (1.08 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400887j&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm400887j%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-2%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400887j" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679abd3fe9502332","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
